

10/824,738

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:

\*\*\*\*\* RECONNECTED TO STN INTERNATIONAL \*\*\*\*\*  
 SESSION RESUMED IN FILE 'REGISTRY' AT 19:14:23 ON 06 DEC 2005  
 FILE 'REGISTRY' ENTERED AT 19:14:23 ON 06 DEC 2005  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)  
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	171.22	172.27

=> file reg

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS	171.22	172.27
FULL ESTIMATED COST	171.22	172.27

FILE 'REGISTRY' ENTERED AT 19:14:32 ON 06 DEC 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2005 HIGHEST RN 869333-72-2  
 DICTIONARY FILE UPDATES: 5 DEC 2005 HIGHEST RN 869333-72-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

\*\*\*\*\*  
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*  
 \*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\738w.str



chain nodes :

13 15 16 17 19 20 21 22 23 24 25 26 27 28 29 30 39 40 41 42 43  
44 45

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

2-16 5-43 9-43 12-13 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44  
20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

2-16 5-43 9-43 12-13 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44

exact bonds :

20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:[\*1-\*2],[\*3-\*4],[\*5-\*6],[\*7-\*8]


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 30:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS  
45:CLASS

L4        STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\738x.str



```

chain nodes :
13 15 16 17 19 20 21 22 23 24 25 26 27 28 29 30 39 40 41 42 43
44 45
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-16 5-43 8-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44
20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-16 5-43 8-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44
exact bonds :
20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30

```



normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:[\*1-\*2],[\*3-\*4],[\*5-\*6],[\*7-\*8]


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 30:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS  
45:CLASS

L5        STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\738y.str



chain nodes :  
 13 15 16 17 19 20 21 22 23 24 25 26 27 28 29 30 39 40 41 42 43  
 44 45  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12  
 chain bonds :  
 1-16 5-43 7-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44  
 20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
 exact/norm bonds :  
 1-16 5-43 7-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44  
 exact bonds :  
 20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:[\*1-\*2],[\*3-\*4],[\*5-\*6],[\*7-\*8]


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 30:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS  
45:CLASS

L6        STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\738z.str



chain nodes :  
 13 15 16 17 19 20 21 22 23 24 25 26 27 28 29 30 39 40 41 42 43  
 44 45  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12  
 chain bonds :  
 5-43 6-16 8-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44  
 20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
 exact/norm bonds :  
 5-43 6-16 8-13 9-43 13-45 15-42 15-41 15-45 16-44 17-40 17-39 17-44  
 exact bonds :  
 20-21 22-25 22-26 23-24 23-27 23-29 24-28 24-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:[\*1-\*2],[\*3-\*4],[\*5-\*6],[\*7-\*8]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS  
 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
 29:CLASS 30:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS  
 45:CLASS

L7 STRUCTURE UPLOADED

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.03

181.30

FILE 'REGISTRY' ENTERED AT 19:27:02 ON 06 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2005 HIGHEST RN 869333-72-2

DICTIONARY FILE UPDATES: 5 DEC 2005 HIGHEST RN 869333-72-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*  
 \*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s 14

SAMPLE SEARCH INITIATED 19:27:06 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 969 TO ITERATE

100.0% PROCESSED 969 ITERATIONS  
SEARCH TIME: 00.00.01

10 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 17513 TO 21247  
PROJECTED ANSWERS: 11 TO 389

L8 10 SEA SSS SAM L4

=> s 15

SAMPLE SEARCH INITIATED 19:27:12 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 186 TO ITERATE

100.0% PROCESSED 186 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2902 TO 4538  
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L5

=> s 16

SAMPLE SEARCH INITIATED 19:27:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 316 TO ITERATE

100.0% PROCESSED 316 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5254 TO 7386  
PROJECTED ANSWERS: 1 TO 80

L10 1 SEA SSS SAM L6

=> s 17

SAMPLE SEARCH INITIATED 19:27:22 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 422 TO ITERATE

100.0% PROCESSED 422 ITERATIONS  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7208 TO 9672  
PROJECTED ANSWERS: 4 TO 200

L11 4 SEA SSS SAM L7

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:27:31 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 18561 TO ITERATE

100.0% PROCESSED 18561 ITERATIONS 244 ANSWERS  
SEARCH TIME: 00.00.01

L12 244 SEA SSS FUL L4

=> search 15  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:27:44 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 3703 TO ITERATE

100.0% PROCESSED 3703 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L13 0 SEA SSS FUL L5

=> search 16  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:27:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 5711 TO ITERATE

100.0% PROCESSED 5711 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01

L14 4 SEA SSS FUL L6

=> search 17  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:28:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 8720 TO ITERATE

100.0% PROCESSED 8720 ITERATIONS 80 ANSWERS  
SEARCH TIME: 00.00.01

L15 80 SEA SSS FUL L7

=> s l12 or l13 or l14 or l15  
L16 328 L12 OR L13 OR L14 OR L15

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	644.46	825.76

FILE 'CAPLUS' ENTERED AT 19:28:31 ON 06 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Dec 2005 VOL 143 ISS 24  
FILE LAST UPDATED: 5 Dec 2005 (20051205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 116

L17 202 L16

=> d 117 fbib ab hitstr 1-202

L17 ANSWER 1 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:1018102 CAPLUS

TI Measurement of inclusion complex formation between cyclophane and biologically relevant amino acids using electrospray ionization, cold-spray ionization and fast atom bombardment mass spectrometry

AU Metori, Koichi; Sei, Yoshihisa; Kimura, Yumiko; Ozawa, Tomoyuki; Yamaguchi, Kentaro; Miyake, Muneharu

CS College of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan

SO Chemical & Pharmaceutical Bulletin (2005), 53(8), 1029-1033

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

AB The investigation of host-guest complex formation between cyclophane TGDMP [a cyclophane bearing 4-dimethylaminopyridinium groups on a dibenzo[b,f][1,5]diazocine skeleton] as a host and L-acidic amino acids such as L-glutamic acid (Glu) and L-aspartic acid (Asp) as guests was carried out using fast atom bombardment (FAB), electrospray ionization (ESI) and cold-spray ionization (CSI) mass spectrometry (MS). The stability constant (Ks) values obtained by the three different MS methods almost agreed. However, the complex ion peaks of novel cyclophane I.8 HCl(CPCn; preparation given) with Glu and Asp were not observed by FAB-MS, but were observed clearly using CSI-MS and ESI-MS. It was concluded that ESI-MS and CSI-MS are available for the determination of Ks values in addition to

FAB-MS.


IT 603956-15-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(inclusion complex formation between cyclophanes and amino acids measured by mass spectrometry)

RN 603956-15-6 CAPLUS

CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:539708 CAPLUS

DN 143:79732

TI Preparation of a water based polyamine epoxy curing agent and uses thereby



PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	EP 1544230	A1	20050622	EP 2003-29483	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005154091	A1	20050714	US 2004-2024	20041202
				EP 2003-29483	A 20031219
	JP 2005200646	A2	20050728	JP 2004-365927	20041217
				EP 2003-29483	A 20031219

AB The present invention relates to a method of preparation of a water based epoxy resin curing agent in dispersion form which is formed by combining an amine-functional dispersion (A) with an amine-functional curing agent (B). A water based epoxy resin curing agent in dispersion form is formed by combining an active amine-hydrogen containing amine-functional dispersion (A) with an active amine-hydrogen containing amine-functional curing agent (B) in solution or emulsion form, wherein said active amine-hydrogen containing amine-functional dispersion (A) comprises a reaction product of (a) a polyamine compound having at least three active amine-hydrogen, and (b) an aqueous epoxy resin dispersion having an epoxy solids equivalent weight of equal to


or greater than 150 g/equiv, and wherein said active amine-hydrogen containing amine-functional curing agent (B) has a solids hydrogen equivalent weight of 50-500 g/equiv; is capable of emulsifying a liquid epoxy resin to produce a stable emulsion; and is capable of yielding coating preps. of high gloss. The curing agent obtained from said method is used for curing two component water based epoxy systems and the uses of such comps. as primer, sealer, etc.

IT 854009-15-7

RL: MOA (Modifier or additive use); USES (Uses)  
(curing agent; preparation of a water based polyamine epoxy curing agent and uses thereby)

RN 854009-15-7 CAPLUS

2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-aminoethyl)amino]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

$$-\text{CH}_2-\text{NH}-\text{CH}_2-\text{CH}_2-\text{NH}_2$$

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:446508 CAPLUS

DN 143:133349

TI Design and synthesis of a novel water-soluble NMDA receptor antagonist with a 1,4,7,10-tetraazacyclododecane group

AU Masuko, Takashi; Metori, Koichi; Kizawa, Yasuo; Kusama, Tadashi; Miyake, Muneharu

CS College of Pharmacy, Nihon University, Chiba, 274-8555, Japan

SO Chemical & Pharmaceutical Bulletin (2005), 53(4), 444-447

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

AB Polyamines, especially spermine, inhibit N-methyl-D-aspartate (NMDA) receptors as open channel blockers. Two types of water-soluble NMDA receptor antagonist, ACCn [i.e., N,N'-methylenebis[(phenylene)oxy]ethyl 1,4,7,10-tetraazacyclododecane bis(acetamide) derivative] and TGCn [i.e., [[(5,11-methanodibenzo[b,f][1,5]diazocine)oxo ethyl]diyl] bis(1,4,7,10-tetraazacyclododecane) derivative], with a 1,4,7,10-tetraazacyclododecane cyclic polyamine group, were synthesized and the effects of both compds. on NMDA receptors were studied using voltage-clamp recordings of recombinant NMDA receptors expressed in *Xenopus* oocytes. These compds. inhibited macroscopic currents in both NR1/NR2A and NR1/NR2B receptor subtypes in oocytes voltage-clamped at -70 mV. Inhibition by the compds. of NR1/NR2A receptors were more prominent than that of NR1/NR2B receptors. The inhibitory effects of ACCn on both NMDA receptors were more potent than those of TGCn.

IT 858641-96-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of N,N'-methylenebis[(phenylene)oxy]ethyl 1,4,7,10-tetraazacyclododecane bis(acetamide) and study of its activity as water-soluble NMDA receptor antagonist)


RN 858641-96-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1-acetamide, N,N'-[methylenebis(4,1-phenyleneoxy-2,1-ethanediyl)]bis-, octahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 8 HCl


IT **603956-15-6P 858642-02-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N,N'-methylenebis[(phenylene)oxy]ethyl 1,4,7,10-tetraazacyclododecane bis(acetamide) and study of its activity as water-soluble NMDA receptor antagonist)


RN 603956-15-6 CAPLUS


CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



RN 858642-02-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid, 10,10'-[methylenebis[4,1-phenyleneoxy-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-, hexakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)





RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2005:136510 CAPLUS  
DN 142:225887  
TI Dental root canal sealing composition containing amino-terminated prepolymer  
IN Klee, Joachim E.  
PA Dentsply de Trey G.m.b.H., Germany  
SO PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013922	A1	20050217	WO 2004-EP8599	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			EP 2003-17391	A 20030731
			US 2004-551348P	P 20040310

AB A dental root canal sealing composition curable in the absence of a polymerization initiator and having a viscosity at 23°C of less than 100 Pas, comprises (i) an amino terminated prepolymer obtainable by reacting (a) one mole of an acrylate and (b) at least n moles of one or more amines, (ii) a di- or polyfunctional acrylate compound or a di- or polyfunctional maleimide compound which is capable of undergoing polyaddn. with the amino-terminated prepolymer (i); (iii) 40 to 85 weight-% of a filler for providing a min. radio-opacity of at least 3mm/mm AI; said composition being in the form of a two-component composition wherein a first component contains the amino terminated prepolymer (i) and optionally filler (iii) and a second component (ii) capable of undergoing polyaddn. with the aminoterminated prepolymer (i) and optionally filler (iii). A prepolymer was prepared from benzylamine and trimethylolpropane triacrylate and cyclohexanedimethanol

diacrylate powder added along with Ca tungstate and zirconia to give a final polymer.

IT 479255-72-6P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(dental root canal sealing composition containing amino-terminated prepolymer)

RN 479255-72-6 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH—CH<sub>2</sub>—Ph

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:633927 CAPLUS

DN 141:140476

TI Preparation of novel nitrogen-containing cyclic compounds as NMDA receptor inhibitors

IN Miyake, Muneharu; Kusama, Tadashi; Masuko, Takashi

PA Nihon University, Japan

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065385	A1	20040805	WO 2004-JP517	20040121

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA


JP 2004262762	A2	20040924	JP 2003-12226	A	20030121
JP 2004262762			JP 2003-12226		20030121

OS MARPAT 141:140476

AB Nitrogen-containing cyclic compds. compds. represented by the following general formula (I), or salts or hydrates thereof [wherein X and Y are the

same or different and each represents CH<sub>2</sub> or CO; Z's are the same or different and each represents CH<sub>2</sub> or CO; A represents an optionally substituted aromatic group; R<sub>1</sub> and R<sub>2</sub> are the same or different and each represents CO or CR<sub>2</sub> (wherein two R's are the same or different and each represents hydrogen, hydroxy or C<sub>1</sub>-6 hydrocarbyl); and R<sub>3</sub> and R<sub>4</sub> are the same or different and each represents optionally substituted C<sub>1</sub>-12 hydrocarbyl] are prepared. These compds. inhibit the calcium ion channel-opening function of an NMDA receptor and thus the excessive influx of calcium ions through NMDA which result in nerve cell death and are useful as cell death inhibitors and brain function protectors in treating and preventing various diseases induced by abnormal excitatory nerve transmission. Thus, p-(HO<sub>2</sub>CCH<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-p-C<sub>6</sub>H<sub>4</sub>(OCH<sub>2</sub>CO<sub>2</sub>H) (preparation given), p-(H<sub>2</sub>NCH<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-p-C<sub>6</sub>H<sub>4</sub>(OCH<sub>2</sub>NH<sub>2</sub>) (preparation given), and Et<sub>3</sub>N were added to CH<sub>2</sub>Cl<sub>2</sub> and refluxed for 24 h followed by reduction of the resulting cyclic diamide (69% yield) with borane-dimethyl sulfide complex in THF under reflux for 24 h to give 83% cyclic diamine (II; R = H). II (R = H) was amidated with [4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH<sub>2</sub>Cl<sub>2</sub> at room temperature

for 12 h to give II (R = Q; R<sub>5</sub> = Boc) which was treated with a mixture of 30% aqueous HCl solution and THF at room temperature for 12 h to give II.8HCl (R = Q; R<sub>5</sub> = H). II.8HCl (R = Q; R<sub>5</sub> = H) markedly inhibited the NMDA receptor expressed in oocytes of South African clawed frog (*Xenopus laevis*).  
 IT 603956-15-6P, Bis[4-(2-aminoethoxy)phenyl]methane  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of novel nitrogen-containing cyclic compds. as NMDA receptor inhibitors, cell death inhibitors, and brain function protectors for treating and preventing various diseases induced by abnormal excitatory nerve transmission)  
 RN 603956-15-6 CAPLUS  
 CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:868472 CAPLUS  
 DN 139:351737  
 TI Lubricants having nitrogen-containing fatty esters for production of carbon fibers  
 IN Usui, Tatsuya; Komatsu, Yukio  
 PA Takemoto Oil and Fat Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003313776	A2	20031106	JP 2002-117430	20020419
				JP 2002-117430	20020419

OS MARPAT 139:351737

AB The lubricant contains at least one of nitrogen-containing compds. selected from (I) polyglycidylamine fatty acid esters, (II) triglycidyl isocyanurate fatty acid esters, and (III) amino compds. derived from reaction products of aromatic polyglycidyl compds. and aliphatic amines. Thus, a lubricant was synthesized by reacting tetraglycidylaminodiphenylmethane 422 g (1 mol) with lauric acid 800 g (4 mol) in the presence of triethanolamine 0.6 g under nitrogen atmospheric at 100° for 10 h. The lubricant exhibits excellent fire resistance, contaminant prevention and cohesive prevention during carbonization in the baking furnace.


IT 618445-16-2P 618445-17-3P

RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)


(production of lubricants having nitrogen-containing fatty esters for production of carbon fibers)

RN 618445-16-2 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(dodecylamino)- (9CI) (CA INDEX NAME)





PAGE 1-B



RN 618445-17-3 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(13-docosenylamino)- (9CI) (CA INDEX NAME)]





L17 ANSWER 7 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:757516 CAPLUS

DN 139:261334

TI Cyclic ether amine derivatives as medicaments for malignant tumors

IN Miyake, Muneharu

PA Nihon University, Japan

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003077906	A1	20030925	WO 2002-JP2540	20020318
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
WO 2003078410	A1	20030925	WO 2002-JP10039	20020927
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
JP 2005526774	T2	20050908	WO 2002-JP2540	A 20020318
			JP 2003-576416	20020927
			WO 2002-JP2540	A 20020318
			WO 2002-JP10039	W 20020927


OS MARPAT 139:261334

AB This invention relates to cyclic ether amine derivs. (I) or salts thereof and also to medicaments comprising the derivs. or salts, wherein Y1 and Y2 may be the same or different and = O atom or two H atoms, and R1 and R2 may be the same or different and = H atom or a (un)substituted alkyl group. I according to the present invention have reparative effect for an abnormality in the expression of c-fos in neuroblastomas or the like and are useful as remedies for various malignant tumors. For example, I.2C1 (R1 = R2 = CH2CH2CH2-4-C5NH4; Y1 = Y2 = O) was prepared in a multistep process starting from 4,4'-dihydroxydiphenylethane and MeO2CHBr and K2CO3 in DMF to give methylene bis(phenoxyacetic acid) which was coupled with bis(4-aminoethoxyphenyl)methane to give the cyclic ether amine derivative which was further treated to give the desired product in 100 % yield.

IT 603956-15-6P



RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of cyclic ether amine derivs. as antitumor agents)  
 RN 603956-15-6 CAPLUS  
 CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:315710 CAPLUS

DN 139:396485

TI Impact-resistant polyurethane based on caprolactam-blocked diisocyanate-biphenol A diglycidyl ether adduct and method of its synthesis

IN Komarov, B. A.; Dzhavadyan, Eh. A.; Perekhrest, A. I.; Hybrechts, Josef; Rozenberg, B. A.

PA Institut Problem Khimicheskoi Fiziki RAN, Russia

SO Russ., No pp. given

CODEN: RUXXE7

DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RU 2194724	C2	20021220	RU 2000-119883 RU 2000-119883	20000726 20000726

AB The invention describes an impact-resistant material comprising modified polyurethane based on a bisphenol A diglycidyl ether of an hydroxy-containing monoamine (preferably monoethanolamine) adduct with ε-caprolactam-blocked diisocyanate (4,4'-diisocyanatocyclohexylmethane preferred) taken in the mole ratio = (1-2):1, resp., and method of its synthesis. Varying functional group ratio and modifying agent content, a 4-6-fold increase in viscous destruction energy as compared to epoxy-amine polymers can be achieved.

IT 625812-56-8P

RL: IMF (Industrial manufacture); POF (Polymer in formulation); PRP (Properties); PREP (Preparation); USES (Uses)

(impact-resistant polyurethane based on caprolactam-blocked diisocyanate-biphenol A diglycidyl ether adduct and method of its synthesis)

RN 625812-56-8 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-, polymer with 1,1'-methylenebis[4-isocyanatocyclohexane] (9CI) (CA INDEX NAME)

CM 1


CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A




PAGE 1-B



CM 2

CRN 5124-30-1

CMF C15 H22 N2 O2



IT 106056-71-7P


RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(monomer; impact-resistant polyurethane based on caprolactam-blocked diisocyanate-biphenol A diglycidyl ether adduct and method of its synthesis)


RN 106056-71-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 9 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:813707 CAPLUS

DN 138:91449

TI Synthesis, characterization, and coating application of novel polyamines

AU Patel, Sanjay V.; Patel, Pritesh G.; Patel, Girish R.

CS Sophisticated Instrumentation Centre for Applied Research and Testing (SICART), Charutar Vidya Mandal (CVM), Vallabh Vidyanagar, 388120, India

SO International Journal of Polymeric Materials (2002), 51(11), 1019-1030

CODEN: IJPMCS; ISSN: 0091-4037

PB Taylor & Francis Ltd.

DT Journal

LA English

AB A series of novel polyamine resins were synthesized by the preparation of ketimine terminated resins from ketimine blocked diethylene triamine (I) and bisester derivative (II) of epoxy resin and subsequent hydrolysis. I was synthesized by the condensation reaction of diethylene triamine with Me iso-Bu ketone. II was synthesized by the reaction of epoxy resin (DGEBA) with amino Et benzoate (AEB). The hydrolysis of ketimine containing resin was evaluated by the change in pH value of the reaction mixture, and by IR spectroscopy and gel permeation chromatog. of the resulting product. The thermal stability and coating properties of the synthesized polyamines were studied in some detail. The hydrolytic rate of ketimine increased with increasing temperature or the amount of added acid.

IT 179727-40-3P 482661-91-6P 482661-92-7P

482661-93-8P 482661-94-9P 482661-95-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; synthesis, characterization, and coating application of novel polyamines)


RN 179727-40-3 CAPLUS

CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 482661-91-6 CAPLUS


CN Benzoic acid, 3,3'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-

propanediyl)imino]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 482661-92-7 CAPLUS  
CN Benzoic acid, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 482661-93-8 CAPLUS  
CN Benzamide, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis[2-[(1,3-dimethylbutylidene)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 482661-94-9 CAPLUS  
 CN Benzamide, 3,3'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis[2-[(1,3-dimethylbutylidene)amino]ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 482661-95-0 CAPLUS  
 CN Benzamide, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis[2-[(1,3-dimethylbutylidene)amino]ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 482661-99-4P 482662-00-0P 482662-01-1P  
 482662-02-2P 482662-03-3P 482662-04-4P


RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
 (synthesis, characterization, and coating application of novel polyamines)

RN 482661-99-4 CAPLUS  
 CN Benzamide, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)


CM 1

CRN 482661-96-1  
CMF C43 H60 N8 O6

PAGE 1-A




PAGE 1-B



CM 2

CRN 1675-54-3  
CMF C21 H24 O4




RN 482662-00-0 CAPLUS  
CN Benzamide, 3,3'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)


CM 1

CRN 482661-97-2  
CMF C43 H60 N8 O6


PAGE 1-A



PAGE 1-B




CM 2

 CRN 1675-54-3  
 CMF C21 H24 O4

 RN 482662-01-1 CAPLUS  
 CN Benzamide, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with  
 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane]  
 (9CI) (CA INDEX NAME)

CM 1


 CRN 482661-98-3  
 CMF C43 H60 N8 O6

PAGE 1-A






PAGE 1-B



CM 2

CRN 1675-54-3  
CMF C21 H24 O4




RN 482662-02-2 CAPLUS  
CN Benzamide, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with  
N-[4-(oxiranylmethoxy)phenyl]-N-(oxiranylmethyl)oxiranemethanamine (9CI)  
(CA INDEX NAME)


CM 1

CRN 482661-96-1  
CMF C43 H60 N8 O6


PAGE 1-A



PAGE 1-B



CM 2


CRN 5026-74-4  
CMF C15 H19 N O4

RN 482662-03-3 CAPLUS  
 CN Benzamide, 3,3'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with  
 N-[4-(oxiranylmethoxy)phenyl]-N-(oxiranylmethyl)oxiranemethanamine (9CI)  
 (CA INDEX NAME)


CM 1

CRN 482661-97-2  
CMF C43 H60 N8 O6

PAGE 1-A




PAGE 1-B



CM 2

CRN 5026-74-4

CMF C15 H19 N O4




RN 482662-04-4 CAPLUS  
 CN Benzamide, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)-, polymer with  
 N-[4-(oxiranylmethoxy)phenyl]-N-(oxiranylmethyl)oxiranemethanamine (9CI)  
 (CA INDEX NAME)


CM 1

CRN 482661-98-3

CMF C43 H60 N8 O6


PAGE 1-A






CM 2


CRN 5026-74-4  
CMF C15 H19 N O4



IT **482661-96-1P 482661-97-2P 482661-98-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis, characterization, and coating application of novel  
 polyamines)  
 RN 482661-96-1 CAPLUS  
 CN Benzamide, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-  
 propanediyl)imino]]bis[N,N-bis(2-aminoethyl)- (9CI) (CA INDEX NAME)




PAGE 1-B




RN 482661-97-2 CAPLUS  
 CN Benzamide, 3,3'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 482661-98-3 CAPLUS  
 CN Benzamide, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[N,N-bis(2-aminoethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:779487 CAPLUS

DN 138:56650

TI Synthesis of amine-cured, epoxy-layered silicate nanocomposites: the influence of the silicate surface modification on the properties

AU Kornmann, Xavier; Thomann, Ralph; Mulhaupt, Rolf; Finter, Jurgen; Berglund, Lars

CS Division of Polymer Engineering, Lulea University of Technology, Lulea, S-97187, Swed.

SO Journal of Applied Polymer Science (2002), 86(10), 2643-2652

CODEN: JAPNAB; ISSN: 0021-8995

PB John Wiley & Sons, Inc.

DT Journal

LA English

AB Fluorohectorites were rendered organophilic through the cation exchange of sodium intergallery cations for protonated monoamine, diamine, and triamine oligopropyleneoxides and octadecylamine, benzylamine, and adducts of octadecylamine and benzylamine with diglycidyl ether of bisphenol A (DGEBA). The influence of the silicate surface modification and compatibility on the morphol. and thermal and mech. properties was examined. Surface modification with protonated octadecylamine and its adduct with DGEBA promoted the formation of microscale domains of silicate layers separated by more than 50 Å, as evidenced by TEM and wide-angle x-ray scattering. Young's modulus of these two nano-composites increased parabolically with the true silicate content, whereas conventionally filled composites exhibited a linear relation. The highest fracture toughness was observed for conventionally filled composites.


IT 479255-71-5P 479255-72-6P

RL: CPS (Chemical process); MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); USES (Uses)


(silicate surface modifier, ion exchange with somasif ME 100 fir intercalating; preparation of bisphenol A diglycidyl ether-amine adduct for synthesis of epoxy-layered silicate nanocomposites)

RN 479255-71-5 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(octadecylamino)- (9CI) (CA INDEX NAME)



PAGE 1-B



RN 479255-72-6 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-  
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



PAGE 1-B



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:234057 CAPLUS  
 DN 136:403504  
 TI Synthesis and characterization of a cationic Gemini surfactant  
 AU Chen, Gong; Huang, Peng-Cheng; Ma, Yun-Rong; Qi, Guo-Ping  
 CS College of Material Science and Engineering, Beijing University of  
 Aeronautics and Astronautics, Beijing, 100083, Peop. Rep. China  
 SO Shiyou Huagong (2002), 31(3), 194-197  
 CODEN: SHHUE8; ISSN: 1000-8144  
 PB Shiyou Huagong Bianjibu  
 DT Journal  
 LA Chinese  
 AB A novel Gemini surfactant with two lipophilic groups and two hydrophilic  
 groups was synthesized using trimethylamine, epichlorohydrin, and  
 bis(2-hydroxy-5-nonylphenyl) methane which was prepared from p-nonylphenol


and formaldehyde. The structure of this Gemini surfactant was characterized by elemental anal., IR and <sup>1</sup>H NMR. The good surface activities of the surfactant was shown obviously by measurement of surface tension and critical micelle concns. in aqueous solution

IT **430474-45-6P**

RL: IMF (Industrial manufacture); PREP (Preparation)  
(synthesis and characterization of a cationic Gemini surfactant)

RN 430474-45-6 CAPLUS

CN 1-Propanaminium, 3,3'-[methylenebis[(4-nonyl-2,1-phenylene)oxy]]bis[2-hydroxy-N,N,N-trimethyl-, dichloride (9CI) (CA INDEX NAME)



● 2 Cl<sup>-</sup>

L17 ANSWER 12 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:171852 CAPLUS

DN 136:216528

TI Preparation of linked benzene derivatives as sodium channel modulators

IN Chinn, Jason P.; Choi, Seok-ki; Fatheree, Paul R.; Marquess, Daniel;  
Turner, S. Derek

PA Advanced Medicine, Inc., USA

SO PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018334	A2	20020307	WO 2001-US27128	20010830
	WO 2002018334	A3	20020613		
	WO 2002018334	B1	20020926		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2000-229572P	P 20000831
	AU 2001086965	A5	20020313	AU 2001-86965	20010830
				US 2000-229572P	P 20000831
				WO 2001-US27128	W 20010830
		US 2003027822	A1	20030206	US 2001-943420
	US 6756400	B2	20040629		



US 2004204460

A1

20041014

US 2000-229572P

P 20000831

US 2004-824738

20040415

US 2000-229572P

P 20000831

US 2001-943420

A3 20010830

OS MARPAT 136:216528

AB Title compds. I [R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, etc.; R2 = bond, (un)substituted alkylene; X = O, NRm wherein Rm = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -heteroaryl, etc.; Y = (un)substituted amine or a (un)substituted heterocyclyl containing at least one N, wherein each nitrogen of the heterocyclyl is substituted with R3 or is linked to R2; R3 = H, alkyl, aryl, oxo, heterocyclyl, etc., or R3 is joined to another substituent of Y to form a (un)substituted C1-4 alkylene group; Q = O, S(O)m, (CR5R6)w, O(CR5R6)rO, N(Rk) where m = 0-2, w = 1-3, r = 2-3; Rk = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; R5 and R6 are independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; or R5 and R6 together with the carbon atom to which they are attached may form a (un)substituted-cycloalkyl or -heterocyclyl; p = 0-4] and their pharmaceutically acceptable salts are prepared and disclosed as sodium channel modulators. Thus, II was prepared from 4,4'-methylenebis(2,6-dimethylphenol) and N-Boc-3-(hydroxymethyl)piperidine under Mitsunobu conditions with successive N-deprotection. As sodium channel modulators, I are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. II exhibited an IC50 value of less than 100  $\mu$ M in a rat cerebellar granule neuron assay. The invention also provides pharmaceutical compns. comprising a compound of formula (I) or a salt thereof, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e.g. a human).

IT 402759-72-2P 402759-73-3P 402759-74-4P

402759-76-6P 402759-81-3P 402759-82-4P

402759-97-1P 402760-02-5P 402760-07-0P

402760-42-3P 402760-44-5P 402760-62-7P

402760-65-0P 402760-77-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of linked benzene derivs. via Mitsunobu reaction of linked phenols with the requisite alc.)

RN 402759-72-2 CAPLUS

CN 2-Propanamine, 1,1'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, (2S,2'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 402759-73-3 CAPLUS

CN 2-Propanamine, 1,1'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, (2R,2'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 402759-74-4 CAPLUS  
 CN 1-Pentanamine, 4,4'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




RN 402759-76-6 CAPLUS  
 CN 1-Propanamine, 2,2'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis[N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 402759-81-3 CAPLUS  
 CN Ethanamine, 2,2'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis[N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 402759-82-4 CAPLUS  
 CN Ethanamine, 2,2'-[methylenebis[(2,6-dimethyl-4,1-phenylene)oxy]]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




RN 402759-97-1 CAPLUS  
 CN 1-Pentanamine, 4,4'-[(1-methylethylidene)bis[(2-methyl-4,1-phenylene)oxy]]bis[N,N-diethyl]- (9CI) (CA INDEX NAME)



RN 402760-02-5 CAPLUS  
 CN 1-Propanamine, 2,2'-[(1-methylethylidene)bis[(2-methyl-4,1-phenylene)oxy]]bis[N,N-dimethyl]- (9CI) (CA INDEX NAME)




RN 402760-07-0 CAPLUS  
 CN 1-Propanamine, 2,2'-[1,2-ethanediylbis[(2,6-dimethyl-4,1-phenylene)oxy]]bis[N,N-dimethyl]- (9CI) (CA INDEX NAME)




RN 402760-42-3 CAPLUS  
 CN 2-Propanamine, 1,1'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis-, (2S,2'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 402760-44-5 CAPLUS  
 CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




RN 402760-62-7 CAPLUS  
 CN 1-Pentanamine, 4,4'-[methylenebis[(2-chloro-4,1-phenylene)oxy]]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



RN 402760-65-0 CAPLUS  
 CN 1-Propanamine, 2,2'-[methylenebis[(2-chloro-4,1-phenylene)oxy]]bis[N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 402760-77-4 CAPLUS  
 CN 1-Propanamine, 2,2'-[methylenebis[(4-methyl-2,1-phenylene)oxy]]bis[N,N-dimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:932572 CAPLUS  
 DN 136:55382  
 TI Ink and apparatus for ink-jet recording  
 IN Soga, Masamori; Tachikawa, Masaichiro; Shingae, Ryuichi  
 PA Matsushita Electric Industrial Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 5 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001354882	A2	20011225	JP 2000-176410 JP 2000-176410	20000613 20000613

OS MARPAT 136:55382  
 AB An ink-jet printing ink comprising dyes, a wetting agent, a penetrating agent, and water is characterized by containing additive  $RC_6H_4C(R')(R')C_6H_4R$  ( $C_6H_4$  = p-phenylene; R, R' = substituent). A recording apparatus using the ink is also claimed.  
 IT **383193-40-6**  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (ink and apparatus for ink-jet recording)  
 RN 383193-40-6 CAPLUS  
 CN Methanamine, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
 (CA INDEX NAME)



L17 ANSWER 14 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:519165 CAPLUS  
 DN 135:108694  
 TI Manufacture of gas-barrier films  
 IN Yamamoto, Tetsuya; Takagi, Hiroyuki; Miyake, Ryuta; Maruyama, Toshihide  
 PA Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan; Daicel Chemical Industries, Ltd.  
 SO Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001192485	A2	20010717	JP 2000-5185	20000114
				JP 2000-5185	20000114

OS MARPAT 135:108694

AB Title films are prepared by coating base films with compns. containing (a) functional silane-terminated organic chains Q1NR1ANR2Q2 [A = divalent aromatic group; R1, R2 = H or alkyl; Q1 = (CH<sub>2</sub>)<sub>a</sub>Si(OR<sub>3</sub>)<sub>3</sub>; Q2 = (CH<sub>2</sub>)<sub>b</sub>Si(OR<sub>4</sub>)<sub>3</sub> with R3, R4 = H, alkyl, acyl; a, b = 1-3], (b) R64-nSi(OR<sub>5</sub>)<sub>n</sub> (R5 = H, alkyl, acyl; R6 = H, alkyl aromatic group; n = 2-4) silanes or silane couplers, and solvents at 10-40° under atom. containing water content of 0.006-0.014 kg/kg. An elec. corona-treated drawn PET film was coated with a composition comprising 2:1 3-aminopropyltrimethoxysilane-resorcinol diglycidyl ether adduct 100, Si(OMe)<sub>4</sub> 250, and MeOH 3,150 parts at 25° and air water content of 0.010 kg/kg to 2-μm thickness and naturally dried to form a film with interlayer adhesion 230 g/15 mm and 80% relative humidity (RH) 0 permeability 10 initially, which were changed to 200 and 14, resp., after soaking in 100° water for 30 min.


IT 117701-78-7P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


(aromatic compound/aminoalkylalkoxysilane adduct-based siloxane gas-barrier coatings applied at controlled conditions for plastic film packagings)

RN 117701-78-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]]- (9CI) (CA INDEX NAME)



PAGE 1-B



L17 ANSWER 15 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:514881 CAPLUS

DN 135:93645

TI Gas- and water vapor-barrier composite films

IN Yamamoto, Tetsuya; Yokoe, Kazuo; Miyake, Ryuta; Maruyama, Toshihide

PA Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan; Daicel Chemical Industries, Ltd.

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001191445	A2	20010717	JP 2000-3773 JP 2000-3773	20000112 20000112

AB The films have coating layers formed by reaction of organic chain-containing silane monomers having functional end groups at both ends with silanes on inorg. thin-film layers on one or both sides of substrate films. Thus, a biaxially oriented PET film was corona discharge-treated, coated with SiO<sub>2</sub> by vapor deposition, and coated with a composition containing a silane monomer (prepared from  $\gamma$ -aminopropyltrimethoxysilane and resorcinol diglycidyl ether) and Si(OMe)<sub>4</sub> to give a transparent film showing 0 permeability (20°, relative humidity 80%) 2 mL/m<sup>2</sup>-24 h and water vapor permeability (40°, relative humidity 90%) 2 g/m<sup>2</sup>-24 h after 30-min storage in boiling water at 100°.

IT **309255-27-4P 349542-47-8P**  
 RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
 (gas- and water vapor-barrier composite films having oxide and silane coating layers)



RN 309255-27-4 CAPLUS

CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), tetramethyl ester, polymer with  
 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]-2-propanol] (9CI) (CA INDEX NAME)

CM 1

CRN 117701-78-7


CMF C33 H58 N2 O10 Si2



CM 2

CRN 681-84-5

CMF C4 H12 O4 Si




RN 349542-47-8 CAPLUS  
 CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), tetramethyl ester, polymer with  
 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-  
 (trimethoxysilyl)propyl]amino]-2-propanol] and 3-(trimethoxysilyl)-1-  
 propanamine (9CI) (CA INDEX NAME)


CM 1

CRN 117701-78-7

CMF C33 H58 N2 O10 Si2




PAGE 1-B



CM 2

CRN 13822-56-5

CMF C6 H17 N O3 Si




CM 3

CRN 681-84-5

CMF C4 H12 O4 Si






IT 117701-78-7P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
(gas- and water vapor-barrier composite films having oxide and silane coating layers)


RN 117701-78-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 16 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:833141 CAPLUS

DN 134:18247

TI Oxygen-barrier plastic films for packagings

IN Yamamoto, Tetsuya; Takagi, Hiroyuki; Miyake, Ryuta; Maruyama, Toshihide

PA Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan; Daicel Chemical Industries, Ltd.

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000326448	A2	20001128	JP 1999-142965	19990524
	CN 1274733	A	20001129	CN 2000-108954	20000523
				JP 1999-142965	A 19990524
				JP 1999-142966	A 19990524

PATENT FAMILY INFORMATION:

FAN 2000:828925

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000327817	A2	20001128	JP 1999-142966	19990524

CN 1274733 A 20001129 CN 2000-108954 20000523  
 JP 1999-142965 A 19990524  
 JP 1999-142966 A 19990524

AB The O-barrier plastic films have coatings exhibiting O permeability 0.1-100 mL/m<sup>2</sup>-24-h at 20, 40, 60, and 80° (temperature measured on coating sides) and formed by reaction of organic chain-containing silane

monomers

with functional terminals on both ends and silanes. The films are suitable for packagings for foods, medicines, sanitary goods, etc. Thus, 1 mol  $\gamma$ -aminopropyltrimethoxysilane and 0.5 mol resorcinol diglycidyl ether were reacted at 50-70° to give (MeO)<sub>3</sub>Si(CH<sub>2</sub>)<sub>3</sub>NHCH<sub>2</sub>CH(OH)CH<sub>2</sub>O-m-C<sub>6</sub>H<sub>4</sub>-OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NH(CH<sub>2</sub>)<sub>3</sub>Si(OMe)<sub>3</sub>, mixed with (EtO)<sub>4</sub>Si at ratio 100:250, applied on a biaxially oriented polypropylene film (20- $\mu$ m thick), and dried to give a 22- $\mu$ m thick barrier film having excellent O barrier property and coating adhesion initially and after 30 min in boiling water, resp.


IT 117701-78-7P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


(monomers; O-barrier plastic films with silsesquioxane-silicate-type O barrier coatings for packagings)

RN 117701-78-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-B



IT 309255-27-4P 309255-29-6P

RL: FFD (Food or feed use); IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(silicate-containing; O-barrier plastic films with silsesquioxane-silicate-type O barrier coatings for packagings)

RN 309255-27-4 CAPLUS


CN silicic acid (H<sub>4</sub>SiO<sub>4</sub>), tetramethyl ester, polymer with 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]-2-propanol] (9CI) (CA INDEX NAME)

CM 1


CRN 117701-78-7

CMF C33 H58 N2 O10 Si2

PAGE 1-A




PAGE 1-B



CM 2

CRN 681-84-5  
CMF C4 H12 O4 Si





RN 309255-29-6 CAPLUS  
CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), tetramethyl ester, polymer with  
1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]-2-propanol] and 3-(trimethoxysilyl)-1-propanethiol (9CI) (CA INDEX NAME)

CM 1

CRN 117701-78-7  
CMF C33 H58 N2 O10 Si2

PAGE 1-A






CM 2

CRN 4420-74-0


CMF C6 H16 O3 S Si



CM 3

CRN 681-84-5

CMF C4 H12 O4 Si



L17 ANSWER 17 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:828925 CAPLUS

DN 134:18604

TI Gas-barrier and moisture-proof films

IN Yamamoto, Tetsuya; Takagi, Hiroyuki; Miyake, Ryuta; Maruyama, Toshihide

PA Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan; Daicel Chemical Industries, Ltd.

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese



FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000327817	A2	20001128	JP 1999-142966	19990524
	CN 1274733	A	20001129	CN 2000-108954	20000523
				JP 1999-142965	A 19990524
				JP 1999-142966	A 19990524

PATENT FAMILY INFORMATION:


FAN 2000:833141

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000326448	A2	20001128	JP 1999-142965	19990524




Page 49

PAGE 1-A




PAGE 1-B



CM 2

CRN 681-84-5  
CMF C4 H12 O4 Si





RN 309255-29-6 CAPLUS  
CN silicic acid (H4SiO4), tetramethyl ester, polymer with  
1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-  
(trimethoxysilyl)propyl]amino]-2-propanol] and 3-(trimethoxysilyl)-1-  
propanethiol (9CI) (CA INDEX NAME)

CM 1

CRN 117701-78-7  
CMF C33 H58 N2 O10 Si2

PAGE 1-A






CM 2

CRN 4420-74-0


CMF C6 H16 O3 S Si



CM 3

CRN 681-84-5

CMF C4 H12 O4 Si



L17 ANSWER 18 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:27390 CAPLUS

DN 132:167012

TI Study on novel polyamides based on ester terminated epoxy resin

AU Patel, Sanjay V.; Raval, Dipak K.; Thakkar, Jatin R.

CS Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar, 388 120, India

SO High Performance Polymers (1999), 11(4), 467-475

CODEN: HPPOEX; ISSN: 0954-0083

PB Institute of Physics Publishing

DT Journal

LA English

AB A bisester was synthesized by the reaction of the epoxy resin bisphenol A diglycidyl ether (DGEBA) with Et 4-aminobenzoate; this bisester was condensed with different aromatic diamines, namely 4,4'-diaminodiphenylmethane (DDM), 4,4'-diaminodiphenyl sulfone (DDS) and benzidine (Ben) to yield novel epoxy based curing agents. The resultant novel epoxy-based polyamides (PAs) were characterized by IR spectroscopy along with the estimation of number average mol. weight (Mn) by gel permeation chromatog.

(GPC). Using differential scanning calorimetry (DSC), the kinetics of the curing reactions of the obtained PAs used as curing agents for DGEBA epoxy resin systems were established by evaluating the usual kinetic parameters.

The thermal behavior of PAs-epoxy cured products was also studied by thermogravimetric anal. (TGA).

IT 259108-62-8P 259108-63-9P 259108-64-0P  
259108-65-1P 259108-66-2P 259108-67-3P

RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(crosslinker; preparation of novel polyamides based on ester-terminated epoxy resin and their use as crosslinkers for epoxy resins)

RN 259108-62-8 CAPLUS


CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with [1,1'-biphenyl]-4,4'-diamine (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B



CM 2

CRN 92-87-5

CMF C12 H12 N2




RN 259108-63-9 CAPLUS

CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)imino-1,4-phenylenecarbonylimino[1,1'-biphenyl]-4,4'-diyliminocarbonyl-1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)] (9CI)




(CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 259108-64-0 CAPLUS  
 CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 4,4'-methylenebis[benzenamine] (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
 CMF C39 H46 N2 O8


PAGE 1-A



PAGE 1-B




CM 2


CRN 101-77-9  
CMF C13 H14 N2

RN 259108-65-1 CAPLUS  
CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)imino-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)]  
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 259108-66-2 CAPLUS  
CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 4,4'-sulfonylbis[benzenamine] (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B



CM 2

CRN 80-08-0


CMF C12 H12 N2 O2 S




RN 259108-67-3 CAPLUS

CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)imino-1,4-phenylenecarbonylimino-1,4-phenylenesulfonyl-1,4-phenyleneiminocarbonyl-1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)]  
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

IT **179727-40-3P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(monomer; preparation of novel polyamides based on ester-terminated epoxy resin and their use as crosslinkers for epoxy resins)


RN 179727-40-3 CAPLUS

CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 259108-68-4P 259108-69-5P 259108-70-8P

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)  
 (preparation of novel polyamides based on ester-terminated epoxy resin and their use as crosslinkers for epoxy resins)

RN 259108-68-4 CAPLUS


CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with [1,1'-biphenyl]-4,4'-diamine and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B



CM 2


CRN 1675-54-3

CMF C21 H24 O4



CM 3

CRN 92-87-5  
CMF C12 H12 N2




RN 259108-69-5 CAPLUS  
CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 4,4'-methylenebis[benzenamine] and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B



CM 2


CRN 1675-54-3

CMF C21 H24 O4



CM 3

CRN 101-77-9  
CMF C13 H14 N2




RN 259108-70-8 CAPLUS  
CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] and 4,4'-sulfonylbis[benzenamine] (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B




CM 2

CRN 1675-54-3  
CMF C21 H24 O4



CM 3

CRN 80-08-0  
CMF C12 H12 N2 O2 S



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 19 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:708480 CAPLUS

DN 131:323974

TI Ink-jet inks containing photopolymerization initiators and recording method

IN Hiromichi, Noguchi

PA Canon Kabushiki Kaisha, Japan

SO Eur. Pat. Appl., 75 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 953613	A2	19991103	EP 1999-108232	19990427
	EP 953613	A3	20030924		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1998-119358	A 19980428
				JP 1998-295452	A 19981016
				JP 1999-103352	A 19990409
	JP 2000186242	A2	20000704	JP 1999-103352	19990409
	JP 3576862	B2	20041013		
				JP 1998-119358	A 19980428
				JP 1998-295452	A 19981016
	US 6428862	B1	20020806	US 1999-294333	19990420
				JP 1998-119358	A 19980428
				JP 1998-295452	A 19981016
				JP 1999-103352	A 19990409
	JP 2000186243	A2	20000704	JP 1999-295609	19991018
				JP 1998-295452	A 19981016



US 2002064603	A1	20020530	US 2001-978104	20011017
US 6500875	B2	20021231		
			JP 1998-119358	A 19980428
			JP 1998-295452	A 19981016
			JP 1999-103352	A 19990409
			US 1999-294333	A3 19990420
JP 2004204240	A2	20040722	JP 2004-64691	20040308
			JP 1998-119358	A 19980428
			JP 1998-295452	A 19981016
			JP 1999-103352	A3 19990409

OS MARPAT 131:323974

AB An ink for ink-jet recording contains a coloring agent, a polymerizable oligomer, water, and a photopolymn. initiator having a solubility in water of 3 percent by weight or more. Another ink for ink-jet recording contains a coloring agent, a polymerizable oligomer having at least two acryloyl groups and a solubility in water of 10 percent by weight or more, a photopolymn.

initiator, and water. The specified polymerizable oligomer or photopolymn. initiator reduces bleeding of the ink on recording media.


IT 249304-66-3

RL: TEM (Technical or engineered material use); USES (Uses)  
(ink-jet inks containing photopolymn. initiators and recording method)


RN 249304-66-3 CAPLUS

CN 1-Propanaminium, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[2-hydroxy-N,N-dimethyl-N-[2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl]-, dichloride (9CI) (CA INDEX NAME)

PAGE 1-A

● 2 Cl<sup>-</sup>

PAGE 1-B



L17 ANSWER 20 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:268334 CAPLUS

DN 129:8587

TI Method and compositions for disrupting the epithelial barrier function  
IN Elias, Peter M.; Feingold, Kenneth R.; Holleran, Walter M.; Thornfeldt, Carl R.

PA Regents of the University of California, USA; Cellegy Pharmaceuticals,

Inc.  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817253	A1	19980430	WO 1997-US19343	19971022
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9749193	A1	19980515	US 1996-733712	A 19961023
				AU 1997-49193	19971022
				US 1996-733712	A 19961023
	US 6190894	B1	20010220	WO 1997-US19343	W 19971022
				US 1998-58401	19980409
				US 1993-33811	B2 19930319
				US 1994-260559	B2 19940616
				US 1996-733712	B1 19961023
	US 6562606	B1	20030513	US 2000-608568	20000630
				US 1993-33811	B2 19930319
				US 1994-260559	B2 19940616
				US 1996-733712	B1 19961023
				US 1998-58401	A1 19980409

## PATENT FAMILY INFORMATION:

FAN 1994:686617

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421271	A1	19940929	WO 1994-US3085	19940321
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	IL 109036	A1	19981227	US 1993-33811	A 19930319
				IL 1994-109036	19940318
				US 1993-33811	A 19930319
	AU 9464136	A1	19941011	AU 1994-64136	19940321
				US 1993-33811	A 19930319
				WO 1994-US3085	W 19940321
	EP 693932	A1	19960131	EP 1994-911673	19940321
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
				US 1993-33811	A 19930319
				WO 1994-US3085	W 19940321
	US 6190894	B1	20010220	US 1998-58401	19980409
				US 1993-33811	B2 19930319
				US 1994-260559	B2 19940616
				US 1996-733712	B1 19961023
	US 6562606	B1	20030513	US 2000-608568	20000630
				US 1993-33811	B2 19930319
				US 1994-260559	B2 19940616
				US 1996-733712	B1 19961023
				US 1998-58401	A1 19980409

AB Epithelial barrier function is disrupted in a host in need of topical administration of a physiol. active substance by applying to the epithelium a barrier-disrupting amount of  $\geq 1$  agent selected from (1)

inhibitors of synthesis of ceramides, acylceramides, glucosylceramides, sphingomyelins, fatty acids, or cholesterol; (2) degradation enzymes for ceramides, acylceramides, glucosylceramides, or sphingomyelins; (3) inhibitors of degradation of phospholipids, glycosphingolipids, glucosylceramides, acylceramides, or sphingomyelins; and (4) inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramides, and cholesterol. Thus, a combination of 5-tetradecyloxy-2-furancarboxylic acid (an inhibitor of acetyl-CoA carboxylase which is the rate-limiting enzyme in free fatty acid synthesis) and  $\beta$ -chloroalanine (an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in ceramide synthesis) increased delivery of lidocaine through mouse stratum corneum by 8-fold in vivo and increased transepidermal water loss. Thus, a combination of 5-tetradecyloxy-2-furancarboxylic acid (an inhibitor of acetyl-CoA carboxylase which is the rate-limiting enzyme in free fatty acid synthesis) and  $\beta$ -chloroalanine (an inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in ceramide synthesis) increased delivery of lidocaine through mouse stratum corneum by 8-fold in vivo and increased transepidermal water loss.


IT 207351-41-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and compns. for disrupting the epithelial barrier function)

RN 207351-41-5 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)di-4,1-phenyleneoxy]bis-(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 21 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:241516 CAPLUS

DN 129:23379

TI Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes

AU Berson, Alain; De Beco, Virginie; Letteron, Philippe; Robin, Marie Anne; Moreau, Claire; El Kahwaji, Johny; Verthier, Nicole; Feldmann, Gerard; Fromentry, Bernard; Pessayre, Dominique

CS INSERM Unite 481 and Centre de Recherche sur les Hepatites Virales (Association Claude Bernard), Hopital Beaujon, Clichy, Fr.

SO Gastroenterology (1998), 114(4), 764-774

CODEN: GASTAB; ISSN: 0016-5085

PB W. B. Saunders Co.

DT Journal

LA English

AB 4,4'-Diethylaminoethoxyhexestrol (DEAEH), amiodarone, and perhexiline cause steatohepatitis in humans. The mechanisms of these effects are unknown for DEAEH and have not been completely elucidated for amiodarone and perhexiline. The aim of this study was to determine these mechanisms. Rat liver mitochondria, cultured rat hepatocytes, or rats were treated with these drugs, and the effects on mitochondrial respiration,  $\beta$ -oxidation, reactive oxygen species formation, and lipid peroxidn. were determined. DEAEH accumulated in mitochondria and inhibited carnitine palmitoyl transferase I and acyl-CoA dehydrogenases; it decreased  $\beta$ -oxidation and caused lipid deposits in hepatocytes. DEAEH also inhibited mitochondrial respiration

and decreased ATP levels in hepatocytes. DEAEH, amiodarone, and perhexiline augmented the mitochondrial formation of reactive oxygen species and caused lipid peroxidn. in rats. Like amiodarone and perhexiline, DEAEH accumulates in mitochondria, where it inhibits both  $\beta$ -oxidation (causing steatosis) and respiration. Inhibition of respiration decreases ATP and also increases the mitochondrial formation of reactive oxygen species. The latter oxidize fat deposits, causing lipid peroxidn. We suggest that ATP depletion and lipid peroxidn. may cause cell death and that lipid peroxidn. products may account, in part, for other steatohepatitis lesions.


IT 2691-45-4, 4,4'-Diethylaminoethoxyhexestrol

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidn. in rat hepatocytes)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 22 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:701876 CAPLUS

DN 127:347692

TI Coating composition as ink receiving layer on printing medium and image forming process

IN Noguchi, Hiromichi; Higuma, Masahiko; Sato, Yuko

PA Canon Kabushiki Kaisha, Japan

SO Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 802245	A1	19971022	EP 1997-106173	19970415
	EP 802245	B1	20011205		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
				JP 1996-94058	A 19960416
				JP 1997-39048	A 19970224
				JP 1997-80194	A 19970331
	JP 10292137	A2	19981104	JP 1997-80194	19970331
	JP 3652057	B2	20050525		
				JP 1996-94058	A 19960416
				JP 1997-39048	A 19970224
	KR 228626	B1	19991101	KR 1997-13706	19970415
				JP 1996-94058	A 19960416
				JP 1997-39048	A 19970224
				JP 1997-80194	A 19970331
	CN 1167132	A	19971210	CN 1997-110735	19970416
	CN 1088733	B	20020807		

JP 1996-94058 A 19960416  
 JP 1997-39048 A 19970224  
 JP 1997-80194 A 19970331

## PATENT FAMILY INFORMATION:

FAN 1999:790893

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6001466	A	19991214	US 1997-838122	19970415
				JP 1996-94058	A 19960416
				JP 1997-37048	A 19970224
				JP 1997-80194	A 19970331
	JP 10292137	A2	19981104	JP 1997-80194	19970331
	JP 3652057	B2	20050525		
				JP 1996-94058	A 19960416
				JP 1997-39048	A 19970224

AB A coating composition comprising cationic fine particles of a crosslinked resin, of average particle diameter 0.1-100  $\mu\text{m}$  and a H<sub>2</sub>O absorption capacity  $\leq 25$  times by volume, and a binder resin is coated on a base material film. Thus, a coating composition containing S-lec KX-1 aqueous solution binder and

crosslinked particles prepared by the emulsion polymerization of polyethylene glycol diglycidyl ether dimethylaminoethylacrylate adduct was applied onto PET base layer film (100  $\mu\text{m}$ ) and dried at 120° for 5 min to give a printing sheet for testing ink jet color printing methods for absorbing speed, print evenness, and fastness.


IT 198016-32-9P

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
 (crosslinked, particles; coating composition as ink receiving layer on printing medium)


RN 198016-32-9 CAPLUS

CN 1-Propanaminium, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[2-hydroxy-N,N-dimethyl-N-[2-[(1-oxo-2-propenyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




L17 ANSWER 23 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:303633 CAPLUS


DN 127:3508

TI Drug-induced lipidosi

AU Miki, Hitoshi  
 CS Hyogo Prefectural Nishinomiya Hospital, Japan  
 SO Saishin Naikagaku Taikei (1996), Volume 11, 317-321. Editor(s): Imura, Hiroo. Publisher: Nakayama Shoten, Tokyo, Japan.  
 CODEN: 64JFAS  
 DT Conference; General Review  
 LA Japanese  
 AB A review with 13 refs., on pathol., symptoms, diagnosis, and treatment of lipidoses induced by 4,4'-diethylaminoethoxyhexestrol and other drug.  
 IT **2691-45-4**, 4,4'-Diethylaminoethoxyhexestrol  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (drug-induced lipidoses)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 24 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1997:275923 CAPLUS  
 DN 126:312194  
 TI Effects of almitrine detriazinyl metabolite upon lysosomal alterations on rat cultured macrophages  
 AU Yamanaka, Yoshihiro; Mochizuki, Rika; Takeda, Toshiaki; Izawa, Yoshihiro; Yamaguchi, Itaru; Fujiwara, Kosaku  
 CS Pharmaceutical Development Research Laboratories, Teijin Ltd., Tokyo, 191, Japan  
 SO Journal of Toxicologic Pathology (1996), 9(4), 407-412  
 CODEN: JTPAE7; ISSN: 0914-9198  
 PB Japanese Society of Toxicologic Pathology  
 DT Journal  
 LA English  
 AB Phospholipidosis-inducing effects of difluorobenzhydrylpiperadine (DFBP) on cultured rat peritoneal macrophages were studied as compared with those of several amphiphilic drugs. At 24 h of exposure to DFBP as well as other amphiphilic drugs, intracytoplasmic acid hematin-stained inclusion bodies were dose-dependently produced in macrophages. Electron microscopy showed lamellar inclusion bodies in macrophages exposed to DFBP. Effective concns. for 30% positivity of treated cells were: 0.43  $\mu$ M/diethylaminoethoxyhexestrol, 1.9  $\mu$ M/perhexiline, 2.8  $\mu$ M/quinacrine, 4.3  $\mu$ M/DFBP, 11  $\mu$ M/chlorcyclizine, and 14  $\mu$ M/propranolol. Neither almitrine nor aspirin induced the cytoplasmic inclusion bodies.  
 IT **2691-45-4**, 4,4'-Diethylaminoethoxyhexestrol  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (effects of almitrine detriazinyl metabolite upon lysosomal alterations on rat cultured macrophages)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 25 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:556923 CAPLUS

DN 125:237606

TI Lysosomal storage of sulfated glycosaminoglycans induced by dicationic amphiphilic drug molecules: significance of the central planar ring system

AU Luellmann-Rauch, Renate; von Witzendorff, Burkhard

CS Department Anatomy, University Kiel, Kiel, D-24098, Germany

SO Pharmacology & Toxicology (Copenhagen) (1996), 79(3), 109-113

CODEN: PHTOEH; ISSN: 0901-9928

PB Munksgaard

DT Journal

LA English

AB The immunomodulatory drug tilorone (2,7-bis[2-(diethylamino)ethoxy]fluoren-9-one) and several congeners are known to disturb the lysosomal degradation of sulfated glycosaminoglycans and thereby induce lysosomal storage of glycosaminoglycans in cultured cells and intact organisms. The mols. of tilorone and congeners consist of a planar aromatic ring system sym. substituted with two aliphatic side chains each carrying a protonizable nitrogen. In a previous study it was proposed that non-degradable glycosaminoglycan-drug complexes are formed by electrostatic interactions and that addnl. intermol. interactions between the drug mols. due to electronic coupling of their central planar ring system are important for formation and stabilization of the glycosaminoglycan-drug complexes and thus for the drug side effect in question. The significance of the central planar ring system was tested in the present study by comparing tilorone and the compound bis( $\beta$ -diethylamino-ethylether)hexestrol (DH) with respect to their potencies to cause lysosomal glycosaminoglycan storage in cultured bovine corneal fibroblasts. DH has the same side chains as tilorone, but its central apolar moiety lacks planarity. At a concentration (1.75  $\mu$ M) which did not cause enhanced secretion of the lysosomal enzyme  $\beta$ -hexosaminidase (E.C. 3.2.1.52), DH was significantly less potent than tilorone in causing storage of [ $^{35}$ S]glycosaminoglycans. This is taken as support of the hypothesis that the planar tricyclic ring system is essential for the high potency of tilorone and its congeners to exert this adverse action.


IT 2691-45-4

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(lysosomal storage of sulfated glycosaminoglycans induced by dicationic amphiphilic drug mols. tilorone and its analog)


RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 26 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1996:387625 CAPLUS  
 DN 125:115380  
 TI Novel epoxy-based polyamides. Part 1.  
 AU Baraiya, Rajesh; Thakkar, Jatin R.  
 CS Dep. Chem., Sardar Patel Univ., Gujarat, India  
 SO International Journal of Polymeric Materials (1996), 32(1-4), 119-123  
 CODEN: IJPMCS; ISSN: 0091-4037  
 PB Gordon & Breach  
 DT Journal  
 LA English  
 AB Ethoxycarbonyl-terminated diglycidyl ether of bisphenol A (DGEBA) was prepared by reaction of the DGEBA with Et 4-aminobenzoate. The title polyamides (PAs) were prepared by the condensation of the diester with various aliphatic diamines viz., 1,2-ethylenediamine (EDA), 1,3-propylenediamine (PDA), 1,4-butylenediamine (BDA), and 1,6-hexamethylenediamine (HMDA). The resultant novel epoxy resin based PAs were characterized by IR spectroscopy and number average mol. weight. As produced, polyamides may act as epoxy curing agent. The kinetic study of the PA-epoxy resin system was established by differential scanning calorimetry, and the kinetic parameters were evaluated. Neat PA-epoxy cured products were also characterized by thermogravimetric anal.  
 IT 179727-45-8P 179727-46-9P 179727-47-0P  
 179727-48-1P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crosslinked; preparation, properties, and crosslinking kinetics of epoxy-based polyamide crosslinking agents for epoxy resins)  
 RN 179727-45-8 CAPLUS  
 CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,2-ethanediamine and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 179727-40-3  
 CMF C39 H46 N2 O8

PAGE 1-A








CM 2

CRN 1675-54-3


CMF C21 H24 O4



CM 3

CRN 107-15-3

CMF C2 H8 N2




RN 179727-46-9 CAPLUS


CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] and 1,3-propanediamine (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8





CM 2


CRN 1675-54-3  
CMF C21 H24 O4


CM 3

CRN 109-76-2  
CMF C3 H10 N2

RN 179727-47-0 CAPLUS  
CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,4-butanedi-amine and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3  
CMF C39 H46 N2 O8



CM 2

CRN 1675-54-3


CMF C21 H24 O4



CM 3

CRN 110-60-1

CMF C4 H12 N2




RN 179727-48-1 CAPLUS


CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,6-hexanediamine and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8






CM 2

 CRN 1675-54-3  
 CMF C21 H24 O4


CM 3


 CRN 124-09-4  
 CMF C6 H16 N2


IT 179727-40-3P


 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

 (monomer; preparation, properties, and crosslinking kinetics of epoxy-based  
 polyamide crosslinking agents for epoxy resins)

RN 179727-40-3 CAPLUS

 CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-  
 propanediyl)imino]]bis-, diethyl ester (9CI) (CA INDEX NAME)


PAGE 1-B



IT 179308-77-1P 179308-78-2P 179308-79-3P

179308-80-6P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (oligomeric; preparation, properties, and crosslinking kinetics of epoxy-based polyamide crosslinking agents for epoxy resins)

RN 179308-77-1 CAPLUS


CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,2-ethanediamine (9CI) (CA INDEX NAME)

CM 1


CRN 179727-40-3

CMF C39 H46 N2 O8

PAGE 1-A




PAGE 1-B



CM 2

CRN 107-15-3

CMF C2 H8 N2




RN 179308-78-2 CAPLUS  
 CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,3-propanediamine (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
 CMF C39 H46 N2 O8

PAGE 1-A



PAGE 1-B



CM 2

CRN 109-76-2  
 CMF C3 H10 N2




RN 179308-79-3 CAPLUS  
 CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,4-butanediamine (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
 CMF C39 H46 N2 O8

PAGE 1-A



PAGE 1-B



CM 2

CRN 110-60-1  
CMF C4 H12 N2


H<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>

RN 179308-80-6 CAPLUS  
CN Benzoic acid, 4,4'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis-, diethyl ester, polymer with 1,6-hexanediamine (9CI) (CA INDEX NAME)


CM 1

CRN 179727-40-3  
CMF C39 H46 N2 O8


PAGE 1-A



PAGE 1-B



CM 2


 CRN 124-09-4  
 CMF C6 H16 N2

 IT 179727-41-4P 179727-42-5P 179727-43-6P  
 179727-44-7P

 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (oligomeric; preparation, properties, and crosslinking kinetics of  
 epoxy-based polyamide crosslinking agents for epoxy resins)


RN 179727-41-4 CAPLUS

 CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-  
 propanediyl)imino-1,4-phenylenecarbonylimino-1,2-ethanediyliminocarbonyl-  
 1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 179727-42-5 CAPLUS

 CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-  
 propanediyl)imino-1,4-phenylenecarbonylimino-1,3-propanediyliminocarbonyl-




1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 179727-43-6 CAPLUS  
CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)imino-1,4-phenylenecarbonylimino-1,4-butanediyliminocarbonyl-1,4-phenyleneimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



\*CC(O)CCNC1=CC=C(C=C1)C(=O)NCCCCCNC(=O)C2=CC=C(C=C2)N\*\*CC(O)COc1ccc(cc1)C(C)(C)c2ccc(O\*)cc2

Page 78

and denoting the presence of mobile structures. This non-bilayer signal appeared most prominently when liposomes were incubated with DEH, a strong fusogenic agent. We conclude that aminoglycosides, like spermine, have the potential to prevent membrane fusion, by inhibiting the development of a critical change in membrane organization, which is associated with fusion.

We

suggest that this capacity could be a determinant in aminoglycoside toxicity.


IT 2691-45-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(aminoglycoside antibiotics prevent the formation of non-bilayer structures in neg.-charged membranes. Comparative studies using fusogenic (bis( $\beta$ -diethylaminoethylether)hexestrol) and aggregating (spermine) agents)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 28 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:789146 CAPLUS

DN 123:198439

TI Method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library

IN Pavia, Michael Raymond; Whitesides, George McClelland; Hangauer, David Garry, Jr.; Hediger, Mark Edward

PA Sphinx Pharmaceuticals Corp., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504277	A1	19950209	WO 1994-US7780	19940707
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			US 1993-101074	A 19930803
			US 1994-239542	A 19940508
CA 2168886	AA	19950209	CA 1994-2168886	19940707
			US 1993-101074	A 19930803
			US 1994-239542	A 19940508
AU 9473293	A1	19950228	AU 1994-73293	19940707
			US 1993-101074	A 19930803
			US 1994-239542	A 19940508
			WO 1994-US7780	W 19940707
EP 712493	A1	19960522	EP 1994-923427	19940707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1993-101074	A 19930803

			US 1994-239542	A	19940508
			WO 1994-US7780	W	19940707
JP 09504511	T2	19970506	JP 1994-505836		19940707
			US 1993-101074	A	19930803
			US 1994-239542	A	19940508
			WO 1994-US7780	W	19940707
ZA 9405731	A	19950307	ZA 1994-5731		19940802
			US 1993-101074	A	19930803

OS MARPAT 123:198439


AB Methods are described for rapidly generating large, rationally designed libraries of structurally diverse, low-mol.-weight compds., using a multicombinatorial approach. More specifically, the method concerns preparation of libraries of certain biphenyl derivs., or analogous concatenated bicyclic aromatic or heteroarom. systems, in several steps, including: (1) providing a solid support with a cleavable linker; (2) preparing a 1st "scaffold", which is a substituted benzene or analogous unit bearing moieties suitable for coupling to both the support and a 2nd scaffold; (3) coupling the 1st scaffold to the support via the linker; (4) preparing a 2nd scaffold which bears a moiety for linking to the 1st scaffold; (5) coupling the 2nd scaffold to the 1st; and (6) cleaving the final product from the linker on the support. The method, including addnl. steps for modification of functional groups in both the unattached and attached scaffolds, was applied to preparation of compds. I [X = bond, n = 1; X = C.tplbond.C, CH:CH, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>, n = 2], which are potential bradykinin antagonists (no data).

IT **167764-40-1DP**, resin-bound **167764-46-7DP**, resin-bound  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of biphenyl derivs. and analogs via combinatorial library method)


RN 167764-40-1 CAPLUS

CN 2H-1-Benzopyran-6-sulfonamide, N-[[[2-[3-[2-[3-[2-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]amino]ethoxy]-4-(mercaptomethyl)phenyl]ethyl]-5-(2-phenylethoxy)phenoxy]ethyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 167764-46-7 CAPLUS  
 CN 2H-1-Benzopyran-6-sulfonamide, N-[[[2-[3-[[3-[2-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]amino]ethoxy]-4-(mercaptomethyl)phenyl]methyl]-5-(2-phenylethoxy)phenoxy]ethyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



IT **167764-41-2P 167764-47-8P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of biphenyl derivs. and analogs via combinatorial library method)  
 RN 167764-41-2 CAPLUS  
 CN Guanidine, [2-[3-[2-[3-[2-[(aminoiminomethyl)amino]ethoxy]-4-methylphenyl]ethyl]-5-(2-phenylethoxy)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 167764-47-8 CAPLUS  
 CN Guanidine, [2-[3-[[3-[2-[(aminoiminomethyl)amino]ethoxy]-4-methylphenyl]methyl]-5-(2-phenylethoxy)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 29 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1995:237206 CAPLUS  
 DN 122:23229  
 TI Study of the effects of basic di- and tri-phenyl derivatives on malignant cell proliferation: an example of the application of Correspondence Factor Analysis to structure-activity relationships (SAR)  
 AU Gilbert, Jacques; Dore, Jean-Christophe; Bignon, Eric; Pons, Michel; Ojasoo, Tiit  
 CS CNRS, CERCOA, Thiais, 94320, Fr.  
 SO Quantitative Structure-Activity Relationships (1994), 13(3), 262-74  
 CODEN: QSARDI; ISSN: 0931-8771  
 PB VCH  
 DT Journal  
 LA English  
 AB The descriptive multivariate method known as Correspondence Factor Anal. (CFA) was used to establish correlations between the structures of three chemical classes of compds. (triphenylacrylonitriles (TPEs), diphenylethylenes (DPEs), and diphenylalkyls) substituted in the para position by either hydroxy or basic groups and their responses in a battery of three biochem. tests, namely the induction of the proliferation of the MCF7 human breast cancer cell-line, the estrogen-irreversible inhibition of MCF7 cell proliferation (herein denoted cytotoxicity), and binding to the estrogen receptor (ER). The power of CFA was illustrated by performing several analyses: (a) Construction of factorial maps that described only the specificity of the response of the TPE population in the tests or both the specificity and amplitude of the response; (b) Use of the factorial maps as math. models for the introduction of new variables. These variables were either further biochem. tests (cytotoxicity under different conditions, inhibition of the activation of protein kinase C) on which the TPE population had been screened or further compds. (DPEs and diphenylalkyls). Relationships among the different tests were thus assessed as well as affiliations of the new compds. with TPEs. The analyses revealed the importance of the presence and configuration of hydroxy groups in ER binding and cell proliferation, but also the ability of non-hydroxylated compds. to induce cell growth independently of their relative affinity for ER. Cytotoxicity could be related to the presence of basic groups but also to resonance of conjugated bis-para-hydroxy di-Ph derivs. Overall, the analyses stressed

the complexity of the relationships between growth-promoting and growth-inhibitor potential of the test-compound populations and suggested the involvement of multiple mechanisms of action.


IT 159860-02-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(application of Correspondence Factor Anal. to structure-activity relationship of basic di- and tri-Ph derivs. on malignant cell proliferation)

RN 159860-02-3 CAPLUS

CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis[N,N-diethyl]- (9CI)  
(CA INDEX NAME)



L17 ANSWER 30 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:163666 CAPLUS

DN 120:163666

TI Preparation of phenoxyethanamines

IN Su, Wei Yang; Speranza, George P.

PA Texaco Chemical Co., USA

SO U.S., 4 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5276192	A	19940104	US 1991-689388 US 1991-689388	19910422 19910422

OS CASREACT 120:163666; MARPAT 120:163666


AB A process for preparing the title compds. comprises reaction of a phenol with a 2-oxazoline to produce an amide ether intermediate, followed by its hydrolysis with H<sub>2</sub>O in presence of H<sub>3</sub>PO<sub>4</sub> catalyst. Yield of the desired phenoxyethanamines is often 98% or better, requiring no subsequent purification. 2-Methyloxazoline and PhOH were heated to 160° for 6 h to give N-[1-(2-phenoxyethyl)]acetamide which was refluxed with H<sub>2</sub>PO<sub>4</sub> and H<sub>2</sub>O for 8 h to give 2-phenoxyethanamine in 98% yield.

IT 74228-86-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, improved process for)

RN 74228-86-7 CAPLUS

CN Ethanamine, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
(CA INDEX NAME)



L17 ANSWER 31 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1994:9676 CAPLUS  
 DN 120:9676  
 TI Hardenable epoxy resin composition  
 IN Murphey, Joseph R.; Totty, Kenneth D.; Anderson, Randy  
 PA Halliburton Co., USA  
 SO Eur. Pat. Appl., 10 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 528595	A1	19930224	EP 1992-307199	19920806
	R: DE, DK, ES, FR, GB, IT, NL				
	US 5232961	A	19930803	US 1991-746850	A 19910819
	CA 2076333	AA	19930220	US 1991-746850	19910819
				CA 1992-2076333	19920818
	AU 9221120	A1	19930225	US 1991-746850	A 19910819
	AU 648683	B2	19940428	AU 1992-21120	19920818
	BR 9203199	A	19930406	US 1991-746850	A 19910819
				BR 1992-3199	19920818
				US 1991-746850	A 19910819

OS MARPAT 120:9676

AB The composition, useful for consolidating particulates into hard permeable masses, comprises a polyepoxide,  $\geq 1$  water-immiscible diluent to lower the viscosity, and an adduct of bisphenol A-epichlorohydrin condensate (I) with an aliphatic amine. Thus, Epon 828 100, Bu glycidyl ether 12, A 1120 2, I-1,4-diaminocyclohexane adduct 64, MeOH 49, Bu lactate 6, and 2,4,6-tris(dimethylaminomethyl)phenol 2-ethylhexanoate 6 parts was slurried, aqueous gel-containing surfactant and sand were added, and Na2S2O8 gel breaker, (HOCH2CH2)3N, and fumaric acid-NaOH solution as crosslinker added. Curing at 120°F for 20 h gave crosslinked gel with compressive strength 600 psi and gel break 3-4 h.

IT 149899-24-1

RL: USES (Uses)  
 (gels, for consolidation of particulates)

RN 149899-24-1 CAPLUS


CN Phenol, 4,4'-(1-methylethylidene)bis-, polymer with (butoxymethyl)oxirane, (chloromethyl)oxirane and 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(4-aminocyclohexyl)amino]-2-propanol] (9CI) (CA INDEX NAME)

CM 1


CRN 149899-23-0

CMF C33 H52 N4 O4

PAGE 1-A








CM 2

CRN 2426-08-6


CMF C7 H14 O2



CM 3

CRN 106-89-8


CMF C3 H5 Cl O



CM 4

CRN 80-05-7

CMF C15 H16 O2



L17 ANSWER 32 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:497505 CAPLUS

DN 119:97505

TI Epoxy resin compositions

IN Hirai, Osamu; Sugiura, Minoru; Saito, Takayuki; Okamoto, Tadashi

PA Hitachi Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04325520	A2	19921113	JP 1991-96591	19910426
				JP 1991-96591	19910426

OS MARPAT 119:97505

AB Title comps., flexible with good adhesive strength, comprise epoxy resins and p-H<sub>2</sub>NR1OC<sub>6</sub>H<sub>4</sub>C<sub>6</sub>H<sub>4</sub>OR1NH<sub>2</sub>-p or (p-H<sub>2</sub>NR1OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>R<sub>2</sub> (R<sub>1</sub> = C<sub>3</sub>-4 alkylene; R<sub>2</sub> = C<sub>1</sub>-3 alkylene, O, S, SO<sub>2</sub>). Thus, a mixture of 100 parts Epikote 828 and 45 parts 2,2-[4-(3-aminopropoxy)phenyl]propane was cured at room temperature

for

24 h and then at 70° for 1 h with flexural modulus 3.1 GPa, deflection at rupture 16%, and adhesive strength 36.6 MPa.

IT **148695-40-3P**

RL: TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(adhesives, preparation of, flexible, with good adhesion)


RN 148695-40-3 CAPLUS

CN Phenol, 4,4'-(1-methylethylidene)bis-, polymer with (chloromethyl)oxirane and 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[1-propanamine] (9CI) (CA INDEX NAME)

CM 1

CRN 4835-05-6


CMF C21 H30 N2 O2



CM 2

CRN 106-89-8


CMF C3 H5 Cl O



CM 3

CRN 80-05-7

CMF C15 H16 O2




IT 4835-05-6P

RL: PREP (Preparation)

(preparation of, crosslinking agent, for epoxy resins)

RN 4835-05-6 CAPLUS

CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
(CA INDEX NAME)

L17 ANSWER 33 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:400277 CAPLUS

DN 117:277

TI Mechanism of allergic cross-reactions. I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody

AU Varga, Janos M.; Kalchschmid, Gertrud; Klein, Georg F.; Fritsch, Peter

CS Dep. Dermatol., Univ. Innsbruck, Innsbruck, 6020, Austria

SO Molecular Immunology (1991), 28(6), 641-54

CODEN: MOIMD5; ISSN: 0161-5890

DT Journal

LA English

AB A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE (I). All DNP-amino acids, that were tested inhibited the binding of the radio-labeled I to DNP covalently attached to polystyrene microplates; however, the concentration for 50% inhibition varied within four orders of magnitude, DNP-L-serine being the most and DNP-L-proline the least potent inhibitor. In addition to DNP analogs, a large number of drugs and other compds. were tested for their ability to compete with DNP for the binding site of I. At the concentration used for screening, 59% of compds. had no significant inhibition; 19% inhibited the binding of I more than 50%. Several families of compds. (tetracyclines, polymyxins, phenothiazines, salicylates, and quinones) that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with I is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.


IT 69-14-7, Trimanyl

RL: BIOL (Biological study)

(binding of, to anti-dinitrophenol monoclonal antibody, allergic cross-reaction mechanism in relation to)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 34 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1992:152023 CAPLUS  
 DN 116:152023  
 TI Preparation of poly(1,3,2-oxazaphospholidine) stabilizers  
 IN Hofmann, Peter; Odorisio, Paul A.; Cunkle, Glen T.; Sabrsula, Don  
 PA Ciba-Geigy Corp., USA  
 SO U.S., 8 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5075481	A	19911224	US 1990-572729	19900823
	EP 473543	A2	19920304	EP 1991-810646	19910814
	EP 473543	A3	19920527		
	R: DE, FR, GB, IT				
				US 1990-572729	A 19900823
				US 1990-572747	A 19900823
				US 1990-572749	A 19900823
CA 2049651	AA	19920224	CA 1991-2049651		19910821
			US 1990-572729	A	19900823
			US 1990-572747	A	19900823
			US 1990-572749	A	19900823
JP 04244093	A2	19920901	JP 1991-234066		19910821
			US 1990-572729	A	19900823
			US 1990-572747	A	19900823
			US 1990-572749	A	19900823
US 5147911	A	19920915	US 1991-764022		19910923
			US 1990-572729	A3	19900823

## PATENT FAMILY INFORMATION:

FAN 1992:129254


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5075483	A	19911224	US 1990-572749	19900823
	EP 473543	A2	19920304	EP 1991-810646	19910814
	EP 473543	A3	19920527		
	R: DE, FR, GB, IT				
				US 1990-572729	A 19900823
				US 1990-572747	A 19900823
				US 1990-572749	A 19900823
CA 2049651	AA	19920224	CA 1991-2049651		19910821
			US 1990-572729	A	19900823
			US 1990-572747	A	19900823
			US 1990-572749	A	19900823
JP 04244093	A2	19920901	JP 1991-234066		19910821
			US 1990-572729	A	19900823
			US 1990-572747	A	19900823

	US 5147909	A	19920915	US 1990-572749 US 1991-764021 US 1990-572749	A A3	19900823 19910923 19900823
FAN	1992:152022					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5075484	A	19911224	US 1990-572747		19900823
	EP 473543	A2	19920304	EP 1991-810646		19910814
	EP 473543	A3	19920527			
	R: DE, FR, GB, IT					
				US 1990-572729 US 1990-572747 US 1990-572749 CA 1991-2049651 US 1990-572729 US 1990-572747 US 1990-572749 JP 1991-234066 US 1990-572729 US 1990-572747 US 1990-572749 US 1991-764262 US 1990-572747	A A A A A A A A A A A A3	19900823 19900823 19900823 19910821 19900823 19900823 19900823 19910821 19900823 19900823 19900823 19910923 19900823
	CA 2049651	AA	19920224			
	JP 04244093	A2	19920901			
	US 5147910	A	19920915			
OS	MARPAT 116:152023					
AB	Title compds. [I; n = 1-4; R1 = (cyclo)alkyl), (substituted) phenylalkyl, aryl; R2-R4 = R1; R3R4 = C3-6 alkylene; T = bond, O, S, SO, SO2, CO, alkylimino, (O-, S-, SO2-, CO-, phenylene-, alkylimino-interrupted) aliphatic hydrocarbyl], were prepared Thus, 2,2,15,15-tetramethyl-5,12-dihydroxy-3,14-diaza-7,10-dioxahexadecane, 2,6-di-tert-butyl-4-[2-(n-octadecyloxycarbonyl)ethyl]phenylphosphorodichlorodite, and Et3N reacted in CH2Cl2 to give title compound II. II at 0.05 weight% in a polypropylene formulation reduced yellowness according to ASTM method D-1925 from 18.2 (controls) to 15.6.					
IT	<b>139626-23-6</b>					
	RL: RCT (Reactant); RACT (Reactant or reagent) (cyclocondensation of, with phosphorodichlorodite, in preparation of oxazaphospholidine stabilizers)					
RN	139626-23-6 CAPLUS					
CN	2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)					



L17 ANSWER 35 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1991:634793 CAPLUS  
 DN 115:234793  
 TI Aqueous compositions for multilayer electrodiode coatings  
 IN Budde, Bettina; Gruetter, Roland; Klein, Klausjoerg  
 PA Herberts G.m.b.H., Germany  
 SO Ger. Offen., 9 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3940782	A1	19910613	DE 1989-3940782	19891209
	CA 2031671	AA	19910610	CA 1990-2031671	19901206
				DE 1989-3940782	A 19891209
	EP 433783	A1	19910626	EP 1990-123408	19901206
	EP 433783	B1	19940316		
	R: AT, BE, DE, ES, FR, GB, GR, IT, NL, SE				
				DE 1989-3940782	A 19891209
				ES 1990-123408	19901206
	ES 2053062	T3	19940716	DE 1989-3940782	A 19891209
				JP 1990-413577	19901207
	JP 03252465	A2	19911111	DE 1989-3940782	A 19891209
AB	The title compns., giving films with good adhesion, impact resistance, and edge covering, contain H <sub>2</sub> O-dispersible binders containing 5-75% (on solids) particles (diameter 0.1-100 $\mu$ m, glass temperature $\geq 70^\circ$ ) prepared from aminoplasts and/or phenolic resins and polymers [weight-average mol. weight (M <sub>w</sub> ) >100,000] containing $\geq 70\%$ (meth)acrylonitrile. Thus, heating 647 g reaction product of 800 g linseed oil and 200 g maleic anhydride (I) with 1623 g Alresat KM 201 (rosin-I-glycerol ester) at 160° for 1 h, neutralizing with 82 g Et <sub>3</sub> N at 100°, and adding 1946 g H <sub>2</sub> O gave a binder dispersion. Milling 500 g this dispersion with 48 g urea resin (particle size 1-22 $\mu$ m, glass temperature 85°) and 72 g 93:7 acrylonitrile-Me acrylate copolymer (M <sub>w</sub> >100,000, glass temperature >90°, particle size 1-95 $\mu$ m) and adding 1100 g binder dispersion and 1480 g H <sub>2</sub> O gave a composition forming smooth, elastic, anodic electrocoat coatings.				
IT	<b>137288-96-1D</b> , reaction products with glyceridyl neocarboxylates				
	RL: USES (Uses)				
	(binders, for waterborne electrophoretic coating compns.)				
RN	137288-96-1 CAPLUS				
CN	Carbamic acid, (3-isocyanatomethylphenyl)-, 2-ethylhexyl ester, polymer with (chloromethyl)oxirane, 4,4'-(1-methylethylidene)bis[phenol] and N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[N,N'-diethyl-1,3-propanediamine] (9CI) (CA INDEX NAME)				
CM	1				
CRN	137288-95-0				
CMF	C31 H52 N4 O2				




CM 2

CRN 54634-94-5

CMF C17 H24 N2 O3


CCI IDS



D1-Me


CM 3

CRN 106-89-8  
CMF C3 H5 Cl O




CM 4

CRN 80-05-7  
CMF C15 H16 O2



L17 ANSWER 36 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1991:405035 CAPLUS  
DN 115:5035  
TI New agents to increase the permeability of the outer membrane of  
Escherichia coli  
AU Katsu, Takashi  
CS Fac. Pharm. Sci., Okayama Univ., Tsushima, 700, Japan  
SO Biochemistry International (1991), 23(2), 413-18  
CODEN: BIINDF; ISSN: 0158-5231  
DT Journal  
LA English  
AB Two diamines were prepared to investigate the structure-activity relation  
required for an increase in the permeability of the outer membrane of E.  
coli. One diamine, bis[4-(2-methylaminoethoxy)phenyl]methane  
dihydrochloride, increased the permeability of the membrane, while the  
other diamine, 1,4-bis(2-methylaminoethoxy)benzene dihydrochloride, did  
not. The result indicated that a bulky hydrophobic moiety is required to  
increase permeability.  
IT 134314-53-7  
RL: BIOL (Biological study)  
(outer membrane permeability of Escherichia coli enhancement by)  
RN 134314-53-7 CAPLUS

CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis[N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 37 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:613277 CAPLUS

DN 113:213277

TI Storage-stable and rapid curing one-component epoxy resin composition

IN Chen, Chen Chi; Reuille, Pamela Sue

PA W. R. Grace and Co., USA

SO Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 365984	A2	19900502	EP 1989-119304	19891018
	EP 365984	A3	19910814		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 02158619	A2	19900619	US 1988-262368	A 19881025
				JP 1989-276176	19891025
				US 1988-262368	A 19881025

AB The title compns., useful for encapsulating semiconductors, comprise epoxy resin, organic anhydrides, and polyamines CMe<sub>2</sub>(p-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH(OH)CH<sub>2</sub>CH<sub>2</sub>R)<sub>2</sub> [I; R = NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub> (70%) and NHCH<sub>2</sub>CH<sub>2</sub>NHC<sub>6</sub>H<sub>4</sub> (30%)]. A uniform mixture of diglycidyl bisphenol A epoxy resin 10, methylhexahydrophthalic anhydride 9, and I 0.4 g was cured at 135° for 90 min, giving a resin with glass temperature 82°.

IT 130431-06-0P

RL: PREP (Preparation)

(preparation of, for potting semiconductors)

RN 130431-06-0 CAPLUS

CN 1,3-Isobenzofurandione, hexahydromethyl-, polymer with 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(diethylamino)propyl]amino]-2-propanol] and 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[2-(phenylamino)ethyl]amino]-2-propanol] and 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] (9CI) (CA INDEX NAME)


CM 1

CRN 130431-05-9


CMF C37 H48 N4 O4



PAGE 1-A




PAGE 1-B




CM 2

CRN 130431-04-8  
CMF C35 H60 N4 O4

PAGE 1-A




PAGE 1-B



CM 3

CRN 25550-51-0  
CMF C9 H12 O3  
CCI IDS




D1-Me

CM 4

CRN 1675-54-3

CMF C21 H24 O4



L17 ANSWER 38 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:593599 CAPLUS

DN 113:193599

TI Thermosetting polyurethane magnetic coatings for recording

IN Haga, Keiichi; Hara, Yasuo; Igarashi, Katsutoshi

PA DeSoto, Inc., USA; Japan Synthetic Rubber Co., Ltd.

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02129217	A2	19900517	JP 1988-256908	19881012
				JP 1988-256908	19881012

AB The title compns. contain polymers of diisocyanates, polyester, polycaprolactone, and/or polyether diols, diols containing CO<sub>2</sub>H or sulf(at)o groups or their alkali metal salts, and compds. containing ≥3 OH or NH groups and/or (poly)oxyalkylene bisphenol derivs. Thus, a polymer (I) was prepared from Nippollan-4009 171.8, (Eto)<sub>2</sub>P(O)CH<sub>2</sub>N(C<sub>2</sub>H<sub>4</sub>OH)<sub>2</sub> 29.6, 4,4'-dicyclohexylmethane diisocyanate 165.5, glycerol 33.1 g, and solvents. A mixture of I 20, Co-doped γ-Fe<sub>2</sub>O<sub>3</sub> 80, Coronate L 3, and solvents 200 parts was coated on a polyester film.

IT **129878-94-0 130172-44-0**


RL: TEM (Technical or engineered material use); USES (Uses)  
(binders, for magnetic coatings)

RN 129878-94-0 CAPLUS

CN Propanenitrile, 3-[bis(2-hydroxyethyl)amino]-, polymer with Coronate L, α-hydro-ω-hydroxypoly(oxy-1,2-ethanediyl), 1,1'-methylenebis[4-isocyanatocyclohexane] and 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(butylamino)-2-propanol] (9CI) (CA INDEX NAME)

CM 1

CRN 129878-93-9  
CMF C29 H46 N2 O4




CM 2

CRN 39278-79-0  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 3

CRN 25322-68-3  
CMF (C2 H4 O)<sub>n</sub> H2 O  
CCI PMS




CM 4

CRN 17209-72-2  
CMF C7 H14 N2 O2



CM 5

CRN 5124-30-1  
CMF C15 H22 N2 O2



RN 130172-44-0 CAPLUS  
CN Phosphonic acid, [[bis(2-hydroxyethyl)amino]methyl]-, diethyl ester,


polymer with Coronate L, 2,4-diisocyanato-1-methylbenzene,  
 $\alpha$ -hydro- $\omega$ -hydroxypoly(oxy-1,4-butanediyl),  
 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-  
 hydroxyethyl)amino]-2-propanol] and  $\alpha,\alpha'$ -[(1-  
 methylethylidene)di-4,1-phenylene]bis[ $\omega$ -hydroxypoly(oxy-1,2-  
 ethanediyl)] (9CI) (CA INDEX NAME)

CM 1


CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A



PAGE 1-B



CM 2

CRN 39278-79-0

CMF Unspecified

CCI PMS, MAN


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 3

CRN 32492-61-8

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C15 H16 O2


CCI PMS



CM 4


CRN 25190-06-1

CMF (C4 H8 O)n H2 O  
CCI PMS




CM 5

CRN 2781-11-5  
CMF C9 H22 N O5 P



CM 6

CRN 584-84-9  
CMF C9 H6 N2 O2




IT **106056-71-7P 129878-93-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 106056-71-7 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 129878-93-9 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(butylamino)- (9CI) (CA INDEX NAME)]




L17 ANSWER 39 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1990:479560 CAPLUS  
 DN 113:79560  
 TI Neutron irradiation effects on model compounds for epoxy and polyimide resins  
 AU Liepins, R.; Wood, L. J.; Tucker, D. S.; Clinard, F. W., Jr.  
 CS Los Alamos Natl. Lab., Los Alamos, NM, 87545, USA  
 SO Radiation Physics and Chemistry (1990), 36(3), 383-91  
 CODEN: RPCHDM; ISSN: 0146-5724  
 DT Journal  
 LA English  
 AB Synthesis and irradiation testing of well-characterized model compds. for com. epoxy and polyimide insulators is presented. Samples prepared from phthal(p-phenoxyphenyl)imide and bisphenol A diglycidyl ether reacted with hexylamine, aniline, and BZOH were irradiated to neutron fluences as high as  $3.32 \times 10^{20} \text{ n m}^{-2}$  for determination of irradiation effect related to neutron damage in well-defined and characterized organic compds. Various chemical and phys. changes observed in the different mol. structures are reported.  
 IT **128736-14-1P 128736-15-2P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and neutron irradiation damage of, as model compound for epoxy resins and polyimides, chemical and phys. properties in relation to)  
 RN 128736-14-1 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(phenylamino)- (9CI) (CA INDEX NAME)]



RN 128736-15-2 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-

(hexylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH—(CH<sub>2</sub>)<sub>5</sub>—Me

L17 ANSWER 40 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:185932 CAPLUS

DN 110:185932

TI Ultrastructural, physicochemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethoxy)hexestrol with negatively-charged phospholipid layers

AU Mingeot-Leclercq, Marie Paule; Schanck, Andre; Ronveaux-Dupal, Marie France; Deleers, Michel; Brasseur, Robert; Ruysschaert, Jean Marie; Laurent, Guy; Tulkens, Paul M.

CS Lab. Chim. Physiol., Univ. Cathol. Louvain, Brussels, B-1200, Belg.

SO Biochemical Pharmacology (1989), 38(5), 729-41

CODEN: BCPA6; ISSN: 0006-2952

DT Journal

LA English

AB Hydrophilic aminoglycoside antibiotics such as gentamicin and cationic amphiphilic drugs such as bis(beta-diethylaminoethoxy)hexestrol (DEH) inhibit lysosomal phospholipases and induce phospholipidosis. This inhibition is probably related to the neutralization of surface neg. charges on which the lysosomal phospholipases A1 and A2 depend to express fully their activities. Using neg. charged liposomes and <sup>31</sup>P-NMR spectroscopy showed that both gentamicin and DEH restrict the phosphate head mobility and, in sonicated vesicles, the appearance of large bilayer structures. Both DEH and gentamicin increased the apparent size of sonicated neg. charged liposomes (but not of neutral liposomes) as measured by quasi-elastic light scattering spectroscopy. Examination of replicas from freeze-etched samples revealed that gentamicin caused aggregation of liposomes, whereas DEH induced their fusion and the formation of intramembranous round structures. Only DEH decrease the fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene, a fluorescent lipid-soluble probe. DEH, but not gentamicin, interfered with the bilayer to hexagonal phase transition occurring in dioleoyl- and dielaidoylphosphatidylethanolamine liposomes upon warming, and caused the appearance of an isotropic signal suggestive of the formation of inverted micelles. In computer-aided conformational anal. of the mols. at a simulated air-water interface, gentamicin displayed a widely-open crescent shape. When surrounded by phosphatidylinositol mols., it remained shaped to establish close contact with the neg. charged phospho groups. DEH could be oriented perpendicularly to the interface, with its two cationic groups associated with the phospho groups and its phenyl- and

diethylethanediyl deeply inserted between and interacting with the aliphatic chains. Thus, although both agents inhibit lysosomal phospholipases, the difference in their interactions with neg.-charged bilayers is likely to result in a different organization of the phospholipids accumulated in vivo, which could lead to different toxicities.


IT 2691-45-4

RL: PRP (Properties)

(interaction of, with phospholipid membranes, conformation changes in, phospholipase inhibition in relation to)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 41 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:631275 CAPLUS

DN 109:231275

TI Aromatic disilanes as glass fiber coating

IN Forro, Juraj; Florovic, Stanislav

PA Czech.

SO Czech., 3 pp.

CODEN: CZXXA9

DT Patent

LA Slovak

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 245889	B1	19861016	CS 1985-2588	19850409
				CS 1985-2588	19850409

OS CASREACT 109:231275

AB Aromatic disilanes (I; R = Me, Et) are prepared by treating epoxide II at 50° with 2 molar equiv (RO)<sub>3</sub>Si(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>. I give with HCO<sub>2</sub>H and AcOH water-soluble salts which modify the surface of glass fibers (no data).


IT 117701-77-6P 117701-78-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as glass fiber coating)

RN 117701-77-6 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(triethoxysilyl)propyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B




RN 117701-78-7 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3-(trimethoxysilyl)propyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 42 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1988:206371 CAPLUS  
 DN 108:206371  
 TI Radiation-curable polyurethane compositions for durable magnetic recording coatings  
 IN Hara, Takeo; Ukaji, Takashi; Bessho, Keiichi; Matsumura, Yoshio  
 PA Japan Synthetic Rubber Co., Ltd., Japan; DeSoto, Inc.  
 SO Jpn. Kokai Tokkyo Koho, 24 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62280270	A2	19871205	JP 1986-124310	19860529
				JP 1986-124310	19860529

AB The title vinyl terminal group-containing polymers are prepared containing urea, amide, and/or ester linkages. In MEK containing 0.2 g Bu<sub>2</sub>Sn dilaurate at 60°, 108.5 g hexamethylene diisocyanate was treated with 107.9 g Teracol 650 and 54.8 g bisphenol A ethoxylate for 4 h, with 2-hydroxyethyl acrylate for 2 h, and then 19.0 g Me<sub>2</sub>C[C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>OH-p]<sub>2</sub> for 2 h to give a polymer which (18 parts) was compounded with Co-containing α-Fe<sub>2</sub>O<sub>3</sub> 80, pentaerythritol triacrylate 2, and MEK 200 parts, coated 6 μm thick (dry) on a polyester film, oriented, and cured by 7 Mrad electron beam to give a coating with good gloss, adhesion, powder fall-off

resistance, and squareness ratio (0.88). A clear film obtained similarly without the magnetic powder had tensile strength 620 kg/cm<sup>2</sup>, elongation 80%, initial modulus 14,000 kg/cm<sup>2</sup>, and THF-insol. content 94%.

IT 114321-56-1 114349-00-7 114357-48-1  
114464-80-1

RL: TEM (Technical or engineered material use); USES (Uses)  
(coatings, electron-beam curable, durable, for magnetic recording media)

RN 114321-56-1 CAPLUS

CN Hexanedioic acid, polymer with 1,4-butanediol, 2-(hydroxymethyl)-2-[[[(1-oxo-2-propenyl)oxy]methyl]-1,3-propanediyl di-2-propenoate, 1,1'-methylenebis[4-isocyanatobenzene], 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and Placel 205AL, block (9CI) (CA INDEX NAME)

CM 1

CRN 106282-86-4

CMF Unspecified

CCI PMS, MAN


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A




PAGE 1-B



CM 3

CRN 3524-68-3

CMF C14 H18 O7



CM 4

CRN 124-04-9  
CMF C6 H10 04




CM 5

CRN 110-63-4  
CMF C4 H10 O2



CM 6

CRN 101-68-8  
CMF C15 H10 N2 O2




RN 114349-00-7 CAPLUS

CN 2-Propenoic acid, 2-(hydroxymethyl)-2-[[[(1-oxo-2-propenyl)oxy]methyl]-1,3-propanediyl ester, polymer with 1,6-diisocyanatohexane, 2-ethyl-2-[[[(1-oxo-2-propenyl)oxy]methyl]-1,3-propanediyl di-2-propenoate,  $\alpha$ -hydro- $\omega$ -hydroxypoly(oxy-1,4-butanediyl), 2-hydroxyethyl 2-propenoate, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and  $\alpha,\alpha'$ -[(1-methylethylidene)di-4,1-phenylene]bis[ $\omega$ -hydroxypoly(oxy-1,2-ethanediyl)], block (9CI) (CA INDEX NAME)


CM 1

CRN 106056-71-7  
CMF C25 H38 N2 O6

PAGE 1-A



PAGE 1-B




CM 2

CRN 32492-61-8

CMF (C2 H4 O)<sub>n</sub> (C2 H4 O)<sub>n</sub> C15 H16 O2

CCI PMS




CM 3

CRN 25190-06-1

CMF (C4 H8 O)<sub>n</sub> H2 O


CCI PMS



CM 4

CRN 15625-89-5


CMF C15 H20 O6



CM 5

CRN 3524-68-3


CMF C14 H18 O7



CM 6

CRN 822-06-0


CMF C8 H12 N2 O2



CM 7

CRN 818-61-1

CMF C5 H8 O3



RN 114357-48-1 CAPLUS


CN 1,3-Cyclopentanedicarboxylic acid, 4,5-bis[[[2-(2-hydroxyethoxy)ethyl]amino]carbonyl]-, polymer with 2,4-diisocyanato-1-methylbenzene, 1,1'-[(2-hydroxyethyl)imino]bis[3-[4-[1-[4-[2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]phenyl]-1-methylethyl]phenoxy]-2-propanol], 2-hydroxyethyl 2-propenoate, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol], PC-D 10L120-800 and Placel 205AL, block (9CI) (CA INDEX NAME)

CM 1


CRN 114357-47-0

CMF C48 H69 N3 O11


PAGE 1-A



PAGE 1-B



PAGE 1-C



CM 2

CRN 106282-86-4

CMF Unspecified


CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 3

CRN 106209-19-2

CMF C17 H28 N2 O10



CM 4

CRN 106097-17-0


CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 5

CRN 106056-71-7  
CMF C25 H38 N2 O6

PAGE 1-A




PAGE 1-B




CM 6

CRN 818-61-1  
CMF C5 H8 O3



CM 7

CRN 584-84-9  
CMF C9 H6 N2 O2



RN 114464-80-1 CAPLUS  
CN 2-Propenoic acid, oxydi-2,1-ethanediyl ester, polymer with Adeka Newace F 1212-5, 1H,3H-benzo[1,2-c:4,5-c']difuran-1,3,5,7-tetrone, 1,6-diisocyanatohexane, α-hydro-ω-hydroxypoly(oxy-1,4-butanediyl), 2-hydroxyethyl 2-propenoate, 1,1'-[(1-

methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and  $\alpha,\alpha'$ -[(1-methylethylidene)di-4,1-phenylene]bis[ $\omega$ -hydroxypoly(oxy-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

CM 1

CRN 114355-31-6

CMF Unspecified

CCI PMS, MAN


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2


CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A



PAGE 1-B




CM 3

CRN 32492-61-8

CMF (C<sub>2</sub> H<sub>4</sub> O)<sub>n</sub> (C<sub>2</sub> H<sub>4</sub> O)<sub>n</sub> C<sub>15</sub> H<sub>16</sub> O<sub>2</sub>

CCI PMS




CM 4

CRN 25190-06-1

CMF (C<sub>4</sub> H<sub>8</sub> O)<sub>n</sub> H<sub>2</sub> O

CCI PMS






CM 5

CRN 4074-88-8


CMF C10 H14 O5



CM 6

CRN 822-06-0


CMF C8 H12 N2 O2



CM 7

CRN 818-61-1


CMF C5 H8 O3



CM 8

CRN 89-32-7

CMF C10 H2 O6



L17 ANSWER 43 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1988:151119 CAPLUS  
 DN 108:151119  
 TI Polymaleimides with good curability and processability

IN Otsuka, Masahiko; Ishimura, Shuichi  
 PA Asahi Chemical Industry Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62205059	A2	19870909	JP 1986-46432	19860305
	JP 07030021	B4	19950405		
	US 4761460	A	19880802	US 1987-21886	19870304
				JP 1986-46432	A 19860305
	EP 241133	A2	19871014	EP 1987-301901	19870305
	EP 241133	A3	19881214		
	EP 241133	B1	19940803		
	R: CH, DE, FR, GB, IT, LI, NL				


AB Polymaleimides Z[CH(OH)CH<sub>2</sub>Q]<sub>2</sub> (Z = polyvalent organic group; Q = maleimido) are soluble in low-boiling solvents and can be cured with compds. having active H or conjugated double bonds, or using radical initiators, to obtain polyimides with good heat resistance and adhesion to substrates, and low thermal expansion. Thus, 187 parts Me<sub>2</sub>C[C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NH<sub>2</sub>-p]<sub>2</sub> was treated with 98 parts maleic anhydride in THF at 25°, then with AcONa and Ac<sub>2</sub>O at 60° for 3 h to give Me<sub>2</sub>C[C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH(OH)CH<sub>2</sub>Q-p]<sub>2</sub> (I) with softening temperature 125-130°. When 100 parts I was mixed with 19 parts CH<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>)<sub>2</sub> and cured at 200° for 4 h, the product showed glass transition temperature 250°, linear thermal expansion coefficient 87 ppm/°C, and shear bonding strength (JIS K 6850 test) 100 kg/cm<sup>2</sup>.

IT 53799-07-8 105511-23-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with maleic anhydride)


RN 53799-07-8 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-amino-(9CI) (CA INDEX NAME)]




RN 105511-23-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[3-amino-(9CI) (CA INDEX NAME)]



L17 ANSWER 44 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1987:207214 CAPLUS

DN 106:207214  
 TI Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver  
 AU Kubo, Masaharu; Hostetler, Karl Y.  
 CS Univ. California, San Diego, CA, 92161, USA  
 SO American Journal of Physiology (1987), 252(3, Pt. 1), E375-E379  
 CODEN: AJPHAP; ISSN: 0002-9513  
 DT Journal  
 LA English  
 AB Diethylaminoethoxyhexestrol (I) [2691-45-4] caused a foam cell lipidosis in humans characterized by phospholipid storage in the liver, spleen, and other tissues, and this represents the first description of acquired lipidosis caused by a drug. It has been proposed that I causes phospholipid fatty liver by concentrating in lysosomes and inhibiting phospholipases but it has not previously been possible to measure the intralysosomal concentration of I. In this paper, for the first time the intralysosomal concentration of this drug is determined in rats. After a single oral dose of I (100 mg/kg) the intralysosomal concentration was 7.9 mM at 2.5 h, 15.6 mM at 12 h, and 20.9 mM at 24 h, resp. The total phospholipid content of lysosomes in drug-treated rats increased 1.9-, 6.0-, and 7.6-fold over control at 2.5, 12, and 24 h, resp. Purified lysosomal phospholipase A1 [9043-29-2] was strongly inhibited by I in vitro. In phospholipid fatty liver, phospholipid accumulation in lysosomes appears to be caused by the presence of I in lysosomes at concns. estimated to be 7.9-20 mM, because drug levels above 1 mM completely block the activity of purified lysosomal phospholipase A1 in vitro.  
 IT 2691-45-4, Diethylaminoethoxyhexestrol  
 RL: BIOL (Biological study)  
 (phospholipidosis of liver from, metabolic basis of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 45 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1987:113525 CAPLUS  
 DN 106:113525  
 TI Diethylaminoethoxyhexestrol inhibition of purified rat liver lysosomal phospholipase A1: role of drug binding to substrate  
 AU Kubo, Masaharu; Hostetler, Karl Y.  
 CS Dep. Med., Univ. California, San Diego, CA, USA  
 SO Journal of Pharmacology and Experimental Therapeutics (1987), 240(1), 88-92  
 CODEN: JPETAB; ISSN: 0022-3565  
 DT Journal  
 LA English  
 AB The inhibition of purified rat liver phospholipase A1 [9043-29-2] by 4,4'-diethylaminoethoxyhexestrol (DH) [2691-45-4] was evaluated and the results correlated with DH binding to sonicated vesicles of di[1-14C]oleoylphosphatidylcholine. The drug bound in a pos. cooperative manner to 2 classes of binding sites on phosphatidylcholine small

unilamellar vesicles, one having an apparent high affinity and low capacity and another having a low affinity and high capacity. The data fit a mixed type of inhibition when the free DH concentration (determined independently in the binding expts.) was used instead of the total drug concentration. Hydrolysis of enzyme-substrate-drug complexes was estimated to occur

at a rate only half that of the enzyme-substrate complex. Results with DH suggest that both drug-enzyme and drug-substrate interactions may be important factors in the inhibition of lysosomal phospholipase A1.


IT **2691-45-4**, 4,4'-Diethylaminoethoxyhexestrol

RL: BIOL (Biological study)

(phospholipase A1 of liver lysosome inhibition by)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 46 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1987:34752 CAPLUS

DN 106:34752

TI Radiation-curable binders for magnetic coating materials

IN Ansel E, Robert; Ukaji, Takashi; Bettsho, Keiichi; Kumano, Koji; Matsumura, Yoshio

PA DeSoto, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61181872	A2	19860814	JP 1985-16357	19850130
				JP 1985-16357	19850130

AB The title binders having good compatibility with magnetic powders and low viscosity for good workability and leveling and forming abrasion-resistant coatings with excellent magnetic characteristics were described including various acrylic-terminated polymers (containing urethane, urea, amide, and/or ester linkages) of mol. weight 2000-100,000. Thus, a mixture of methylenebis(4-cyclohexyl isocyanate) 71.9, dibutyltin dilaurate 0.2, and MEK 300 g at 60° was treated with a mixture of 125.6 g Teracol 650 and 15.5 g Epikote 828 diacrylate, stirred at 60° for 4 h, treated with 9.6 g pentaerythritol triacrylate at 60° for 2 h, and treated with 77 g HOZQZQZOH (Z = polyoxytetramethylene; Q = pyromellitic acid residue) at 60° for 7 h to give an electron beam-curable binder resin.

IT **106056-72-8P 106100-64-5P 106222-72-4P**

**106247-18-1P**

RL: PREP (Preparation)

(manufacture of, as electron beam-curable binders, for magnetic coatings)

RN 106056-72-8 CAPLUS


CN 2-Propenoic acid, 2-(hydroxymethyl)-2-[[[(1-oxo-2-propenyl)oxy]methyl]-1,3-propanediyl ester, polymer with α-hydro-ω-hydroxypoly(oxy-1,4-butanediyl), α-hydro-ω-hydroxypoly(oxy-1,4-butanediyl)

2,4-ester with 1,2,4,5-benzenetetracarboxylic acid (3:2),  
 1,1'-methylenebis[4-isocyanatocyclohexane], 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and (1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)] di-2-propenoate (9CI) (CA INDEX NAME)


CM 1

CRN 106056-71-7  
 CMF C25 H38 N2 O6

PAGE 1-A




PAGE 1-B




CM 2

CRN 106056-70-6  
 CMF (C4 H8 O)<sub>n</sub> (C4 H8 O)<sub>n</sub> (C4 H8 O)<sub>n</sub> C20 H10 O15  
 CCI PMS

PAGE 1-A




PAGE 1-B




CM 3

CRN 25190-06-1  
 CMF (C4 H8 O)<sub>n</sub> H2 O  
 CCI PMS




CM 4

CRN 5124-30-1  
 CMF C15 H22 N2 O2




CM 5

CRN 4687-94-9  
 CMF C27 H32 O8




PAGE 1-B



CM 6

CRN 3524-68-3  
 CMF C14 H18 O7



RN 106100-64-5 CAPLUS


CN 2-Propenoic acid, 2-(hydroxymethyl)-2-[[[(1-oxo-2-propenyl)oxy]methyl]-1,3-propanediyl ester, polymer with 1,3-diisocyanatomethylbenzene,  $\alpha$ -hydro- $\omega$ -hydroxypoly(oxy-1,4-butanediyl),  $\alpha$ -hydro- $\omega$ -hydroxypoly(oxy-1,4-butanediyl) 1,5-ester with 1,2,4,5-benzenetetracarboxylic acid (3:2), 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and (1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)] di-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A



PAGE 1-B




CM 2


CRN 106056-70-6

CMF (C4 H8 O)<sub>n</sub> (C4 H8 O)<sub>n</sub> (C4 H8 O)<sub>n</sub> C20 H10 O15

CCI PMS

PAGE 1-A






CM 3

CRN 26471-62-5

CMF C9 H6 N2 O2

CCI IDS




D1-Me

CM 4

CRN 25190-06-1

CMF (C4 H8 O)n H2 O


CCI PMS



CM 5


CRN 4687-94-9

CMF C27 H32 O8






PAGE 1-B



CM 6

CRN 3524-68-3

CMF C14 H18 O7



RN 106222-72-4 CAPLUS

CN 2-Propenoic acid, (1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)] ester, polymer with 1,3-diisocyanatomethylbenzene, 1,2-ethanediamine, 2-hydroxyethyl 2-propenoate, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] and Placel 220N1 (9CI) (CA INDEX NAME)

CM 1

CRN 106097-18-1

CMF Unspecified

CCI PMS, MAN


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2


CRN 106056-71-7

CMF C25 H38 N2 O6

PAGE 1-A




PAGE 1-B



CM 3


CRN 26471-62-5  
CMF C9 H6 N2 O2  
CCI IDS




D1-Me

CM 4

CRN 4687-94-9  
CMF C27 H32 O8




PAGE 1-B




CM 5

CRN 818-61-1  
CMF C5 H8 O3



CM 6

CRN 107-15-3  
CMF C2 H8 N2




RN 106247-18-1 CAPLUS

CN 1,3-Cyclopentanedicarboxylic acid, 4,5-bis[[[2-(2-hydroxyethoxy)ethyl]amino]carbonyl]-, polymer with  $\alpha$ -(2-aminomethylethyl)- $\omega$ -(2-aminomethylethoxy)poly[oxy(methyl-1,2-ethanediyl)], 1,4-butanediol, 1,2-ethanediol, 1,2-ethanediylbis[oxy(2-hydroxy-3,1-propanediyl)] bis(2-methyl-2-propenoate), hexanedioic acid, 2-hydroxyethyl 2-propenoate, 1,1'-methylenebis[4-isocyanatobenzene] and 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2-hydroxyethyl)amino]-2-propanol] (9CI) (CA INDEX NAME)

CM 1

CRN 106209-19-2


CMF C17 H28 N2 O10



CM 2

CRN 106056-71-7

CMF C25 H38 N2 O6



PAGE 1-A


PAGE 1-B



CM 3

CRN 68856-43-9

CMF C16 H26 O8




CM 4

CRN 9046-10-0

CMF (C3 H6 O)<sub>n</sub> C6 H16 N2 O

CCI IDS, PMS




2 ( D1-Me )

CM 5

CRN 818-61-1


CMF C5 H8 O3



CM 6

CRN 124-04-9


CMF C6 H10 O4



CM 7

CRN 110-63-4

CMF C4 H10 O2



CM 8

CRN 107-21-1


CMF C2 H6 O2

HO-CH<sub>2</sub>-CH<sub>2</sub>-OH

CM 9

CRN 101-68-8

CMF C15 H10 N2 O2



L17 ANSWER 47 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:628632 CAPLUS

DN 105:228632

TI Flexible polyfunctional epoxy resins

IN Ishimura, Shuichi; Katayose, Mitsuru

PA Asahi Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61166821	A2	19860728	JP 1985-6612	19850117
				JP 1985-6612	19850117
AB	Epoxy resins [X <sub>2</sub> NCH <sub>2</sub> CH(OH)CH <sub>2</sub> O] <sub>2</sub> Z (X = glycidyl, Z = arylene) prepared from the amino alcs. and epihalohydrins have good curability, flexibility, and adhesion and are useful in coatings, elec. insulators, construction materials, adhesives, etc. Thus, heating 210 g 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis(1-amino-2-propanol) and 184 g epichlorohydrin in 60 g 1:1 PhMe-EtOH .apprx.10 h at 70° gave an epoxy resin which was mixed with 4 phr dicyandiamide, coated (20 μ) on Al, and cured 10 min at 200° to give a coating with crosscut adhesion 100/100, flexibility <2 mm, and pencil hardness 3H.				
IT	<b>105511-21-5 105511-22-6 105511-24-8</b>				
	RL: USES (Uses)				
	(coatings and adhesives, flexible)				
RN	105511-21-5 CAPLUS				
CN	2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-amino-, polymer with (chloromethyl)oxirane (9CI) (CA INDEX NAME)				

CM 1


CRN 53799-07-8

CMF C21 H30 N2 O4



CM 2


CRN 106-89-8  
CMF C3 H5 Cl 0



RN 105511-22-6 CAPLUS  
CN 2-Propanol, 1,1'-[methylenebis(4,1-phenyleneoxy)]bis[3-amino-, polymer with (chloromethyl)oxirane (9CI) (CA INDEX NAME)


CM 1

CRN 13932-27-9  
CMF C19 H26 N2 O4



CM 2


CRN 106-89-8  
CMF C3 H5 Cl 0



RN 105511-24-8 CAPLUS  
CN 2-Propanol, 1,1'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[3-amino-, polymer with (chloromethyl)oxirane (9CI) (CA INDEX NAME)

CM 1


CRN 105511-23-7  
CMF C21 H26 Br4 N2 O4



CM 2

CRN 106-89-8

CMF C3 H5 Cl O



L17 ANSWER 48 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1986:461480 CAPLUS  
 DN 105:61480  
 TI Unsaturated cyclic amido-substituted ether compounds  
 IN Itoh, Hiroshi; Tanaka, Tomio; Nitta, Atsuhiko; Kamio, Hideo  
 PA Mitsui Toatsu Chemicals, Inc., Japan  
 SO Eur. Pat. Appl., 78 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 155177	A2	19850918	EP 1985-301695	19850312
	EP 155177	A3	19870204		
	EP 155177	B1	19901031		
	R: CH, DE, FR, GB, IT, LI, NL, SE				
				JP 1984-46532	A 19840313
	JP 60193955	A2	19851002	JP 1984-46532	19840313
	JP 05073739	B4	19931015		
	US 4649219	A	19870310	US 1985-708568	19850306
				JP 1984-46532	A 19840313
	CA 1244012	A1	19881101	CA 1985-475877	19850306
			JP 1984-46532	A 19840313	

OS CASREACT 105:61480

AB Unsatd. cyclic amido-substituted ether compds. I (Z1, Z3 = cyclic group; Z4 = C1-5 alkylene, C2-5 alkenylene, oxyalkylene group, or aminoalkylene group; R3, R4 = halogen, OH, oxo, CN, NO2, SH, S, or a salt thereof, C1-20 alkyl, C2-15 alkenyl, C1-20 haloalkyl, amine group or substituted amine, H, lower alkyl, a carbonyl group, an acid group or salt thereof, or amidopolymethylene group; Z2 = O, carbonyl, thio, sulfonyl, azo, C1-5 alkylene, C2-5 alkenylene; R2 = H or Me; a = 0-5; m = 4-20; n, p = 0-4 and cannot = 0 at the same time, b = 0 or 1) are useful as crosslinking agents or reactive diluents for hygroscopic polymers. Thus, 1.96 g acrylic amide and 4.0 g 2,2-bis(4-bromobutoxyphenyl)propane were dissolved in 20 mL DMF and heated at 0-5° for 6 h in the presence of KOH and phenothiazine to give 3.01 g 2,2-bis[4-(4-acrylamidobutoxy)phenyl]propane II. N-Acryloylpyrrolidine containing 0.2% II was mixed with 1% tert-butylperoxy-2-ethylhexanoate and polymerized at 40° for 50 h to

give a hygroscopic flexible block polymer.  
 IT **102413-94-5P**  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 102413-94-5 CAPLUS  
 CN 2-Propenamide, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-4,1-butanediyl)]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

=CH<sub>2</sub>

IT **102413-93-4P 102414-11-9P**  
 RL: PREP (Preparation)  
 (preparation of, as crosslinking agent for unsatd. polymers)  
 RN 102413-93-4 CAPLUS  
 CN 2-Propenamide, N,N'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy-4,1-butanediyl]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

=CH<sub>2</sub>


RN 102414-11-9 CAPLUS  
 CN 2-Propenamide, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-4,1-butanediyl)]bis[2-methyl- (9CI) (CA INDEX NAME)]





L17 ANSWER 49 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1985:616982 CAPLUS  
 DN 103:216982  
 TI Thiosulfate-containing polymers as water-borne thermosetting coatings. II  
 AU Thames, Shelby F.; Harris, Jeffery R.; Hutchens, Dale E.  
 CS Dep. Polym. Sci., Univ. South. Mississippi, Hattiesburg, MS, 39406-5125, USA  
 SO Proceedings of the Water-Borne and Higher-Solids Coatings Symposium (1985), 12th, 5-7  
 CODEN: PWHS5; ISSN: 0164-0402  
 DT Journal  
 LA English  
 AB Water-soluble or water-thinned coatings were prepared by the synthesis of thiosulfate-modified epoxy resins, ring-opening syntheses between aminoethanethiosulfuric acid and a variety of com. epoxy resins, and the synthesis of polymers by copolymn. of thiosulfate-containing monomers with various acrylic monomers.  
 IT **99316-25-3**  
 RL: USES (Uses)  
 (model compound, for aminoethanethiosulfuric acid-modified epoxy resins, for coatings)  
 RN 99316-25-3 CAPLUS  
 CN Ethanesulfonic acid, 2,2'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



L17 ANSWER 50 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1985:184853 CAPLUS  
 DN 102:184853  
 TI Polyether bisbiguanides  
 IN Eakin, Murdoch Alan; Gunn, Donald Murray; Pemberton, Dennis  
 PA Imperial Chemical Industries PLC, UK  
 SO Eur. Pat. Appl., 41 pp.

CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 125827	A1	19841121	EP 1984-302901	19840430
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 59210062	A2	19841128	GB 1983-12662	A 19830509
				JP 1984-91182	19840509
				GB 1983-12662	A 19830509
AB	Antibacterial RNR1C(:NR2)NHC(:NH)NR3(CH2)nXX1X2(CH2)n1NR4C(:NH)NHC(:NR5)NR6R7 [I; R, R1, R6, R7 = H, cycloalkyl, (un)substituted alkyl, Ph; NRR1, NR6R7 = heterocyclic; R3, R4 = H, cycloalkyl, (un)substituted alkyl, Ph, naphthyl, CHPh2; R2, R5 = H, alkyl; n, n1 ≥ 2; X, X2 = O, S; X1 = CMe2, (un)interrupted polymethylene, p-C6H4, p-(CH2)2C6H4] (.apprx.140 starting materials and products) were prepared Thus, p-(BrCH2)2C6H4 was treated with H2NCH2CH2SH to give p-(H2NCH2CH2SCH2)2C6H4, which reacted with Me2CHNHC(:NH)NHCN to give p-[Me2CHNHC(:NH)NHC(:NH)NHCH2CH2SCH2]2C6H4. Compds. of formula I had min. inhibitory concns. of 1-12 µg/mL against 8 gram-pos. bacteria and Candida albicans, and 25-250 µg/mL against 14 gram-neg. bacteria.				
IT	<b>96146-69-9P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, with cyanoguanidine)				
RN	96146-69-9 CAPLUS				
CN	Benzenemethanamine, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis-, dihydrochloride (9CI) (CA INDEX NAME)				




● 2 HCl

IT **96146-96-2P 96146-97-3P 96146-98-4P**  
**96146-99-5P 96147-00-1P 96147-01-2P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of, as bactericide)

RN 96146-96-2 CAPLUS


CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-ethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 96146-97-3 CAPLUS  
CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 96146-98-4 CAPLUS  
CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 96146-99-5 CAPLUS  
CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 96147-00-1 CAPLUS  
CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 96147-01-2 CAPLUS  
 CN Imidodicarbonimidic diamide, N,N''''-[(1-methylethylidene)bis(4,1-phenyleneoxy-3,1-propanediyl)]bis[N'-cyclohexyl-, dihydrochloride (9CI)  
 (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B



IT 4835-05-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with cyanoguanidine)  
 RN 4835-05-6 CAPLUS  
 CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)

(CA INDEX NAME)



L17 ANSWER 51 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:145242 CAPLUS

DN 102:145242

TI Amphiphilic cationic drugs and phospholipids influence the activities of  $\beta$ -galactosidase and  $\beta$ -glucosidase from liver lysosomal fraction of untreated rats

AU Harder, Achim; Dodt, Gabi; Debuch, Hildegard

CS Inst. Physiol. Chem., Univ. Koeln, Cologne, D-5000/41, Fed. Rep. Ger.

SO Biological Chemistry Hoppe-Seyler (1985), 366(2), 189-93

CODEN: BCHSEI; ISSN: 0177-3593

DT Journal

LA English

AB The influence of amphiphilic drugs and phospholipids on the activities of  $\beta$ -galactosidase (I) and  $\beta$ -glucosidase from liver lysosomal fractions of untreated rats, isolated by affinity chromatog. using castor bean lectins, was studied in vitro. Chloroquine (93  $\mu$ M) inhibited I activity by .apprx.30%, whereas O,O'-bis(diethylaminoethyl)hexestrol showed no inhibitory effect. Neutral phospholipids (phosphatidylcholine, phosphatidylethanolamine, sphingomyelin) inhibited I slightly. I activity was drastically reduced in the presence of acidic phospholipids [phosphatidylinositol, phosphatidylserine, bis(monoacylglycero)phosphate]. Lysosomal  $\beta$ -glucosidase was strongly inhibited by chloroquine and O,O'-bis(diethylaminoethyl)hexestrol. The neutral phospholipids showed only a moderate inhibitory effect, whereas the acidic phospholipids were stimulators. Bis(monoacylglycero)phosphate was by far the best stimulating compound

IT 64280-25-7


RL: BIOL (Biological study)

(galactosidase and glucosidase of liver lysosomes response to)

RN 64280-25-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 52 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:133599 CAPLUS

DN 102:133599


TI Epoxy based UV dual cure coatings

AU Noomen, A.  
 CS Sikkens B. V., Sassenheim, 2170 BA, Neth.  
 SO FATIPEC Congress (1984), 17th(1), 255-74  
 CODEN: FAPVAP; ISSN: 0430-2222  
 DT Journal  
 LA English  
 AB High volume shrinkage during curing and poor adhesion to steel, typical for the conventional UV-curable coatings, were eliminated by using an unsatd. epoxy resin which was cured to a touch dry state with a UV lamp, allowed to relax, and then cured to completion by heating in the presence of a ketimine curing agent. Optimal number of unsatd. groups in the resin, resin backbone structure, ketimine type, photoinitiator, and UV lamp were selected utilizing factorial exptl. design. The resins studied had aromatic or cycloaliph. backbone and contained 1-3 acrylic groups. The ketimines included a reaction product (I) [95415-50-2] of isophoronediamine with Me iso-Bu ketone, a bisphenol A diglycidyl ether-isophoronediamine adduct (II) [95415-51-3] and  $[-H_2CCH(CONHCH_2CH_2N:C_6H_5)_n]$  [95297-55-5]. The photoinitiators used were benzil [134-81-6] and 2-isopropylthioxanthone (III) [5495-84-1], and the lamps were normal or blue. The backbone structure, number of unsatd. groups, and type of lamp had no significant effect on the adhesion. The best adhesion was achieved with benzil and II. The best through cure was obtained with a resin containing 3 acrylic groups in the presence of I and III. A 2-pack primer was formulated having limited pot life and good adhesion to steel.


IT **95415-51-3**  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (crosslinking agents, for heat- and UV-curable acrylic epoxy resin coatings)

RN 95415-51-3 CAPLUS  
 CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[3,3,5-trimethyl-5-[[[(1-methylpentylidene)amino]methyl]cyclohexyl]amino]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



L17 ANSWER 53 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1985:106036 CAPLUS

DN 102:106036  
 TI Diethylaminoethoxyhexestrol causes hypertriglyceridemia in guinea pigs  
 AU Hostetler, Karl Y.; Pappu, Anuradha S.; Witztum, Joseph L.  
 CS Dep. Med., Univ. California, San Diego, CA, 92161, USA  
 SO Biochimica et Biophysica Acta, Lipids and Lipid Metabolism (1985), 833(1), 165-9  
 CODEN: BBLLA6; ISSN: 0005-2760  
 DT Journal  
 LA English  
 AB Treatment of rats, monkeys and man with diethylaminoethoxyhexestrol (I) [2691-45-4] causes phospholipid storage in liver and other tissues. However, this drug has not been reported to alter plasma lipoprotein levels. When guinea pigs were treated with diethylaminoethoxyhexestrol, the fasting plasma triacylglycerol levels increased dramatically, from 43 to 1281 mg/dL, after only 5 doses of 12.5 mg/kg. Diethylaminoethoxyhexestrol-treated guinea pigs had reduced postheparin lipoprotein lipase [9004-02-8] activity. In addition, in vitro assays showed that this agent inhibited guinea pig postheparin lipoprotein lipase. It is hypothesized that diethylaminoethoxyhexestrol causes hypertriglyceridemia in guinea pigs because these animals are known to have low levels of serum activator for lipoprotein lipase and may be unusually susceptible to agents that inhibit lipoprotein lipase activity. The ability to produce hypertriglyceridemia in guinea pigs provides an animal model in which the metabolic consequences of hypertriglyceridemia can be studied.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (hypertriglyceridemia from, in guinea pig)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 54 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1984:433075 CAPLUS  
 DN 101:33075  
 TI Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A  
 AU Pappu, Anuradha; Hostetler, Karl Y.  
 CS Dep. Med., Veterans Adm. Med. Cent., San Diego, CA, 92161, USA  
 SO Biochemical Pharmacology (1984), 33(10), 1639-44  
 CODEN: BCPA6; ISSN: 0006-2952  
 DT Journal  
 LA English  
 AB The hydrolysis of the neutral phospholipids, phosphatidylethanolamine and phosphatidylcholine, by rat liver lysosomal phospholipase A [9001-84-7] was inhibited to a greater degree than the hydrolysis of the acidic phospholipid, phosphatidylinositol, by the cationic amphiphilic drugs imipramine [50-49-7], propranolol [525-66-6], 4,4'-bis(diethylaminoethoxy)- $\alpha,\beta$ -diethyldiphenylethane [2691-45-4], and chlorpromazine [50-53-3]. In drug-induced lipidosis, the predominance of acidic phospholipids may be due to redirection of phospholipid metabolism towards the formation of acidic



phospholipids, with a resultant increased delivery of these lipids to lysosomes. It does not appear to be due to decreased enzymic hydrolysis of drug-acidic phospholipid complexes, at least when pure phospholipid substrates are used. Lysosomal storage of both acidic and neutral phospholipids appears to be caused by inhibition of lysosomal phospholipase action, in view of the probable high intralysosomal levels of these agents.


IT **2691-45-4**

RL: BIOL (Biological study)

(phospholipids hydrolysis by phospholipase A of liver lysosome inhibition by)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 55 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1984:157431 CAPLUS

DN 100:157431

TI Bonding of a simulated epoxy resin to aluminum surfaces studied by XPS

AU Bolouri, H.; Pethrick, R. A.; Affrossman, S.

CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, G1 1XL, UK

SO Applications of Surface Science (1977-1985) (1983), 17(2), 231-40

CODEN: ASUSDD; ISSN: 0378-5963

DT Journal

LA English

AB The adhesion was studied by XPS of diamine I [82000-98-4], a model compound for epoxy resins, on an anodized Al alloy and an Al alloy cleaned by ion bombardment and then exposed to oxygen. Thick adsorbed layers gave a narrow N 1s spectrum similar to that of the bulk material though assignment of binding energies was complicated by differential charging effects. The N 1s spectra of monomol. overlayers showed two types of N present. The high binding energy component was assigned to N bonded to the surface in a chelate structure in agreement with previous inelastic-electron-tunneling spectroscopy studies. Subsequent exposure to water altered the bonding of the N to the surface.


IT **82000-98-4**

RL: PEP (Physical, engineering or chemical process); PROC (Process)


(adsorption of, on aluminum alloys, mechanism of, as model for adhesion of epoxy resins)

RN 82000-98-4 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(diethylamino)- (9CI) (CA INDEX NAME)



L17 ANSWER 56 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1984:4370 CAPLUS  
 DN 100:4370  
 TI Experimental phospholipidosis induced by 4,4'-diethyl-  
 aminoethoxyhexestrol. Morphological and biochemical interpretations  
 AU Tashiro, Yukio; Watanabe, Yonosuke; Enomoto, Yasuhiro  
 CS Sch. Med., Keio Univ., Tokyo, 160, Japan  
 SO Acta Pathologica Japonica (1983), 33(5), 929-42  
 CODEN: APJAG; ISSN: 0001-6632  
 DT Journal  
 LA English  
 AB The effect of a generalized phospholipidosis-inducing drug,  
 diethylaminoethoxyhexestrol (DH, a coronary vasodilator), was studied  
 using rats. The initial alterations are characterized by the appearance  
 of abnormal cytoplasmic inclusion bodies. At the early stage of DH  
 administration, they appeared near the Golgi apparatus and consisted of polar  
 lipid, mainly phospholipids. The lysosome was regarded as the primary  
 site of the drug-induced morphol. changes. The drug-induced abnormal  
 cytoplasmic inclusion bodies were of 3 basic morphol. types, i.e.,  
 multilamellated, crystalloid, and finger-print-like bodies. Addnl., many  
 intermediate forms were found showing structural features of those basic  
 types. These drug-induced cytoplasmic changes, namely storage of  
 phospholipids, were considered to be reversible both morphol. and biochem.  
 after the cessation of DH administration. Drug-induced lipidosis might be  
 useful for studying the cytol. events of lysosomal storage of lipids;  
 however, it is not thought to be useful for studying inherited lipidosis  
 in human.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (phospholipidosis from, biochem. and morphol. of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-  
 phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 57 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1983:584960 CAPLUS  
 DN 99:184960  
 TI Polyelectrolyte complex as chemical sensitizer of photographic emulsions  
 IN Ivanov, B. M.; Shapka, V. Kh.; Kravtsov, V. S.; Tyurina, T. G.; Gnidashev,  
 V. V.; Sviridenko, M. N.  
 PA Dnepropetrovsk Chemical-Technological Institute, USSR; "Svema" Industrial  
 Enterprises, Shostka; All-Union Scientific-Research Institute of the  
 Photographic-Chemical Industry, Shostka  
 SO U.S.S.R.  
 From: Otkrytiya, Izobret., Prom. Obrazttsy, Tovarnye Znaki 1983, (23), 80.  
 CODEN: URXXAF  
 DT Patent  
 LA Russian  
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI SU 1024461 A1 19830623 SU 1982-3402165 19820302  
 SU 1982-3402165 19820302  
 AB A polyelectrolyte complex of formula  $[RNMe_2ZNMe_2]^{2+n}[XX']^{2-n}$  is used as a chemical sensitizer for photog. emulsions, where R = I, II, III or IV; Z = V, (CH<sub>2</sub>)<sub>2</sub>, or (CH<sub>2</sub>)<sub>6</sub>; X = NaS<sub>2</sub>O<sub>2</sub><sup>-</sup>; X' = Cl<sup>-</sup>; n = 10-30.  
 IT 87612-82-6 87612-84-8 87612-86-0  
 RL: USES (Uses)  
 (photog. emulsion sensitizer)  
 RN 87612-82-6 CAPLUS  
 CN Poly[oxy-1,3-phenyleneoxy(2-hydroxy-1,3-propanediyl)(dimethyliminio)(2-hydroxy-1,3-propanediyl)oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)(dimethyliminio)(2-hydroxy-1,3-propanediyl) salt with thiosulfurous acid (H<sub>2</sub>S<sub>2</sub>O<sub>2</sub>) (1:1)] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 87612-81-5  
 CMF (c37 H54 N2 O8)n  
 CCI PMS


PAGE 1-A



PAGE 1-B



CM 2  
 CRN 87612-65-5  
 CMF O2 S2



RN 87612-84-8 CAPLUS  
 CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)(dimethyliminio)-1,2-ethanediyl(dimethyliminio)(2-hydroxy-1,3-

propanediyl) salt with thiosulfurous acid (H<sub>2</sub>S<sub>2</sub>O<sub>2</sub>) (1:1)] (9CI) (CA INDEX NAME)


CM 1

CRN 87612-83-7


CMF (C<sub>27</sub> H<sub>42</sub> N<sub>2</sub> O<sub>4</sub>)<sub>n</sub>

CCI PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 87612-65-5

CMF O<sub>2</sub> S<sub>2</sub>



RN 87612-86-0 CAPLUS

CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)(dimethyliminio)-1,6-hexanediyl(dimethyliminio)(2-hydroxy-1,3-propanediyl) salt with thiosulfurous acid (H<sub>2</sub>S<sub>2</sub>O<sub>2</sub>) (1:1)] (9CI) (CA INDEX NAME)


CM 1

CRN 87612-85-9


CMF (C<sub>31</sub> H<sub>50</sub> N<sub>2</sub> O<sub>4</sub>)<sub>n</sub>

CCI PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 87612-65-5

CMF 02 S2



L17 ANSWER 58 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1983:552041 CAPLUS  
 DN 99:152041  
 TI Effect of chloroquine and o,o'-bis(diethylaminoethyl)hexestrol on acidic phospholipid membranes  
 AU Harder, Achim; Hille, Karl Heinz; Debuch, Hildegard  
 CS Inst. Physiol. Chem., Univ. Koeln, Cologne, Fed. Rep. Ger.  
 SO Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie (1983), 364(8), 997-1001  
 CODEN: HSZPAZ; ISSN: 0018-4888  
 DT Journal  
 LA English  
 AB The amphiphilic drugs chloroquine (I) [54-05-7] and o,o'-bis(diethylaminoethyl)hexestrol (II) [64280-25-7] are able to form complexes with the acidic phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol [4537-77-3]. The dissociation consts. of the complexes with chloroquine are independent of pH in the range investigated (4-7) as well as of temperature (4°-40°). The phase transition temperature of phospholipid is markedly reduced by both drugs, the effect is reversible by addition of Ca<sup>2+</sup>. Apparently, the drugs can increase the fluidity of acidic phospholipid membranes.  
 IT **87404-61-3**  
 RL: FORM (Formation, nonpreparative)

(formation of, as model for bis(diethylaminoethyl)hexestrol interaction with acidic phospholipid membrane)

RN 87404-61-3 CAPLUS


CN Hexadecanoic acid, 1-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyloxy]methyl]-1,2-ethanediyl ester, compd. with (R\*,S\*)-2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethylethanamine] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 64280-25-7

CMF C30 H48 N2 O2


Relative stereochemistry.



CM 2

CRN 4537-77-3

CMF C38 H75 O10 P



IT **64280-25-7**


RL: BIOL (Biological study)

(interaction with acidic phospholipid membrane of, phosphatidylcholine complexation as model for)

RN 64280-25-7 CAPLUS


CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L17 ANSWER 59 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1983:216399 CAPLUS  
 DN 98:216399  
 TI Studies of the curing of epoxide resins. XXXXI. The chemical structure of the intermediates in the curing process for epoxide resins cured with 1,6-hexanediamine in the presence of salicylic acid  
 AU Shimbo, Masaki; Harai, Shinichi  
 CS Fac. Eng., Kansai Univ., Suita, 564, Japan  
 SO Nippon Kagaku Kaishi (1983), (4), 571-7  
 CODEN: NKAKB8; ISSN: 0369-4577  
 DT Journal  
 LA Japanese  
 AB bisphenol A diglycidyl ether [1675-54-3] was cured at 30° with 1,6-hexanediamine [124-09-4] in the presence or absence of salicylic acid (I) [69-72-7] as an accelerator. The curing process in these systems was monitored by measurements of the mol. weight and functional groups in the products. The structures of the intermediates isolated from the cured resin using I as an accelerator were also determined. The product of this accelerated system showed a high conversion of the secondary amino group. Intermediates having mol. wts. 340-1600 were isolated, and their structures were determined by gel permeation chromatog., vapor pressure osmometry, NMR, and titrational analyses. The mol. chain of the reaction products was probably made from alternating diepoxide and diamine units.  
 IT **85961-14-4P**  
 RL: FORM (Formation, nonpreparative); PREP (Preparation)  
 (formation of, in polymerization of bisphenol A diglycidyl ether with hexanediamine)  
 RN 85961-14-4 CAPLUS  
 CN 2-Propanol, 1,1'-[[6-[[3-[4-[1-[4-[3-(6-aminohexyl)-2-hydroxypropoxy]phenyl]-1-methylethyl]phenoxy]-2-hydroxypropyl]amino]hexyl]imino]bis[3-[4-[1-methyl-1-[4-(oxiranylmethoxy)phenyl]ethyl]phenoxy]]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A







L17 ANSWER 60 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1983:5481 CAPLUS

DN 98:5481

TI Fast curing polyepoxide coating compositions with good pot life

IN McFadden, Russell T.

PA Dow Chemical Co., USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4353819	A	19821012	US 1981-243278	19810313
				US 1981-243278	19810313


AB The title compns. contain salts of nonvolatile amines with HCl and HBr or HI, glycidyl ester or ether polymers, solvents, and volatile ketones. Thus, a solution of polymer from Bu methacrylate 155, 2-ethylhexyl acrylate 84, methacrylic acid 77, and styrene 105 g in 455 g BuOH was heated with 54.0 g ethylenimine at 80° for 1 h and neutralized with 12.8 g 36% HCl and 82.9 g 49% HBr to give a solution having Gardner color 2, pH 6.4-6.5, and viscosity 3260 cP at 25°. A mixture of this solution 60.4, bisphenol A-epichlorohydrin copolymer [25068-38-6] (DER 331, epoxy equivalent 190) 23.8, EtOCH<sub>2</sub>CH<sub>2</sub>OH 20.6, and MEK 28.3 g had viscosity 61, 64, 75, and 97 cP after 1, 2, 4, and 6 h, resp., compared with gelation in 2 h with CH<sub>3</sub>CCl<sub>3</sub> in place of MEK. A 4-mil film (dry basis) of the solution on steel when cured 24-36 h at 25° was hard, clear, and adherent.

IT 83903-57-5

RL: MOA (Modifier or additive use); USES (Uses)  
(crosslinking agents, for epoxy resin coatings)

RN 83903-57-5 CAPLUS

CN Ethanamine, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis-, hydrobromide hydrochloride (9CI) (CA INDEX NAME)



●x HBr

●x HCl

L17 ANSWER 61 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1982:218353 CAPLUS

DN 96:218353

TI Mechanism of thermal degradation of low-molecular-weight compounds modeling the structure of network polymers from diepoxides and aromatic and aliphatic amines

AU Zarkhina, T. S.; Zelenetskii, A. N.; Zarkhin, L. S.; Karmilova, L. V.; Prut, E. V.; Enikolopyan, N. S.

CS USSR

SO Vysokomolekulyarnye Soedineniya, Seriya A (1982), 24(3), 584-95

CODEN: VYSAAF; ISSN: 0507-5475

DT Journal

LA Russian


AB Thermal degradation of low-mol.-weight compds. [e.g., N-(2-hydroxy-3-phenoxypropyl)aniline [16112-55-3]] modeling the structure of epoxy polymers crosslinked with aromatic or aliphatic amines is an initiated process which proceeds by the radical-chain mechanism via cleavage of C $\beta$  - C $\alpha$ N bonds with formation of PhOH, AcH, and Me<sub>2</sub>CO in the most cases. The initial temperature of degradation of aromatic amine derivs. was higher than that of aliphatic ones due to the inhibiting action of intermediate radicals of the former. The study was carried out in vacuum at 25-400° using mass spectrometry of the degradation products, m/e values, structures, and cleavage types.

IT 82000-98-4

RL: PEP (Physical, engineering or chemical process); PROC (Process) (thermal degradation of, mechanism of, as model for amine-crosslinked epoxy polymers)


RN 82000-98-4 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(diethylamino)- (9CI) (CA INDEX NAME)



L17 ANSWER 62 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1982:174195 CAPLUS  
 DN 96:174195  
 TI Changes in brain polyphosphoinositide metabolism induced by cationic amphiphilic drugs in vitro  
 AU Pappu, Anuradha S.; Hauser, George  
 CS Ralph Lowell Lab., McLean Hosp., Belmont, MA, 02178, USA  
 SO Biochemical Pharmacology (1981), 30(23), 3243-6  
 CODEN: BCPCA6; ISSN: 0006-2952  
 DT Journal  
 LA English  
 AB propranolol [525-66-6] (0.1 mM) and other cationic amphiphilic drugs enhanced the incorporation of inorg. phosphate-<sup>32</sup>P into polyphosphoinositides in rat cerebral cortex preps. in vitro. The extent of this drug-induced enhancement of labeling was partly regulated by the availability of cytidine and inositol. The increase in polyphosphoinositide metabolism appeared to be limited to neural tissues and was greater in gray than in white matter.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (polyphosphoinositide metabolism by brain cortex response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 63 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1982:69885 CAPLUS  
 DN 96:69885  
 TI Fire-resistant flexible phenolic resins  
 PA Matsushita Electric Works, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56118414	A2	19810917	JP 1980-21890	19800222
				JP 1980-21890	A 19800222

AB Resol phenolic resins containing bisphenol derivative units having halophenylaminohydroxypropyl groups are useful in manufacture of elec. insulators having good flexibility and fire resistance. Thus, a mixture of PhOH 940, 55% HCHO 736, and Et<sub>3</sub>N 10.1 parts was refluxed 85 min and cooled to ≤50°. A mixture of MeOH 600, Sb<sub>2</sub>O<sub>3</sub> 50, and 2,2-bis[3,5-bis(hydroxymethyl)-4-[2-hydroxy-3-(2,4,6-tribromoanilino)propoxy]phenyl]propane 500 parts was added to the above product to form a varnish which was applied to 254-μ kraft paper and dried. The above prepregs were laminated and pressed to give 1.6-mm copolymer [80181-30-2]-impregnated sheets having self extinguishing time 5.5 s and falling ball impact strength 9.0 kg/cm.


IT **80181-30-2**  
 RL: USES (Uses)  
 (elec. insulators, with improved flexibility and fire resistance)

RN 80181-30-2 CAPLUS  
 CN Formaldehyde, polymer with 5,5'-(1-methylethylidene)bis[2-[2-hydroxy-3-[(2,4,6-tribromophenyl)amino]propoxy]-1,3-benzenedimethanol] and phenol (9CI) (CA INDEX NAME)


CM 1

CRN 80181-29-9  
 CMF C37 H40 Br6 N2 O8

PAGE 1-A




PAGE 1-B




CM 2

CRN 108-95-2  
 CMF C6 H6 O




CM 3

CRN 50-00-0  
 CMF C H2 O



L17 ANSWER 64 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1982:45991 CAPLUS  
 DN 96:45991  
 TI Lipid-biochemical characterization of various kinds of lysosomes


- AU Matsuzawa, Yuji; Ishikawa, Katsunori; Tarui, Seichiro; Yamamoto, Akira; Hostetler, Karl Y.  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Rinsho Kagaku Shinpojumu (1980), 20, 2-9  
 CODEN: RKASDA; ISSN: 0386-3417  
 DT Journal  
 LA Japanese  
 AB Administration of antiinflammatory chloroquine [54-05-7] or 4,4'-bis(diethylaminoethoxy)  $\alpha,\beta$ -diethyldiphenylethane (DH) [2691-45-4] to rats in oral doses of 100 mg/kg for 7 days causes phospholipid and cholesteryl ester accumulation in the liver. The lipids of subcellular fractions from control rats and rats treated with chloroquine, DH, and Triton WR-1339 [25301-02-4] were studied. The phospholipid content of liver is increased 1.5-fold by chloroquine or DH treatment but is unaffected by Triton WR-1339. Chloroquine and DH cause a shift of acid phosphatase from the light mitochondrial fraction to the heavy mitochondrial fraction. Multilamellar bodies, an ultrastructural hallmark of chloroquine and DH-induced lipidosis, were isolated in a highly-purified form from the heavy mitochondrial fraction of chloroquine- or DH-treated rats. They are highly enriched in acid phosphatase indicating their lysosomal origin. In addition, they contain large amts. of phospholipids, cholesterol, and cholesteryl ester and are the sole site of bis(monoacylglycero)phosphate and the enzyme which catalyzes its synthesis from phosphatidylglycerol. Anal. of the phospholipid content showed that the entire excess phospholipid content of chloroquine- or DH-treated liver can be accounted for by the drug-induced multilamellar bodies. Triton WR-1339-induced lysosomes, which were isolated for comparison, also contain bis(monoacylglycero)phosphate and bis(monoacylglycero)phosphate synthetase. However, they differ from the drug-induced lysosomes in that their sphingomyelin content is much higher and their total phospholipid and phosphatidylinositol content much lower. The multilamellar bodies are the principal intracellular site of accumulation of chloroquine and DH. Increased delivery of phospholipid to lysosomes and decreased lysosomal catabolism of phospholipid are the factors which are thought to cause this exptl. lipidosis. High levels of phosphatidylinositol in the multilamellar body may be in part responsible for the increased content of bis(monoacylglycero)phosphate since it has been identified as an acyl donor in bis(monoacylglycero)phosphate synthesis.
- IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (lipidosis from, lysosome membrane lipids in)
- RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



- L17 ANSWER 65 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1981:614903 CAPLUS  
 DN 95:214903  
 TI Alterations of phospholipid metabolism in rat cerebral cortex mince induced by cationic amphiphilic drugs  
 AU Pappu, Anuradha S.; Hauser, George  
 CS Ralph Lowell Lab., McLean Hosp., Belmont, MA, 02178, USA

- SO Journal of Neurochemistry (1981), 37(4), 1006-14  
CODEN: JONRA9; ISSN: 0022-3042
- DT Journal
- LA English
- AB Cationic amphiphilic drugs (CADs) of varied clin. use were screened to determine their capacity to alter the pattern of labeling with  $^{32}\text{P}$ i of cerebral cortex mince phospholipids. The altered phospholipid labeling patterns were qual. similar, the prominent features being reduced incorporation into phosphatidylcholine and increased incorporation into phosphatidic acid. Relative potencies were:  $(\pm)$ -propranolol-HCl [3506-09-0] > chlorpromazine-HCl [69-09-0] = 4,4'-bis(diethylaminoethoxy)  $\alpha,\beta$ -diethyldiphenylethane [64280-25-7] > desipramine [50-47-5] > dibucaine-HCl [61-12-1] > pimozone [2062-78-4] > oxymetazoline-HCl [2315-02-8] = fenfluramine [458-24-2] = haloperidol [52-86-8] = chloroquine [54-05-7] > amphetamine-HCl [2706-50-5] = no drug added. Propranolol was used to study the action of CADs further. Its effect was time- and dose-dependent, but in contrast with pineal gland, no label appeared in phosphatidyl-CMP (CDP-diacylglycerol), nor did dialysis of the mince to reduce diffusible substrates or exogenous addition of substrates cause appearance of liponucleotide. Thus, lack of diffusible precursors is not responsible for CAD effects in vitro. Pulse-chase expts. with  $^{32}\text{P}$ i and  $[2-^3\text{H}]$ glycerol suggested that inhibition of phosphatidate phosphohydrolase [9025-77-8] may be partly responsible for the observed alterations in phospholipid labeling in the presence of CADs. The relation of these results to the induction of lipidoses by these drugs is discussed.
- IT 64280-25-7  
RL: BIOL (Biological study)  
(phospholipid metabolism by brain cerebral cortex response to, lipidoses induction in relation to)
- RN 64280-25-7 CAPLUS
- CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



- L17 ANSWER 66 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN
- AN 1981:449323 CAPLUS
- DN 95:49323
- TI Study of the complex-formation reaction in the amino derivative-bismuth(3+)-iodide system by the spectrophototurbidimetric titration method
- AU Popov, A. I.; Oleshko, G. I.
- CS Perm. Farm. Inst., Perm, USSR
- SO Farmatsiya (Moscow, Russian Federation) (1981), 30(3), 73-5  
CODEN: FRMTAL; ISSN: 0367-3014
- DT Journal
- LA Russian
- AB Complexation between several pharmaceuticals (amine derivs.) and  $\text{Bi}(\text{NO}_3)_3$  in the presence of  $\text{I}^-$  was studied by mixing 5 mL 0.0005M amine derivative, 5 mL 0.001  $\text{HNO}_3$  5 mL 0.01 N KI and water (to 20 mL), and titrating at 620 nm

with 0.0005M Bi(NO<sub>3</sub>)<sub>3</sub>. A pos. reaction was indicated by formation of a microheterogeneous system and change in the absorbance. Aromatic amine derivs. showed no complexation. Hydrophilic groups had a significant effect on the formation of ternary complexes. The hydroxyl group in the base makes the ternary complex soluble in water. The tertiary N in the aliphatic chain and heterocycle improves the complexation. The method may be used for quant. determination of amine drugs.


IT 69-14-7

RL: BIOL (Biological study)

(complexation of, with bismuth-iodide, spectrophototurbidimetry in)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 67 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1981:58255 CAPLUS

DN 94:58255

TI Effects of chloroquine and 4,4'-bis(diethylaminoethoxy) $\alpha,\beta$ -diethyldiphenylethane on the incorporation of [3H]-glycerol into the phospholipids of rat liver lysosomes and other subcellular fractions, in vivo

AU Matsuzawa, Yuji; Hostetler, Karl Y.

CS Dep. Med., VA Med. Cent., San Diego, CA, 92161, USA

SO Biochimica et Biophysica Acta, Lipids and Lipid Metabolism (1980), 620(3), 592-602

CODEN: BBLA6; ISSN: 0005-2760

DT Journal

LA English

AB Treatment of rats with chloroquine (I) [54-05-7] or 4,4'-bis(diethylaminoethoxy) $\alpha,\beta$ -diethyldiphenylethane (II) [2691-45-4] (both at 100 mg/kg/day for 7 days, orally) resulted in greatly enhanced incorporation of [3H]glycerol into lysosomal phospholipids in spite of the fact that the incorporation of [3H]glycerol into microsomal phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol by de novo synthesis was reduced. Phosphatidylglycerol was labeled at a greatly increased rate, especially in

liver


microsomes from I or II-treated rats, while the incorporation of [3H]glycerol into phosphatidylinositol in microsomes was reduced. Apparently, I and II exert a specific effect on phosphatidylglycerol metabolism in liver. [3H]Glycerol incorporation into bis(monoacylglycerol)phosphate was found only in lysosomes. Apparently there is an increase in the transfer of newly-synthesized microsomal phospholipids to lysosomes and/or decreased lysosomal catabolism of phospholipids in I- and II-treated rat liver. The mechanisms involved in drug-induced lipidosis are discussed.

IT 2691-45-4

RL: BIOL (Biological study)

(lipidosis from, liver phospholipid metabolism in relation to)

RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 68 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1981:15385 CAPLUS

DN 94:15385

TI 2-Amido- or 2-amino-alkyl ethers of polyhydric polyphenols

IN Kaiser, Mark E.; Smith, Harry A.

PA Dow Chemical Co., USA

SO U.S., 7 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4195154	A	19800325	US 1977-824768	19770815
				US 1977-824768	A 19770815


AB Polyphenols I (Z = alkylene, alkylidene; Z1 = chemical bond, O, S, alkylene, alkylidene; R, R1, and R2 are each independently inert substituents; q = 0-10; n = 0, 1, 2, 3; m and p are each independently 0, 1, 2, 3, 4) reacted with oxazolines II (R3 = H, hydrocarbyl; R4, R5, R6, and R7 are each independently H, alkyl, hydroxyalkyl) and catalysts, Sn salts or group IB, IIB, VIB, VIIB, or VIII transition metal salts, to give the resp. ethers III [at least two of the R8 groups are CR6R7R4R5NHCOR3 and the other(s) is/are H]; were effective as curing agents for epoxy resins. Bisphenol A was heated with 2-ethyl-2-oxazoline and Zn(OAc)2 to yield the bis(2-propionamidoethyl) ether.

IT 74228-86-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and bactericidal and fungicidal activity and for crosslinking of epoxy resins)

RN 74228-86-7 CAPLUS

CN Ethanamine, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
 (CA INDEX NAME)



IT 74218-37-4P 74218-38-5P 74228-85-6P


74228-87-8P 74244-10-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 74218-37-4 CAPLUS




CN Propanamide, N,N'-[(1-methylethylidene)bis[(dibromo-4,1-phenylene)oxy-2,1-ethanediyl]]bis- (9CI) (CA INDEX NAME)



4 ( D1-Br )

RN 74218-38-5 CAPLUS


CN Ethanamine, 2,2'-[(1-methylethylidene)bis[(dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



4 ( D1-Br )


RN 74228-85-6 CAPLUS

CN Propanamide, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)




RN 74228-87-8 CAPLUS

CN Benzamide, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)



RN 74244-10-3 CAPLUS


CN Ethanamine, 2,2'-[(1-methylethylidene)bis[(dibromo-4,1-phenylene)oxy]]bis-, hydrochloride (9CI) (CA INDEX NAME)



4 ( D1- Br )

● x HCl

L17 ANSWER 69 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1980:542820 CAPLUS  
 DN 93:142820  
 TI Effects of cationic amphiphilic drugs on phospholipid metabolism in the nervous system  
 AU Hauser, G.; Pappu, A. S.; Smith, T. L.; Eichberg, J.  
 CS McLean Hosp., Belmont, MA, 02178, USA  
 SO Progress in Clinical and Biological Research (1980), 39(Neurochem. Clin. Neurol.), 469  
 CODEN: PCBRD2; ISSN: 0361-7742  
 DT Journal  
 LA English  
 AB In the rat pineal gland propranolol [525-66-6] caused changes in the phospholipid labeling pattern which were not related to adrenergic receptor stimulation. The most striking change was an increase in phosphatidyl-CMP. Several local anesthetics, tricyclic antidepressants, imidazolines, and phenothiazines, as well as chloroquine [54-05-7] and diethylaminoethoxyhexestrol [2691-45-4] had similar effects. In the cerebral cortex, similar phospholipid changes were observed except no phosphatidyl-CMP was detected.  
 IT 2691-45-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (phospholipid metabolism by nervous system response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 70 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1980:437028 CAPLUS  
 DN 93:37028  
 TI Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine

and 4,4'-bis(diethylaminoethoxy) $\alpha,\beta$ -diethyldiphenylethane

AU Matsuzawa, Yuji; Hostetler, Karl Y.  
 CS Dep. Med., VA Med. Cent., San Diego, CA, 92161, USA  
 SO Journal of Biological Chemistry (1980), 255(11), 5190-4  
 CODEN: JBCHA3; ISSN: 0021-9258


DT Journal  
 LA English

AB The effect chloroquine (I) [54-05-7] or 4,4'-bis(diethylaminoethoxy)- $\alpha,\beta$ -diethyldiphenylethane (II) [ 2691-45-4], cationic amphiphilic agents, on a soluble delipidated preparation from rat liver lysosomes which contains phospholipase A [9001-84-7] and C [9001-86-9] activity was examined. Both compds. were potent inhibitors of lysosomal phospholipase A and C activities. However, these agents did not cause substantial inhibition of the lysosomal phospholipase A which catalyzes the transacylation step in the synthesis of bis(monoacylglycero)phosphate, a lysosomal marker lipid which is greatly increased in this drug-induced phospholipidosis. The inhibition of lysosomal phospholipases A and C was reversible since full activity could be restored by dialysis or desalting. The mechanism of inhibition of lysosomal phospholipases A and C by these drugs is as yet unknown and will require purification of the resp. enzymes. The enzymes inhibition by these 2 compds. may be a major factor in the biochem. pathogenesis of drug-induced phospholipidosis.

IT 2691-45-4  
 RL: BIOL (Biological study)  
 (phospholipase A and C inhibition by)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 71 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1980:418861 CAPLUS

DN 93:18861


TI Studies on the metabolism in human liver of a coronary vasodilator, 4,4'-diethylaminoethoxy hexestrol

AU Tsujimura, Ryotaro; Aakeda, Shozo  
 CS Sch. Med., Mie Univ., Tsu, Japan  
 SO Mie Medical Journal (1979), 29(2), 99-108  
 CODEN: MMJJAI; ISSN: 0026-3532


DT Journal  
 LA English

AB 4,4'-Diethylaminoethoxyhexestrol-2HCl (I) [69-14-7] and its metabolites were extracted from the livers of autopsied patients having undergone long-term treatment with I as a coronary vasodilator. The identification of I and its metabolites was undertaken by using a gas-liquid chromatog.-high resolution mass spectrometer. The compds. extracted from human liver were identical with those of I, N-deethylated derivative, and 3 other metabolites which were formed in minor amts. It is suggested that the metabolic pattern of I in human liver differs from that in rat liver, as rat liver can oxidize I, whereas human liver can not. Human liver can, however, metabolize I most often in the direction of N-deethylation. However, N-deethylated metabolite can not be conjugated in liver and

therefore can not be made water soluble  
 IT **2691-45-4D**, metabolites  
 RL: FORM (Formation, nonpreparative)  
 (formation of, by liver)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



IT **69-14-7**  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (metabolism of, by liver)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 72 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1980:174485 CAPLUS  
 DN 92:174485  
 TI Studies on drug-induced lipidosis: subcellular localization of phospholipid and cholesterol in the liver of rats treated with chloroquine or 4,4'-bis(diethylaminoethoxy) $\alpha,\beta$ -diethyldiphenylethane  
 AU Matsuzawa, Yuji; Hostetler, Karl Y.  
 CS Dep. Med., VA Med. Cent., San Diego, CA, 92161, USA  
 SO Journal of Lipid Research (1980), 21(2), 202-14  
 CODEN: JLPRAW; ISSN: 0022-2275  
 DT Journal  
 LA English  
 AB Administration of chloroquine phosphate (I phosphate) [50-63-5] or 4,4'-bis(diethylaminoethoxy) $\alpha,\beta$ -diethyldiphenylethane (DH) [2691-45-4] to rats in oral doses of 100 mg/kg for 7 days causes phospholipid and cholesteryl ester accumulation in liver. To further characterize this drug-induced lipidosis, the lipids of subcellular fractions from control rats and rats treated with I, DH, and Triton WR-1339 were isolated and characterized. The phospholipid content of liver was increased 1.5-fold by I or DH treatment but was unaffected by Triton WR-1339. Acid phosphatase was increased by treatment with these 3 agents. I and DH cause a shift of acid phosphatase from the light mitochondrial fraction (L) to the heavy mitochondrial fraction (M).


Multilamellar bodies, an ultrastructural hallmark of I- and DH-induced lipidosis, were isolated in a highly-purified form from the M fraction of I- or DH-treated rats. They were highly enriched in acid phosphatase indicating their lysosomal origin. In addition, they contained large amounts of phospholipid, cholesterol [57-88-5] and cholesteryl ester and were the sole site of bis(monoacylglycero)phosphate and the enzyme which catalyzes its synthesis from phosphatidylglycerol. Anal. of the phospholipid content of the resp. control and drug-treated liver fractions showed that the entire excess phospholipid content of I- or DH-treated liver can be accounted for by the drug-induced multilamellar bodies. Triton WR-1339-induced lysosomes, which were isolated for comparison, also contained bis(monoacylglycero)phosphate and bis(monoacylglycero)phosphate synthetase. However, they differed from the drug-induced lysosomes in that their sphingomyelin content was much higher and their total phospholipid and phosphatidylinositol content was much lower. The multilamellar bodies were the principal intracellular site of accumulation of I and DH, resp. Increased delivery of phospholipid to lysosomes and decreased lysosomal catabolism of phospholipid were the factors which were thought to cause this exptl. lipidosis. High levels of phosphatidylinositol in the multilamellar body may be in part responsible for the increased content of bis(monoacylglycero) phosphate since it has been identified as an acyl donor in bis(monoacylglycero)phosphate synthesis.

IT 2691-45-4

RL: BIOL (Biological study)  
(phospholipids of liver subcellular fractions response to)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 73 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1980:23556 CAPLUS

DN 92:23556

TI Polyalkylated 4-aminopiperidine derivatives

IN Soma, Nobuo; Morimura, Syoji; Yoshioka, Takao; Kurumada, Tomoyuki

PA Sankyo Co., Ltd., Japan

SO U.S., 46 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4166813	A	19790904	US 1978-903592	19780508
	JP 53144579	A2	19781215	JP 1977-57271	A 19770518
	JP 63032784	B4	19880701	JP 1977-57271	19770518
					A

PATENT FAMILY INFORMATION:

FAN 1979:104959

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 2821579	A1	19781130	DE 1978-2821579	19780517
	DE 2821579	C2	19900802		
	JP 53144579	A2	19781215	JP 1977-57271	A 19770518
	JP 63032784	B4	19880701	JP 1977-57271	19770518


AB Polyalkylated 4-aminopiperidine derivs. and their acid addition salts are useful as heat and light stabilizers for polymers and are less volatile and impart less color than conventional stabilizers. Thus, 150 mL MeOH containing 21.2 g 4-butylamino-2,2,6,6-tetramethylpiperidine [36177-92-1] and 17.0 g 2,2-bis[p-(2,3-epoxypropoxy)phenyl]propane [1675-54-3] was refluxed 5 h to give 2,2-bis[4-[3-[N-butyl-N-(2,2,6,6-tetramethyl-4-piperidyl)amino]-2-hydroxypropoxy]phenyl]propane (I) [69303-52-2]. A mixture containing polypropylene [9003-07-0] 100, stearyl 3-(4-hydroxy-3,5-di-tert-butylphenyl) propionate 0.2, and I 0.25 part was blended 10 min at 200° and compression molded into films having 4.6 elongation retention ratio (the ratio of the time required for stabilized test specimens to reach 50% elongation at break to that required for an unstabilized sample).

IT 69268-61-7 69268-80-0


RL: PEP (Physical, engineering or chemical process); PROC (Process) (heat and light stabilizers, for polymers)

RN 69268-61-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(2,2,6,6-tetramethyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)




PAGE 1-B




RN 69268-80-0 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[(1,2,2,6,6-pentamethyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)




PAGE 1-B



L17 ANSWER 74 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1979:502066 CAPLUS  
 DN 91:102066  
 TI Differential effects of chloroquine and of several other amphiphilic cationic drugs upon rat choroid plexus  
 AU Frisch, W.; Luellmann-Rauch, R.  
 CS Dep. Anat., Univ. Kiel, Kiel, D-2300, Fed. Rep. Ger.  
 SO Acta Neuropathologica (1979), 46(3), 203-8  
 CODEN: ANPTAL; ISSN: 0001-6322  
 DT Journal  
 LA English  
 AB Several cationic amphiphilic drugs, each of which is known to induce generalized lipidosis in rats, were compared with respect to their cytotoxic effects on rat choroid plexus epithelium. Chloroquine diphosphate [50-63-5] induced large cytoplasmic vacuoles, whereas the other drugs (quinacrine-2HCl [69-05-6], 4,4'-diethylaminoethoxyhexestrol [2691-45-4], chlorphentermine-HCl [151-06-4], iprindole-HCl [20432-64-8], 1-chloro-amitriptyline [52845-72-4], clomipramine-HCl [17321-77-6]) caused formation of lamellated or crystalloid inclusions as usually seen in drug-induced lipidosis. The ultrastructure of the chloroquine-induced vacuoles suggested storage of water-soluble materials (polar lipids and/or nonlipid materials) in addition to nonwater-soluble polar lipids.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (lipidosis of choroid plexus from)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]



L17 ANSWER 75 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1979:161888 CAPLUS  
 DN 90:161888  
 TI The formation of N-de-ethyl derivatives of 4,4'-bis(β-diethylaminoethoxy)-α,β-diethyldiphenylethane by red blood cells  
 AU Matsuzawa, Yuji; Yamamoto, Akira; Wada, Fumio  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Rinsho Kagaku Shinpojumu (1978), Volume Date 1977, 17, 116-21  
 CODEN: RKASDA; ISSN: 0386-3417  
 DT Journal  
 LA Japanese  
 AB 4,4'-Bis(β-diethylaminoethoxy)-α,β-diethyldiphenylethane (I) [2691-45-4] was incorporated into erythrocytes and was deethylated. This deethylation was mainly mediated by Hb. Apparently, under physiol. conditions, drug metabolism occurs not only in the liver but also in erythrocytes.  
 IT 2691-45-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (dealkylation of, by erythrocytes, drug metabolism in relation to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 76 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1979:104959 CAPLUS  
 DN 90:104959  
 TI Polyalkylated 4-aminopiperidine derivatives  
 IN Soma, Nobuo; Morimura, Syoji; Yoshioka, Takao; Kurumada, Tomoyuki  
 PA Sankyo Co., Ltd., Japan  
 SO Ger. Offen., 109 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2821579	A1	19781130	DE 1978-2821579	19780517
	DE 2821579	C2	19900802		
	JP 53144579	A2	19781215	JP 1977-57271	A 19770518
	JP 63032784	B4	19880701	JP 1977-57271	19770518



A

## PATENT FAMILY INFORMATION:

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4166813	A	19790904	US 1978-903592	19780508
	JP 53144579	A2	19781215	JP 1977-57271	19770518
	JP 63032784	B4	19880701	JP 1977-57271	19770518

A

AB Compound I (R = R2 = H, R1 = Me) (II) [69303-51-1], compound I (R = Me, R1 = R2 = H) [69268-80-0], compound I (R = Me, R1 = R2 = Ac) [69268-81-1], 2-hydroxy-1,3-bis[N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)amino]propane [69268-58-2], 1,2-bis[3-[N-butyl-N-(2,2,6,6-tetramethyl-4-piperidyl)amino]-2-hydroxypropoxy]ethane [69268-59-3], bis[3-[N-butyl-N-(2,2,6,6-tetramethyl-4-piperidyl)amino]-2-hydroxypropyl] 1,2-cyclohexanedicarboxylate [69268-60-6], and 19 similar compds. are prepared as heat and light stabilizers for polymers. The compds. have low volatility and do not discolor polymers. Thus, 2,2,6,6-tetramethyl-4-(methylamino)piperidine [62995-79-3] and 2,2-bis[4-(2,3-epoxypropoxy)phenyl]propane [1675-54-3] were used to prepare II. The addition of 0.25% II to polypropylene [9003-07-0] containing 0.2% phenolic antioxidant increased the degradation resistance in UV light by a factor of 5.7, compared with 2.0 with Tinuvin 327 instead of II.

IT 69268-61-7P 69268-80-0P


RL: PREP (Preparation)

(manufacture of, as stabilizers for plastics)


RN 69268-61-7 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-((2,2,6,6-tetramethyl-4-piperidiny)amino)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 69268-80-0 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-((1,2,2,6,6-pentamethyl-4-piperidiny)amino)]- (9CI) (CA INDEX NAME)



PAGE 1-B



L17 ANSWER 77 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1979:103593 CAPLUS

DN 90:103593

TI p,p'-(2-Diethylaminoethoxy)-3,4-diphenylhexane dihydrochloride

IN Machon, Zdzisław; Kuczyński, Leonard; Zawisza, Tadeusz

PA Farmaceutyczno-Chemiczna Spółdzielnia Pracy "Labor", Pol.

SO Pol., 2 pp.

CODEN: POXXA7

DT Patent

LA Polish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	PL 85193	P	19760430	PL 1972-159295	19721205
				PL 1972-159295	A 19721205


AB The title compound was prepared in 98% yield by treating Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl with (p-HOC<sub>6</sub>H<sub>4</sub>)EtCHCHEt(C<sub>6</sub>H<sub>4</sub>OH-p) in presence of NaOH at 81° 4-5 h followed by treatment with HCl.

IT **69-14-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 69-14-7 CAPLUS


·CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L17 ANSWER 78 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1978:501892 CAPLUS  
 DN 89:101892  
 TI Herbicidal and algicidal compositions  
 IN Lacefield, William Bryant  
 PA Eli Lilly and Co., USA  
 SO Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2738873	A1	19780302	DE 1977-2738873	19770829
				US 1976-719485	A 19760831
	GB 1584428	A	19810211	GB 1977-35528	19770824
				US 1976-719485	A 19760831
	BE 858216	A1	19780228	BE 1977-8353	19770830
				US 1976-719485	A 19760831
	JP 53029929	A2	19780320	JP 1977-105718	19770830
				US 1976-719485	A 19760831
	FR 2363285	A1	19780331	FR 1977-26316	19770830
				US 1976-719485	A 19760831
	BR 7705756	A	19780627	BR 1977-5756	19770830
				US 1976-719485	A 19760831
	NL 7709612	A	19780302	NL 1977-9612	19770831
				US 1976-719485	A 19760831
AB	I (R = H, halogen, MeO, NO <sub>2</sub> ; R <sub>1</sub> = H, C <sub>1</sub> -2 alkyl or CH <sub>2</sub> CH <sub>2</sub> OH; R <sub>2</sub> = H, C <sub>1</sub> -4 alkyl, benzyl, cyclohexyl, CH <sub>2</sub> CH <sub>2</sub> OH; n = 0 or 1; m = 2, 3 or 4 when n = 0 and 2 when n = 1; X = CH <sub>2</sub> , CH <sub>2</sub> CH <sub>2</sub> , CH <sub>3</sub> CH, or S) and their salts are algicides and herbicides. Thus, 2,2'-methylenebis[3-(4-chlorophenoxy)-N-butylpropylamine) di-HCl [66742-70-9] controlled the weeds Ceratophyllum demersum, Hydrilla verticillate, and the algae Chlorella, Scenedesmus, and Anacystis. The synthesis of I is given.				
IT	66742-62-9P 66742-70-9P 66742-75-4P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and algicidal and herbicidal activities of)				
RN	66742-62-9 CAPLUS				
CN	1-Propanamine, 3,3'-[methylenebis(2,1-phenyleneoxy)]bis[N,N-dimethyl]-, dihydrochloride (9CI) (CA INDEX NAME)				




● 2 HCl

RN 66742-70-9 CAPLUS  
 CN 1-Butanamine, N,N'-[methylenebis[(4-chloro-2,1-phenylene)oxy-3,1-propanediyl]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-75-4 CAPLUS  
CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 66742-66-3P 66742-67-4P 66742-71-0P  
66742-73-2P 66742-74-3P 66742-80-1P  
66742-83-4P 66742-84-5P 66742-85-6P  
66776-62-3P 66776-63-4P  
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and herbicidal activity of)  
RN 66742-66-3 CAPLUS  
CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-67-4 CAPLUS  
 CN Cyclohexanamine, N,N'-[methylenebis[(4-chloro-2,1-phenylene)oxy-3,1-propanediyl]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-71-0 CAPLUS  
 CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N-(1,1-dimethylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 66742-73-2 CAPLUS  
 CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[-N-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 66742-74-3 CAPLUS

CN 2-Butanamine, N,N'-[methylenebis[(4-chloro-2,1-phenylene)oxy-3,1-propanediyl]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-80-1 CAPLUS  
CN Benzenemethanamine, N,N'-[methylenebis[(4-chloro-2,1-phenylene)oxy-3,1-propanediyl]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-83-4 CAPLUS  
CN 2-Butanamine, 4,4'-[methylenebis[(4-nitro-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-84-5 CAPLUS  
CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 66742-85-6 CAPLUS  
CN Ethanamine, 2,2'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 66776-62-3 CAPLUS


CN 2-Butanamine, 4,4'-[methylenebis[(4-methyl-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 66776-63-4 CAPLUS

CN 2-Butanamine, 4,4'-[1,2-ethanediylbis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 66742-63-0P 66742-65-2P 66742-68-5P  
66742-72-1P 66742-76-5P 66742-81-2P  
66742-82-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as algicide and herbicide)

RN 66742-63-0 CAPLUS


CN 2-Butanamine, 4,4'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 66742-65-2 CAPLUS  
CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-68-5 CAPLUS  
CN Ethanol, 2,2'-[methylenebis[(4-chloro-2,1-phenylene)oxy-3,1-propanediylimino]]bis-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 66742-72-1 CAPLUS  
CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 66742-76-5 CAPLUS  
 CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N-propyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 66742-81-2 CAPLUS  
 CN 1-Propanamine, 3,3'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis[N-ethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 66742-82-3 CAPLUS  
 CN 2-Butanamine, 4,4'-[methylenebis[(4-methoxy-2,1-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 79 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1978:500113 CAPLUS  
 DN 89:100113  
 TI Drug-induced retinal lipidosis: differential susceptibilities of pigment epithelium and neuroretina toward several amphiphilic cationic drugs  
 AU Drenckhahn, Detlev; Luellmann-Rauch, Renate  
 CS Dep. Anat., Univ. Kiel, Kiel, Fed. Rep. Ger.  
 SO Experimental and Molecular Pathology (1978), 28(3), 360-71  
 CODEN: EXMPA6; ISSN: 0014-4800  
 DT Journal  
 LA English  
 AB A series of various cationic amphiphilic drugs induced generalized storage of polar lipids. The effects upon rat retina of 4 lipidosis-inducing drugs (triparanol [78-41-1], chloroquine [54-05-7], 4,4'-diethylaminoethoxyhexestrol [2691-45-4], and chlorcyclizine [82-93-9]) were studied and compared. Rats were treated with high oral drug doses (ranging from 50 to 150 mg/kg) for several weeks. Basically, all drugs induced lipidosis-like retinal changes but with great differences in the distributional pattern of the alterations throughout the retinal layers. Triparanol affected only the pigment epithelium and Mueller cells. Chloroquine and 4,4'-diethylaminoethoxyhexestrol affected mainly the sensory retina (neurons and Mueller cells). Chlorcyclizine changed both the pigment epithelium and the sensory retina to similar degrees. These differences are tentatively suggested to be due to differential affinities of the drugs to individual polar lipids.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (eye retina lipidosis from)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 80 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1978:499556 CAPLUS  
 DN 89:99556  
 TI Study on the metabolism of 4,4'-diethylaminoethoxyhexesterol in rat liver by high resolution gas chromatography-mass spectrometry  
 AU Tsujimura, Ryotaro; Hasegawa, Yoshikazu; Itagaki, Matahiro  
 CS Sch. Med., Mie Univ., Tsu, Japan  
 SO GC-MS News (1975), 3(1), 2-3  
 CODEN: GMNEDS; ISSN: 0388-1288  
 DT Journal  
 LA Japanese  
 AB Chromatog. analysis of the title compound [2691-45-4], a vasodilator, and its metabolites in rat liver showed 5 components corresponding to these compds. The analysis of liver exts. of patients receiving the compound showed different metabolites than were observed in the rat, indicating that the metabolic pathways in humans are different from those in rats.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (as diethylaminoethoxyhexesterol metabolite, in liver)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]



RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (metab. of, in liver, species difference in)


L17 ANSWER 81 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1978:197739 CAPLUS  
 DN 88:197739  
 TI Interferometric determination of pharmaceuticals  
 AU Laipanov, A. Kh.; Laipanova, R. Ya.  
 CS Kursk. Med. Inst., Kursk, USSR  
 SO Farmatsiya (Moscow, Russian Federation) (1978), 27(2), 67-8  
 CODEN: FRMTAL; ISSN: 0367-3014  
 DT Journal  
 LA Russian  
 AB Mesatone [59-42-7], ephedrine [299-42-3], and corazole [54-95-5] in aqueous injection solns. and diethiphen [69-14-7] in tablets (after extraction with CHCl<sub>3</sub>) were subjected to interferometric anal. and the concns. of drugs were determined by comparison of the exptl. results with calibration curves. The relative errors for determination of these drugs by interferometry were 0.33, 0.35, 0.40, and 0.44%, resp.  
 IT **69-14-7**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, in tablets, by interferometry)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)]



● 2 HCl

L17 ANSWER 82 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1978:182747 CAPLUS  
 DN 88:182747  
 TI Lysosomal phospholipids from rat liver after treatment with different drugs  
 AU Tjong, Hong Boe; Lepthin, Jochen; Debuch, Hildegard  
 CS Inst. Physiol. Chem., Univ. Koeln, Cologne, Fed. Rep. Ger.  
 SO Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie (1978), 359(1), 63-9  
 CODEN: HSZPAZ; ISSN: 0018-4888  
 DT Journal  
 LA English  
 AB After rats were treated with 5 different drugs p-ethoxyacetanilide (I) [62-44-2], indomethacin [53-86-1], Na noramidopyrine methanesulfonate [68-89-3], o,o'-bis(diethylaminoethyl)hexestrol [64280-25-7], and chloroquine diphosphate [50-63-5] for 3-4 wk lysosomal fractions from liver cells contained widely varying amts. of acid phosphatase [9001-77-8] indicating that the concentration of lysosomes within these fractions differed. Further, the amts. and patterns of phospholipids reflected this fact. When lysobisphosphatidic acid was condensed as marker lipid for secondary lysosomes, significant quantities of this acidic phospholipid were found only in those lysosomal fractions which were also rich in acid phosphatase activity. Twelve percent of the lysosomal phospholipids from animals receiving the hexestrol derivative, and 19% of those from the chloroquine experiment were present as this acidic phospholipid. The fatty acid comps. of this lysosomal phospholipid were not the same in all lysosome fractions. The more lysobisphosphatidic acid present in the lysosomes, the more unsatd. are the fatty acids. Thus, after treatment with chloroquine, more than 90% of the fatty acids from this fraction are unsatd.; C22:6 represents about 70% of the total.  
 IT 64280-25-7  
 RL: BIOL (Biological study)  
 (phospholipids of liver lysosomes response to)  
 RN 64280-25-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 83 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1978:48464 CAPLUS

DN 88:48464

TI Studies on drug-induced lipidosis. VIII. Correlation between drug accumulation and acidic phospholipids

AU Matsuzawa, Yuji; Yamamoto, Akira; Adachi, Susumu; Nishikawa, Mitsuo

CS 2nd Dep. Intern. Med., Osaka Univ. Med. Sch., Osaka, Japan

SO Journal of Biochemistry (Tokyo, Japan) (1977), 82(5), 1369-77

CODEN: JOBIAO; ISSN: 0021-924X

DT Journal

LA English

AB The effect of 4,4'-bis( $\beta$ -diethylaminoethoxy)- $\alpha,\beta$ -diethyldiphenylethane (I) on lipid metabolism in the liver differed considerably in different animal species, humans, monkeys, and rats, because of differences in drug-metabolizing ability. Monkeys retain considerable drug-metabolizing ability as compared with humans, but the I-hydroxylating activity in monkeys seems to be much lower than in rats. The hydroxyl derivative was the major substance which accumulated in rat liver following the administration of I, while I itself and its N-dealkylated substances accumulated in monkey liver. N-dealkylated substances were also observed in human liver, but the amount was much smaller than in monkeys. Bis(monoacylglyceryl)phosphate (BMGP), did not increase as much in monkey liver as in human liver, but a marked increase in phosphatidylinositol (PI) was observed in monkey liver during administration of I. The concentration of


acidic phospholipids (BMGP + PI) in the liver showed a close correlation with the accumulation of the drug (I plus its metabolites), irrespectively of species differences. Among subcellular particles isolated from monkey liver following administration of I, the crude mitochondrial fraction, including lysosomes, was richest in BMGP.

IT 2691-45-4

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(metabolism of, lipidosis in relation to)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 84 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1977:584203 CAPLUS

DN 87:184203

TI Aromatic diisocyanates

IN Richter, Reinhard H.; Tucker, Benjamin W.; Ulrich, Henri

PA Upjohn Co., USA

SO U.S., 7 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.


KIND

DATE


APPLICATION NO.

DATE

PI US 4051166 A 19770927 US 1976-693793 19760608  
 US 1976-693793 A 19760608  
 AB Cyanoethylation of PhOH with acrylonitrile over  $\text{AlCl}_3$  gave 75%  
 4-NC(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH, further cyanoethylation over  $\text{CuCl-Me}_3\text{COK}$  gave 67%  
 4-NC(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>4</sub>O(CH<sub>2</sub>)<sub>2</sub>CN, and this was hydrogenated and the resultant  
 4-H<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>C<sub>6</sub>H<sub>4</sub>O(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub> (71% yield) phosgenated to give 60%  
 4-OCN(CH<sub>2</sub>)<sub>3</sub>C<sub>6</sub>H<sub>4</sub>O(CH<sub>2</sub>)<sub>3</sub>NCO. Similarly, using  $\text{Me}_3\text{COK}$  as O-alkylation  
 catalyst, catechol, resorcinol, hydroquinone, and bisphenol A were  
 converted to o-, m- and p-C<sub>6</sub>H<sub>4</sub>[O(CH<sub>2</sub>)<sub>3</sub>NCO]<sub>2</sub> and [4-OCN(CH<sub>2</sub>)<sub>3</sub>O-C<sub>6</sub>H<sub>4</sub>]<sub>2</sub>CMe<sub>2</sub>,  
 resp. A prepolymer was prepared from a tetramethylene glycol and  
 p-C<sub>6</sub>H<sub>4</sub>[O(CH<sub>2</sub>)<sub>3</sub>NCO]<sub>2</sub>, which was polymerized with p-C<sub>6</sub>H<sub>4</sub>(OCH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub> to give a  
 water-white light-stable urethane polymer.  
 IT **4835-05-6P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and phosgenation of)  
 RN 4835-05-6 CAPLUS  
 CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
 (CA INDEX NAME)




L17 ANSWER 85 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:531702 CAPLUS  
 DN 87:131702  
 TI Drug metabolism and changes in acidic phospholipids in drug-induced  
 lipidosis  
 AU Yamamoto, Akira; Matsuzawa, Yuji  
 CS Osaka Univ., Osaka, Japan  
 SO Nippon Rinsho Taisha Gakkai Kiroku (1975), 12, 53  
 CODEN: NRTKDI  
 DT Journal  
 LA Japanese  
 AB Marked accumulation of the specific acidic phospholipid  
 bis(monoacylglycerol) phosphate (BMGP) in liver and other organs was observed  
 in lipidosis induced by 4,4'-bis(β-diethylaminoethoxy)α,β-  
 diethyldiphenylethane (I). In expts. with rat liver, a highly significant  
 concentration correlation was observed between log [I + hydroxylated I] and  
 [BMGP +  
 phosphatidylinositol] up to 0.1% I dose. This I dose-concentration correlated  
 with the critical concentration of I required for phospholipidic liver  
 cirrhosis  
 induction previously reported. At a level higher than this I concentration,  
 acidic phospholipids increased abruptly. The metabolism of I was preceded by  
 N-deethylation in man and monkey and by hydroxylation in rat.  
 IT **2691-45-4**  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (metabolism of, lipidosis from)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-  
 phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 86 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:528220 CAPLUS  
 DN 87:128220  
 TI Systematic, generic, chemico-toxicological research in forensic toxicology. Part III. Comparison of IR and  $\Delta$ IR obtained under programmed and isothermal temperature conditions  
 AU Marozzi, E.; Gambaro, V.; Lodi, F.; Pariali, A.  
 CS Ist. Med. Leg. Assicurazioni, Univ. Milano, Milan, Italy  
 SO Farmaco, Edizione Pratica (1977), 32(7), 330-62  
 CODEN: FRPPAO; ISSN: 0430-0912  
 DT Journal  
 LA Italian  
 AB Gas-chromatog. data are presented on .apprx.350 drugs of forensic-toxicol. interest. These data are mainly the retention index (IR) values obtained on OV1 and OV17 columns under programmed and isothermal temperature conditions and the differences ( $\Delta$ IR) obtained for the individual substances on the 2 columns. Use of the IR to express gas-chromatog. mobility gave well-reproducible data, with respect to both variations in temperature and comparison of values obtained from different labs. Taken alone, the  $\Delta$ IR has low power for identifying a compound, but when used together with the IR values it constitutes a useful element for further narrowing the possibilities. The use of IR as a new approach to gas-chromatog. investigations in forensic toxicol. is suggested.  
 IT **64280-25-7**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, by gas chromatog., in forensic chemical)  
 RN 64280-25-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L17 ANSWER 87 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:511781 CAPLUS  
 DN 87:111781  
 TI Effect of diethyphen on the tonicity of cerebral vessels and total arterial pressure  
 AU Pavlova, L. I.; Gaevyi, M. D.  
 CS Semipalatinsk. Med. Inst., Semipalatinsk, USSR  
 SO Farmakologiya i Toksikologiya (Moscow) (1977), 40(4), 412-14  
 CODEN: FATOAO; ISSN: 0014-8318  
 DT Journal



LA Russian  
 AB Diethyphen (I) [69-14-7] at 1-10 mg/kg injected i.v. or 0.1-0.2 mg/kg injected intracarotidly into anesthetized cats decreased tonus of intra- and extracranial blood vessels. At 5-10 mg/kg i.v. it also decreased arterial pressure.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (blood pressure and brain blood vessel response to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)]bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 88 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:144722 CAPLUS  
 DN 86:144722  
 TI Polymer-concrete mixture  
 IN Surov, A. N.; Shkundov, G. V.; Figovskii, O. L.; Kruglov, B. I.; Moshinskii, L. Ya.; Enikeev, A. R.; Gusman, E. L.; Vorob'ev, B. V.; Krykova, L. S.  
 PA Moscow State Trust of Finishing Works No. 5, USSR  
 SO U.S.S.R.  
 From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1977, 54(1), 101-2.  
 CODEN: URXXAF

DT Patent  
 LA Russian

FAN, CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 541818	T	19770105	SU 1974-2090490 SU 1974-2090490	19741231 A 19741231

AB A polymer-concrete composition with increased wear and impact resistance is prepared by adding 9-31% metallic filler and 0.2-1.9% polymeric additive [H<sub>2</sub>H[C<sub>1</sub>CH<sub>2</sub>CH(OH)CH<sub>2</sub>]CHCH<sub>2</sub>NH[C<sub>1</sub>CH<sub>2</sub>CH(OH)CH<sub>2</sub>]CHCH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH(OH)CH<sub>2</sub>]2Q.4HCl where Q = CMe<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>O<sub>2</sub>)<sub>2</sub> (para isomer) (I [62251-34-7]) or CH(OH)[CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CMe<sub>2</sub>C<sub>6</sub>H<sub>4</sub>O]<sub>2</sub> (all para) (II [62251-35-8]) to portland cement 26-35, mineral filler 25-47, and pigment 0.5-1.2 weight%, with the balance being water.

IT 62251-34-7


RL: USES (Uses)

(in concrete for impact and wear resistance)

RN 62251-34-7 CAPLUS


CN 2-Hexanol, 6,6'-[(1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)imino]]bis[4-[(2-amino-5-chloro-4-hydroxypentyl)amino]-, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C


---CH<sub>2</sub>Cl


L17 ANSWER 89 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:107827 CAPLUS  
 DN 86:107827  
 TI Hardenable polyurethane substances  
 IN Jackle, William A.; Mazzeo, Michael P.; Gillis, Marina N.  
 PA Thiokol Chemical Corp., USA  
 SO Ger. Offen., 90 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2625399	A1	19761230	DE 1976-2625399	19760605
	DE 2625399	C3	19790322		
				US 1975-585150	A 19750609
				US 1976-685215	19760511
	US 4136092	A	19790123	US 1976-685215	19760511
				US 1975-585150	A2 19750609
	ZA 7602922	A	19770427	ZA 1976-2922	19760517
				US 1975-585150	A 19750609
	AU 7614160	A1	19771124	AU 1976-14160	19760521


AU 498161	B2	19790215		
SE 7606353	A	19761210	US 1975-585150	A 19750609
BE 842680	A1	19761001	SE 1976-6353	19760604
DK 7602527	A	19761210	US 1975-585150	A 19750609
FR 2345471	A1	19771021	BE 1976-167698	19760608
FR 2345471	B1	19800620	US 1975-585150	A 19750609
CA 1081391	A1	19800708	DK 1976-2527	19760608
NL 7606208	A	19761213	US 1975-585150	A 19750609
JP 51150599	A2	19761224	US 1976-685215	A 19760511
JP 54022237	B4	19790804	FR 1976-17266	19760608
GB 1533190	A	19781122	US 1975-585150	A 19750609
			US 1976-685215	A 19760511
			GB 1976-23947	19760609
			US 1975-585150	A 19750609
			US 1976-685215	A 19760511
AB	Noncarcinogenic diamino- and triamino-S-triazine derivs. are used instead of MOCA as polyurethane elastomer hardeners, giving good pot life and phys. properties. Thus, 100 parts of a prepolymer from poly(ethylene-propylene adipate) of mol. weight 2500 and an excess of TDI to give NCO content 3-4%, was combined with 14 parts N-octadecylmelamine (I) [21840-04-0] and 0.5 part triethylenediamine and vulcanized 16 h at 100° in a closed mold, giving a cured polyurethane rubber sample with tensile strength 6340 psi, elongation 640%, shore A hardness 73, 100% modulus 475, and tear strength 413, compared with values of 6150 psi, 740%, 78, 500, and 413, resp., for a control molding cured with 10 parts MOCA. The analogous compound N-hexylmelamine [61912-25-2] was not mutagenic at concns. at which it was toxic when tested against strains of <i>Saccharomyces cerevisiae</i> and <i>Salmonella typhimurium</i> .			
IT	61912-54-7			
	RL: USES (Uses)			
	(vulcanizing agents, for urethane rubbers, with reduced toxicity)			
RN	61912-54-7 CAPLUS			
CN	2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-[[4-amino-6-(hexylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)			

PAGE 1-A






L17 ANSWER 90 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:50790 CAPLUS  
 DN 86:50790  
 TI NMR studies on the molecular basis of drug-induced phospholipidosis. II. Interaction between several amphiphilic drugs and phospholipids  
 AU Seydel, Joachim K.; Wassermann, Otmar  
 CS Dep. Pharm. Chem., Borstel Res. Inst., Borstel, Fed. Rep. Ger.  
 SO Biochemical Pharmacology (1976), 25(21), 2357-64  
 CODEN: BCPA6; ISSN: 0006-2952  
 DT Journal  
 LA English  
 AB The binding of several amphiphilic drugs with phospholipids was studied by NMR; of the drugs studied, most gave a distinct but quant. different interaction with phosphatidylcholine. Increasing lipophilicity of the drugs was correlated with an increase in binding. The degree of signal broadening in the NMR spectra was determined by the ratio of drug/lipid concentration  
 Strong interaction of the drugs occurred with phospholipids, e.g. phosphatidylcholine and phosphatidylethanolamine, whereas less polar lipids, e.g. diacylglycerol or digalactosyldiglyceride, showed no interaction. Cholesterol antagonized the phospholipid/drug interaction. Drug-induced phospholipidosis is apparently caused by interaction of the drug with phospholipids so preventing metabolic degradation of the lipids.  
 IT **2691-45-4**  
 RL: PRP (Properties)  
 (interaction of, with phospholipids, phospholipidosis in relation to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 91 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:26498 CAPLUS  
 DN 86:26498  
 TI Inhibition of acid esterase in rat liver by 4,4'-diethylaminoethoxyhexestrol  
 AU Kasama, Kazuo; Yoshida, Katsumi; Takeda, Susumu; Tsujimura, Ryotaro; Hasegawa, Shinichi

CS Sch. Med., Mie Univ., Tsu, Japan  
 SO Lipids (1976), 11(10), 718-21  
 CODEN: LPDSAP; ISSN: 0024-4201  
 DT Journal  
 LA English  
 AB The effect of 4,4'-diethylaminoethoxyhexestrol (I) [2691-45-4] on acid esterase [9013-79-0] in rat liver was studied in vivo and in vitro. The acid esterase activity in the livers of rats treated with 0.125% I for 1 week decreased >60% as compared with that in untreated rats. The addition of I to the incubation medium caused considerable inhibition of the acid esterase activity in lysosome from untreated rat liver, and the inhibition type appeared to be noncompetitive. The acid lipase [9001-62-1] activity in rat liver lysosome was also inhibited by I. Some antihistamic agents and chloroquine [54-05-7] also inhibited the acid esterase activity in rat liver lysosome. I-induced lipidosis may be caused by the inhibition of lipolytic hydrolases which in turn overloads the lysosomes.  
 IT **2691-45-4**  
 RL: PRP (Properties)  
 (esterase inhibition by, in liver lysosomes)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 92 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1976:516798 CAPLUS  
 DN 85:116798  
 TI Studies on drug-induced lipidosis: VII. Effects of bis-β-diethylaminoethylether of hexestrol, chloroquine, homochlorocyclizine, prenylamine, and diazacholesterol on the lipid composition of rat liver and kidney  
 AU Yamamoto, Akira; Adachi, Susumu; Matsuzawa, Yuji; Kitani, Teruo; Hiraoka, Akira; Seki, Koichi  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Lipids (1976), 11(8), 616-22  
 CODEN: LPDSAP; ISSN: 0024-4201  
 DT Journal  
 LA English  
 AB 4,4'-Bis(β-diethylaminoethoxy)-α,β-diethyldiphenylethane-2HCl (I) [69-14-7], which had been shown to induce a type of lipidosis resembling Niemann-Pick disease, was given orally to rats at 20-150 mg/kg/day for 1 or 2 weeks. An enlargement of the liver with marked increases in free cholesterol [57-88-5], total phospholipids, and phosphatidylinositol was caused by administration of a larger dose. The increase in bis(monoacylglycerol) phosphate (BMGP), which is peculiar to this kind of drug-induced lipidosis, as well as the length of time. Similar changes were also observed in kidney. Among several other drugs tested, chloroquine [54-05-7] and 22,25-diazacholesterol [24887-57-8] brought on as much increase in BMGP as treatment with I.  
 IT **69-14-7**  
 RL: BIOL (Biological study)  
 (lipid composition of kidney and liver response to)

RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 93 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1976:414793 CAPLUS  
 DN 85:14793  
 TI Generic systematic chemical toxicological research in forensic toxicology. Part I. Considerations of the gas chromatographic analysis method in generic chemical toxicology  
 AU Marozzi, E.; Gambaro, V.; Lodi, F.; Pariali, A.  
 CS Ist. Med. Leg. Assicurazioni, Univ. Milano, Milan, Italy  
 SO Farmaco, Edizione Pratica (1976), 31(4), 180-211  
 CODEN: FRPPAO; ISSN: 0430-0912  
 DT Journal  
 LA Italian  
 AB The gas-chromatog. retention indexes (IR) of 232 compds. of toxicol. interest (almost all of which are drugs) were determined isothermally at 180° on SE30, OV1, and OV17; for 60 of the compds., IR were also detd on QF4. The data for .apprx.100 of the substances were compared statistically among themselves when appropriate (SE30 and OV1) and with literature data. In general, no statistically significant deviations were found in the series compared. Statistical anal. indicated that the data for gas-chromatog. mobility, expressed as IR, are reproducible to a good degree, even when the assays are carried out in different labs. This means that IR are of considerable diagnostic value. Using the IR value in general gas-chromatog. chemical-toxicol. investigations, one can rapidly restrict the anal. of an unknown compound to a very limited range of possibilities. Since the IR are repeatable they may be used not only for work with a single gas chromatograph but for interlab. comparisons.  
 IT **2691-45-4**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (gas chromatog. of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 94 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1976:38706 CAPLUS  
 DN 84:38706  
 TI Morphological and biochemical changes in the liver of various species in experimental phospholipidosis after diethylaminoethoxyhexestrol treatment  
 AU De la Iglesia, Felix A.; Feuer, George; McGuire, Edward J.; Takada, Akira  
 CS Warner-Lambert Res. Inst., Sheridan Park, ON, Can.  
 SO Toxicology and Applied Pharmacology (1975), 34(1), 28-44  
 CODEN: TXAPA9; ISSN: 0041-008X  
 DT Journal  
 LA English  
 AB Following the administration of diethylaminoethoxyhexestrol (I) [2691-45-4], rabbits, rats, mice, dogs, and guinea pigs developed microscopic and biochem. abnormalities, while hamsters were less affected. In the liver of affected species characteristic subcellular changes were found, accompanied by phospholipid accumulation. Hepatic lesions consisted of concentric lamellar bodies with varying degrees of osmic affinity, representing secondary lysosomes characterized by cytochem. methods. Accumulation of these bodies was also seen in Kupffer, endothelial, and biliary epithelial cells. The intensity of the changes was related to species susceptibility. Biochem. studies revealed an overall increase of total phospholipids in the affected species, together with changes in the relative distribution of individual phospholipids and the appearance of unidentified components. The activity of microsomal drug metabolizing enzymes and microsomal phospholipid synthesis were diminished. The lesions closely resembled those observed in man after treatment with I and are related to altered phospholipid metabolism with subsequent changes in microsomal drug metabolizing enzyme activity.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (liver toxicity in phospholipidosis from, species in relation to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]



L17 ANSWER 95 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1975:536981 CAPLUS  
 DN 83:136981  
 TI Spectrophotometric determination of amines using an ion pair complex with triphenylmethane dyes  
 AU Ogata, Koreharu; Sakaguchi, Takeichi; Ichikawa, Yoshiko; Deguchi, Fumiko; Funaoka, Noriko; Kiyota, Chiomi  
 CS Fac. Pharm. Sci., Univ. Chiba, Chiba, Japan  
 SO Bunseki Kagaku (1975), 24(5), 279-83  
 CODEN: BNSKAK; ISSN: 0525-1931  
 DT Journal  
 LA Japanese  
 AB Tetrabromophenolphthalein Et ester [1176-74-5] and tertiary amine form an ion pair complex which was extracted from alkaline solution into 1,2-dichloroethane and has an absorption maximum at about 600 nm. By this method some drugs (10-7-10-4M), 4,4'-diethylaminoethoxy- $\alpha,\beta$ -diethyldiphenylethane-2HCl [69-14-7], 10,2-(diethylamino)propylphenothiazine-HCl

[1094-08-2], 3-phenyl-5-(diethylaminoethyl)-1,2,4-oxadiazole citrate [1949-20-8], and 3-( $\beta$ -diethylaminoethyl)-4-methyl-7-carbethoxy-2-oxo-(1,2-chromene)-HCl [655-35-6], can be determined at  $\gamma_{\max}$  612, 608, 610, 612, and 584 nm, and at pH 11, 8, 8, 10, and 8 resp. The composition of the ion pair complexes were studied by ir and mass spectra.


IT 69-14-7

RL: ANT (Analyte); ANST (Analytical study)

(determination of, spectrophotometric, tetrabromophenolphthalein ethyl ester in)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)]bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 96 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1975:515933 CAPLUS

DN 83:115933

TI Antistatic agents

IN Tsutsui, Takayuki; Mabuchi, Minoru; Imai, Kiyoko; Noda, Hiroyuki; Tsuchida, Eishun

PA Research Institute for Production Development, Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50046750	A2	19750425	JP 1973-72460	19730627
	JP 53035584	B4	19780928		
				JP 1973-72460	A 19730627

AB Quaternary ammonium compound polymers were used as antistatic agents. Thus, 43.1 g 2,2-bis[p-(2-hydroxy-3-dimethylaminopropoxy)phenyl]propane and 41.3 g 2,2-bis[p-(2-hydroxy-3-chloropropoxy)phenyl]propane were heated in 550 ml MeOH at 100° for 3 hr to prepare a polymer [51753-98-1] which was dissolved in MeOH and coated on a hard PVC [9002-86-2] board.

IT 56399-05-4

RL: USES (Uses)

(antistatic agents, for PVC)

RN 56399-05-4 CAPLUS


CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-chloro-, polymer with 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-(dimethylamino)-2-propanol] (9CI) (CA INDEX NAME)

CM 1

CRN 56399-04-3

CMF C25 H38 N2 O4







CM 2

CRN 4809-35-2

CMF C21 H26 C12 O4




L17 ANSWER 97 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1975:453118 CAPLUS  
 DN 83:53118  
 TI Bis(monoacylglyceryl) phosphate and acyl phosphatidylglycerol isolated from human livers of lipidosis induced by 4,4'-diethylaminoethoxyhexestrol  
 AU Kasama, Kazui; Yoshida, Katsumi; Takeda, Susumu; Akeda, Shozo; Kawai, Kazuo  
 CS Sch. Med., Mie Univ., Tsu, Japan  
 SO Lipids (1974), 9(4), 235-43  
 CODEN: LPDSAP; ISSN: 0024-4201  
 DT Journal  
 LA English  
 AB Bis(monoacylglyceryl)phosphate and acyl phosphatidylglycerol were isolated from the liver of 2 patients with 4,4'-diethylaminoethoxyhexestrol (I) [2691-45-4]-induced lipidosis.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (metabolism of by liver, in lipidosis)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 98 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1975:437661 CAPLUS  
 DN 83:37661  
 TI Mechanism for the effect of vasodilating agents on collateral blood inflow into the zone of acute ischemia of the myocardium

AU Sapozhkov, A. V.  
 CS Kemer. Med. Inst., Kemerovo, USSR  
 SO Farmakologiya i Toksikologiya (Moscow) (1975), 38(2), 177-80  
 CODEN: FATOAO; ISSN: 0014-8318  
 DT Journal  
 LA Russian  
 AB In dogs with myocardial ischemia, blockade of M-cholinoreactive structures with atropine did not change the pos. effect of papaverine [58-74-2] or diethyphen [69-14-7] on collateral coronary circulation and potentiated the beneficial effect of euphylline [317-34-0]. Inhibition of sympathetic innervation with octadine did not alter the effect of diethyphen but markedly shortened and decreased the effects of papaverine and euphylline, resp., on blood flow in the ischemic zone.  $\beta$ -Adrenoreceptor blockade with nethalide inhibited the pos. effects of euphylline, but not diethyphen. The vasodilators attenuated pituitrin-induced spasms of the intraarterial anastomoses and vessels in the ischemic zone.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (heart circulation response to, in ischemia, mechanism of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 99 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1975:92951 CAPLUS  
 DN 82:92951  
 TI Electron microscopic studies on livers with drug induced phospholipidosis  
 AU Horii, Yoshiyuki  
 CS Third Dep. Intern. Med., Kyoto Prefect. Univ. Med., Kyoto, Japan  
 SO Kyoto-furitsu Ika Daigaku Zasshi (1974), 83(8), 479-502  
 CODEN: KFIZA0; ISSN: 0023-6012  
 DT Journal  
 LA Japanese  
 AB Morphol. and histochem. changes were studied in human and rat livers during hexestrol bis( $\beta$ -diethylaminoethyl ether)-2HCl (I) [2691-45-4]-induced phospholipidosis. Numerous cytoplasmic inclusion bodies with myelinlike structures were observed in both the I-treated human and rat liver cells. These inclusion bodies remained for a long time (18 months) after discontinuation of I treatment in human liver whereas in the rat liver they disappeared rapidly after I administration was discontinued. Acid phosphatase [9001-77-8] activities were observed in the inclusion bodies, sometimes within Golgi vacuoles or Golgi lamella. The inclusion bodies were probably derived from endoplasmic reticulum of Golgi system. They were sequestered in the cytoplasm of the liver cells and digested in the presence of lysosomal enzyme and excreted mostly into the bile canaliculi and into the capillary spaces.

IT **2691-45-4**RL: BIOL (Biological study)  
(liver damage from)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 100 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1975:16535 CAPLUS

DN 82:16535

TI Bisamino alcohols

IN Iwakura, Yoshio; Isawa, Shinichi; Hayano, Fusakazu; Kurita, Keisuke

PA Asahi Chemical Industry Co., Ltd.

SO Jpn. Tokkyo Koho, 3 pp.

CODEN: JAXXAD

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49013764	B4	19740403	JP 1966-26341	19660427
				JP 1966-26341	19660427

AB Bis(amino alcs.) with 2 OH and 2 NH<sub>2</sub> groups in a mol. were prepared by reaction of bifunctional 1,2-epoxy compds. (I; Z = e.g., alkylene, arylene, aralkylene) with 5-100 times theor. amts. of aqueous NH<sub>3</sub> at 0-60° in a solvent. Thus, 5 parts I (Z = p-phenylene) was dissolved in 50 parts Me<sub>2</sub>CO with heating, cooled to room temperature, the solution added slowly to a mixture of 35 parts concentrated NH<sub>4</sub>OH and 35 parts Me<sub>2</sub>CO, the mixture shaken well and kept 3-4 days at room temperature to give 60% 1,4-bis(2-hydroxy-3-aminopropoxy)benzene. Similarly, I [Z = m-phenylene, (CH<sub>2</sub>)<sub>4</sub>, (CH<sub>2</sub>)<sub>3</sub>, (CH<sub>2</sub>)<sub>20</sub>(CH<sub>2</sub>)<sub>2</sub>, isopropylidenebis-p-phenylene] gave the corresponding bis-(amino alcs.).

IT **53799-07-8P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 53799-07-8 CAPLUS

CN 2-Propanol, 1,1'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[3-amino- (9CI) (CA INDEX NAME)



L17 ANSWER 101 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1974:420997 CAPLUS  
 DN 81:20997  
 TI Lipid analysis of rat livers treated with 4,4'-diethylaminoethoxy  
 hexestrol dihydrochloride  
 AU Akeda, Shozo; Kawai, Kazuo; Tsujimura, Ryotaro; Kazama, Kazuo; Takeda,  
 Susumu  
 CS Sch. Med., Mie Prefect Univ., Tsu, Japan  
 SO Saibo Seibutsugaku Shimpojiimu (1972), 23, 131-5  
 CODEN: SSSJAZ; ISSN: 0371-3180  
 DT Journal  
 LA Japanese  
 AB The lamellar inclusion bodies isolated from the liver of rats treated with  
 4,4'-diethylaminoethoxyhexestrol-2HCl [69-14-7] contained  
 phospholipids and neutral lipids, but not glycolipids.  
 Lysobisphosphatidic acid is contained in lamellar inclusion bodies and  
 these bodies differ in composition from myelin sheath.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (phospholipids of liver after treatment with)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-  
 phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 102 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:416733 CAPLUS  
 DN 81:16733  
 TI Use of extraction photometry in the analysis of diethyphen  
 AU Solovei, N. V.  
 CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR  
 SO Fiz.-Khim. Metody Anal. Kontr. Proizvod., Mater. Konf. Rab. Vuzov (Vyssh.  
 Uch. Zaved.) Zavod. Lab. Yugo-Vostoka SSSR, 4th (1972), Meeting Date 1971,  
 Volume 3, 27-9. Editor(s): Bezhaev, M. S. Publisher: Dagestan. Gos.  
 Univ., Makhachkala, USSR.  
 CODEN: 27RUAM  
 DT Conference  
 LA Russian  
 AB Diethyphen in a 0.02% aqueous solution reacts with a 0.001M bromophenol blue  
 solution in a buffer of pH 2.5 in a 1:2 stoichiometric ratio to form a yellow  
 compd; having a  $\lambda_{max}$  of 400 nm. The product can be extracted with  
 CHCl<sub>3</sub> and analyzed photometrically using a standard calibration curve. The  
 relative error in this method is 1.11%. The precision of the method was  
 improved 2.7 times by using differential photometry instead of  
 continuous-extraction photometry; and optimum exptl. conditions were  
 determined by  
 the use of simplex exp. planning with two factors: comparison solution and  
 sample solution  
 IT 69-14-7  
 RL: ANT (Analyte); ANST (Analytical study)

(determination of, spectrometric)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 103 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1974:133023 CAPLUS

DN 80:133023

TI Hexestrol bis(beta-diethylaminoethylether) and salts

IN Tsumi, Shoichiro

SO Jpn. Tokkyo Koho, 2 pp.

CODEN: JAXXAD

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48038695	B4	19731119	JP 1970-7204	19700127
				JP 1970-7204	A 19700127


AB p-Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>-p (I), with potent coronary vasodilating action, was prepared by heating hexestrol with Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OH in PhMe at reflux for 5 hr in the presence of concentrated H<sub>2</sub>SO<sub>4</sub>. I was converted to its HCl salt.

IT 2691-45-4P 52071-92-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, (9CI) (CA INDEX NAME)




RN 52071-92-8 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


L17 ANSWER 104 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:128717 CAPLUS  
 DN 80:128717  
 TI Synthesis of Mannich bases of 2,2'-methylenebis(3,4,6-trichlorophenoxyacetic acid) and their antimicrobial activities  
 AU Kim, Jong Ho  
 CS Dep. Chem., Kyung Hee Univ., Seoul, S. Korea  
 SO Yakhak Hoechi (1972), 16(2), 97-107  
 CODEN: YAHOA3; ISSN: 0513-4234  
 DT Journal  
 LA Korean  
 AB Mannich bases of 2,2'-methylene bis(3,4,6-trichlorophenoxy)acetic acid were synthesized as potential antimicrobial agents and were tested against a variety of organisms. The 34 compds. studied differed in their min. inhibitory concns. for different bacterial and fungal species, but 2,2'-methylene bis[ $\alpha$ -(3,4,6-trichlorophenoxy)- $\beta$ -(m-hydroxy-p-carboxyphenylamine)propionic acid] [50884-24-7] seemed to be most active over the entire spectrum of organisms.  
 IT 50884-24-7P 52515-45-4P 52515-46-5P  
 52515-47-6P 52515-48-7P 52515-49-8P  
 52515-50-1P 52515-51-2P 52515-52-3P  
 52515-53-4P 52515-54-5P 52515-55-6P  
 52515-56-7P 52515-57-8P 52515-58-9P  
 52515-59-0P 52515-60-3P 52515-61-4P  
 52515-62-5P 52515-63-6P 52515-64-7P  
 52515-65-8P 52515-66-9P 52515-67-0P  
 52515-68-1P 52515-71-6P 52515-72-7P  
 52515-73-8P 52569-22-9P 52569-23-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and antimicrobial activity of)  
 RN 50884-24-7 CAPLUS  
 CN Benzoic acid, 4,4'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy(2-carboxy-2,1-ethanediyl)imino]]bis- (9CI) (CA INDEX NAME)




RN 52515-45-4 CAPLUS  
 CN Benzoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy(2-carboxy-2,1-ethanediyl)imino]]bis- (9CI) (CA INDEX NAME)




RN 52515-46-5 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 52515-47-6 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(4-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-48-7 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-49-8 CAPLUS  
 CN Benzoic acid, 4,4'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy(2-carboxy-2,1-ethanediyl)imino]]bis[2-hydroxy- (9CI) (CA INDEX NAME)







RN 52515-50-1 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-51-2 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(3-nitrophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-52-3 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-53-4 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-chlorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-54-5 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(4-chlorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-55-6 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-chloro-4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-56-7 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-methyl-4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-57-8 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-58-9 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-59-0 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(phenylamino)- (9CI) (CA INDEX NAME)




RN 52515-60-3 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(2-phenylhydrazino)- (9CI) (CA INDEX NAME)




RN 52515-61-4 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(methylamino)- (9CI) (CA INDEX NAME)




RN 52515-62-5 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 52515-63-6 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 52515-64-7 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(diethylamino)- (9CI) (CA INDEX NAME)




RN 52515-65-8 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(butylamino)- (9CI) (CA INDEX NAME)




RN 52515-66-9 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-67-0 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(hydroxyamino)- (9CI) (CA INDEX NAME)



RN 52515-68-1 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(cyclohexylamino)- (9CI) (CA INDEX NAME)




RN 52515-71-6 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-(2-pyridinylamino)- (9CI) (CA INDEX NAME)







RN 52515-72-7 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[(4-sulfo-phenyl)amino]- (9CI) (CA INDEX NAME)




RN 52515-73-8 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[(4-sulfo-1-naphthalenyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 52569-22-9 CAPLUS  
 CN Benzoic acid, 3,3'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy(2-carboxy-2,1-ethanediyl)imino]]bis- (9CI) (CA INDEX NAME)




RN 52569-23-0 CAPLUS  
 CN Propanoic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[3-[(2-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




L17 ANSWER 105 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:104025 CAPLUS  
 DN 80:104025

TI Animal and organ specificity of morphological alterations after a chronic chlorphentermine dose  
 AU Parwaresch, Mohammad R.; Reil, Gert H.; Seiler, Klaus U.  
 CS Pathol. Inst., Univ. Kiel, Kiel, Fed. Rep. Ger.  
 SO Research in Experimental Medicine (1973), 161(4), 272-88  
 CODEN: REXMAS; ISSN: 0300-9130  
 DT Journal  
 LA German  
 AB Foam cells and intracellular inclusion bodies were observed in several organs (lung, liver, spleen, and adrenals) of different animals (rats, guinea pigs, mice, and rabbits) following chronic i.v. injection of 50-100 g chlorphentermine (I) [461-78-9]/kg or oral administration of 0.25-2.0 g I/l. drinking water. Similar observations were reported for chloroquine [54-05-7], triparanol [78-41-1], and 4,4'-diethylaminoethoxyhexestrol [2691-45-4]. The structural alterations may be due to the common amphiphilic properties of I and the above drugs. These substances may interact with phospholipids thus protecting them against lipase [9001-62-1] degradation activity. This drug-induced phospholipidosis is not limited to a specific group of drugs.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (foams cells from chlorphentermine in relation to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 106 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:91369 CAPLUS  
 DN 80:91369  
 TI Lipidosis induced by a coronary vasodilator, 4,4'-diethylaminoethoxyhexestrol dihydrochloride  
 AU Akeda, Shozo  
 CS Sch. Med., Mie Univ., Tsu, Japan  
 SO Mie Medical Journal (1973), Volume Date 1972-1973, 22(2-3), 65-96  
 CODEN: MMJJAI; ISSN: 0026-3532  
 DT Journal  
 LA English  
 AB Electron and light microscopy of the liver tissue from autopsy cases of patients who have undergone longterm therapy with the coronary vasodilator 4,4'-diethylaminoethoxy hexestrol dihydrochloride (I) [69-14-7] revealed the formation of cytoplasmic lamellar inclusion bodies in a variety of tissue cells, and the appearance of lysobiphosphatidic acid and desmosterol at a significantly high levels. Similar results were obtained in rats when treated orally with I. Analysis of fatty acid composition of lysobiphosphatidic acid isolated from the human liver tissue indicated the presence of approx. 85% unsatd. fatty acids. The possible mechanism of I-induced lipidosis is discussed.  
 IT **69-14-7**  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (toxicity of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-

phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 107 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:66840 CAPLUS  
 DN 80:66840  
 TI Experimental study on the effects of the administration of 4,4'-diethylaminoethoxyhexestrol dihydrochloride in albino rats. II. Electron microscopic and electron microscopic cytochemical studies on early changes in the liver cells  
 AU Inada, Shuichi  
 CS Sch. Med., Hiroshima Univ., Hiroshima, Japan  
 SO Hiroshima Daigaku Igaku Zasshi (1973), 21(1/2), 41-60  
 CODEN: HDIZAB; ISSN: 0018-2087  
 DT Journal  
 LA Japanese  
 AB 4,4'-Diethylaminoethoxyhexestrol-2-HCl (I) [69-14-7] (40 or 50 mg/kg) given i.p. to rats increased the number of multivesicular bodies and of autophagic vacuoles containing mitochondria and eventually myeloid bodies appeared in the liver.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (liver ultrastructure response to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 108 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:44243 CAPLUS  
 DN 80:44243  
 TI Electron microscope study on the drug-induced phospholipidosis. I. Drug-administration experiments in rats during a short period  
 AU Takahashi, Hitoshi; Tsuji, Tadasu; Oku, Masayuki; Mizuno, Norisuke  
 CS First Dep. Intern. Med., Nara Med. Univ., Kashihara, Japan  
 SO Nippon Rinsho Denshi Kenbikyo Gakkaishi (1973), 6(1), 35-43

CODEN: NRDGBQ; ISSN: 0021-4981

DT Journal

LA Japanese

AB The oral administration of 50 mg 4,4'-bis(ethylaminoethyl) hexestrol (I) [2691-45-4]/kg/day to rats induced phospholipidosis. Small dense myeloid bodies were observed by electron microscope in the vicinity of bile canaliculus. These bodies transformed gradually into clear bodies and their number increased. The number of large dense myeloid bodies increased 1-2 weeks after I administration. After 4 weeks, dark and clear myeloid bodies with varying sizes occupied a large portion of the hepatocyte cytoplasm. Myeloid bodies also appeared in Kupffer cells and reticuloendothelial cells of the spleen after I administration.


IT 2691-45-4

RL: BIOL (Biological study)

(phospholipid metabolic disorder from, myeloid body formation in relation to)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 109 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1974:22823 CAPLUS

DN 80:22823

TI Secondary phospholipidosis caused by 4,4'-bis(β-diethylaminoethoxy)hexestrol

AU Shikata, Toshio

CS Sch. Med., Univ. Tokyo, Tokyo, Japan

SO Rinsho Byori (1973), 21(5), 389-94

CODEN: RBYOAI; ISSN: 0047-1860

DT Journal

LA Japanese

AB Administration of 4,4'-bis(β-diethylaminoethoxy)hexestrol (I) [2691-45-4], a coronary vasodilator, caused secondary phospholipidosis in patients. Lipid deposition was observed in all tissues and cells, particularly in livers. Electron microscopy showed myelin-like substances in the cytoplasm. Symptoms of hepatocirrhosis were noted in severe cases. A great portion of I was accumulated in the body after administration. More than 2 g I was detected in the liver of patients with hepatocirrhosis.

IT 2691-45-4

RL: BIOL (Biological study)

(phospholipidosis in response to)


RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)

```

L17  ANSWER 110 OF 202  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   1973:143582  CAPLUS
DN   78:143582
TI   Unusual deposit of lipids due to drugs with special reference to medically
      significant lipoidosis
AU   Shikata, Toshio; Kanetaka, Tatsuji
CS   Med. Sch., Univ. Tokyo, Tokyo, Japan
SO   Kagaku to Seibutsu (1972), 10(10), 689-97
      CODEN: KASEAA; ISSN: 0453-073X
DT   Journal; General Review
LA   Japanese
AB   A discussion and review with 15 refs. comparing the actions of
      3,4-bis[p-( $\beta$ -diethylaminoethoxy)phenyl]hexane (I) [ 2691-45-4
      ] on lipid metab and liver cells with those of the structurally similar
      compds. clomiphen [911-45-5] and hexestrol [5635-50-7], which do not
      affect liver cells. The clin. symptoms of medicinal phospholipoidosis are
      included.
IT   2691-45-4
      RL: BIOL (Biological study)
          (lipid metabolism response to)
RN   2691-45-4  CAPLUS
CN   Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-
      phenyleneoxy)]bis[N,N-diethyl- (9CI)  (CA INDEX NAME)

```



Page 202


of the sum of the drug and free cholesterol to the sum of the acidic phospholipids was .sim.2.11. After administration of I to rats at 30 mg/day for 10 days, the major metabolite in the liver was found to be a derivative of I which had 1 hydroxyl group in the benzene ring.

IT 69-14-7

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(metabolism of, lipid metabolism in relation to)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 112 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1973:52982 CAPLUS

DN 78:52982

TI Biochemical properties of the intracellular inclusion with lamellar structure isolated from liver of the rat administered with hexestrol bis(beta-diethylaminoethyl ether) dihydrochloride

AU Akeda, Shozo; Kawai, Kazuo; Takeda, Susumu; Tsujimura, Ryotaro; Kosaka, Yoshitane

CS Sch. Med., Univ. Mie, Tsu, Japan

SO Igaku no Ayumi (1972), 83(1), 30-1

CODEN: IGAYAY; ISSN: 0039-2359

DT Journal

LA Japanese


AB After the oral administration of hexestrol bis(beta-diethylaminoethyl ether)-2HCl (I-2HCl) [2691-45-4] (50 mg/kg/day, for 3 weeks) to rats, intracellular inclusion bodies, which had a lamellar structure, were found in the liver and contained I, lyso-bisphosphatidic acid, and desmosterol [313-04-2]. The inclusion bodies had a phospholipid to sterol ratio of 5:1. The major phospholipid present was phosphatidylcholine while the major sterols were free cholesterol [57-88-5] and cholesterol esters.

IT 69-14-7

RL: BIOL (Biological study)  
(lipids of liver inclusion bodies in response to)


RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L17 ANSWER 113 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:560722 CAPLUS  
 DN 77:160722  
 TI Gas liquid chromatographic determination of 3,4-bis[(p-β-diethylaminoethoxy)phenyl] hexane  
 AU Kooi, Yoshinori; Imai, Kazuhiro; Tamura, Zenzo; Shikata, Toshio  
 CS Sch. Pharm., Univ. Tokyo, Tokyo, Japan  
 SO Igaku no Ayumi (1972), 81(9), 565-6  
 CODEN: IGAYAY; ISSN: 0039-2359  
 DT Journal  
 LA Japanese  
 AB Autopsied liver tissue containing 3,4-bis-[p-(β-diethylaminoethoxy)phenyl]hexane (I) [2691-45-4], a coronary vasodilator, was minced, homogenized with HCl, centrifuged and chromatographed on an Amberlite XAD-2 column; the column was washed and eluted with an AcOH-MeOH mixture; the eluates evaporated to dryness and dissolved in acetone, and subjected to gas chromatog. By using cholestane-3-one as an internal standard, the I content of 3 liver cirrhotic patients was 0.04-0.14%/mg. wet weight liver. Higher amts. of I (0.22%) was found in the liver of a female patient (age 80), who had ceased I administration (43 g total) 1 year before her death.  
 IT 2691-45-4  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, in liver, after death)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]




L17 ANSWER 114 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:535769 CAPLUS  
 DN 77:135769  
 TI Hypercholesterolemia induced with 4,4'-diethylaminoethoxyhexostrol in the rabbit  
 AU Nakamura, Haruo; Ishikawa, Masako  
 CS Sch. Dent., Hokkaido Univ., Sapporo, Japan  
 SO Igaku to Seibutsugaku (1971), 83(4), 167-70  
 CODEN: IGSBAL; ISSN: 0019-1604  
 DT Journal



LA Japanese  
 AB 4,4'-Bis(ethylaminoethyl)hexestrol (I) [2691-45-4], given s.c. at 5 mg/kg/day for 10 days, increased serum cholesterol [57-88-5],  $\beta$ -lipoprotein, globulin, and macroglobulin and decreased serum albumin in normal or cholesterol-fed rabbits.  
 IT **2691-45-4**  
 RL: PRP (Properties)  
 (cholesterol of blood serum in response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 115 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:456645 CAPLUS  
 DN 77:56645  
 TI Effect of vasodilators on the development of collateral circulation in the myocardium following occlusion of the coronary artery  
 AU Sapozhkov, A. V.  
 CS Kemerov. Med. Inst., Kemerovo, USSR  
 SO Farmakologiya i Toksikologiya (Moscow) (1972), 35(3), 299-302  
 CODEN: FATOAO; ISSN: 0014-8318  
 DT Journal  
 LA Russian  
 AB Tests on dogs subjected to ligation of the left coronary artery showed that papaverine (I) [58-74-2] (2 mg/kg), diethyphen [69-14-7] (2 mg/kg), or euphyllin [317-34-0] (4 mg/kg) administered i.v. daily for 3 weeks stimulated development of the collateral blood circulation in the myocardial ischemic region. Strophanthin [560-53-2] (0.1 rat unit/kg) was ineffective alone but it slightly potentiated the myocardial action of euphyllin.  
 IT **69-14-7**  
 RL: BIOL (Biological study)  
 (collateral circulation development response to, in ischemia)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 116 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN


AN 1972:432271 CAPLUS  
 DN 77:32271  
 TI Ultrastructural demonstration of excessively accumulated free cholesterol in the hepatic cells in a case of so-called phospholipidosis  
 AU Kobayashi, Hisando; Tauchi, Hisashi  
 CS Dep. Clin. Pathol., Aichi Cancer Cent. Hosp., Nagoya, Japan  
 SO Nagoya Journal of Medical Science (1972), 34(3), 259-66  
 CODEN: NJMSAG; ISSN: 0027-7622  
 DT Journal  
 LA English  
 AB Electron microscopy showed numerous myelin figures and contiguous aggregates of fibrillar networks in the hepatic cells of a male adult with generalized deposition of phospholipid in the body organs, probably induced by 2 years of therapy with coralgil. Free cholesterol had accumulated in these myelin figures and aggregates, and in the mitochondria.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (phospholipidosis in relation to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 117 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:414687 CAPLUS  
 DN 77:14687  
 TI Lididosis associated with the drug retention, and its species specificity  
 AU Yamamoto, Akira; Adachi, Susumu; Ishikawa, Katsunori; Yokomura, Tohru; Matsuzawa, Yuji; Nishikawa, Mitsuo  
 CS Sch. Med., Univ. Osaka, Osaka, Japan  
 SO Igaku no Ayumi (1972), 80(2), 75-6  
 CODEN: IGAYAY; ISSN: 0039-2359  
 DT Journal  
 LA Japanese  
 AB Biopsied liver specimens of persons given 2,2'-(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)bis[N,N-diethylethanamine] [hexestrol 4,4'-bis[2-(diethylamino)ethyl ether](I) [2691-45-4], which induced phospholipidosis, showed 0.85-1.77% I (wet weight) along with phospholipids (2.78-5.24%) and free cholesterol [57-88-5] (0.49-1.47%). The phospholipid contained lysobis(phosphatidic acid) and phosphatidylinositol. Administration of I to rats (20 mg/kg/day for 8 weeks) caused reversible phospholipidosis of the liver and spleen, and the condition disappeared 8 weeks after the last I injection. Rat liver metabolized I to hydroxylated derivs. Humans had little or no ability to metabolize I.  
 IT 2691-45-4  
 RL: BIOL (Biological study)  
 (lipids of liver in response to)

RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 118 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:414577 CAPLUS  
 DN 77:14577  
 TI Biochemical properties of a myelin-like body isolated from liver of hexestrol 4,4'-bis[2-(diethylamino)ethyl] ether dihydrochloride-administered rats  
 AU Akeeda, Shozo; Kawai, Kazuo; Tsujimura, Ryotaro; Kosaka, Yoshitane; Terada, Makoto  
 CS Mie Prefect. Med. Coll., Tsu City, Japan  
 SO Igaku no Ayumi (1972), 80(4), 201-2  
 CODEN: IGAYAY; ISSN: 0039-2359  
 DT Journal  
 LA Japanese  
 AB Thin layer chromatog. of the lipids of the myelin-like bodies appearing in the livers of rats given the synthetic estrogen hexestrol 4,4'-bis[2-(diethylamino)ethyl] ether-2HCl (I-2HCl) [69-14-7] (100 mg/kg/day for 4 weeks) revealed phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, lysolecithin, cardiolipin, lysobis(phosphatidic acid), cholesterol [57-88-5], free fatty acids, cholesterol esters, and triglycerides. No cerebroside or sulfatide was found.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (lipids of liver in response to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L17 ANSWER 119 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:400554 CAPLUS  
 DN 77:554  
 TI Drug-induced lipodosis (V). Changes in the lipid composition of rat liver and spleen following the administration of hexestrol bis(2-diethylaminoethyl) ether

AU Adachi, S.; Matsuzawa, Y.; Yokomura, T.; Ishikawa, K.; Uhara, S.; Yamamoto, A.; Nishikawa, M.  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Lipids (1972), 7(1), 1-7  
 CODEN: LPDSAP; ISSN: 0024-4201  
 DT Journal  
 LA English  
 AB Hexestrol bis(2-diethylaminoethyl)ether-2HCl (I) [69-14-7] given orally to rats for 2-12 weeks increased total phospholipids and free cholesterol [57-88-5] in the liver after 2 weeks and triglycerides after 8 weeks; the level of lysobisphosphatidic acid increased in both the liver and spleen, reaching a maximum at 8 weeks. Phosphatidylinositol increased maximum in the spleen also at 8 weeks. I decreased serum cholesterol maximum after 12 weeks. The effects of I in rats differed considerably from those observed in man.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (lipid metabolism by liver and spleen response to, species in relation to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 120 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:135844 CAPLUS  
 DN 76:135844  
 TI Immunosuppressive effects of a coronary vasodilator, 4,4'-diethylaminoethoxyhexestrol, in mice  
 AU Kawada, Kenichi  
 CS Tokyo Med. Dent. Univ., Tokyo, Japan  
 SO Ochanomizu Igaku Zasshi (1971), 19(3), 71-6  
 CODEN: OCIZAD; ISSN: 0472-4674  
 DT Journal  
 LA Japanese  
 AB The long term administration of 4,4'-diethylaminoethoxyhexestrol (I) [2691-45-4] (10 mg/kg/day, 8-12 weeks) inhibited the antibody formation induced in mice by repeated injections of O-type human erythrocytes as antigen.  
 IT 2691-45-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (immunosuppressant activity of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 121 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:54338 CAPLUS  
 DN 76:54338  
 TI Effect of etafon [analog of dialicor] on vascular tone  
 AU Nikolaevskii, V. A.  
 CS Voronezh. Med. Inst., Voronezh  
 SO Trudy Voronezhskogo Gosudarstvennogo Meditsinskogo Instituta (1970), 79, 115-17  
 CODEN: TVMDAJ; ISSN: 0376-1428  
 DT Journal  
 LA Russian  
 AB Etafon injected i.v. into cats decreased the coronary vessel tone after 3 sec, arterial pressure after 9-12 sec and the peripheral vessel tone after 18-20 sec. At a dose of 1.5-3mg/kg, etafon increased the respiratory movement amplitude and frequency; a dose of 5mg/kg was lethal. Evidently, the vascular tone decrease was due to the myotropic properties of etafon.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (blood vessel tonus in response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 122 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1972:32651 CAPLUS  
 DN 76:32651  
 TI Drug-induced lipidosis. III. Lipid composition of the liver and some other tissues in clinical cases of Niemann-Pick-like syndrome induced by 4,4'-diethylaminoethoxyhexestrol  
 AU Yamamoto, Akira; Adachi, Susumu; Ishikawa, Katsunori; Yokomura, Tokru; Kitani, Teruo; Nasu, Terushi; Imoto, Tsutomu; Nishikawa, Mitsuo  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Journal of Biochemistry (Tokyo, Japan) (1971), 70(5), 775-84  
 CODEN: JOBIAO; ISSN: 0021-924X  
 DT Journal  
 LA English  
 AB In subjects with foam cell syndrome, induced by 4,4'-diethylaminoethoxyhexestrol-2HCl, free cholesterol and total phospholipids were increased in the liver. Marked increases in hepatic lysobisphosphatidic acid and phosphatidylinositol also occurred. An increase in lysobisphosphatidic acid was also detected in spleen, muscle, lymph nodes, and urinary sediment. However, this phospholipid was not increased in leucocytes. Accumulation of 4,4'-diethylaminoethoxyhexestrol itself was

detected by thin layer chromatog. of total lipids. Gas chromatog. anal. of the total sterol showed an increase in desmosterol in tissues and in blood serum. The syndrome resembled Niemann-Pick disease in some respects.

IT

69-14-7

RL: BIOL (Biological study)


(Niemann-Pick disease from, lipids of liver in)

RN

69-14-7 CAPLUS

CN

Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 123 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1972:27899 CAPLUS

DN 76:27899

TI Thermophysical characteristics of drugs and granular materials

AU Gorodnichev, V. I.; Borisov, G. N.; Egorova, V. I.

CS Leningr. Khim.-Farm. Inst., Leningrad, USSR

SO Khimiko-Farmatsevticheskii Zhurnal (1971), 5(11), 57-9

CODEN: KHFZAN; ISSN: 0023-1134

DT Journal

LA Russian

AB A method of two temperature-time intervals was employed for determining temperature conductivity,

a, heat conductivity,  $\lambda$  and volume enthalpy,  $C_v$ , at 23-4° and 0% humidity, of hexamidine, amidopyrine, methionine, aspirin, phenacetin, and of granulates of citramon, Ca gluconate, ethoxyd, cyclodol, dimedrol, diethiphen, and asphen.

IT

69-14-7

RL: BIOL (Biological study)


(granules, thermophys. properties of)

RN

69-14-7 CAPLUS

CN

Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 124 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1972:15365 CAPLUS

DN 76:15365

TI Crosslinked, water-containing epoxy polyadducts

IN Goebel, Wilhelm; Von Bonin, Wulf

PA Farbenfabriken Bayer A.-G.

SO Ger., 7 pp.

CODEN: GWXXAW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1495843	A	19690410	DE 1964-F44369	19641104
	DE 1495843	B	19710923		

AB Solidified water-in-oil emulsions of polyamine-crosslinked epoxy resins are prepared with polyalkoxylated polyester emulsifiers. Thus, to a solution of emulsifier (reaction product of carboxyl-terminated adipic acid-diethylene glycol polyester [9010-89-3] 4308, polyethylene glycol [25322-68-3] 862, and bisphenol A epoxy resin 431 parts) 12 and N,N'-(oxyditetramethylene)diethylenediamine [4067-18-9] 15 in oxydiethylene p-(2,3-epoxypropoxy)benzoate [33147-06-7] 100 parts is added 100 parts H<sub>2</sub>O at 10.deg. to give a non-pourable paste which hardens to a light yellow solid containing fine drops of emulsified H<sub>2</sub>O.

IT 35097-89-3P

RL: PREP (Preparation)

(manufacture of, emulsifiers in)

RN 35097-89-3 CAPLUS


CN 1,2-Ethanediamine, N,N'-[(1-methylethylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl)]bis-, polymer with 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[oxirane] and N-oxiranyl-N-phenyloxiranamine (9CI) (CA INDEX NAME)

CM 1

CRN 47612-95-3

CMF C23 H36 N4 O2

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—CH<sub>2</sub>—NH<sub>2</sub>


CM 2

CRN 46153-25-7  
CMF C10 H11 N O2



CM 3

CRN 1675-54-3  
CMF C21 H24 O4



L17 ANSWER 125 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1971:464629 CAPLUS

DN 75:64629

TI Polyimide preparation from bisamino alcohols with tetracarboxylic acid dianhydride

IN Iwakura, Yoshio; Izawa, Shinichi; Hayano, Nobukazu; Kurita, Keisuke

PA Asahi Chemical Industry Co., Ltd.

SO Jpn. Tokkyo Koho, 6 pp.

CODEN: JAXXAD

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 46009597	B4	19710311	JP	19671018
AB	A linear OH-containing polyamide, such as a 4,4'-bis(2-hydroxy-3-aminopropoxy)diphenylmethane-pyromellitic dianhydride copolymer prepared in DMF, is refluxed in toluene or otherwise condensed to prepare a polyimide.				
IT	26712-65-2				
	RL: USES (Uses) (in polyimide manufacture)				
RN	26712-65-2 CAPLUS				
CN	1,2,4,5-Benzenetetracarboxylic 1,2:4,5-dianhydride, polymer with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)				


CM 1

CRN 13932-27-9  
CMF C19 H26 N2 O4





CM 2

CRN 89-32-7  
CMF C10 H2 O6

L17 ANSWER 126 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1971:440525 CAPLUS

DN 75:40525

TI Identification tests for Diethiphenes, Paramion and Dienestrol acetate

AU Solovei, N. V.

CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR

SO Farmatsiya (Moscow, Russian Federation) (1971), 20(2), 72-3

CODEN: FRMTAL; ISSN: 0367-3014

DT Journal

LA Russian

AB The title compds. were identified by color reactions with the appropriate reagent. Thus, to 2 ml 0.02% aqueous-solution of diethiphenes (I) was added 0.5 ml 0.1% bromphenol blue and the mixture shaken 30 sec with 2 ml  $\text{CHCl}_3$ . A crimson color forms with a maximum adsorption at 582  $\mu\text{m}$ ; sensitivity 8  $\gamma/\text{ml}$ . Similarly, with I and bromphenol red a yellow color forms; absorption 400  $\mu\text{m}$ ; sensitivity 40  $\gamma/\text{ml}$ . Also, with I and bromcresol purple (II) a yellow color forms; absorption 400  $\mu\text{m}$ ; sensitivity 4  $\gamma/\text{ml}$ . With paramion and II a yellow color forms; sensitivity 20  $\gamma/\text{ml}$ . In the identification of dienestrol (III), to 2 ml 0.04% alc. solution of III (or the alc. extract of tablets) was added 2 ml of an alkaline-solution of  $\text{NH}_2\text{OH}\cdot\text{HCl}$  (2:1 3N  $\text{NaOH}$ -13.9% aqueous-solution  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ).


After 5 min a ml 4N  $\text{HCl}$  and 1 ml 15% solution ammonium ferric alum in a 5% solution  $\text{HNO}_3$  was added to give a red-brown color adsorption 440  $\mu\text{m}$ ; sensitivity 8  $\gamma/\text{ml}$ .

IT 69-14-7

RL: PROC (Process)  
(identification of)


RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 127 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1971:418479 CAPLUS  
 DN 75:18479  
 TI Experimental and clinical tests on the influence "trimanyl" on lipid metabolism  
 AU Gurda, Marian; Szczeciakowska, Lesława; Janicki, Kazimierz  
 CS III Klin. Chorob Wewn., Akad. Med., Cracow, Pol.  
 SO Przegląd Lekarski (1970), 26(10), 784-6  
 CODEN: PRLKAV; ISSN: 0033-2240  
 DT Journal  
 LA Polish  
 AB No changes in serum turbidity, lipidograms, and especially no drop in mean  $\beta$ -lipoprotein level were seen 3-6 hr after a single i.v. injection of 0.02 g of Trimanyl (3,4-bis[p-[ $\beta$ -(diethylamino)-ethoxy]phenyl]hexane-2HCl), assayed in a group of 20 patients.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (lipid metabolism in response to)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 128 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1971:403122 CAPLUS  
 DN 75:3122  
 TI Drug-induced lipidosis in human cases and in animal experiments. Accumulation of an acidic glycerophospholipid  
 AU Yamamoto, Akira; Adachi, Susumu; Kitani, Teruo; Shinji, Yoshitake; Seki, Koichi; Nasu, Terushi; Nishikawa, Mitsuo  
 CS Med. Sch., Osaka Univ., Osaka, Japan  
 SO Journal of Biochemistry (Tokyo, Japan) (1971), 69(3), 613-15  
 CODEN: JOBIAO; ISSN: 0021-924X  
 DT Journal  
 LA English  
 AB Investigation of 6 patients with a foam cell syndrome showed that a coronary vasodilator, 4,4-diethylaminoethoxyhexestrol-2HCl (I), had been invariably used in these cases for more than 6 months. Female rats were given I orally (10 mg/day). The rats were sacrificed at 3 days, 2, 3, and 4 weeks after administration of I. A detectable increase in lysobisphosphatidic acid in spleens was observed at 3 days. At the end of 2 weeks, the increase became detectable also in livers and kidney. The amount of the acidic phospholipid continued to increase until it reached 10% of the total phospholipid in the spleen and 7% of the total phospholipid in the liver at the end of 4 weeks. An unidentified lipid component also appeared in the tissues of the I-treated animals. The same spot was also found in human cases. This component was alkaline stable and could be seen on


thin-layer chromatog. even after mild alkaline treatment of the total lipids. Administration of I caused vacuolization in leukocytes very rapidly. The change was seen on careful examination of blood smears stained with May-Giemsa solution

IT 69-14-7

RL: BIOL (Biological study)  
(lipidosis from)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 129 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1971:97756 CAPLUS

DN 74:97756

TI Characteristics of the action exerted by some drugs on the vessels and anastomoses of isolated cat heart

AU Sapozhkov, A. V.

CS Kemerov. Med. Inst., Kemerovo, USSR

SO Farmakologiya i Toksikologiya (Moscow) (1971), 34(1), 60-3

CODEN: FATOAO; ISSN: 0014-8318

DT Journal

LA Russian


AB Papaverine (I), diethiphen, euphyllin, Na nucleinate, ATP, heparin, caffeine, catron, and nialamide, in decreasing order of activity, increased the total and retrograde perfusate flow from the base of the ligated anterior descending branch of the coronary artery in isolated cat heart. Except for ATP and heparin this effect varied inversely with the concentration, and at higher concns. the effects of catron and nialamide were actually reversed. Glutamic acid decreased the levels of both total and retrograde blood flow. Repeated perfusion with the above solution had less effect than the initial perfusion on isolated heart vessel anastomoses.

IT 69-14-7

RL: BIOL (Biological study)  
(heart circulation response to)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 130 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:531746 CAPLUS

DN 73:131746

TI Polyamides or polyesters, used as binders in photoconductive compositions

IN Laakso, Thomas M.; Fowler, William F., Jr.

PA Eastman Kodak Co.

SO Fr. Demande, 32 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2012798		19700327		

US 19690128


AB [p-NH(CH<sub>2</sub>)<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>CR<sub>1</sub>R<sub>2</sub>C<sub>6</sub>H<sub>4</sub>O(CH<sub>2</sub>)<sub>3</sub>NHCOOC<sub>6</sub>H<sub>4</sub>-p-]<sub>n</sub> (I), prepared from [p-H<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>]<sub>2</sub>CR<sub>1</sub>R<sub>2</sub> (II) and MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>Me or di-Me terephthalate, and (p-COCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CR<sub>1</sub>R<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>A<sub>0</sub>-p)<sub>n</sub> (III), prepared from (p-EtO<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CR<sub>1</sub>R<sub>2</sub> (IV) and the appropriate diols, where R<sub>1</sub> = H or Me; R<sub>2</sub> = Me, iso-Pr, 3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>, or 1-naphthyl; and A = p-xylylene, (CH<sub>2</sub>)<sub>4</sub>, p-phenylene, or 1,4-cyclohexylenedimethylene are improved binding agents for known electrophotographic photoconducting comps. comprising a photoconductor prepared from ClCOCOC<sub>6</sub>H<sub>4</sub> and Ph<sub>3</sub>N, 4-(4-amyloxyphenyl)-2,6-bis(ethylphenyl)-pyrylium sensitizer, and CH<sub>2</sub>Cl<sub>2</sub>. Ethanolysis and reduction over Raney-Co of (p-NCCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CR<sub>1</sub>R<sub>2</sub> (V) gave IV and II, resp. E.g., heating 0.62 mole (p-HOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CMeC<sub>6</sub>H<sub>4</sub>Cl-p and 13.6 moles acrylonitrile at 100° for 17 hr in the presence of CuCl and NaOMe gave V (R<sub>1</sub> = Me, R<sub>2</sub> = p-ClC<sub>6</sub>H<sub>4</sub>), which was treated with EtOH in benzene in the presence of HCl to give IV (R<sub>1</sub> = Me, R<sub>2</sub> = p-ClC<sub>6</sub>H<sub>4</sub>) (VI). Heating a mixture of 0.015 mole VI and 0.0057 mole of a 67:33 trans-cis mixture of cyclohexane-1,4-dimethanol in the presence of iso-Pr titanate for 2 hr at 235° and mixing at 0.1 mm for 1 hr gave an amber-colored, glassy solid III in >90% yield having inherent viscosity 0.14 in 1:1 phenol-PhCl. I were prepared similarly.

IT 4835-05-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 4835-05-6 CAPLUS

CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
(CA INDEX NAME)



L17 ANSWER 131 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1970:529442 CAPLUS  
 DN 73:129442  
 TI Comparative coronary vasodilating action of papaverine, corontin, and etafen derivatives  
 AU Nikolaevskii, V. A.  
 CS Voronezh. Gos. Med. Inst., Voronezh, USSR  
 SO Vop. Farmakol. Regul. Deyatel. Serdtsa, Mater. Simp. (1969), 124-6.  
 Editor(s): Kudrin, A. N. Publisher: Mosk. Med. Inst., Moscow, USSR.  
 CODEN: 22EZA5  
 DT Conference  
 LA Russian  
 AB In acute expts. on 42 cats the effects of papaverine, corontin, etafen [hexestrol bis(diethylaminoethyl) ether], and derivs. on circulation and coronary vasodilation were compared. Doses from 1.5 to 3.0 mg/kg were used. Etafen was as effective as corontin on coronary circulation and less hypotensive than papaverine and corontin. The toxicity estimated on 300 mice of the used substances was similar; etafen derivs. K-42 and K-72 were less toxic and their effects on coronary circulation were higher than of etafen.  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (blood vessels of heart dilation by)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 132 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1970:56101 CAPLUS  
 DN 72:56101  
 TI Polyamides from bis(amino alcohols) and dicarboxylic acid chlorides  
 IN Iwakura, Yoshio; Izawa, Shinichi; Hayano, Nobukazu; Kurita, Keisuke  
 PA Asahi Chemical Industry Co., Ltd.  
 SO Jpn. Tokkyo Koho, 6 pp.  
 CODEN: JAXXAD  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 44028319	B4	19691121	JP	19660427
AB	Preparation of polyamides from bis(amino alcs.) and dicarboxylic acid chlorides				

is described. Bis(amino alcs.) used were 1,4-bis(2-hydroxy-3-aminopropoxy)benzene (I), 1,3-bis-(2-hydroxy-3-aminopropoxy)benzene (II), 1,4-bis(2-hydroxy-3-aminopropoxy)butane, 4,4'-bis(2-hydroxy-3-aminopropoxy)diphenylmethane, and 2,5-dihydroxyhexamethylenediamine. Dicarboxylic acid chlorides used were sebacoyl chloride (III), terephthaloyl chloride, and isophthaloyl chloride. E.g., 4.49 g parts Et3N was added to 6 parts I in 70 parts MeCONMe2. III (5.62 parts) in 10 parts dry tetrahydrofuran (IV) was poured into the above mixture with vigorous stirring at -10°. After rinsing with 10 parts IV and stirring at -10° for 10 min and at room temperature for 1.5 hr, the mass was poured into H2O to deposit a fibrous polyamide in 95% yield. The logarithmic viscosity number was 1.12 in m-cresol (0.5 g/100 ml) at 30°. The softening and glass-transition temps. were 185 and 90°, resp.


IT **13932-27-9**

RL: USES (Uses)

(polymers with dicarboxylic acid chlorides)

RN 13932-27-9 CAPLUS

CN 2-Propanol, 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino- (8CI) (CA INDEX NAME)



L17 ANSWER 133 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:20482 CAPLUS

DN 72:20482

TI Evaluation of antianginal drugs on rabbits by electrocardiographic technique

AU Iwaki, Riichiro; Kudo, Yoshitaka; Ishiko, Junichi; Irikura, Tsutomu

CS Kyorin Chem. Lab., Tokyo, Japan

SO Yakugaku Zasshi (1969), 89(9), 1185-98

CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Japanese

AB Effect of medicinals on electrocardiographic tests was examined using pentobarbital-anesthetized normal and arteriosclerotic rabbits in order to develop a therapeutic agent for angina pectoris. Examns. were made on the acute effect of various medicinals as follows: (1) hypoxemia test: ST depression at the time of low-O loading in arteriosclerotic rabbit; (2) isoproterenol test: ST depression at the time of isoproterenol loading in normal and arteriosclerotic rabbits; (3) vasopressin test: ST and T elevation at the time of vasopressin loading in normal rabbits; (4) coronary arterial ligation method: ST elevation by chronic coronary arterial ligation in normal rabbits; (5) respiratory quotient (RPQ) index test: measurement of RPQ index, which is an indirect index of O consumption by myocardium, with each medicinal. The medicinals which showed some effect were adenosine, 4,4'-(diethylaminoethoxy)hexestrol, pronethalol, and iproveratril, in (1), 4,4'-(diethylaminoethoxy)-hexestrol, propranolol, pronethalol, and iproveratril in (2), dipyridamol in (3), ATP, adenosine, 4,4'-(diethylaminoethoxy)-hexestrol, and propranolol in (4), and ATP, dipyridamol, propranolol, 4,4'-(diethylaminoethoxy)hexestrol, and nitroglycerin in (5).


IT **2691-45-4**

RL: BIOL (Biological study)

(in treatment of angina pectoris)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 134 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:13111 CAPLUS

DN 72:13111

TI Polythiazolines

AU Iwakura, Yoshio; Kurita, Keisuke; Hayano, Fusakazu

CS Univ. Tokyo, Tokyo, Japan

SO Journal of Polymer Science, Polymer Chemistry Edition (1969), 7(11), 3075-87

CODEN: JPLCAT; ISSN: 0449-296X

DT Journal

LA English

AB Polythioureas having pendant hydroxyl groups were prepared by the polyaddn. reaction of bisaminoalcohols and diisothiocyanates. The polythioureas had inherent viscosities in the range of 0.22-1.08 dl/g and gave transparent films by solution casting. These polythioureas were converted to polythiazolines by treatment with poly(phosphoric acid) or to poly(thiazoline-oxazolines) by treatment with a mixture of poly(phosphoric acid) and a polar solvent.

IT 25655-14-5P 25669-30-1P 25669-32-3P  
25852-55-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 25655-14-5 CAPLUS

CN Isothiocyanic acid, p-phenylene ester, polymer with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4



CM 2


CRN 4044-65-9

CMF C8 H4 N2 S2




RN 25669-30-1 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)iminocarbonthioylimino-1,4-phenyleneiminocarbonthioylimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 25669-32-3 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)iminocarbonthioylimino-1,3-phenyleneiminocarbonthioylimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B



RN 25852-55-5 CAPLUS  
 CN Isothiocyanic acid, m-phenylene ester, polymer with 1,1'-[methylenabis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)


CM 1

CRN 13932-27-9  
 CMF C19 H26 N2 O4



CM 2

CRN 3125-77-7  
 CMF C8 H4 N2 S2



L17 ANSWER 135 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1969:523930 CAPLUS

DN 71:123930

TI Antiinflammatory etherified bisaryl compounds

IN Werner, Lincoln Harvey

PA CIBA Corp.

SO U.S., 7 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3449418	A	19690610	US 1965-515752	19651222
				US 1965-515752	A 19651222

AB Antiinflammatory, antiprotozoal, antifungal, and particularly antiparasitic agents I (n = 0 or 1, R1 = H, OH, or alkyl; R2 = alkyl, cycloalkyl, cycloalkylalkyl, carboxyalkyl, aralkyl, or aryl; R3 = alkyl, halogen, or nitro; and R4 and R5 = H, alkyl, or halogen), are prepared from the corresponding bisphenols by reaction of their Na salts with


N,N-dimethylaminoalkyl halides. Thus, 2.25 g. of a 53% suspension of NaH in mineral oil are added slowly with stirring, under N, to a solution of 9.6 g. II in 25 ml. HCONMe<sub>2</sub>, the mixture stirred 1 hr. at room temperature, 6.7 g. Cl(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub> added, and the mixture kept 8 hrs. at 70-80° to give III, m. 249-51° (iso-PrOH-EtOAc). Similarly prepared are I (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, n, and m.p. given): -, -, 3-Me, 4-O-(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 0, 258-60°; -, -, 3-tert-Bu, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 0, 302° (decomposition); H, H, 3-Me, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 1, 212-14°; H, H, 3-tert-Bu, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 1, 305° (decomposition); H, 3-cyclohexen-1-yl, 2-Me, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 1, 173-5°; H, Ph, 2-Me, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-tert-Bu, 1, 234-8°; -, -, 3-Me, 4-OCH<sub>2</sub>CHMeNMe<sub>2</sub>.HCl, 5-tert-Bu, 0, 263-4°; -, -, 3-Me, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-Me, 0, 288° (decomposition); Me, CH<sub>2</sub>CH<sub>2</sub>CONMe<sub>2</sub>, 3-NO<sub>2</sub>, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, H, 1, .apprx.95°; Me, CH<sub>2</sub>CH<sub>2</sub>CONMe<sub>2</sub>, 3-Cl, 4-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 5-Cl, 1, 110-15°; H, H, 2-O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl, 3-Cl, 5,6-Cl<sub>2</sub>, 1, 140°.

IT 24002-72-0P 24002-73-1P 24002-79-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 24002-72-0 CAPLUS


CN Propylamine, 3,3'-[methylenebis[(2-tert-butyl-6-methyl-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

RN 24002-73-1 CAPLUS


CN Propylamine, 3,3'-[methylenebis[(2,6-di-tert-butyl-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl


RN 24002-79-7 CAPLUS

CN Propylamine, 3,3'-[methylenebis[(3,4,6-trichloro-o-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 136 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:489845 CAPLUS  
 DN 71:89845  
 TI Combined action of strophanthin and vasodilating substances upon collateral circulation and oxygen tension in an ischemic myocardium  
 AU Sapozhkov, A. V.  
 CS Kemerov. Med. Inst., Kemerovo, USSR  
 SO Farmakologiya i Toksikologiya (Moscow) (1969), 32(4), 418-21  
 CODEN: FATOA0; ISSN: 0014-8318  
 DT Journal  
 LA Russian  
 AB kstrophanthin administered i.v. to dogs at 0.2 rat units/kg. in combination with Euphyllin (4 mg./kg.) or papaverine-HCl (2 mg./kg.) increased the retrograde blood flow synergistically. Strophanthin did not potentiate the stimulatory action of diethylphen (2 mg./kg.) on this parameter. Euphyllin, diethylphen, and papaverine accelerated and the first 2 compds. weakened the pressor action of strophanthin on the systemic arterial pressure. Strophanthin combined with Euphyllin increased O tension in the center of the ischemia, in its border area, and in the intact myocardium.  
 IT 69-14-7  
 RL: BIOL (Biological study)  
 (circulation response to strophanthin and, in heart ischemia)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 137 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:479633 CAPLUS  
 DN 71:79633  
 TI Pharmacological studies on drugs acting in the circulatory system on coronary, cerebral, renal, mesenteric, and femoral circulations  
 AU Iwaki, Riichiro; Ishiko, Junichi; Kudo, Yoshitaka; Irikura, Tsutomu  
 CS Kyorin Chem. Lab., Tokyo, Japan  
 SO Yakugaku Zasshi (1969), 89(5), 726-9  
 CODEN: YKKZAJ; ISSN: 0031-6903  
 DT Journal  
 LA Japanese  
 AB Effects on the blood flow of various systems and on systemic blood pressure were examined by i.v. and intraarterial administration of drugs to pentobarbital-anesthetized dogs. The coronary blood flow was >100% increased by ATP, adenosine, 1-allyl-adenosine, papaverine, dipyridamol, and adrenaline. ATP (i.v.) increased the cerebral blood flow in the initial stage but decreased it later, while adenosine acted in the opposite manner. Theophylline alone somewhat increased the renal blood flow. The femoral blood flow was >50% increased by adenosine, 1-allyl-adenosine, papaverine, carbocromen, theophylline, and hexestrol bis( $\beta$ -diethylaminoethyl ether).  
 IT **2691-45-4**  
 RL: BIOL (Biological study)  
 (circulation response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]




L17 ANSWER 138 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:413435 CAPLUS  
 DN 71:13435  
 TI Polyimides having pendant hydroxy and acetoxy groups. II. Polyimides derived from bis(amino alcohols)  
 AU Iwakura, Yoshio; Kurita, Keisuke; Hayano, Fusakazu  
 CS Univ. Tokyo, Tokyo, Japan  
 SO Journal of Polymer Science, Polymer Chemistry Edition (1969), 7(2), 609-20  
 CODEN: JPLCAT; ISSN: 0449-296X  
 DT Journal  
 LA English  
 AB Polyamic acids were prepared from bis(amino alcs.) and pyromellitic dianhydride. They were converted to polyimides having pendant hydroxy groups by heating them in toluene or xylene ( $\eta_{inh}$  = 0.22-0.34 dl./g.). Treatment of these polyamic acids with a mixture of pyridine and Ac<sub>2</sub>O gave polyimides having pendant acetoxy groups ( $\eta_{inh}$  = 0.22-1.04 dl./g.). These acetoxy polyimides were converted to hydroxypolyimides ( $\eta_{inh}$  = 0.20-0.81 dl./g.) by an ester-exchange reaction. The hydroxypolyimides were easily acetylated to give acetoxypolyimides.  
 IT **26712-65-2**, 1,2,4,5-Benzenetetracarboxylic 1,2:4,5-dianhydride, polymer with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol]  
 RL: USES (Uses)  
 (acetylated)  
 RN 26712-65-2 CAPLUS

CN 1,2,4,5-Benzenetetracarboxylic 1,2:4,5-dianhydride, polymer with  
1,1'-[methylenabis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA  
INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4



CM 2

CRN 89-32-7

CMF C10 H2 O6



IT 26712-65-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 26712-65-2 CAPLUS

CN 1,2,4,5-Benzenetetracarboxylic 1,2:4,5-dianhydride, polymer with  
1,1'-[methylenabis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA  
INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4




CM 2

CRN 89-32-7

CMF C10 H2 O6



L17 ANSWER 139 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:406574 CAPLUS  
 DN 71:6574  
 TI Choice of optimum conditions for analysis of diethyphen[4,4'-bis(diethylamioethoxy)- $\alpha,\beta$ -diethyldiphenylethane dihydrochloride] using double-beam differential spectrophotometry  
 AU Belikov, V. G.; Kokovkin-Shcherbak, N. I.; Solovei, N. V.  
 CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR  
 SO Farmatsiya (Moscow, Russian Federation) (1969), 18(2), 32-9  
 CODEN: FRMTAL; ISSN: 0367-3014  
 DT Journal  
 LA Russian  
 AB Absolute, direct differential, and inverse methods were used for spectrophotometric anal. at 274 m $\mu$ . Of the three methods investigated, the direct differential method was the best, giving the least relative error in the detns. The relative errors for the anal. of title compound in tablets and solution were  $\pm 0.37$  and  $\pm 0.17$  resp. Relative errors caused by the instrument, the cell, and the dilution of solution were also investigated. Calibration curves used for these detns. are given together with the results of these detns.  
 IT **69-14-7**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (anal. of, by double-beam differential spectrophotometry)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 140 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:56108 CAPLUS  
 DN 70:56108  
 TI Effect of vasodilator agents on collateral coronary circulation and myocardial oxygen tension  
 AU Sapozhkov, A. V.  
 CS Kemerov. Med. Inst., Kemerovo, USSR  
 SO Farmakologiya i Toksikologiya (Moscow) (1968), 31(6), 687-90  
 CODEN: FATOAO; ISSN: 0014-8318  
 DT Journal

LA Russian  
 AB Papaverine, chloracyzin, and diethyphen at 2 and 10 mg./kg. and diaphylline at 4 and 20 mg./kg. increased the retrograde coronary blood flow in anesthetized dogs without significantly changing the systemic arterial pressure. The vasodilator agents in small doses increased the level of O tension in the central end boundary zones on the myocardial ischemia. Dilation of the lumen of the intraarterial anastomoses and changes in the vascular resistance to the retrograde flowing blood apparently are involved in the action of these compds.

IT **69-14-7**  
 RL: BIOL (Biological study)  
 (coronary circulation response to)

RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L17 ANSWER 141 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:46124 CAPLUS  
 DN 70:46124  
 TI Clinical and experimental studies on the effect of trimanyl on lipid metabolism. I  
 AU Janicki, Kazimerz; Gurda, Marian; Szczeciakowska, Lesława  
 CS Akad. Med., Cracow, Pol.  
 SO Przegląd Lekarski (1968), 24(7), 608-9  
 CODEN: PRLKAV; ISSN: 0033-2240  
 DT Journal  
 LA Polish  
 AB Fasting patients with coronary diseases and arteriosclerosis were injected i.v. with 0.02 g. of Trimanyl [hexestrol bis(diethylaminoethyl) ether] immediately after lipid loading or without loading. Trimanyl lowered the plasma lipid level 3 hrs. after the lipid loading and injection. The decreases in the lipid levels in patients without lipid loading were statistically nonsignificant.


IT **69-14-7**  
 RL: BIOL (Biological study)  
 (lipid metabolism response to)

RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 142 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1969:36344 CAPLUS  
 DN 70:36344  
 TI Receptor sites for dipyridamole, prenylamine, and hexestrol bis (diethylaminoethyl) ether. Effect on the bioelectric activity of rabbit brain  
 AU Janicki, Kazimierz; Trabka, Jan; Gatarski, Julian  
 CS Akad. Med., Cracow, Pol.  
 SO Polski Tygodnik Lekarski (1968), 23(37), 1395-7  
 CODEN: POLEAQ; ISSN: 0032-3756  
 DT Journal  
 LA Polish  
 AB Electroencephalographic expts. showed that the title drugs had neurotropic properties. Prenylamine acted as an activating-desynchronizing drug; dipyridamole showed an opposite activity. Hexestrol bis-(diethylaminoethyl) ether revealed lowest effects on the bioelec. activity of rabbit brain and on behavior of the animals.  
 IT **2691-45-4**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (brain electrical activity of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 143 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1968:115059 CAPLUS  
 DN 68:115059  
 TI Polymeric products from N,N'-disubstituted-bis-2-oxazolidinones and bisphenol  
 AU Nishizaki, Shunichiro; Fukami, Akira  
 CS Mitsubishi Elec. Corp., Amagasaki, Japan  
 SO Kogyo Kagaku Zasshi (1967), 70(10), 1835-6  
 CODEN: KGKZA7; ISSN: 0368-5462  
 DT Journal  
 LA Japanese  
 AB Polymers were prepared by ring opening and the CO2 elimination reaction of N-substituted-bis(2-oxazolidinones) such as N,N'-terephthaloyl-,



N,N'-isophthaloyl-, and N,N'-oxydibenzoylbis(2-oxazolidinone) with 4,4-isopropylidenediphenol. The reaction was carried out in the presence of 1 mole % NaOMe at 160° for 4 hrs. and then at 200-30° for 8 hrs. Ir spectra of the products showed the characteristic absorption of poly(ether amides), and the presence of weak bands due to ester linkages was also confirmed. The reduced viscosities of the polymers were in the range 0.20-0.28 dl./g. in HCONMe<sub>2</sub> at 30°. The polymers are soluble in HCONMe<sub>2</sub>, AcNMe<sub>2</sub>, and m-cresol, and the m.ps. are in the range 82-146°.


IT 32031-61-1P 32031-62-2P 32106-73-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 32031-61-1 CAPLUS

CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,2-ethanediyliminocarbonyl-1,4-phenylenecarbonylimino-1,2-ethanediyl] (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 32031-62-2 CAPLUS

CN Poly[oxy-1,2-ethanediyliminocarbonyl-1,4-phenyleneoxy-1,4-phenylenecarbonylimino-1,2-ethanediyl-1,4-phenylene(1-methylethylidene)-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 32106-73-3 CAPLUS  
 CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,2-ethanediyliminocarbonyl-1,3-phenylenecarbonylimino-1,2-ethanediyl] (9CI)  
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 144 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1967:517575 CAPLUS  
 DN 67:117575  
 TI Aromatic polyether polyureas


IN Ando, Tadanao; Kataoka, Seiichi; Imoto, Tatsuya  
 PA Japan, Bureau of Industrial Technology  
 SO Jpn. Tokkyo Koho, 5 pp.  
 CODEN: JAXXAD  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 42016078	B4	19630902	JP	19631004
AB	<p>Diamines of the formula <math>p\text{-[H}_2\text{N(CH}_2\text{)}_3\text{]C}_6\text{H}_4\text{O(CH}_2\text{)nC}_6\text{H}_4\text{[(CH}_2\text{)}_3\text{NH}_2\text{]-p}</math> (I) or <math>p\text{-[H}_2\text{N(CH}_2\text{)}_3\text{]C}_6\text{H}_4\text{(CH}_2\text{)nC}_6\text{H}_4\text{[O(CH}_2\text{)}_3\text{NH}_2\text{]-p}</math> (II) are heated with (PhO)<sub>2</sub>CO or urea to give the title polymers. Heating equimolar reactants in the presence of a stabilizer yields linear polymers, soluble in cresol and having fiber-forming properties. Thus, a mixture of 10.23 g. I (n = 4) (III), 6.15 g. (PhO)<sub>2</sub>CO, 20 ml. m-cresol (IV), and 0.057 g. lauric acid (V) was heated at 219-20° for 1 hr. under N, evacuated slowly to 1 mm. while distilling off IV, and heated another hr. to give a pale yellow resin, softening at 215-21°, intrinsic viscosity <math>[\eta]</math> 1.74 dl./g. (in IV at 25°). Use of 10.32 g. III and 0.116 g. V gave a fiber-forming polymer of <math>[\eta]</math> 0.69, and polymerization of 10.88 g. III and 6.53 g. (PhO)<sub>2</sub>CO with 0.122 g. V yielded a colorless resin of <math>[\eta]</math> 1.13 dl./g., which gave a tough film. Similarly, other polymers were prepared [diamine (n), stabilizer, softening temperature, and in dl./g. <math>[\eta]</math> given]: I (2), V, 272-4°, 0.48; I (3), V, 204-8°, 1.04 (VI); I (5), V, 185-92°, 1.04; I (5), stearylamine, -, 1.18; I (6), V, 202-8°, 0.90; II (3), V, 95-101°, 0.19; II (2), V, 244-7°, -. A 70.3 <math>\mu</math> film from VI had a tensile strength of 5.9 kg./mm.<sup>2</sup></p>				
IT	<p>30552-55-7P 30552-56-8P 31986-36-4P            32129-34-3P            RL: IMF (Industrial manufacture); PREP (Preparation)            (manufacture of, fibers and films from)</p>				
RN	30552-55-7 CAPLUS				
CN	Carbonic acid, polyamide with 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)				

CM 1

CRN 4835-05-6


CMF C21 H30 N2 O2



CM 2

CRN 463-79-6


CMF C H2 O3



RN 30552-56-8 CAPLUS  
 CN Carbonic acid, polyamide with 3,3'-[ethylenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)


CM 1

CRN 15449-15-7  
 CMF C20 H28 N2 O2




CM 2

CRN 463-79-6  
 CMF C H2 O3





RN 31986-36-4 CAPLUS  
 CN Poly[oxy-1,3-propanediyliminocarbonylimino-1,3-propanediyl-1,4-phenylene(1-methylethylidene)-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 32129-34-3 CAPLUS  
 CN Poly(oxy-1,3-propanediyliminocarbonylimino-1,3-propanediyl-1,4-phenylene-1,2-ethanediyl-1,4-phenylene) (9CI) (CA INDEX NAME)

PAGE 1-A





L17 ANSWER 145 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1967:444153 CAPLUS

DN 67:44153

TI Polyamides containing pendant hydroxyl groups and their derived polyoxazolines

AU Iwakura, Yoshio; Izawa, Shinichi; Hayano, Fusakazu; Kurita, Keisuke

CS Univ. Tokyo, Tokyo, Japan

SO Makromolekulare Chemie (1967), 104(1), 66-76

CODEN: MACEAK; ISSN: 0025-116X

DT Journal

LA English

AB Bisamino alcs. were prepared by allowing a bisepoxide and a large excess of aqueous NH<sub>3</sub> in an organic solvent to stand at room temperature for 2-4 days.

The mixture

was concentrated under reduced pressure, and the resulting bisamino alc., of general formula R[OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NH<sub>2</sub>]<sub>2</sub>, was purified by distillation or recrystn. from benzene or toluene (R, compound number, reaction solvent, % yield, and b.p. or m.p. given): (CH<sub>2</sub>)<sub>4</sub>, (I), acetone, 77, b0.05 167°; m-C<sub>6</sub>H<sub>4</sub>, (II), MeOH, 40, b0.02 210°; p-C<sub>6</sub>H<sub>4</sub>, III, acetone, 60, m. 128-32°; p-C<sub>6</sub>H<sub>4</sub>, (IV), acetone, 68, m. 169-73°; methylenebis(p-phenylene), (V), dioxane, 88, m. 120-6°. The meso and racemic isomers, III and IV, were separated by fractional recrystn. from acetone and MeOH. The compds. were condensed with diacid chlorides by low-temperature solution polycondensation, using Et<sub>3</sub>N or N-methylmorphine as an acid acceptor and Me<sub>2</sub>NAC as a solvent. The polymers were precipitated by

pouring

the reaction mixture into water, and gave tough, transparent films upon solution casting. Intrinsic viscosities were measured in m-cresol or Cl<sub>2</sub>CHCO<sub>2</sub>H at a concentration of 0.05 g./100 ml. and 30° (bis-amino alc., acid chloride, % yield, inherent viscosity, and m.p. given): I, sebacoyl chloride (VI), 80, 0.59, 75°; I, isophthaloyl chloride (VII), 81, 0.57, 80°; I, terephthaloyl chloride (VIII), 81, 0.53, 81°; II, VI, 100, 0.41, 90°; II, VII, 92, 0.36, 150°; II, VIII, 98, 0.64, 160°; III, VI, 85, 1.12, 185°; III, VIII, 91, 1.09, 190°; III, VIII, 80, 0.64, 260° (decompose); IV, VI, 98, 1.45, 250° (decompose); IV, VI, 99, 0.55, 200°; IV, VIII, 98, 1.00, 250° (decompose); V, VI, 96, 0.91, 160°; V, VII, 95, 0.77, 170°; V, VIII, 97, 0.68, 270° (decompose).

3,3'-(p-Phenylenedioxy)bis(1-benzamido-2-hydroxypropane) was prepared as a model compound from III and BzCl, and had essentially the same ir spectrum as the III-VII polyamide. The polymers were insol. in acetone, MeOH, n-hexane, tetrahydrofuran, dioxane, toluene, and water; and soluble to varying degrees in Me<sub>2</sub>NCHO, Me<sub>2</sub>NAC, m-cresol, and Cl<sub>2</sub>CHCO<sub>2</sub>H. solubility in HCO<sub>2</sub>H and ACOH varied. Oxazoline formation was investigated by preparing 1-amino-2-hydroxy-3-phenoxypropane, m. 90.0-1.5°, from Ph glycidyl ether and NH<sub>3</sub>. Treatment with BzCl gave 1-benzamido-2-hydroxy-3-phenoxypropane, m. 126.5-7.5°. Treatment with SOCl<sub>2</sub> gave 2-phenyl-5-phoxymethyl-2-oxazoline, m. 81-3°, picrate m. 145.0-7.5° (EtOAc). The polyamides were treated with SOCl<sub>2</sub>, giving the polyoxazoline hydrochlorides. Inherent viscosities were measured at a

concentration of 0.5 g./100 ml. Me<sub>2</sub>NCHO at 30° (polyamide treated, inherent viscosity, and m.p. given): II-VII, 0.05, 92°; III-VII, 0.28, 143°; IV-VII, 0.16, 152°; IV-VIII, 0.22, 158°; V-VII, 0.06, 90°; V-VIII, 0.07, 142°. The ir spectra of the model compound and the polyoxazoline were nearly identical.

IT 30703-65-2P 30703-66-3P 32105-48-9P  
32109-70-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and cyclization of)


RN 30703-65-2 CAPLUS

CN Isophthalic acid, polyamide with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4



CM 2

CRN 121-91-5

CMF C8 H6 O4




RN 30703-66-3 CAPLUS

CN Terephthalic acid, polymer with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4



CM 2


CRN 100-21-0

CMF C8 H6 O4




RN 32105-48-9 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)iminocarbonyl-1,4-phenylenecarbonylimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 32109-70-9 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)iminocarbonyl-1,3-phenylenecarbonylimino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A






IT 13932-27-9P 30703-64-1P 32109-69-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 13932-27-9 CAPLUS

CN 2-Propanol, 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino- (8CI) (CA INDEX NAME)




RN 30703-64-1 CAPLUS

CN Sebacic acid, polymer with 1,1'-[methylenebis(p-phenyleneoxy)]bis[3-amino-2-propanol] (8CI) (CA INDEX NAME)

CM 1

CRN 13932-27-9


CMF C19 H26 N2 O4



CM 2

CRN 111-20-6

CMF C10 H18 O4




RN 32109-69-6 CAPLUS


CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy(2-hydroxy-1,3-propanediyl)imino(1,10-dioxo-1,10-decanediyl)imino(2-hydroxy-1,3-propanediyl)] (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 1-B




L17 ANSWER 146 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1967:422785 CAPLUS  
 DN 67:22785  
 TI Synthesis of polyamides by cyanoethylation of bisphenols. IX. Properties of some polyamides with p-phenyleneoxy groups in the chain  
 AU Ando, Tadanao; Kataoka, Seiichi  
 CS Govt. Ind. Res. Inst. Osaka, Osaka, Japan  
 SO Kobunshi Kagaku (1966), 23(259), 774-84  
 CODEN: KOKAAM; ISSN: 0023-2556  
 DT Journal  
 LA Japanese  
 AB cf. CA 65: 4011g. Phys. properties of polyamide fibers with p-phenyleneoxy groups, such as hydroquinone residues, bisphenol residues, and diphenoxyalkane structures in the chain have been studied. The polymers have the structures  $\text{-NH(CH}_2\text{)}_3\text{OC}_6\text{H}_4\text{(CH}_2\text{)}_3\text{NHCO(CH}_2\text{)}_3\text{CO-}$ ,  $\text{-NH(CH}_2\text{)}_3\text{OC}_6\text{H}_4\text{CH}_2\text{C}_6\text{H}_4\text{(CH}_2\text{)}_3\text{NHCO(CH}_2\text{)}_3\text{CO-}$ , and,  $[\text{-NH(CH}_2\text{)}_3\text{C}_6\text{H}_4\text{(CH}_2\text{)}_n\text{OC}_6\text{H}_4\text{(CH}_2\text{)}_3\text{NHCO(CH}_2\text{)}_4\text{CO-}]_n$ , where  $n = 2$  and  $4$ . The glass transition temps. of these polyamides determined by dilatometry are  $57\text{-}82^\circ$  and these are shifted to higher temps. by the introduction of p-phenylene groups in the chain. The initial Young's moduli for undrawn fibers of the polyamides are  $150\text{-}200$  kg./mm.<sup>2</sup> Even by stretching at a high draw ratio, the initial modulus does not increase to more than  $460$  kg./mm.<sup>2</sup> The effect of low stretching on the initial modulus is explained in terms of the change in conformation from planar zigzag to partially twisted.  
 IT 30623-65-5 30623-66-6 30623-67-7  
 30898-32-9 31985-71-4 31985-72-5  
 31985-73-6 32127-69-8  
 RL: USES (Uses)  
 (fibers from, phys. properties of)  
 RN 30623-65-5 CAPLUS  
 CN Sebacic acid, polyamide with 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)  
 CM 1  
 CRN 4835-05-6  
 CMF C21 H30 N2 O2



CM 2


CRN 111-20-6  
CMF C10 H18 O4



RN 30623-66-6 CAPLUS  
CN Adipic acid, polyamide with 3,3'-[methylenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)

CM 1

CRN 4934-34-3  
CMF C19 H26 N2 O2



CM 2


CRN 124-04-9  
CMF C6 H10 O4



RN 30623-67-7 CAPLUS  
CN Sebacic acid, polyamide with 3,3'-[methylenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)


CM 1

CRN 4934-34-3  
CMF C19 H26 N2 O2



CM 2


CRN 111-20-6  
CMF C10 H18 O4



RN 30898-32-9 CAPLUS  
CN Acetic acid, [isopropylidenebis(p-phenyleneoxy)]di-, polyamide with 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis[propylamine] (8CI) (CA INDEX NAME)


CM 1

CRN 4835-05-6  
CMF C21 H30 N2 O2




CM 2

CRN 3539-42-2  
CMF C19 H20 O6




RN 31985-71-4 CAPLUS  
CN Poly[oxy(2-oxo-1,2-ethanediyl)imino-1,3-propanediyl]oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,3-propanediylimino(1-oxo-1,2-ethanediyl)oxy-1,4-phenylene(1-methylethylidene)-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 31985-72-5 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy-1,3-propanediylimino(1,6-dioxo-1,6-hexanediyl)imino-1,3-propanediyl] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 31985-73-6 CAPLUS  
 CN Poly[oxy-1,4-phenylenemethylene-1,4-phenyleneoxy-1,3-propanediylimino(1,10-dioxo-1,10-decanediyl)imino-1,3-propanediyl] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 32127-69-8 CAPLUS  
 CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,3-propanediylimino(1,10-dioxo-1,10-decanediyl)imino-1,3-propanediyl] (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 147 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1966:456603 CAPLUS

DN 65:56603

OREF 65:10530a-b

TI Primary diamines

IN Wegler, Richard; Regel, Erik; Andres, Karl H.

PA Farbenfabriken Bayer A.-G.


SO 2 pp.

DT Patent


LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1219039		19660616	DE	19590926
AB	Title compds. of formula $\text{CH}_2[\text{R}'\text{C}_6\text{H}_3\text{O}(\text{CH}_2\text{CHRO})_n(\text{CH}_2)_3\text{NH}_2]_2$ (I), useful as curing agents for epoxy resins, were prepared by condensation of 2 moles aryl aminoalkyl ether (II) with 0.8-1.5 moles $\text{CH}_2\text{O}$ in a strong acid medium at 80-120°. In I, R is H or Me; R' is H, alkyl, cycloalkyl, aryl, or alkoxy; and n is 0-3. The II were prepared by reduction of the resp. phenoxyalkylnitriles (prepared by method of Ger. 670,357, CA 33, 29071) with H over Raney-Ni. Thus, 2-phenoxypropionitrile was hydrogenated to 3-phenoxypropylamine (III) over Raney Ni in tetrahydrofuran at 60°. To a solution of 150 g. III in 200 g. 50% $\text{H}_2\text{SO}_4$ was added 54 ml. 32% $\text{CH}_2\text{O}$ solution dropwise and the mixture heated 14 hrs. at 80°. After cooling and neutralization with NaOH solution, an 86% yield of a mixture of 87% para and 13% ortho isomers of bis(3-aminopropoxyphenyl)methane was obtained. Similarly, the I (R= H, R1= Me, and n = 0) were prepared				
IT	4934-34-3, Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis-6903-21-5, Propylamine, 3,3'-[methylenebis[(3-methyl-p-phenylene)oxy]]bis- 6903-22-6, Propylamine, 3,3'-[methylenebis[(3-methyl-o-phenylene)oxy]]bis- 7065-57-8, Propylamine, 3,3'-[methylenebis(o-phenyleneoxy)]bis- (preparation of)				
RN	4934-34-3 CAPLUS				
CN	Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)				




RN 6903-21-5 CAPLUS  
 CN Propylamine, 3,3'-[methylenebis[(3-methyl-p-phenylene)oxy]]bis- (7CI, 8CI)  
 (CA INDEX NAME)



RN 6903-22-6 CAPLUS  
 CN Propylamine, 3,3'-[methylenebis[(3-methyl-o-phenylene)oxy]]bis- (7CI, 8CI)  
 (CA INDEX NAME)



RN 7065-57-8 CAPLUS  
 CN Propylamine, 3,3'-[methylenebis(o-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)



L17 ANSWER 148 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1966:420517 CAPLUS  
 DN 65:20517  
 OREF 65:3775h,3776a-d  
 TI Synthetic estrogen series. II. Ethers of m,m'-dimethyldienestrol and -hexestrol  
 AU Marson, L. M.  
 CS Reed & Carnrick Res. Lab., Kenilworth, NJ  
 SO Farmaco, Edizione Scientifica (1964), 19(6), 543-5  
 CODEN: FRPSAX; ISSN: 0430-0920  
 DT Journal


LA English

AB I and II are prepared and no difference between estrone, I, and II is noticed after evaluation in rats. Thus, a mixture of 5 g. purified promethestryl dipropionate (III) (m. 115°) and 10 ml. 70% MeOH is refluxed 0.5 hr. to give 84%  $\gamma$ -promethestrol (IV), m. 145-5.5° (55% EtOH). Recrystd. III (m. 114-16°, Meprane Dipropionate) (5 g.) is similarly treated to give 82%  $\beta$ -promethestrol (V), m. 153-4° (45% EtOH). A mixture of 3,4-bis(3-methyl-4-hydroxyphenyl)-2,4-hexadiene (VI), 20 ml. EtOH, 15 ml. solution containing 1 g. NaOH, and .apprx.0.4 mole MeI is refluxed to give 69% p,p'-dimethyl ether, m. 101° (EtOH), of VI. Similarly prepared is I (R = PhCH<sub>2</sub>), m. 154-6° (decomposition) (iso-PrOH). Similarly prepared are the following II (R, m.p., % yield, and alc. reactant given): Me, 105-6° (EtOH), 52, IV; Me, 113-14° (EtOH), 68, V; Et, 100-1° (EtOH), 59, V; Pr, 88° (EtOH), 47, V; Bu, 69-70° (EtOH), 39, V; amyl, 48-50°, 35, V; CH<sub>2</sub>CO<sub>2</sub>H, 201-4° (decomposition) (MeOH), 20, V; morpholinocarbonylmethyl, 237-8° (EtOH), 46, V; Me, 122-32° (EtOH), 65, m-promethestrol (VII). A mixture of 3 g. VI, 40 ml. Me<sub>2</sub>CO, 1 g. NaOH, and 0.03 mole Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl is refluxed 1 hr. to give 48% I(R = CH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>)<sub>2</sub>HCl, m. 227° (decomposition) (EtOH). Similarly prepared (from V) are the following II (R, salt, m.p., and % yield given): CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, 2HCl, 247° (EtOH-Me<sub>2</sub>CO), 45; CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, 2MeI, 290-2° (decomposition) (MeOH), 91; CH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>, 2HCl, 229° (EtOH), 50; CH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>, 2PhCH<sub>2</sub>Br, 210-12° (C<sub>6</sub>H<sub>6</sub>EtOH), 60. VI is hydrogenated to give VII,  $\lambda$  230 m $\mu$  (log  $\epsilon$  4.3). A mixture of 3.3 g. 3,4-bis(3-methyl-4-hydroxyphenyl)-3,4-hexanediol and MeI is refluxed in the presence of NaOH to give 89% 3,4-bis(m-methyl-p-anisyl)-3,4-hexanediol, m. 201-3° (EtOAc). A mixture of 58 g. EtCHO, 1 g. ZnCl<sub>2</sub>, and 122 g. o-MeC<sub>6</sub>H<sub>4</sub>OMe is saturated with HCl 2.5 hrs. at 15-20° to give o-methyl-p-propenylanisole (VIII). A mixture of 12 g. hexestryl di-Me ether, 50 ml. CHCl<sub>3</sub>, and 25 ml. HOAc is saturated with HCl 15 min. in the presence of 0.1 g. ZnCl<sub>2</sub>, 2.41 g. trioxymethylene added, and the mixture kept 48 hrs. at 37° to give 14% m,m'-bis(chloromethyl)-hexestryl dimethyl ether (IX), m. 157-63° (CHCl<sub>3</sub>). IX (1.92 g.) is treated with 0.68 g. AlCl<sub>3</sub> and 0.38 g. NaBH<sub>4</sub> to give 40% II (R = Me), m. 121-3° (EtOH). VIII (9.7 g.) is treated with 0.7 g. NaBH<sub>4</sub> and 3.4 g. BF<sub>3</sub> etherate to give II (R = Me), 122-4° (EtOH).

IT 7288-00-8, Ethylamine, 2,2'-[(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride 7288-01-9, Triethylamine, 2,2'-[(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxy]]bis-, dihydrochloride 7384-74-9, Ammonium, [(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxyethylene]]bis[trimethyl-iodide] 10439-47-1, Ammonium, [(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxyethylene]]bis[benzyl-diethyl- bromide] (preparation of)


RN 7288-00-8 CAPLUS

CN Ethylamine, 2,2'-[(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)




● 2 HCl

RN 7288-01-9 CAPLUS  
CN Triethylamine, 2,2'''-[(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxy]]bis-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



● 2 HCl


RN 7384-74-9 CAPLUS  
CN Ammonium, [(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxyethylene]]bis[trimethyl-], diiodide (8CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

RN 10439-47-1 CAPLUS  
CN Ammonium, [(1,2-diethylethylene)bis[(2-methyl-p-phenylene)oxyethylene]]bis[benzyl-diethyl-], dibromide (8CI) (CA INDEX NAME)





● 2 Br<sup>-</sup>

L17 ANSWER 149 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1966:52498 CAPLUS

DN 64:52498

OREF 64:9843f-g,9844a

TI Polymeric phosphonamides

IN Nielsen, Morris L.; Deebel, George F.

PA Monsanto Research Corp.

SO 2 pp.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3227685		19660104	US	19611121

AB The title polymers are prepared by the reaction of an aromatic phosphonic dihalide, e.g.  $\text{PhP}(\text{O})\text{Cl}_2$  (I), with an amino ether, e.g. 2,2-bis[4-(3-aminopropoxy)phenyl]propane (II). Such ethers are made from alkylidene diphenols, which are prepared by the reaction of a saturated aliphatic ketone with a phenol. Thus, a solution of 17.9 g. I in 115 ml.  $\text{CHCl}_3$  was added dropwise to a mixture of 75 ml.  $\text{H}_2\text{O}$ , 7.3 g.  $\text{NaOH}$ , and 35.93 g. II. After stirring 2 hrs., the  $\text{CHCl}_3$  layer was allowed to sep. and the polymer (III) was precipitated from it by addition of  $\text{C}_6\text{H}_{14}$ . III was filtered and dried in vacuo at  $75^\circ$ ; yield 83%, decompose  $300^\circ$ . Analysis showed repeating units of the structure IV. These polymers are useful as impregnants and adhesives for laminates and as the resinous base for oil-vehicle coatings. They can be spun into filaments from solns., cast, and melt-extruded into fibers and other com. shapes.

IT 4835-05-6, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis-(phosphonamide polymers from phosphonic dihalides and)

RN 4835-05-6 CAPLUS

CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



L17 ANSWER 150 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1965:463792 CAPLUS

DN 63:63792

OREF 63:11764g-h,11765a-d

TI Polycarboxamides from organic dicarboxylic acids and bis(aminopropoxyaryl) alkanes

IN Preston, Jack; Huffman, William A. H.; Smith, Ralph W.

PA Monsanto Co.

SO 7 pp.

DT Patent

LA Unavailable


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3197434		19650727	US	19600317


AB Linear polycarbonamides formed by condensing organic dicarboxylic acids and bis(aminopropoxyaryl)alkanes and their use as textile products, such as filaments, fibers, and yarns, are described. To prepare 2,2-bis[4-(3-aminopropoxy)phenyl]propane, 91.2 g. high-purity bisphenol A, m. 160.5-162°, was added to a high-pressure vessel. Then, 0.8 g. dry Na tert-butoxide was added to catalyze the dicyanoethylation reaction. CuCl (4 g.) for stabilizing the acrylonitrile subsequently added was also placed in the reactor and the ingredients mixed well. Then, relatively cold, unstabilized acrylonitrile was poured cautiously onto the resulting mixture. A vigorous reaction occurred when the acrylonitrile came into contact with the catalyst, but it subsided rapidly. Addition of acrylonitrile was continued until 400 ml. had been added. The reaction mixture was stirred and heated to 100° in the absence of air for 1 hr. and then stirred and heated at 104 ± 4° for an addnl. 17.5 hrs. under a pressure of 13.5-20.0 psig. to form the intermediate dinitrile. Unreacted acrylonitrile was removed from the reaction mixture by reduced pressure evaporation. The acrylonitrile thus removed was collected for re-use in a flask partly immersed in a solid CO<sub>2</sub>-acetone bath. The residue was dissolved in 500 ml. CHCl<sub>3</sub> and the resulting solution was filtered. The filtrate containing the dinitrile reaction product was washed successively with 5 100-ml. portions of 5% aqueous NaOH, 2 125-ml. portions of 5% HCl, and 1 250-ml. portion of H<sub>2</sub>O. The washed organic solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and CHCl<sub>3</sub> distilled. The residue (98.6 g.) was dissolved in hot EtOH and the hot solution treated with activated C. After filtering, the solution was cooled to precipitate the dinitrile. Purification by recrystn. with EtOH was repeated 3 more times. The precipitated material was the dinitrile, 2,2-bis[4-(2-cyanoethoxy)phenyl]propane (I), m. 78-9° and a slightly buff color. The yield was 60% of theoretical yield. It was combined with similar material produced in addnl. runs. The combined samples (.apprx.185 g.) were recrystd. twice from 700 ml. portions of the CCl<sub>4</sub>-EtOH azeotrope. The purified dinitrile m. 80-80.5°. Bis[4-(3-aminopropoxy)phenyl]methane, m. 115.5-16°, was similarly prepared. To a Waring Blendor, 275 ml. H<sub>2</sub>O, 10 ml. CHCl<sub>3</sub>, a slight excess over 0.02 mole I, 45 ml. N KOH, and 0.3 g. Na lauryl sulfate were added and the mixture emulsified by agitation. Then, 0.02 mole terephthaloyl chloride dissolved in 40 ml. CHCl<sub>3</sub> was added during 1-2 min. to the rapidly stirred emulsion. Two 5-ml. portions of CHCl<sub>3</sub> were used to transfer quantitatively the diacid chloride. Stirring was continued for 2 min. and 5-10 ml. N HCl was added to break the emulsion. The precipitated polymer was filtered, washed twice with EtOH, a dilute base, and H<sub>2</sub>O and dried in vacuo at 50°, giving 8.5 g. (92% yield), m.p. 220-5°. The polymer yielded cold-drawable filaments. Its sp. viscosity was 0.38 as determined by dissolving 0.5 g. in 100 ml. m-cresol.

IT 4934-34-3, Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (and amide polymers with terephthaloyl chloride)

RN 4934-34-3 CAPLUS  
 CN Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)



IT **4835-05-6**, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis- (and amide polymers with tetrachloroterephthaloyl chloride)  
 RN 4835-05-6 CAPLUS  
 CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)



L17 ANSWER 151 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1965:402686 CAPLUS

DN 63:2686

OREF 63:434g-h,435a

TI Determination of cyanocobalamin in injections

AU Gstirner, F.; Baveja, S. K.

CS Univ. Bonn, Germany

SO Mitteilungen der Deutschen Pharmazeutischen Gesellschaft (1965), 35(2), 29-33

From: Pub. in Arch. Pharm. 298(2)


CODEN: MDPGAA; ISSN: 0012-0561

DT Journal


LA German

AB A modified Van Melle's method (CA 50, 4461b) is described. The sample (200  $\gamma$ ) is purified with an ion-exchange column, cyanocobalamin (I) converted to the dicyano complex and determined by absorbance at 587 m $\mu$ . The result is calculated by comparing with a standard curve. Carboxyl cation-exchange resin Amberlite XE 97 (II) (15 g.) is purified by washings with H<sub>2</sub>O, 1N NaOH, citrate buffer (III) (pH 4.0), 0.1N HCl, 85% Me<sub>2</sub>CO, and dioxane, followed again by III to pH 4. The pH of a sample solution was adjusted to 4.0 with III and the solution transferred to the ion-exchange column. The flow rate was adjusted to 2 ml./min. The yellow impurities were eluted with 0.1 N HCl until the eluant became colorless. Excess HCl was removed from side-walls with cotton. The column was further eluted with 85% Me<sub>2</sub>CO (at a rate of 1 ml./min.) and with 25 ml. of 0.1N HCl and finally, I was eluted with dioxane, and the eluates were collected in a vessel 3.5 ml. 0.1N HCl. For the spectrophotometric determination the solns. prepared were: (a) 4 ml. dioxane + 0.1N HCl (in a 6:4 ratio) + 1 ml. borate buffer (IV) (pH 9.5) (b) 4 ml. of the dioxane eluate + 1 ml. IV (c) same as a but replacing IV with 1 ml. 10% aqueous KCN (d) same as b but replacing IV with the KCN solution The absorbance was determined 30 min. after preparation of

the last solution The detns. were performed under the hood, and the glass windows were covered with black paper, because of the KCN reagent, and for



```
L17  ANSWER 152 OF 202  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   1965:402685  CAPLUS
DN   63:2685
OREF 63:434f-g
TI   Bromatometric determination of organic bases
AU   Montequi, R.; de Valderrama, E. F.; Collado, M. C.
SO   Anales Real Acad. Farm. (1964), 30(5), 281-91
DT   Journal
LA   Spanish
AB   The Reinecke salts of a series of physiol. active bases contained in com.
      pharmaceutical preps. were quant. determined with 0.1N KBrO3 as previously
      described (CA 53, 20697d; 57, 8661e; CA 58, 7787b). The bases were
      D-tubocurarine chloride, Coralgil, Elvetil, lignocaine-HCl
      (lidocaine-HCl), Spasmo-Papamid, (2-diethylaminoethyl ester of
       $\alpha$ -phenyl-1-piperidineacetic acid), and N,N-bis( $\gamma$ -phenylpropyl)-
      ethylamine citrate. Amts. of 4.56-30.15 mg. were used. The accuracy was
       $\pm 0.95\%$ .
IT   2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-
      phenyleneoxy)]bis-
      (determination of)
RN   2691-45-4  CAPLUS
CN   Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-
      phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)
```



Page 248

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal


LA German

AB In cats, the circulatory action of intravenous injections of the title substance (Trimanyl) was investigated by means of heat conductivity probes. Myocardial circulation and circulation in the cerebral cortex increased with increased doses. With 0.2 and 0.4 mg./kg., circulation increased very slightly in the skeletal musculature, while no changes were observed in liver and renal cortex circulation. More than 0.4 mg./kg. caused a slight drop in blood pressure and doses  $\geq 0.8$  mg./kg. caused slight redns. in the circulation of liver, renal cortex, and skeletal muscle.

IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
(circulatory response to)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 154 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1964:487248 CAPLUS

DN 61:87248

OREF 61:15226f-h

TI The effects of 4,4'-bis(ethylaminoethoxy)hexestrol dihydrochloride (Coralgil) on the coronary circulation

AU Takenaka, Fumio; Takeya, Norihide; Miyake, Nobuaki; Oka, Kazumoto; Nasu, Toshiaki; Murakoshi, Hirokazu

SO Kumamoto Medical Journal (1964), 17(1), 36-43

CODEN: KUMJAX; ISSN: 0023-5326

DT Journal

LA Unavailable


AB The cardiovascular effects of the title compound (I) were studied on the isolated dog heart, pig coronary artery, and whole anesthetized dogs and rabbits. In the isolated dog heart, I, above 0.1 mg., increased the coronary blood flow. The cardiac contractile force was unaffected but was decreased when I was above 0.8 mg. I at 0.8 mg. reduced the O<sub>2</sub>, lactate, and glucose consumptions. The effects of I were not influenced by pretreatment with nethalide. Polarographic myocardial O<sub>2</sub> (PMCO) was increased without changes in blood pressure in the rabbit. Doses over 4 mg./kg. resulted in a decreased PMCO and blood pressure. I did not influence the electrocardiogram in the dog but reduced the heart rate, blood pressure, and respiration. Pretreatment with atropine had no effect. The effects of noradrenaline and acetylcholine on blood pressure were not influenced by pretreatment with I. I, above  $3 \times 10^{-4}$  g./ml., caused a relaxation of the pig coronary arterial strip. The same effect was seen on rabbit aortic strips in concns. of I of  $1.5 \times 10^{-6}$  and  $3 \times 10^{-5}$  g./ml. It was indicated that I acts directly upon the heart and vascular smooth muscles.

IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-

phenyleneoxy)]bis-, dihydrochloride  
(circulatory response to)

RN 69-14-7 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)]bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 155 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1964:476335 CAPLUS

DN 61:76335

OREF 61:13241e-f

TI Bis(3-aminopropoxyphenyl)alkanes

IN Holsten, John R.; Huffman, William A. H.; Preston, Jack

PA Monsanto Co.

SO 3 pp.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3148215		19640908	US	19600317
				US	19600317

AB Cold CH<sub>2</sub>:CHCN (400 ml.) added gradually to a 2 l. stirred autoclave charged with 91.2 g. (p-HOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CMe<sub>2</sub>, 0.8 g. NaO-Bu-tert, and 4 g. Cu<sub>2</sub>Cl<sub>2</sub>, the mixture heated 17.5 hrs. at 104 ± 4° and 13.5-20.0 lb./in.<sup>2</sup>, unreacted CH<sub>2</sub>:CHCN removed, and the residue crystallized from CHCl<sub>3</sub> and EtOH gave 60% (p-NCCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CMe<sub>2</sub>, m. 80-80.5°. Hydrogenation of the dinitrile in ammoniacal (MeOCH<sub>2</sub>)<sub>2</sub> with Raney Co at 84118°/2900-3200 lb./in.<sup>2</sup> gave (p-H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CMe<sub>2</sub>, b<sub>0.4</sub> 216-17°. In a similar manner (p-NCCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CH<sub>2</sub>, m. 115-16°, and (p-H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CH<sub>2</sub> were obtained from (p-HOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CH<sub>2</sub>.

IT **4835-05-6**, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis- **4934-34-3**, Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (preparation of)


RN 4835-05-6 CAPLUS

CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)




RN 4934-34-3 CAPLUS

CN Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)




L17 ANSWER 156 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1964:471883 CAPLUS  
 DN 61:71883  
 OREF 61:12523c-d  
 TI Effect of hexestrol bis(diethylaminoethyl)ether (DAH) on the general circulation and coronary blood flow  
 AU Kovac, A. G. B.; Mitsanyi, A.  
 CS Med. Univ., Budapest, Hung.  
 SO Wien. Med. Wochschr. (1964), 114(23), 401-5  
 DT Journal  
 LA Unavailable  
 AB DAH is free of side-effects, on the isolated rabbit heart it works as a coronary vasodilator, but on the heart of the anesthetized dog it produces only mild coronary dilation. In 21 anesthetized dogs (2.5-5 mg. DAH/kg.) arterial blood pressure decreased and coronary and peripheral blood flow increased. This was also found in animals pretreated with dibenamine. The effect of DAH is similar to that of papaverine.  
 IT 2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis- (circulatory response to)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 157 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1964:454662 CAPLUS  
 DN 61:54662  
 OREF 61:9431d-e  
 TI Hypocholesteremic 2,3-diphenylacrylonitriles  
 AU Hughes, G. M. K.; Moore, P. F.; Stebbins, R. B.  
 CS Chas. Pfizer & Co., Inc., Groton, CT  
 SO Journal of Medicinal Chemistry (1964), 7(4), 511-18  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA Unavailable  
 AB The diethylaminoethyl ethers of 4-stilbenol, stilbesterol, hexestrol, and estradiol have been shown to be hypocholesteremic by inhibiting the reduction of desmosterol to cholesterol. Extensive series of dialkylaminoalkoxy derivs. of stilbene, 2,3-diphenyl-acrylonitrile, and 2,3-diphenyl-2-pentenitrile have been made and their hypocholesteremic activity has been determined; members of the last class with trans stereochemistry are


particularly potent agents.  
 IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
 (preparation of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L17 ANSWER 158 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1964:454661 CAPLUS  
 DN 61:54661  
 OREF 61:9431b-d  
 TI Synthesis of isoimides  
 AU Bhatia, P. L.; Gupta, S. N.  
 CS Meerut Coll.  
 SO Indian Journal of Chemistry (1964), 2(7), 295-6  
 CODEN: IJOCAP; ISSN: 0019-5103  
 DT Journal  
 LA Unavailable  
 AB Dehydration of the corresponding N-arylphthalamic acids (I) with trichloroacetic anhydride in dioxane employing the exptl. conditions of Roderick and B. (CA 59, 6304h) gave the following phthalisoimides (II) (R, m.p., and % yield given): m-chlorophenyl, 93-5°, 66; m-tolyl, 147-50°, 68; p-ethoxyphenyl, 123°, 65; and p-bromophenyl, 166-7°, 71. Also the following known II were prepared (R given): p-methoxyphenyl, o-methoxyphenyl, p-chlorophenyl, o-chlorophenyl, p-tolyl, and o-tolyl. The infrared spectra of all the isoimides showed bands at 5.56 and 5.90  $\mu$  corresponding to C=O and C.tplbond.N, resp. I were prepared by the method described earlier (R. and B., loc. cit.). N-(p-Bromophenyl)-phthalamic acid, m. 189-91° was prepared by the reaction of equimolar amts. phthalic anhydride and p-bromoaniline at room temperature  
 IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
 (preparation of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl


L17 ANSWER 159 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1963:424490 CAPLUS  
 DN 59:24490  
 OREF 59:4455g-h  
 TI Inhibition of cholesterol biosynthesis in the rat by 3 $\beta$ -[2-(diethylamino)ethoxy] androst-4-en-17-one hydrochloride U18666A)  
 AU Phillips, Wm. A.; Avigan, Joel  
 CS Upjohn Co., Kalamazoo, MI  
 SO Proceedings of the Society for Experimental Biology and Medicine (1963), 112, 233-6  
 CODEN: PSEBAA; ISSN: 0037-9727  
 DT Journal  
 LA Unavailable  
 AB Given orally, the title compound (I), a new inhibitor of cholesterol biosynthesis, caused marked reduction in liver and serum sterols and appearance of desmosterol in livers of rats. Reduction of serum sterols by I was obtained in rats in which hypercholesterolemia was induced by Triton WR-1339. I increased incorporation of acetate-1-C14 into liver digitonin-precipitable sterols 4-fold and into liver fatty acids 2-fold. Hexestrol bis( $\beta$ -diethylaminoethyl)ether di-HCl also caused appearance of desmosterol in rats; hexestrol,  $\alpha$ -(diethylamino)ethanol, and p-(diethylaminoethoxy)toluene-HCl did not.  
 IT 69-14-7, Triethylamine, 2,2'-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
 (desmosterol in liver after administration of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 160 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1963:82286 CAPLUS  
 DN 58:82286  
 OREF 58:14174b-f  
 TI Synthesis of polyamides by cyanoethylation of bisphenol. III. Preparation

- of polyamides from dihydroxybiphenyl and dihydroxydiphenylethane
- AU Ando, Tadanao; Kataoka, Seiichi
- CS Osaka Ind. Tech. Examination Inst., Japan
- SO Kogyo Kagaku Zasshi (1962), 65, 2057-61
- CODEN: KGKZA7; ISSN: 0368-5462
- DT Journal
- LA Unavailable
- AB cf. Osaka Kogyo Gijutsu Shikensho Kiho 13, 73(1962); CA; 57, 8733e.  
 4,4'-Bis( $\gamma$ -aminopropoxy)-biphenyl (I) (4 g.), b3 259-60°, m.  
 153-4°, was prepared by treating 5 g. bis( $\beta$ -cyanoethoxy)biphenyl  
 (II) with 120 ml. EtOH, 0.8 g. Raney Co, and 80 kg./cm.<sup>2</sup> H at 70°  
 for 6 hrs. II, m. 187-8°, was prepared in a 27 g. yield by refluxing  
 22.8 g. 4,4'-dihydroxybiphenyl in 212 g. acrylonitrile with 2 ml. Triton B  
 (40% aqueous solution of trimethylbenzyl ammonium hydroxide) for 4 days.  
 1,2-Bis[4-( $\gamma$ -aminopropoxy)phenyl]ethane (III), b2 248-54°, m.  
 97-8% was prepared in a 4 g. yield by the reduction of 5 g. 1,2-bis[4-  
 ( $\beta$ -cyanoethoxy)phenyl]ethane (IV) in a similar procedure as for the  
 preparation of I. IV, m. 157-8°, was prepared in an 8 g. yield by treating  
 7.5 g. 4,4'-dihydroxydiphenylethane in a similar procedure as in the  
 preparation of II. Nylon salts of I adipic acid, m. 213-15°, I azelaic  
 acid, m. 208-10°, I sebacic acid, m. 194-6°, III adipic  
 acid, m. 188-9°, III azelaic acid, m. 186-9°, and III  
 sebacic acid, m. 207-9°, were prepared by crystallization from EtOH solution  
 The above nylon salts, as well as nylon salts of bis[4-( $\gamma$ -  
 aminopropoxy)phenyl] methane (V) and of 2,2-bis[4-( $\gamma$ -  
 aminopropoxy)phenyl] propane (VI), were condensed at 244-5°  
 (diethylene glycol vapor bath) for 6-7 hrs. in N and for 30 min. under 200  
 mm. Hg. The resulting polyamides melted as follows: I adipic acid,  
 320-9°; I azelaic acid, 247-9°; I sebacic acid,  
 252-9°; V adipic acid, 219-21°; V azelaic acid,  
 166-8°; V sebacic acid, 197-201°; III adipic acid,  
 264-6°; III azelaic acid, 212-14°; III sebacic acid,  
 219-20°; and VI sebacic acid, 118-23°. The polysebacamides  
 of I, V, and III showed a crystalline diffraction diagram, but that of VI was  
 amorphous. The Me side chain in the diphenylalkane structure of the  
 polyamide from VI was thought to prevent crystallization. The polyamides of V,  
 III, and VI were capable of forming fibers but not the polyamide of I.  
 The polyamides with an even number of methylene groups in the alkane part  
 melted higher than those with an odd number thus verifying the so-called  
 zigzag relation.
- IT 15449-15-7, Propylamine, 3,3'-[ethylenebis(p-phenyleneoxy)]di-  
 (preparation of)
- RN 15449-15-7 CAPLUS
- CN Propylamine, 3,3'-[ethylenebis(p-phenyleneoxy)]bis- (8CI) (CA INDEX NAME)



- L17 ANSWER 161 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN
- AN 1963:68617 CAPLUS
- DN 58:68617
- OREF 58:11781f-h,11782a-b
- TI Cholesterol biosynthesis. V. The time course and pathway of the later  
 stages of cholesterol biosynthesis in the livers of intact rats
- AU Goodman, Dewitt S.; Avigan, Joel; Steinberg, Daniel
- CS U.S. Public Health Serv., Bethesda, MD
- SO Journal of Biological Chemistry (1963), 238, 1287-93

CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA Unavailable

AB Studies have been conducted of the time course of the distribution of radioactivity in rat liver nonsaponifiables at several short intervals after the intravenous injection of 2-<sup>14</sup>C-DL-mevalonic acid. Recently developed thin-layer chromatographic techniques were employed that permit separation of many of the sterol intermediates in cholesterol biosynthesis. Both normal and triparanol-fed rats were studied, and biochem. techniques were used to aid in the identification of some of the intermediate compds. The appearance of radio-activity in liver sterol was extremely rapid. After 2 min. 7% of the injected radioactivity was present in liver nonsaponifiables, and 43% of this was contained in sterols; 57% of the nonsaponifiable radioactivity was present as squalene. After 30 min., 11% of the injected radioactivity was present in the nonsaponifiables, and 89% of this was contained in sterols. Within the sterol fraction, radioactivity was found primarily in lanosterol, an intermediate zone,  $\Delta^7$  (+ $\Delta^8$ )-cholesterol, and cholesterol. The relative amount of radioactivity in the first three of these decreased progressively from the maximum found at 2 min., which is consistent with the conclusion that these components lie on the major biosynthetic pathway to cholesterol. After 2 min., 53% of the sterol radioactivity was in lanosterol and only 19% in cholesterol; by 30 min., 76% of the sterol radioactivity was in cholesterol. The evidence presented suggests that the radioactivity in the intermediate zone from normal rats was contained in a C<sub>28</sub> sterol mixture containing compds. with both saturated and unsatd. side chains. The results

also


indicate that in normal rats no significant radioactivity was contained in  $\Delta^7,24$ -cholestadienol or in zymosterol, whereas major amts. of radioactivity were present in one or both of these compds. in triparanol-treated rats. Only traces of radioactivity were found in 24,25-dihydrolanosterol and in desmosterol throughout the time period studied. It is probable that neither of these compds. lies on the major normal pathway of cholesterol biosynthesis. Reduction of the side chain probably occurs mainly at some intermediate stage in the sequence of reactions that modify the configuration of the sterol nucleus. Side chain reduction does not occur exclusively at any one point, however, but does occur to different degrees at several or perhaps at all points in the normal pathway from lanosterol to cholesterol.

IT 107744-23-0, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride


(effect on reduction of desmosterol and lanosterol)

RN 107744-23-0 CAPLUS

CN Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride (7CI) (CA INDEX NAME)



DN 58:68616  
 OREF 58:11781e-f  
 TI Cholesterol biosynthesis. IV. Reduction of lanosterol to 24,25-dihydrolanosterol by rat liver homogenates  
 AU Avigan, Joel; Goodman, DeWitt S.; Steinberg, Daniel  
 CS U.S. Public Health Serv., Bethesda, MD  
 SO Journal of Biological Chemistry (1963), 238, 1283-6  
 CODEN: JBCHA3; ISSN: 0021-9258  
 DT Journal  
 LA Unavailable  
 AB cf. CA 56, 10753i. The anaerobic reduction of labeled lanosterol, biosynthetically prepared from 2-C<sup>14</sup>-mevalonic acid, to 24,25-dihydrolanosterol has been demonstrated with rat liver homogenates. Enzymic activity was associated with cell particles, mostly with microsomes, and required reduced triphosphopyridine nucleotide. The enzyme was completely inhibited on addition of N-ethylmaleimide or p-chloromercuribenzoate, and did not require a bivalent cation for activity. Attempts to demonstrate the reversibility of side chain reduction of lanosterol during both anaerobic and aerobic incubations were not successful. Triparanol and two other inhibitors of cholesterol biosynthesis blocked the reduction of both lanosterol and desmosterol in vitro. Unlabeled lanosterol or desmosterol added to the incubation medium caused a comparable inhibition of reduction of C<sup>14</sup>-lanosterol. It is possible that a single enzyme is responsible for the reduction of both sterol substrates.  
 IT **107744-23-0**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride  
 (effect on reduction of desmosterol and lanosterol)  
 RN 107744-23-0 CAPLUS  
 CN Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride (7CI) (CA INDEX NAME)



● HCl


L17 ANSWER 163 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1963:66281 CAPLUS  
 DN 58:66281  
 OREF 58:11275b-c  
 TI Bis[4-(3-aminopropoxy)phenyl]alkanes  
 IN Imoto, Minoru; Imoto, Tatsuya; Ando, Tadanav  
 PA Mitsubishi Chemical Industries Co. Ltd.  
 SO 1 p.  
 DT Patent  
 LA Unavailable  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 37004319		19620613	JP	19600302


AB A solution of 50 g. 2,2-bis[4-(2-cyanoethoxy)phenyl] propane in 500 cc. MeOH is shaken in a H stream (100 atmospheric) of 80° in the presence of 5 g. Raney Ni, filtered, the filtrate evaporated, the residue dissolved in 1 l.

C6H6, washed with 5% NaOH, and distilled in vacuo to give 20 g. 2,2-bis[4-(3-aminopropoxy)phenyl]propane, b<sub>3</sub> 250-3°; benzoyl derivative m. 153.54°. These are changed to polyamides, useful as synthetic resins or synthetic fibers.

IT **4835-05-6**, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis-  
(manufacture of)  
RN 4835-05-6 CAPLUS  
CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI)  
(CA INDEX NAME)



IT **105862-58-6**, Benzamide, N,N'-[isopropylidenebis(p-phenyleneoxytrimethylene)]bis-  
(preparation of)  
RN 105862-58-6 CAPLUS  
CN Benzamide, N,N'-[isopropylidenebis(p-phenyleneoxytrimethylene)]bis- (7CI)  
(CA INDEX NAME)



L17 ANSWER 164 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1963:52982 CAPLUS

DN 58:52982

OREF 58:8973g-h,8974a-b

TI Bisphenol ethers

PA CIBA Ltd.

SO 34 pp.

DT Patent


LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 613143		19620726	BE	
	FR 1331933			CH	19611206
	US 3247199		1966	FR	
				US	

AB Compds. I, in which X and Y can be H, Cl, or Br, n 2 or 3, R Me or R<sub>2</sub> pentamethylene, R' can be alkyl group, and NR'<sub>2</sub> a morpholino group, have antipyretic, analgesic, and antiinflammatory properties. Na (2.3 g.) is dissolved in 100 ml. EtOH, 19 g. [3,4-Br(HO)C<sub>6</sub>H<sub>3</sub>]<sub>2</sub>CMe<sub>2</sub> in 200 ml. EtOH added, then 15 g. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl dissolved in 70 ml. C<sub>6</sub>H<sub>6</sub>, and the mixture refluxed 2 hrs., then cooled, filtered, and evaporated to dryness in vacuo. The residue is dissolved in 300 ml. ether-100 ml. EtOAc, and the solution extracted with 2N HCl. The extract is made alkaline with 10N, NaOH, the mixture extracted with ether-EtOAc, the organic extract dried, and the solvent evaporated. The residue


is dissolved in 50 ml. alc. and a concentrated solution of 19 g. citric acid in EtOH added to give [3,4-Br(Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O)C<sub>6</sub>H<sub>3</sub>]<sub>2</sub>CMe<sub>2</sub> dicitrate, m. 129-31° (alc.). Similarly prepared are the following I (R, X, Y, n, R', and m.p. of di-HCl salt, unless otherwise stated, given): Me, Br, H, 2, Me, 201° (iso-PrOH); Me, Br, H, 3, Me, 206° (iso-PrOH); Me, Cl, H, 2, Et, dicitrate 149-50° (90% EtOH); Me, Cl, H, 3, Me, 197-8° (iso-PrOH); Me, Cl, Cl, 2, Me, 220° (EtOAc-iso-PrOH); Me, Cl, Cl, 2, Et, 207-8° (ether-iso-PrOH); Me, Cl, Cl, 3, Me, 232° (iso-PrOH-EtOAc); Me, Br, Br, 2, Et, 208-9° (decomposition) (EtOAc-iso-PrOH); Me, Br, Br, 3, Et, 205-6°; Me, Br, Br, 2, (NR'<sub>2</sub> = )morpholino, 206-7° (freebase m. 120-2°); Me, H, Br, 2, (NR'<sub>2</sub> = )morpholino, 234-7°; R<sub>2</sub> = pentamethylene, Cl, Cl, 2, Et, dicitrate 125-6°; and R<sub>2</sub> = pentamethylene, H, Cl, 2, Et, dicitrate 121-3°. Also prepared is 2,4-Br[3,4-Br(HO)C<sub>6</sub>H<sub>3</sub>CMe<sub>2</sub>]<sub>2</sub>C<sub>6</sub>H<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>; citrate m. 125-7° (alc.).

- IT **90980-42-0**, Propylamine, 3,3'-[isopropylidenebis[(2,6-dibromo-p-phenylene)oxy]]bis[N,N-diethyl-, dihydrochloride **101034-39-3**, Ethylamine, 2,2'-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride **101057-51-6**, Ethylamine, 2,2'-[isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride **101677-10-5**, Propylamine, 3,3'-[isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride **102288-45-9**, Propylamine, 3,3'-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride **102288-49-3**, Propylamine, 3,3'-[isopropylidenebis[(2-chloro-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride **107386-70-9**, Triethylamine, 2,2'-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis-, dicitrate **107527-39-9**, Triethylamine, 2,2'-[isopropylidenebis[(2,6-dibromo-p-phenylene)oxy]]bis-, dihydrochloride (preparation of)
- RN **90980-42-0** CAPLUS
- CN Propylamine, 3,3'-[isopropylidenebis[(2,6-dibromo-p-phenylene)oxy]]bis[N,N-diethyl-, dihydrochloride (7CI) (CA INDEX NAME)




● 2 HCl

- RN **101034-39-3** CAPLUS
- CN Ethylamine, 2,2'-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (7CI) (CA INDEX NAME)




● 2 HCl

RN 101057-51-6 CAPLUS  
 CN Ethylamine, 2,2'-[isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (7CI) (CA INDEX NAME)




● 2 HCl

RN 101677-10-5 CAPLUS  
 CN Propylamine, 3,3'-[isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (7CI) (CA INDEX NAME)




● 2 HCl

RN 102288-45-9 CAPLUS  
 CN Propylamine, 3,3'-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis[N,N-dimethyl-, dihydrochloride (7CI) (CA INDEX NAME)



● 2 HCl

RN 102288-49-3 CAPLUS  
 CN Propylamine, 3,3'-[isopropylidenebis[(2-chloro-p-phenylene)oxy]]bis-[N,N-dimethyl-, dihydrochloride (7CI) (CA INDEX NAME)




● 2 HCl

RN 107386-70-9 CAPLUS  
 CN Triethylamine, 2,2'''-[isopropylidenebis[(2-bromo-p-phenylene)oxy]]bis-, dicitrate (7CI) (CA INDEX NAME)

CM 1


CRN 107386-69-6  
 CMF C27 H40 Br2 N2 O2




CM 2

CRN 77-92-9  
 CMF C6 H8 O7






RN 107527-39-9 CAPLUS  
 CN Triethylamine, 2,2'''-[isopropylidenebis[(2,6-dibromo-p-phenylene)oxy]]bis-, dihydrochloride (7CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 165 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1963:21714 CAPLUS  
 DN 58:21714  
 OREF 58:3633e-f  
 TI Relations between structure and albumin-binding of amines tested with crossing-paper electrophoresis  
 AU Bickel, M. H.; Bovet, D.  
 CS Ist. Super. Sanita, Rome  
 SO Journal of Chromatography (1962), 8, 466-74  
 CODEN: JOCRAM; ISSN: 0021-9673  
 DT Journal  
 LA Unavailable  
 AB cf. CA 56, 4041h. A total of 75 N-containing substances was screened with regard to their interaction with blood albumin by means of crossing-paper electrophoresis (loc. cit.). Only tertiary amines with at least 1 substantial radical interact, whereas primary and secondary amines and quaternary NH<sub>4</sub><sup>+</sup> salts do not. With mixed amines, interaction only occurs if the tertiary N dominates the other amino groups.  
 IT 2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis- (albumin binding by)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 166 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1962:443504 CAPLUS

DN 57:43504

OREF 57:8733e-h

TI Preparation of polyamides from cyanoethylated compounds of bisphenols

AU Ando, Tadanao; Imoto, Tatsuya; Imoto, Minoru

CS Osaka Ind. Res. Inst., Osaka

SO Kogyo Kagaku Zasshi (1962), 65, 132-6

CODEN: KGKZA7; ISSN: 0368-5462

DT Journal


LA Unavailable

AB 2,2-Bis[4-( $\beta$ -cyanoethoxy)phenyl]propane (I) was prepared in 66% yield by dissolving 2,2-bis(4-hydroxyphenyl)propane in excess acrylonitrile and refluxing for 20-30 hrs. in the presence of  $\text{PhCH}_2\text{N}(\text{Me})_3\text{OH}$ . Similarly, bis[4-( $\beta$ -cyanoethoxy)phenyl]methane was prepared in 57% yield from 4,4'-dihydroxydiphenylmethane. 2,2-Bis[4-( $\gamma$ -aminopropoxy)phenyl]propane (III) and bis[4-( $\gamma$ -aminopropoxy)phenyl]methane (IV) were prepared in 68% yield by reduction of I and II in EtOH in the presence of Raney Co under 80 kg./sq. cm. initial pressure of H at 80° for 2 hrs. Condensation polymers were obtained by heating the nylon salts of III and IV with dicarboxylic acids, such as adipic (V), azelaic (VI), terephthalic (VII), sebacic (VIII), thapsic (IX), decamethylenedicarboxylic (X), or 4,4'-dihydroxydiphenylmethane-o,o'-diacetic acids (XII). Polymers from III gave transparent and strong resins (except from V) and polymers from IV were opaque, had higher m.p. than polymers from IV, and had good fiber forming properties. For polymers from III, dibasic acid, polymerization temperature, reaction time (hrs.), m.p.,  $[\eta]_{25}$  in m-cresol, color, and properties were: V, 240.57°, 6, 85-100°, 0.19, pale-yellow, transparent; VI, 240.68°, 8, 73-84°, -, pale-yellow, transparent; VIII, 222-5°, 8, 98-100°, -, colorless, transparent; IX, 207-55°, 5, 121-8°, -, orange, transparent; XI, 240-68°, -, 121-6°, 0.25, pale-yellow; XII, 262-6°, 7, 128-35°, 0.28, brown, transparent. For polymers from IV, dibasic acid, polymerization temperature, reaction time (hrs.), m.p., intrinsic viscosity at 25° in m-cresol, color, and properties were: V, 222-4°, 8, 0.48, milky-white, opaque; VI, 257-69°, 6, 166-8°, 0.27, white, opaque; VIII, 253-61°, 4, 185-7°, 0.34, white, opaque; X, 252-6°, 5, 181-3°, 0.31, brown, opaque; IX, 260-4°, 5, 175-8°, 0.37, pale-yellow, opaque; XII, 255-63°, 6, 124-50°, 0.39, pale-yellow, transparent.

IT 4835-05-6, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis- 4934-34-3, Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (preparation of)

RN 4835-05-6 CAPLUS


CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)




RN 4934-34-3 CAPLUS

CN Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)

NAME)



L17 ANSWER 167 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1962:439242 CAPLUS  
 DN 57:39242  
 OREF 57:7868c-d  
 TI Effect of 3,4-bis[4-(2-diethylaminoethoxy)phenyl]hexane dihydrochloride (M.G. 345) in angina pectoris  
 AU Balatre, P.; Merlen, J. F.  
 CS Fac. Med., Lille, Fr.  
 SO Therapie (1960), 15, 83-9  
 CODEN: THERAP; ISSN: 0040-5957  
 DT Journal  
 LA Unavailable  
 AB M.G. 345 (I) had in mice an intravenous L.D.50 of 13.5, subcutaneously 150, and orally 345 mg./kg. Parenteral applications provoked strong irritation and even sclerosis. I increased the coronary flow 2.5 times more than did theophylline, and had no estrogenic action. I reduced the frequency, the duration, and the intensity of angina crises in over 50% of the cases.  
 IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride (in angina pectoris treatment)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L17 ANSWER 168 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1962:60413 CAPLUS  
 DN 56:60413  
 OREF 56:11491c-h  
 TI Cyanoethylation of bisphenols  
 AU Holsten, J. R.  
 CS Chemstrand Research Center, Inc., Durham, NC  
 SO Journal of Organic Chemistry (1961), 26, 3607-9  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA Unavailable  
 AB -Bis[p-(2-cyanoethoxy)phenyl]-methane (I) and 2,2-bis[p-(2-cyanoethoxy)phenyl]propane (II) were prepared by dicyanoethylation of

bis(4-hydroxy-phenyl)methane (III) and 2,2-bis(4-hydroxyphenyl)propane (IV), resp. The cyanoethylations were carried out in an autoclave which was fully described. A mixture of 91.2 g. IV, m. 160.5-62°, 0.8 g. NaOBu-tert and 4.0 g. Cu<sub>2</sub>Cl<sub>2</sub> was placed in the autoclave and treated cautiously with 400 ml. cold distilled, unstabilized acrylonitrile (V), resulting in a vigorous reaction. The autoclave was closed, the mixture stirred and heated to 100° during 1 hr., heated under autogenous pressure (13.5-20 lb./sq. in. gage) at 104 ° 17.5 hrs., cooled to room temperature, unreacted V removed, the residue extracted with CHCl<sub>3</sub>, the mixture filtered, the filtrate washed with 5% aqueous NaOH solution, 5% HCl, and water till the organic layer was neutral, dried, and the solvent removed to give 98.6 g. buff-colored solid. This was recrystd. from absolute EtOH after treatment with decolorizing C to afford 80.3 g. II, m. 78-9°. Two recrystns. from 5:2 CCh-absolute EtOH gave 74.6 g. II, m. 80.0-80.5°. A mixture of 164 g. II, 250 ml. 1,2-dimethoxyethane, 25 g. Raney Co, and 97 g. NH<sub>3</sub> was charged into a hydrogenation bomb, hydrogenated at 2900-3200 lb./sq. in. gage and 48-118°, the catalyst filtered off under a N blanket, and the solvent removed in vacuo to give 163 g. viscous caramel liquid. Distillation through a Claisen head gave 138 g. 2,2-bis[p-(3-aminopropoxy)-phenyl]propane, clear viscous liquid, b<sub>0.04</sub> 216-17.5°. Di-cyanoethylation of III was carried out similarly, and I isolated by removal of excess V followed by extraction with CHCl<sub>3</sub>. The residue from CHCl<sub>3</sub> was recrystd. from 4:1 dioxane-water, dioxane, and 50 ml. dioxane to give I, m. 115.5-16.0°. An anal. sample was recrystd. from AcOEt then 5:5:2 dioxane-EtOH-H<sub>2</sub>O to give I, m. 117.0-17.2°. A mixture of 30.3 g. I, 500 ml. 1,2-dimethoxyethane, 10 g. Raney Co, and 115 g. NH<sub>3</sub> was hydrogenated as in the case of II, the crude diamine flash distilled at 0.5 mm., then re-distilled through a Vigreux column to give 19.5 g. bis[p-(3-aminopropoxy)phenyl]methane, b<sub>0.5</sub> 219-22°. The purity of this sample was rather dubious since low N analysis values were obtained. The compound, however, underwent condensation polymerizations typical of diamines.

IT 4835-05-6, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis- 4934-34-3, Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (preparation of)


RN 4835-05-6 CAPLUS

CN 1-Propanamine, 3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis- (9CI) (CA INDEX NAME)




RN 4934-34-3 CAPLUS

CN Propylamine, 3,3'-[methylenebis(p-phenyleneoxy)]bis- (7CI, 8CI) (CA INDEX NAME)




L17 ANSWER 169 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1962:57603 CAPLUS  
 DN 56:57603  
 OREF 56:10967d-e  
 TI Study of the mechanism of the catalytic synthesis of methyl alcohol by the change in the [electronic] work function  
 AU Rusov, M. T.; Kozub, G. M.; Vlasenko, V. M.  
 SO Dopovidi Akademii Nauk Ukrain's'koi RSR (1961) 935-7  
 CODEN: DUKRA4; ISSN: 0375-8435  
 DT Journal  
 LA Unavailable  
 AB cf. CA 55, 18251b, 19066i. Previously postulated scheme of the formation of MeOH from CO and H gas was confirmed by the change in the work function during the adsorption of the reaction components and during the catalysis on the ZnO-CrO<sub>3</sub> catalysts.  
 IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
 (pharmacology of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 170 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1962:57602 CAPLUS  
 DN 56:57602  
 OREF 56:10967c-d  
 TI Investigations on Raney Ni catalysts XI. Interaction of Raney Ni and substrate in hydrogenation reactions  
 AU Csuros, Z.; Petro, J.; Holly, S.  
 CS Tech. Univ., Budapest  
 SO Acta Chimica Academiae Scientiarum Hungaricae (1961), 29, 351-71  
 CODEN: ACASA2; ISSN: 0001-5407  
 DT Journal  
 LA English  
 AB Changes in the H content of the catalyst during hydrogenation reactions were established. Some points of view are given for the determination of the optimum ratio of catalyst to substrate. According to the results, this ratio may markedly affect the purity of the end product. At higher temperature, the affinity of the substrate to the H of the catalyst increased.  
 IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride  
 (pharmacology of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 171 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1962:10341 CAPLUS

DN 56:10341

OREF 56:1941c-e

TI Anticholesterolemic and antilipemic action of coronary dilating hexestrone derivatives which are not estrogenic

AU Annoni, Guiseppe; Longaretti, Aldo

CS Ospedale Civile, Magenta, Italy

SO Medizinische Welt (1961) 1945-7

CODEN: MEWEAC; ISSN: 0025-8512

DT Journal


LA Unavailable

AB 4,4'-Bis(diethylaminoethoxy)hexestrone was administered intravenously (10 mg.), intramuscularly (10 mg.), orally (25 mg. 3-4 times), or rectally (10 mg.) daily for 20-30 days. The serum cholesterol (I) was lowered in 80% of the cases, and the decrease was dependent on the initial serum concentration of I. The decrease of I was greatest after intravenous administration. Sex was not a factor. The I decrease was observed after 10 days, was greater at 20-30 days, and did not decrease after this time. I increased again 8-10 days after the end of the therapy and was back to the initial value after 2-3 months. Changes in the total serum lipid followed the same pattern as I. The  $\alpha$ -lipoprotein increased slightly and the  $\beta$ -lipoprotein decreased an average of 28%. The lipid P showed an indefinite increase. The decrease in the various components was never to values below normal.

IT 2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(effect on cholesterol and lipids in serum)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 172 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1961:32986 CAPLUS

DN 55:32986

OREF 55:6446d-g


TI (Disubstituted amino)alkyl aryl ethers

IN Eimers, Erich

PA Farbenfabriken Bayer Akt.-Ges.

DT Patent  
 LA Unavailable  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1056144		19590430	DE	
AB	The title compds., useful as stabilizers for chlorine-containing polymers, accelerators for polymerization reactions, and pharmaceutical intermediates, were prepared by heating (a) a mixture of a tertiary amino alkanol (I) and a diaryl carbonate or an alkyl aryl carbonate, resp., or (b) a mixture of I and a dialkyl carbonate and a phenol. Thus, a mixture of PhOH 94, OC(OEt) <sub>2</sub> (II) 125, HO(CH <sub>2</sub> ) <sub>2</sub> NEt <sub>2</sub> (III) 117, and K <sub>2</sub> CO <sub>3</sub> 0.1 parts was stirred and the temperature allowed to rise in 6 hrs. to 180°, during which time 102 parts by volume was distilled. The temperature was then maintained 5 hrs. at 180-200°. Distillation in vacuo yielded 166 parts PhO(CH <sub>2</sub> ) <sub>2</sub> NEt <sub>2</sub> (IV), b <sub>18</sub> 135-9°. Similarly obtained were β-(Et <sub>2</sub> NCH <sub>2</sub> CH <sub>2</sub> O)C <sub>10</sub> H <sub>7</sub> , b <sub>16</sub> 208-13°, from β-naphthol, II, and III; m-ClC <sub>6</sub> H <sub>4</sub> O(CH <sub>2</sub> ) <sub>2</sub> NEt <sub>2</sub> , b <sub>16</sub> 100-10°, from m-ClC <sub>6</sub> H <sub>4</sub> OH, II, and III; m-Et <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> OC <sub>6</sub> H <sub>4</sub> O(CH <sub>2</sub> ) <sub>2</sub> NEt <sub>2</sub> , b <sub>1</sub> 170°, from resorcinol, II, and III; p-Et <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> OC <sub>6</sub> H <sub>4</sub> CMe <sub>2</sub> C <sub>6</sub> H <sub>4</sub> O(CH <sub>2</sub> ) <sub>2</sub> NEt <sub>2</sub> -p, b <sub>0.5</sub> 220-40°, from p-HOC <sub>6</sub> H <sub>4</sub> CMe <sub>2</sub> C <sub>6</sub> H <sub>4</sub> OH-p, II, and III; p-MeC <sub>6</sub> H <sub>4</sub> N(CH <sub>2</sub> CH <sub>2</sub> OPh) <sub>2</sub> , b <sub>14</sub> 74°, from p-MeC <sub>6</sub> H <sub>4</sub> N(CH <sub>2</sub> CH <sub>2</sub> OH) <sub>2</sub> , II, and PhOH; PhO(CH <sub>2</sub> ) <sub>4</sub> NEt <sub>2</sub> , b <sub>25</sub> 159-60°, from PhOH, II, and HO(CH <sub>2</sub> ) <sub>4</sub> NEt <sub>2</sub> ; p-Et <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> OC <sub>6</sub> H <sub>4</sub> CO <sub>2</sub> (CH <sub>2</sub> ) <sub>3</sub> Me, b <sub>0.6</sub> 172-9°, from p-HOC <sub>6</sub> H <sub>4</sub> CO <sub>2</sub> (CH <sub>2</sub> ) <sub>3</sub> Me, II, and III; IV from OC(OPh) <sub>2</sub> and III.				
IT	117372-31-3, Triethylamine, 2,2'''-[isopropylidenebis(p-phenyleneoxy)]bis- (preparation of)				
RN	117372-31-3 CAPLUS				
CN	Triethylamine, 2,2'''-[isopropylidenebis(p-phenyleneoxy)]bis- (6CI) (CA INDEX NAME)				



L17 ANSWER 173 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1961:3962 CAPLUS

DN 55:3962

OREF 55:806g-i

TI Comparative studies on the effect of common coronary vasodilators in anesthetized and waking dog

AU Dorner, J.; Wick, E.

CS Univ. Giessen, Germany

SO Arzneimittel-Forschung (1960), 10, 631-6

CODEN: ARZNAD; ISSN: 0004-4172


DT Journal

LA Unavailable

AB Blood pressure, coronary circulation, and cardiac frequency in the normal and anesthetized dog were determined after administration of a number of drugs. Persantin had a better effect with regard to intensity and duration of increase of circulation than papaverine (I) and nitroglycerin (II). Administration of I and II was often followed by a primary or secondary decrease of coronary circulation, probably as a result of hemodynamic changes of circulation. Hydroxyethyltheophylline, aminophylline, and


"4,4'-diethylamino-ethoxyhexestrol" (Trimanyl) had only slight effect on coronary circulation; morphine showed an occasional effect. Com. organ exts. Recosenin and Lacarnol as well as ATP had no effect.

IT 69-14-7, Trimanyl 2691-45-4, Triethylamine,  
2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(effect on coronary circulation)  
RN 69-14-7 CAPLUS  
CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 2691-45-4 CAPLUS  
CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 174 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1959:106821 CAPLUS  
DN 53:106821  
OREF 53:19166a-d  
TI Pharmacology of some new coronary dilators and especially of ethyl flavone-7-hydroxyacetate  
AU Setnikar, I.; Zanolini, T.  
CS Lab. Dr. Recordati, Milan  
SO Farmaco, Edizione Scientifica (1956), 11, 855-82  
CODEN: FRPSAX; ISSN: 0430-0920  
DT Journal  
LA Unavailable  
AB The L.D.50 of Et flavone-7-hydroxyacetate given to mice intraperitoneally was 3200 mg./kg. The toxicity was 1/21 of that of khellin, 1/8.5 that of flavone, 1/6.7 that of AmONO, and 1/16 that of glycerol trinitrate. The subacute toxicity tested by intraperitoneal injections in mice was lower than that of khellin. Chronic toxicity in oral administration with the food was low; 2.5 g./kg. daily did not influence weight and did not produce symptoms of poisoning. The coronary dilator effect, determined in the isolated rabbit heart by the Langendorff method was 14 times that of khellin, 6 times that of flavone, equal to AmONO, and about 7 times that of glycerol trinitrate. The therapeutic index, therefore, is quite favorable. The coronary dilator effect was marked even at low perfusion pressure. The drug did not influence arterial pressure of respiration in anesthetized animals. It had an antispasmodic action similar to khellin and of equal




strength, which was caused by direct action on the smooth muscles. The efficacy in bronchospasms was lightly inferior to that of khellin but, in view of the low toxicity, the efficacy in that respect still was better than that of khellin.

IT 2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(heart dilating action of)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 175 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1959:64003 CAPLUS

DN 53:64003

OREF 53:11644g-h

TI Oxygen consumption by white mice

AU Fanslow, Donald J.

CS Yankton Coll., Yankton

SO Proc. S. Dakota Acad. Sci (1958), 37, 177-83

DT Journal


LA Unavailable

AB The metabolic rate expressed as l. o consumed/hr./kg. of body weight is less for obese mice than normal mice. Oral doses of l-triiodothyronine markedly increased the metabolic rate.

IT 2691-45-4, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(biol. effects of)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 176 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1959:64002 CAPLUS

DN 53:64002

OREF 53:11644g

TI New objectives of hormone treatment

AU Bausi, H. W.

CS Hosp. St. Georg, Hamburg, Germany


SO Medizinische Klinik (Muenchen, Germany) (1959), 54, 673-6

CODEN: MEKLA7; ISSN: 0723-5003


DT Journal

LA Unavailable

AB The effects of triiodothyroacetic acid and 4,4'-diethylaminohexestrol are discussed.  
 IT **2691-45-4**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
 (biol. effects of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 177 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1959:64001 CAPLUS  
 DN 53:64001  
 OREF 53:11644f-g  
 TI Anxiety, skin conductance, and alcohol. A study of the relation between anxiety and skin conductance and the effect of alcohol on the conductance of subjects in a group  
 AU McDonnell, G. J.; Carpenter, J. A.  
 CS Yale Univ.  
 SO Quart. J. Studies Alc. (1959), 20, 38-52  
 DT Journal  
 LA Unavailable  
 AB Unavailable  
 IT **2691-45-4**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
 (biol. effects of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)




L17 ANSWER 178 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1958:108836 CAPLUS  
 DN 52:108836  
 OREF 52:19239i,19240a-b  
 TI Coated or lined plastic articles  
 IN Pinsky, Jules; Adakonis, Albert E.; Nielsen, Alvin R.  
 PA Plax Corp.  
 DT Patent  
 LA Unavailable  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2836318		19580527	US	

- AB Polyethylene squeeze bottles or similar articles are lined with a cured mixture of an epoxy resin composition consisting of 2 components. The 1st (I), consists of 10-90% by weight of a reaction product (II) of epichlorohydrin (III), (4-HOC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CMe<sub>2</sub>, and an epoxy alc.; and 10-90% of a reaction product of III and 2,4-(4-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>)(HO)C<sub>6</sub>H<sub>3</sub>C(Me)<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH-4 (IV). The 2nd (V) is 3,4-epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanecarboxylate. I and V are mixed in a weight ratio of 1:1 to 75:1. Thus, 34 parts I was mixed with 1 part V. Four parts of this mixture was mixed with 1 part [4-H<sub>2</sub>N(CH<sub>2</sub>CH<sub>2</sub>NH)<sub>2</sub>CH<sub>2</sub>CH(OH)CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>]<sub>2</sub>CMe<sub>2</sub> (VI). The final mixture was diluted with MeCOEt to a solids content of 65%. Polyethylene bottles were lined with the composition and the linings cured at 190°F. for 2 hrs. The bottles were filled with C<sub>6</sub>H<sub>14</sub>, toluene, EtOAc, and CCl<sub>4</sub> and stored at 73°F. for 286 days. The linings were highly resistant to attack by these chemicals.
- IT 108248-15-3, 2-Propanol, 1,1'-[isopropylidenebis(p-phenyleneoxy)]bis[3-[[2-[(2-aminoethyl)amino]ethyl]amino]- (as curing agent for epoxy resin mixts. for lining polyethylene bottles)
- RN 108248-15-3 CAPLUS
- CN 2-Propanol, 1,1'-[isopropylidenebis(p-phenyleneoxy)]bis[3-[[2-[(2-aminoethyl)amino]ethyl]amino]- (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 179 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1958:92765 CAPLUS

DN 52:92765

OREF 52:16307g-i

TI Muscle relaxing compounds containing quaternary ammonium and ether functions

IN Morren, H.

DT Patent

LA Unavailable


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 511221		19520901	BE	

AB Compds. of the formula  $Z(C_6H_4OC_2H_4NMe_3I-p)_2$ , wherein Z represents an aliphatic residue, are prepared by the reaction of an alkali 4,4'-diphenolate of Z with two moles 2-dialkylaminochloroethane followed by the quaternation with an alkyl halide. Thus are prepared the compds. of the above formula wherein Z represents: -CH:CPr-, m. 214°; -(CH)<sub>2</sub>-, m. above 300°; -CH:CMe-, m. 245°; -CH:CET-, m. 154°;


-CH:C(Pr-iso)-, m. 205°; -CH:CBu-, m. 219°; -(Cet)2-, cis, m. 183°, trans, m. 255°; -(CBu)2-, m. 226°; -(C6H13-n)2-, m. 182°; (CH2)2-, m. 254°; -CH2CHMe-, m. 175°; -CH2CHEt-, m. 171°; -(CHEt)2-, m. 250°; -CH2CH(Pr-iso)-, m. 175°; -CH2CHBu-, m. 180°.

IT 120526-71-8, Ammonium, [ethylenebis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] 122239-56-9, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide]  
(preparation of)  
RN 120526-71-8 CAPLUS  
CN [Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI)  
(CA INDEX NAME)



● 2 I<sup>-</sup>

RN 122239-56-9 CAPLUS  
CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)




● 2 I<sup>-</sup>

L17 ANSWER 180 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1956:64433 CAPLUS  
DN 50:64433  
OREF 50:11995i,11996a-c  
TI Chemical constitution and pharmacology of stilbene and diphenylethane derivatives. Synthetics of curare action. II  
AU Cavallini, G.; Costa, E.; Ferrari, W.; Massarani, E.; Paulesu, F.  
CS Univ. Cagliari, Sardinia  
SO Farmaco, Edizione Scientifica (1955), 10, 861-72  
CODEN: FRPSAX; ISSN: 0430-0920  
DT Journal  
LA Unavailable  
AB cf. C.A. 49, 6453e. Heating 5.7 g. hexestrol, 1.8 g. powdered NaOH, and 50 cc. Me2CO 1 hr., adding during 30 min. 10.6 g. Pr2NCH2CH2Cl, refluxing 2 hrs., filtering, evaporating the Me2CO, treating the solid with HCl in EtOH, and washing with Et2O gives 10 g. (p-Pr2NCH2CH2OC6H4CHEt)2.2HCl (I), m. 262-3°. Analogously is obtained 40% (p-Pr2NCH2CH2C6H4Cet)2.2HCl

(II), m. 256° (from MeOH). Refluxing 6 hrs. 5.04 g. of the free base of I, 8.1 g. PrI, and 5 cc. PrOH, precipitating with Et<sub>2</sub>O, and keeping several days at 0° gives 3.5 g. dipropiodide (III), m. 125-7°. The analog (IV) of III prepared in 24% yield from II by the same method, m. 149-52°. Refluxing 6 hrs. 4.7 g. (p-Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Et)<sub>2</sub>, 7.6 g. C<sub>5</sub>H<sub>11</sub>I, and 20 cc. PrOH and precipitating with Et<sub>2</sub>O gives 3.5 g. of the di-C<sub>5</sub>H<sub>11</sub>I quaternary compound (V), m. 187-8° (from EtOH), soluble in MeOH, EtOH, Me<sub>2</sub>CO, CHCl<sub>3</sub> and hot H<sub>2</sub>O, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>. Similarly is obtained 25% of the stilbene analog (VI) of V, m. 196-8°, of the same solubility. Tests for curare action in rabbits and pigeons showed the following min. active doses (mg./kg.): III, 0.75; IV 1; V, 0.35; and VI, 0.25. The compds. have a strong anticholinesterase action, especially against serum cholinesterase. The anticholinesterase activity is not related to the paralyzing action.

IT **854873-77-1**, Dipropylamine, N,N'-[(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis-  
(preparation of)  
RN 854873-77-1 CAPLUS  
CN Dipropylamine, N,N'-[(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis-  
(5CI) (CA INDEX NAME)



L17 ANSWER 181 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1956:49829 CAPLUS

DN 50:49829

OREF 50:9597d-f

TI Central antinicotinic activity of 4-hydroxystilbene and 4-hydroxydiphenylethane derivatives

AU Mantegazza, P.; Tommasini, R.

CS Univ. Milan

SO Archives Internationales de Pharmacodynamie et de Therapie (1955), 103, 371-403

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal


LA English

AB The 1-methyl-2-diethylaminoethyl and the 3-diethylaminopropyl ethers of 4-hydroxydiphenylethane (I) and 4-hydroxystilbene (II) were 15-30 times more active than Parpanit or Diparcol in antagonizing nicotine tremors in rabbits, and the activity is long-lasting. In all, 23 derivs. were tried. The derivs. of I were effective for longer, but were less active than the II series. Both have local anesthetic but no curare-like activity. Many derivs. of II increased the effects of adrenaline and noradrenaline on the blood pressure and nictitating membrane, and caused intense and prolonged bradycardia. The derivs. of I, especially 3-diethylaminopropyl, antagonize the nicotine-like drugs specifically at the orthosympathetic ganglia level.

IT **2691-45-4**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(nicotine inhibition by)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 182 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1956:20321 CAPLUS

DN 50:20321

OREF 50:4225c-e

TI Nordihydroguaiac resin acid

IN Sugimoto, Norio; Okumura, Kentaro


PA Tanabe Drug Manufg. Co.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 29004626	B4	19540726	JP	
AB	(RCH <sub>2</sub> CHMe) <sub>2</sub> (I, R = 3,4-CH <sub>2</sub> O <sub>2</sub> C <sub>6</sub> H <sub>3</sub> ) (4 g.) in 10 ml. Et <sub>2</sub> O poured into MeMgI (2 g. Mg, 10 g. MeI, and 20 ml. Et <sub>2</sub> O), heated, the Et <sub>2</sub> O removed, the residue in 50 ml. PhMe heated 3 hrs. at 110°, the product decomposed at 0° with 50 ml. 10% HCl, the PhMe layer extracted with Et <sub>2</sub> O, the Et <sub>2</sub> O layer extracted with 30 ml. 5% NaOH, the NaOH layer neutralized with HCl at 0°, the oily layer heated 1 hr. at 205-10° with 10.5 g. C <sub>5</sub> H <sub>5</sub> N.HCl, the product poured into ice water, extracted with Et <sub>2</sub> O, washed with 20 ml. 2% Na <sub>2</sub> CO <sub>3</sub> , extracted with 30 ml. 5% NaOH, the NaOH layer acidified with HCl, extracted with Et <sub>2</sub> O, and the Et <sub>2</sub> O removed gives 2.5 g. oil, yielding on recrystn. from AcOEt-petr. ether 1.3 g. I [R = 3,4-(HO) <sub>2</sub> C <sub>6</sub> H <sub>3</sub> ], m. 184-5°.				
IT	<b>120526-71-8</b> , Ammonium, [ethylenebis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] <b>122239-56-9</b> , Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] (preparation of)				
RN	120526-71-8 CAPLUS				
CN	[Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)				



● 2 I<sup>-</sup>

RN 122239-56-9 CAPLUS

CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

L17 ANSWER 183 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1956:20320 CAPLUS

DN 50:20320

OREF 50:4225a-c

TI Quaternary amino compounds


IN Morren, Henri G.

DT Patent


LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 726260		19550316	GB	
AB	<p>4-HOC<sub>6</sub>H<sub>4</sub>ZC<sub>6</sub>H<sub>4</sub>OH-4 (I) was converted to its alkali-metal diphenate, and then treated with 2 mol R<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl to give after quaternization with MeI, (4-Me<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>ZC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>NMe<sub>3</sub>-4)I<sub>2</sub> (II). Thus, to I (Z = CH:CPr) (cf. Dodds, et al., C.A. 38, 3637.5) 1 mol dissolved in absolute EtOH and treated with a stoichiometric quantity of Na was added Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl 2 mol 15%, and the mixture heated under reflux 2 h., cooled, NaCl filtered off, the filtrate treated with MeI 2 mol 15%, refluxed 1-2 h., and allowed to crystalline to give II (Z = CH:CPr), m. 214°. Similarly prepared were the following II (Z and m.p. given): CH:CH, above 300°; CH:CMe, 245°; CH:Cet, 154°; CH:CPr-iso, 205°; CH:CBu, 219°; trans-EtC:Cet, 255°; cis-EtC:Cet, 183°; BuC:CBu, 226°; (C<sub>6</sub>H<sub>13</sub>)C:C(C<sub>6</sub>H<sub>13</sub>), 182°; CH<sub>2</sub>CHPr, 167°; CH<sub>2</sub>CH<sub>2</sub>, 254°; CH<sub>2</sub>CHMe, 175°; CH<sub>2</sub>CHEt, 171°; EtCHCHEt, 250°; CH<sub>2</sub>CHPr-iso, 175°; CH<sub>2</sub>CHBu, 180°. The following are new I (Z and m.p. given): CH<sub>2</sub>CHMe, 171-2.5°; CH<sub>2</sub>CHEt, 99.5-100.5°; CH<sub>2</sub>CHPr-iso, 101-2°; and CH<sub>2</sub>CHBu, 74-6°. These compds. promote muscle relaxation.</p>				
IT	<p><b>120526-71-8</b>, Ammonium, [ethylenebis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] <b>122239-56-9</b>, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] (preparation of)</p>				
RN	120526-71-8 CAPLUS				
CN	[Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)				

● 2 I<sup>-</sup>


RN 122239-56-9 CAPLUS  
 CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)

● 2 I<sup>-</sup>

L17 ANSWER 184 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1955:70877 CAPLUS  
 DN 49:70877  
 OREF 49:13518b-d  
 TI Quaternary nitrogen derivatives of 4,4'-ethoxy- $\alpha,\beta$ -diethyldiphenylethane of considerable curare action  
 AU Mantegazza, P.; Fiorio, G.  
 CS Univ. Milan  
 SO Farmaco, Edizione Scientifica (1955), 10, 322-36  
 CODEN: FRPSAX; ISSN: 0430-0920  
 DT Journal  
 LA Unavailable  
 AB Compds. of the general formula  $R(CH_2)_{20}-p-C_6H_4(CH_2)_2-p-C_6H_4O(CH_2)_2R'$  were investigated on the elec. stimulated phrenic-nerve-diaphragm preparation of the rat. The R and R' in this report were identical and comprised the following groups: N-Me<sub>3</sub>I (I), NMe<sub>2</sub>EtI (II), NMeEt<sub>2</sub>I (III), NEt<sub>3</sub>I (IV), NMe<sub>2</sub>-CH<sub>2</sub>PhBr (V), NEt<sub>2</sub>CH<sub>2</sub>PhBr (VI). All compds. showed an inhibitory effect in the strength of which was a logarithmic function of the concentration. The sequence in decreasing efficacy was as follows: III, II, IV, I, V, and VI. III and II were 1.6 and 1.3 times as effective as d-tubocurarine, resp. with compds. with R = R' = NPr<sub>3</sub> and NEt<sub>2</sub>C<sub>5</sub>H<sub>11</sub> (anion not named) no relation between dosage and inhibitory effect was found. The effect was either nil or total. The time required to obtain a certain effect of inhibition increased with the weight of the substituting groups.  
 IT 120526-71-8, Ammonium, [ethylenebis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] 122239-56-9, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] 643724-35-0, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmet-hyl-iodide]




(as muscle relaxant)  
 RN 120526-71-8 CAPLUS  
 CN [Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI)  
 (CA INDEX NAME)




● 2 I<sup>-</sup>

RN 122239-56-9 CAPLUS  
 CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)




● 2 I<sup>-</sup>

RN 643724-35-0 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl diethyl-hyl-bromide] (5CI) (CA INDEX NAME)




● 2 Br<sup>-</sup>

RN 719278-53-2 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (5CI) (CA INDEX NAME)


● 2 I<sup>-</sup>

L17 ANSWER 185 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1955:33379 CAPLUS  
 DN 49:33379  
 OREF 49:6453e-g  
 TI Chemical constitution and pharmacological properties of stilbene and diphenylethane derivatives. Synthetic curariform drugs  
 AU Cavallini, G.; Costa, E.; Ferrari, W.; Massarani, E.  
 CS Univ. Cagliari, Milan  
 SO Archives Internationales de Pharmacodynamie et de Therapie (1954), 99, 283-97  
 CODEN: AIPTAK; ISSN: 0003-9780  
 DT Journal  
 LA Unavailable  
 AB cf. C.A. 48, 10690e. In all, 72 Me, Et, benzyl, and ar-nitrobenzyl derivs. of the bis-(alkylamino)stilbestrol and the -hexestrol series containing 2 quaternary N were studied for their curare-like action in the rabbit and pigeon. Similar derivs. of either series had about equal activity. They all showed high and prolonged curariform activity, which was increased in duration and decreased in potency by increasing the size of the alkyl radical. All showed an antiacetylcholine effect on the frog rectus abdominis and anticholinesterase action on both serum and nerve enzyme.  
 IT 643724-35-0, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] 736105-09-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl- salts] (pharmacol. of)  
 RN 643724-35-0 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] (5CI) (CA INDEX NAME)

● 2 Br<sup>-</sup>

RN 719278-53-2 CAPLUS


CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (5CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

RN 736105-09-2 CAPLUS

CN Ethanaminium, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 186 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1954:60369 CAPLUS

DN 48:60369

OREF 48:10690d-i,10691a-d

TI Biphenyl, stilbene, and diphenylethane derivatives. II

AU Cavallini, G.; Massarani, E.

CS Lab. Maggioni, Milan, Italy

SO Farmaco, Edizione Scientifica (1953), 8, 503-19

CODEN: FRPSAX; ISSN: 0430-0920


DT Journal

LA Unavailable

AB cf. C.A. 48, 6407i. Compds. of the types (4-ROC<sub>6</sub>H<sub>4</sub>)<sub>2</sub> (I), (4-ROC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Et)<sub>2</sub> (II), and (4-ROC<sub>6</sub>H<sub>4</sub>CET)<sub>2</sub> (III) are described. Stirring 15 g. ClCH<sub>2</sub>CN dropwise into refluxing I (R = H) (IV) in 200 cc. Me<sub>2</sub>CO containing 8 g. NaOH (powdered under Me<sub>2</sub>CO), filtering, and evaporating gives 13.5 g. I (R = NCCH<sub>2</sub>) (V), m. 120-2° (from EtOH), soluble in cold MeOH, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, and CHCl<sub>3</sub>, and in hot EtOH, insol. in H<sub>2</sub>O, Et<sub>2</sub>O, and CCl<sub>4</sub>. The same method gives II (R = NCCH<sub>2</sub>) (VI), m. 145-7°, soluble in Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and in hot MeOH and EtOH, insol. in H<sub>2</sub>O, Et<sub>2</sub>O, and CCl<sub>4</sub>. Refluxing 2.64 g. V 2 hrs. with 4% aqueous NaOH, treating the solution with CO<sub>2</sub> until it is neutral to phenolphthalein, filtering the separated IV, and adding HCl ppts. 1.3 g. I (R = HO<sub>2</sub>CCH<sub>2</sub>) (VII), m. 272-4°. VI gives 76% II (R = HO<sub>2</sub>CCH<sub>2</sub>), m. 222-4°, soluble in MeOH, EtOH, and Me<sub>2</sub>CO, insol. in H<sub>2</sub>O, Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>. Adding 3.22 g. Me<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>Cl slowly to 2.7 g. II (R = H) and 0.8 g. NaOH in 30 cc. refluxing Me<sub>2</sub>CO, filtering after 30 min., evaporating at 100°, dissolving the residue in EtOH, and acidifying with HCl gives 3.25 g. II (R = ClH.Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>) (VIII), m. 246-8°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH, insol. in Et<sub>2</sub>O, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>. Similarly is obtained 49% III (R = ClH.Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>), m. 245-7°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH, insol. in the other solvents. Refluxing 3.84 g. VII and 2.43 g. Et<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>Cl 4 hrs. in 50 cc. iso-PrOH gives on cooling impure crystals which, extracted from dilute Na<sub>2</sub>CO<sub>3</sub> solution with Et<sub>2</sub>O, the extract

dried with Na<sub>2</sub>SO<sub>4</sub>, evaporated, and the residue treated in EtOH with HCl ppts. 1.5 g. I (R = ClH.Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O<sub>2</sub>CCH<sub>2</sub>), m. 188-9°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH, insol. in other organic solvents. II (R = Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O<sub>2</sub>CCH<sub>2</sub>.H<sub>2</sub>O), m. 186-7°, soluble in H<sub>2</sub>O, EtOH, MeOH, CHCl<sub>3</sub>, and hot Me<sub>2</sub>CO, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>, is analogously prepared in 28% yield, and II (R = Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O<sub>2</sub>CCH<sub>2</sub>.HCl), m. 174-6°, soluble in H<sub>2</sub>O, MeOH, hot EtOH, and hot CHCl<sub>3</sub>, insol. in Et<sub>2</sub>O, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>, in 33% yield. Refluxing 4.12 g. of the base of VIII 15 hrs. in 20 cc. EtOH with 2.88 g. MeI gives 5.8 g. of the dimethiodide (II, R = IMe<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>), m. 272-3° (from EtOH), soluble in warm H<sub>2</sub>O, EtOH, and MeOH, insol. in Et<sub>2</sub>O, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>. III (R = IMeEt<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O<sub>2</sub>CCH<sub>2</sub>), m. 139-41°, soluble in MeOH and in hot H<sub>2</sub>O and EtOH, insol. in Et<sub>2</sub>O, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>, is obtained in 86% yield; the II analog, m. 209-11°, soluble in H<sub>2</sub>O, MeOH, and EtOH, insol. in Et<sub>2</sub>O, Me<sub>2</sub>CO, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>, in 90% yield; and the I analog, m. 75°, soluble in H<sub>2</sub>O, MeOH, Me<sub>2</sub>CO, and hot EtOH, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>, in 85% yield. EtI with the base of VIII gives the diethiodide (II, IMe<sub>2</sub>EtNCH<sub>2</sub>CH<sub>2</sub>), m. 261°, soluble in MeOH and in hot H<sub>2</sub>O, EtOH, and Me<sub>2</sub>CO, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, CHCl<sub>3</sub>, and CCl<sub>4</sub>, in 92% yield, and the III analog, m. 256-7°, soluble in MeOH and Me<sub>2</sub>CO and in hot H<sub>2</sub>O, EtOH, and CHCl<sub>3</sub>, insol. in C<sub>6</sub>H<sub>6</sub>, Et<sub>2</sub>O, and CCl<sub>4</sub>, in 77% yield. Refluxing 4.12 g. VIII and 3.08 g. PhCH<sub>2</sub>Br 30 min. in 24 cc. Me<sub>2</sub>CO gives 37% II [R = BrMe<sub>2</sub>(PhCH<sub>2</sub>)NCH<sub>2</sub>CH<sub>2</sub>], m. 208-10°, soluble in H<sub>2</sub>O, MeOH, and CHCl<sub>3</sub> and in hot EtOH and Me<sub>2</sub>CO, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>; III analog (70%), m. 205-7°, soluble in MeOH, CHCl<sub>3</sub>, and in hot H<sub>2</sub>O and EtOH, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>. II, R = [BrEt<sub>2</sub>(PhCH<sub>2</sub>)NCH<sub>2</sub>CH<sub>2</sub>] (58%), m. 206-8°, soluble in MeOH, EtOH, and CHCl<sub>3</sub>, and in hot H<sub>2</sub>O, insol. in the other solvents. 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Br gives 84% II [R = BrEt<sub>2</sub>(p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>)NCH<sub>2</sub>CH<sub>2</sub>], m. 205-7°, soluble in MeOH, Me<sub>2</sub>CO, CHCl<sub>3</sub>, hot H<sub>2</sub>O, and hot EtOH, insol. in Et<sub>2</sub>O, C<sub>6</sub>H<sub>6</sub>, and CCl<sub>4</sub>; the III analog, m. 208-10°, was not recrystd. because of decomposition; it is soluble in MeOH, EtOH, and hot H<sub>2</sub>O, insol. in the other solvents. Refluxing VIII 30 min. with Me<sub>2</sub>SO<sub>4</sub> in C<sub>6</sub>H<sub>6</sub> gives 87% dimethosulfate (II, R = Me<sub>2</sub>SO<sub>4</sub>.Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>), m. 259-61°, soluble in H<sub>2</sub>O, MeOH, hot EtOH, and Me<sub>2</sub>CO, insol. in the other solvents; III analog (56%), m. 284-6°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH, insol. in the other solvents. II (R = BrNMeEt<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>) (67%), m. 235-6°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH; III analog (72%), m. 194-5°, soluble in H<sub>2</sub>O, MeOH, and hot EtOH.


IT 122239-56-9, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] 643724-35-0, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diet hyl-bromide]  
(preparation of)  
RN 122239-56-9 CAPLUS  
CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

RN 643724-35-0 CAPLUS

CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] (5CI) (CA INDEX NAME)



● 2 Br<sup>-</sup>

L17 ANSWER 187 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1954:4660 CAPLUS

DN 48:4660

OREF 48:879e-g

TI New curare compounds with prolonged action

AU Costa, E.; Ferrari, W.; Murtas, L.

CS Univ. Cagliari, Italy

SO Farmaco, Edizione Scientifica (1953), 8, 520-37

CODEN: FRPSAX; ISSN: 0430-0920

DT Journal


LA Unavailable

AB The compds. investigated had the following structures: (:CETC<sub>6</sub>H<sub>4</sub>OR-4)<sub>2</sub> (A), (CHETC<sub>6</sub>H<sub>4</sub>OR-4)<sub>2</sub> (B), and (4-(RO)C<sub>6</sub>H<sub>4</sub>)<sub>2</sub> (C), in which R was -C<sub>2</sub>H<sub>4</sub>NEt<sub>2</sub>(CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>)Br (I), C<sub>2</sub>H<sub>4</sub>NEt<sub>2</sub>(CH<sub>2</sub>Ph)Br (II), or CH<sub>2</sub>CO<sub>2</sub>C<sub>2</sub>H<sub>4</sub>NEt<sub>2</sub>(Me)I (III). The paralyzing effect by various methods of administration and the cardiovascular action were determined in rabbits. Compds. of types A and B with I or II showed a high degree of curare action of long duration. C and III were not potent. The curare effect was antagonized by tensilon. Tested on the rectus muscle of the frog, they were antagonistic to acetylcholine, caused flaccid paralysis in the pigeon, and had a moderate anticholinesterase activity. The effect was strongly increased by work. At curarizing doses they did not affect the blood pressure or the electrocardiogram and did not alter the drop in blood pressure caused by vagal stimulation. Intramuscular or intraperitoneal application is less desirable than the intravenous route, because the dose necessary is far higher and it is more difficult to avoid respiratory paralysis. The doses varied between 0.075 and 0.5 mg. per kg.

IT 643724-35-0, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] (pharmacology of)


RN 643724-35-0 CAPLUS

CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] (5CI) (CA INDEX NAME)



● 2 Br<sup>-</sup>

L17 ANSWER 188 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1954:4659 CAPLUS  
 DN 48:4659  
 OREF 48:879c-e  
 TI Narcosis in aquatic animals in presence of surface-active agents  
 AU Dastugue, G.; Boulonnais, M.  
 SO Annales Pharmaceutiques Francaises (1953), 11, 497-509  
 CODEN: APFRAD; ISSN: 0003-4509  
 DT Journal  
 LA Unavailable  
 AB The hypnotic effect of chloral hydrate, xylocaine, and maxiton but not of evadon on tadpoles is enhanced considerably by the presence of Tween 80. The effect is proportional to the concentration of Tween and the change in surface tension. The activity of surface-active agents was found at dilns. 1:1,000,000 to 1:100 in decreasing sequence as follows: Biocidan, MSA (desogen), eucalyptole, Na laurylsulfonate, C<sub>6</sub>H<sub>6</sub>, Tween, Na taurocholate, and EtOH. The various factors which may have an influence are discussed.  
 IT **643724-35-0**, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide]  
 (pharmacol. of)  
 RN 643724-35-0 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[benzyl-diethyl-bromide] (5CI) (CA INDEX NAME)



● 2 Br<sup>-</sup>

L17 ANSWER 189 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1954:3398 CAPLUS  
 DN 48:3398  
 OREF 48:591c-h  
 TI Ether groups in quaternary ammonium compounds  
 AU Morren, H. G.; Trolin, S.; Strubbe, H.; Grivsky, E.  
 SO Journal de Pharmacie de Belgique (1952), 7, 295-307

CODEN: JPBEAJ; ISSN: 0047-2166

DT Journal


LA Unavailable

AB Quaternary compds. of the general formulas ROR and ROR'OR, where R is an aliphatic quaternary amino halide group and R' is an aryl or arylaliphatic group, are prepared by known methods. The following compds. are reported: [X Me<sub>3</sub>N(CH<sub>2</sub>)<sub>n</sub>]<sub>2</sub>O (X, n, m.p., and crystallization solvent given): Br, 2, 300°, EtOH-Et<sub>2</sub>O; Br, 3, 254-5°, EtOH-Et<sub>2</sub>O; I, 4, 170°, EtOH-Me<sub>2</sub>CO; Cl, 5, 197-8°, EtOH-Me<sub>2</sub>CO-Et<sub>2</sub>O; Br, 5, 155-6°, EtOH-Me<sub>2</sub>CO; I, 5, 162-3°, EtOH. Also (m.p. and crystallization solvent): [IEt<sub>3</sub>N(CH<sub>2</sub>)<sub>5</sub>]<sub>2</sub>O, 204°, EtOH-Et<sub>2</sub>O; [IMEt<sub>2</sub>N(CH<sub>2</sub>)<sub>5</sub>]<sub>2</sub>O, 168°, EtOH-Et<sub>2</sub>O; [IME<sub>3</sub>N(CH<sub>2</sub>)<sub>6</sub>]<sub>2</sub>O, hygroscopic; IMe<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>3</sub>I, 207-8°, EtOH-Et<sub>2</sub>O; IMe<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub>I, 72°, EtOH; IMe<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>5</sub>OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>3</sub>I, 145°, EtOH-Me<sub>2</sub>CO; [IME<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>]<sub>2</sub>O, 107°, EtOH; [p-IME<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>]<sub>2</sub>, 240°, EtOH; [p-IME<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>]<sub>2</sub>CH<sub>2</sub>, 241°, EtOH. A group of compds. with the general formula p-IME<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CY:CY'C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>3</sub>I-p-(Y, Y', m.p., and crystallization solvent given): H, H, 300°, water; H, Me, 245°, EtOH; H, Et, 154°, EtOH-Et<sub>2</sub>O; H, iso-Pr, 205°, EtOH-Et<sub>2</sub>O; H, Pr, 214°, EtOH; Et, Et (trans), 255°, EtOH; Et, Et (cis), 183°, EtOH; Bu, Bu, 226°, EtOH; C<sub>6</sub>H<sub>13</sub>, C<sub>6</sub>H<sub>13</sub>, 182°, EtOH. Reduced forms, RCHYCHYR': H, H, 254°, EtOH; H, Me, 175°, EtOH; H, Et, 171°, EtOH; H, iso-Pr, 137°, EtOH; H, Pr, 167°, EtOH; H, Bu, 180°, EtOH; Et, Et, 250°, EtOH. Saturated diphenols were prepared as follows: α-propyl-4,4'-dimethoxystilbene (cf. Dodds, et al., C.A. 38, 3637.5) in EtOH or AcOEt, is hydrogenated 3 hrs. with Raney Ni and H at 120 kg. pressure and 130°, the catalyst removed, and the solvent evaporated; distillation gives 92% 1,2-bis(p-methoxyphenyl)pentane, b<sub>0.25</sub> 164-6°. The demethylated diphenol (yield 55%), m. 83.5-4°. Compds. corresponding to the general formula p-ROC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CHYC<sub>6</sub>H<sub>4</sub>OR-p where R is Me are [Y, b.p./mm., and yield (%) given]: Me, (not distilled); Et, b<sub>0.5</sub> 155-6°/0.5, 94, iso-Pr, 148-50°/0.3, 80; Bu, 145-150°/0.2, Homologs where R is H: [Y, m.p., and yield (%) given]: Me, 171-2.5°, 20; Et, 99.5-100.5°, 80; iso-Pr, 101-2°, 35; Bu, 74-6°, 62. Where crystallization of the diphenol after demethylation is difficult, the dibenzoate is prepared, purified, and saponified, and the diphenol liberated with CO<sub>2</sub>. Some of the quaternary compds. reported showed curarelike biol. activity.

IT **120526-71-8**, Ammonium, [ethylenebis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] **122239-56-9**, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide]


(preparation of)

RN 120526-71-8 CAPLUS

CN [Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI)  
(CA INDEX NAME)● 2 I<sup>-</sup>

RN 122239-56-9 CAPLUS

CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

L17 ANSWER 190 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1953:62929 CAPLUS

DN 47:62929

OREF 47:10696b-e

TI Pharmacology of two series of synthetic curarizing agents

AU Levis, Suzanne; Preat, Serge; Dauby, Jacques

SO Archives Internationales de Pharmacodynamie et de Therapie (1953), 93, 46-54

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal

LA Unavailable


AB Series A (R = p-(Ime<sub>3</sub>NCH<sub>2</sub>CH<sub>2</sub>O)) and series B were studied for their actions in curarizing laboratory animals. RC<sub>6</sub>H<sub>4</sub>C<sub>6</sub>H<sub>4</sub>R (249), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>R (253), RC<sub>6</sub>H<sub>4</sub>H<sub>4</sub>CH:CHC<sub>6</sub>H<sub>4</sub>R (266), RC<sub>6</sub>H<sub>4</sub>CH:C(Me)C<sub>6</sub>H<sub>4</sub>R (260), RC<sub>6</sub>H<sub>4</sub>CH:C(Et)C<sub>6</sub>H<sub>4</sub>R (256), RC<sub>6</sub>H<sub>4</sub>CH:C(iso-Pr)C<sub>6</sub>H<sub>4</sub>R (270), RC<sub>6</sub>H<sub>4</sub>CH:C(Bu)C<sub>6</sub>H<sub>4</sub>R (265), RC<sub>6</sub>H<sub>4</sub>CH:C(Pr)C<sub>6</sub>H<sub>4</sub>R (258), RC<sub>6</sub>H<sub>4</sub>C(Et):C(Et)C<sub>6</sub>H<sub>4</sub>R (228), RC<sub>6</sub>H<sub>4</sub>C(Et):C(Et)C<sub>6</sub>H<sub>4</sub>R (263), RC<sub>6</sub>H<sub>4</sub>C(Bu):C(Bu)C<sub>6</sub>H<sub>4</sub>R (264), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>R (251), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(Me)C<sub>6</sub>H<sub>4</sub>R (261), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(Et)C<sub>6</sub>H<sub>4</sub>R' (255), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(iso-Pr)C<sub>6</sub>H<sub>4</sub>R (268), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(Pr)C<sub>6</sub>H<sub>4</sub>R (259), RC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH(Bu)C<sub>6</sub>H<sub>4</sub>R (267), RC<sub>6</sub>H<sub>4</sub>CH(Et)CH(Et)R (230), and BrMe<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>NMe<sub>3</sub>Br (248), BrMe<sub>3</sub>N(CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>3</sub>Br (250), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>4</sub>O(CH<sub>2</sub>)<sub>4</sub>NMe<sub>3</sub>I (252), ClMe<sub>3</sub>N(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>5</sub>NMe<sub>3</sub>Cl (222C), BrMe<sub>3</sub>N(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>5</sub>NMe<sub>3</sub>Br (222B), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>5</sub>NMe<sub>3</sub>I (222A), IEt<sub>3</sub>N(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>5</sub>NEt<sub>3</sub>I (273), ImeEt<sub>2</sub>N(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>5</sub>NEt<sub>2</sub>MeI (272), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>6</sub>O(CH<sub>2</sub>)<sub>6</sub>NMe<sub>3</sub>I (257), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>3</sub>NMe<sub>3</sub>I (254), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)<sub>2</sub>NMe<sub>3</sub>I (217), Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>2</sub>NMe<sub>3</sub>I (208), and Ime<sub>3</sub>N(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>NMe<sub>3</sub>I (210) were tested, and compared to d-tubocurarine. Nos. 249, 253, 270, 251, 248, 250, 252, 257, 254, 217, 210, and also 261 and 208 were discarded as showing little activity. Nos. 256, 258, 265, 228, 263, 264, 267, 230, 272 and 273 showed 2-6 times the activity of tubocurarine, but the effects were of very long duration. 222B was slow to act. The actions of 222A and 222C were effective and of brief duration, and that of 268 was longer. These 3 drugs are considered suitable for clinical trial.

IT 120526-71-8, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] 122239-56-9, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethyl-iodide] (pharmacology of)


RN 120526-71-8 CAPLUS

CN [Ethylenebis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)



● 2 I<sup>-</sup>


RN 122239-56-9 CAPLUS  
 CN [(1,2-Diethylethylene)bis(p-phenyleneoxyethylene)]bis[trimethylammonium iodide] (6CI) (CA INDEX NAME)

● 2 I<sup>-</sup>


L17 ANSWER 191 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1953:12092 CAPLUS  
 DN 47:12092  
 OREF 47:2148f-i,2149a-c  
 TI Synthesis of some amino derivatives of diphenylmethane  
 AU Benoit, Germaine; Eliopoulos, Fanny  
 SO Bulletin de la Societe Chimique de France (1951) 890-5  
 CODEN: BSCFAS; ISSN: 0037-8968  
 DT Journal  
 LA Unavailable  
 AB A series of 1, 1-bis(p-aminophenyl)-alkanes (I), the corresponding [p-(2-diethylaminoethyl)amino-phenyl]alkanes (II), as well as the 1, 1-bis(p-diethylamino-ethoxyphenyl)alkanes (III) were prepared and their bacteriostatic and pharmacol. properties studied. Series I was synthesized from Ph alkyl ketones (prepared by the Friedel-Crafts reaction) by treatment with PhMgBr, dehydration of the carbinol, hydrogenation of the ethylenic derivative, nitration, and reduction. Series II was prepared by heating I with Et<sub>2</sub>NC<sub>2</sub>H<sub>4</sub>Cl in a sealed tube 15 hrs. at 130°. Series III was prepared from 1, 1-bis(p-hydroxyphenyl)alkanes. The following compds. were prepared: Ph<sub>2</sub>C(OH)CH<sub>2</sub>R (R given): H, m. 90°; Me, m. 94°; Et, m. 65°; Bu, b. 215-20°; Am, b<sub>15</sub> 210°. Ph<sub>2</sub>C:CHR: H, b<sub>15</sub> 150°; Me, m. 52°; Et, b. 160-3°; Pr, b<sub>17</sub> 170°; Bu, b<sub>12</sub> 178-80°; Am, b<sub>12</sub> 185-8°; C<sub>10</sub>H<sub>21</sub>, m. 8-9°, b<sub>0.3</sub> 189-92°, d<sub>2323</sub> 0.938, n<sub>D23</sub> 1.536. Ph<sub>2</sub>CHCH<sub>2</sub>R: H, b<sub>30</sub> 157-60°, n<sub>D23.7</sub> 1.5743; Me, b<sub>12</sub> 150°; Et, b<sub>15</sub> 153-5°; Pr, b<sub>11</sub> 160°; Bu, b<sub>15</sub> 185°; Am, b<sub>3</sub> 180°; C<sub>10</sub>H<sub>21</sub>, b<sub>12</sub> 216-17°, d<sub>2323</sub> 0.928, n<sub>D23</sub> 1.5225. (p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>-CHCH<sub>2</sub>R: H, m. 107°; Me, m. 144°; Et, m. 112°; Pr, m. 92°; Bu, oil; Am, oil; C<sub>10</sub>H<sub>21</sub>, oil. (p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>CHCH<sub>2</sub>R: H, m. 118° (2HCl, m. 209°); Me, m. 44° [2HCl, m. 230° (decomposition) (from iso-PrOH and Et<sub>2</sub>O)]; Et,

b0.4 198-200° [2HCl, m. 165-8° (decomposition)]; Pr, b0.3 204° [2HCl, m. 181-3° (decomposition)]; Bu, b1.5 225-30° [2HCl, m. 175-8° (decomposition)]; Am, b4 255-60° [2HCl, m. 182-5° (decomposition)]; C10H21, b0.1 242-5° [2HCl, m. 145-8° (decomposition)]. (p-Et2NC2H4NHC6H4)2CHR: H, b4 275-80°; CCl3 (IV) [picrate, m. 40° (decomposition)]; Me, b0.1 215°; Et, b5 280-3°; Pr, b0.8 220-2°; Bu, b0.9 256-8°; Am, b0.3 242-5°; C6H13, b1 267-70°. (p-HOC6H4)2CHR: H, m. 163°; Me, b0.7 215°; Et, b20 275°, m. 130°; Pr, b0.4 230°, m. 136° (from C6H6); Bu, b0.08 200-4°, m. 124°; C6H13, b0.01 225°, m. 111° (from C6H6). (p-Et2NC2H4OC6H4)2-CHR: H, b0.2 240-3° [2HCl, m. 166° (from iso-PrOH)]; Me, b0.8 257° (2HCl, m. 176°); Et, b0.2 243° (2HCl, m. 181°); Pr, b0.5 250° [2HCl, m. 135° (from iso-PrOH and Et2O)]; Bu, b0.9 245-50°; C6H13, b0.2 245° (2HCl, m. 161°). Only IV has bacteriostatic activity [about 0.2 that of (p-H2NC6H4)2SO2] but it is too toxic. The I, in large dose, increase the bradycardic action of acetylcholine on the chloralosed dog. Blocking of the NH2 functions by means of a Et2NCH2CH2 group reverses this action. In small doses, these latter compds. increase the coronary output of the isolated rabbit heart; this is followed by a decrease of the contractile power of the heart muscle, the more rapid the shorter the aliphatic chain attached to the methylene group. The III have similar, but less pronounced properties.

IT **159860-02-3**, Triethylamine, 2,2'''-[methylenebis(p-phenyleneoxy)]bis- **857168-23-1**, Triethylamine, 2,2'''-[methylenebis(p-phenyleneoxy)]bis-, dihydrochloride (preparation of)  
 RN 159860-02-3 CAPLUS  
 CN Ethanamine, 2,2'-[methylenebis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)]




RN 857168-23-1 CAPLUS  
 CN Triethylamine, 2,2'''-[methylenebis(p-phenyleneoxy)]bis-, dihydrochloride (5CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 192 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1952:49594 CAPLUS  
 DN 46:49594  
 OREF 46:8266f-h  
 TI Some synthetic curare substances  
 AU Cavallini, G.; Ferrari, W.; Mantegazza, P.; Massarani, E.

- CS Univ. Milan  
 SO Farm. sci. e tec. (Pavia) (1951), 6, 815-26  
 DT Journal  
 LA Unavailable  
 AB cf. C.A 45, 5819g. The minimal paralyzing doses in rabbits of (p-Et<sub>2</sub>Me+NC<sub>2</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>CEt:)<sub>2</sub> 2I- (I), m. 260-1°, its Et<sub>3</sub>N+analog (II), m. 255°, (p-Et<sub>2</sub>MeNC<sub>2</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Et)<sub>2</sub> 2I-(III), m. 245°, and its Et<sub>3</sub>N analog (IV), m. 250-1, estradiol bis(2-diethylaminoethyl)ether-2-MeI (V), m. 225-6°, and trans, trans-Δ<sup>5</sup>,6-androstene-3,17-diol bis(2-diethylaminoethyl) ether-2MeI (VI), m. 246-8°, were 0.045, 0.075, 0.045, 0.075, 0.1, and 0.1 mg./kg. The rabbit tolerates 10 times the min. ED of I and of V if artificial respiration is given. The poisoning with V at this dose wears off after 1 h., 3 times that dose after 2 h. Ten times the min. dose of V does not affect the blood pressure in the dog. The curarelike effect in the rabbit is enhanced by eserine, whereas Congo red has a protective action. Tests on the rectus muscle of the frog reveal an antiacetylcholine effect. Repeated doses of V and VI show undiminished activity. V has many advantages in clin. use; its drawback is a lack of antagonism to prostigmine which, however, is of minor importance since it is rapidly detoxified during artificial respiration.
- IT 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide]  
 (curare action of)
- RN 719278-53-2 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (5CI) (CA INDEX NAME)




● 2 I<sup>-</sup>

- L17 ANSWER 193 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1952:48437 CAPLUS  
 DN 46:48437  
 OREF 46:8040a-i,8041a-b  
 TI Antituberculous compounds. VIII. Phenolic 2-diethylaminoethyl ethers and analogs  
 AU Lowe, J. L.; Peak, D. A.; Watkins, T. I.  
 CS Boots Pure Drug Co. Ltd., Nottingham, UK  
 SO Journal of the Chemical Society, Abstracts (1951) 3286-92  
 CODEN: JCSAAZ; ISSN: 0590-9791  
 DT Journal  
 LA Unavailable  
 AB cf. C.A. 46, 2005a. The observations of Chapman et al. (C.A. 41, 7436b), of the high activity, in vitro, of the bis(diethylaminoethyl) ethers of stilbestrol and hexylresorcinol has been extended by the preparation of a number of analogous bis- and mono(diethylaminoethyl) ethers. Considerable simplification of the mol. is possible without loss of activity in vitro. As with the compds. examined by Chapman, no activity in vivo could be

observed. (p-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Et)<sub>2</sub> (5.4 g.) in 320 cc. 0.5 N KOH, treated (1 hr.) with 20.3 g. iodine in aqueous KI, stirred an addnl. hr., the K salt precipitated with 50 cc. 10 N KOH, and the product precipitated with SO<sub>2</sub>, gives 10.5 g. 3,4-bis(4-hydroxy-3,5-diiodophenyl)hexane, m. 239.5-40° (decomposition). AmCOC<sub>2</sub> (49 g.), added to 53 g. AlCl<sub>3</sub> in 100 cc. CS<sub>2</sub>, warmed on the steam bath until solution resulted, cooled to 0°, treated (1 hr.) with 50 g. p-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub> in 200 cc. CS<sub>2</sub>, kept 21 hrs. at room temperature, and decomposed with dilute HCl and ice, gives 25 g. unchanged phenol and 38 g. 2-hexanoyl-1,4-dimethoxy-benzene (2-hexanoylhydroquinone di-Me ether) (I), b<sub>0.5</sub> 132-4°, m. about 15°, gives a green FeCl<sub>3</sub> reaction in EtOH. I (28 g.) and 14 g. 80% N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in 28 cc. absolute EtOH, refluxed 2.5 hrs., heated to 150°, 56 g. KOH added, and the mixture heated to 170°, give 16.5 g. 2-hexyl-1,4-dimethoxy-benzene (2-hexylhydroquinone di-Me ether) (II), b<sub>0.1</sub> 90-4°; 5.25 g. II and 50 cc. 48% HBr, refluxed 2 hrs., give 3.18 g. 2-hexylhydroquinone, b<sub>1</sub> 152°, m. 88°. p-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub> (44 g.) and 40 g. NaOH in 280 cc. ice-cold H<sub>2</sub>O, treated (N atmospheric) with 54.2 g. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl, shaken 16 hrs., and heated 2 hrs. at 100°, give 43.7 g. p-HOC<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub> (III), b<sub>2</sub> 161°, m. 81° (picrate, yellow, m. 129°); 5.23 g. III and 7.1 g. MeI in 50 cc. EtOH containing 0.575 g. Na, refluxed 48 hrs., give 1.3 g. p-C<sub>6</sub>H<sub>4</sub>(OMe)<sub>2</sub>, m. 56° (76% disproportionation of III); EtI gives 2 g. p-C<sub>6</sub>H<sub>4</sub>(OEt)<sub>2</sub>, m. 66° (96% disproportionation). Attempted alkylation with C<sub>6</sub>H<sub>13</sub>Br gives 3.5 g. p-C<sub>6</sub>H<sub>4</sub>(OCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>)<sub>2</sub> (IV), b<sub>2</sub> 174° (picrate, m. 183-4°) (90% disproportionation); 10.45 g. III and 1.15 g. Na in 50 cc. EtOH, refluxed 16 hrs., give 3.5 g. IV (45% disproportionation). The following methods were used for preparing Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub> derivs.: (A) 1 mol. Na and 1-1.2 mols. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl for each phenolic group were refluxed 1-10 hrs.; (B) the phenol in 2.5 equivs. 3.5 N NaOH was shaken 16-64 hrs. with 3-4 mols. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl; (C) the phenol was dissolved in MeOH containing 1 equivalent MeONa and C<sub>6</sub>H<sub>6</sub>, the MeOH removed, and the Na salt refluxed 24 hrs. with 1 mol. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl. 3,4-Bis[p-(2-diethylaminoethoxy)phenyl]hexane-2HCl, m. 222° (A, 46%). 3,4-Bis[4-(2-diethylaminoethoxy)-3,5-diiodophenyl]hexane-2HCl, m. 241° (A, 35%). 4,4'-Bis(2-diethylaminoethoxy)biphenyl-2HCl, m. 235° (A, 38.5%). Bis[p-(2-diethylaminoethoxy)phenyl]sulfone direineckate, m. 165° (dihydrate, m. 130°) (A, 29%). Na(1.7 g.) in 100 cc. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OH, treated with 10 g. (CH<sub>2</sub>)<sub>8</sub>Br<sub>2</sub> and heated overnight at 100°, gives 1,8-bis(2-diethylaminoethoxy)octane, b<sub>3</sub> 140°; Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl gives 21% bis(2-diethylaminoethyl) ether, b<sub>0.5</sub> 85° (dipicrate, m. 132.5°); this results in 16% yield in the alkylation of p-ETOC<sub>6</sub>H<sub>4</sub>OH with Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl (B). 1,4-Bis(2-diethylaminoethoxy)-2-hexylbenzene dipicrate, m. 125.5° (B, 71.5%). p-C<sub>6</sub>H<sub>4</sub>(NHCHO)<sub>2</sub> (4.1 g.) in 100 cc. Me<sub>2</sub>CO and 100 cc. MeOH, treated with 13.55 g. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl and 10 g. K<sub>2</sub>CO<sub>3</sub> and refluxed 5 hrs., and the residual oil hydrolyzed by refluxing 2 hrs. with 30 cc. 5 N HCl, give p-bis(2-diethylaminoethylamino)benzene, b<sub>1</sub> 180°. 1-(2-Diethylaminoethoxy)-4-ethoxybenzene, b<sub>5</sub> 183-6° (B, 71%); picrate, m. 77-8°. 4-Butoxy-1-(2-diethylaminoethoxy)benzene, b<sub>0.5</sub> 128° (B, 45%). 1-(2-Diethylaminoethoxy)-4-octyloxybenzene, b<sub>1.3</sub> 190° (B, 54.5%). p-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub> (5.5 g.) and 20.6 g. C<sub>6</sub>H<sub>13</sub>Br, added to 5.6 g. KOH in 50 cc. EtOH and refluxed 3 hrs., give 8.36 g. p-dihexyloxybenzene (hydroquinone dihexyl ether), m. 45°. p-(2-Diethylaminoethoxy)toluene-HCl, m. 107° (A, 72%). 3,5-Dichloro-4-(2-diethylaminoethoxy)toluene, b<sub>1</sub> 114-17° (C, 56%); picrate, m. 155-6°. 3,5-Dichloro-2-(2-diethylaminoethoxy)toluene, b<sub>2</sub> 132-4° (C, 79%); HCl salt, m. 153-4°. 1-(2-Diethylaminoethoxy)-4-propylbenzene-HCl, m. 141-2°. 1-(2-Diethylaminoethoxy)-4-hexylbenzene b<sub>0.5</sub> 140° (A, 75%). 2,6-Di-Cl derivative, b<sub>1</sub> 167-71° (A, 61%). 4-(2-


Diethylaminoethoxy)propiofenone (IV), b1 152° (A, 64%); HCl salt, m. 149-50°. IV and PrMgBr in ether, refluxed 45 min., decomposed with HCl and ice, and the aqueous layer nearly neutralized with NaOH and treated with excess solid NaHCO<sub>3</sub>, give crude 1-[2-(diethylaminoethoxy)-4-(1-ethyl-1-hydroxybutyl-)]benzene (V), b0.3 146-51° (HCl salt, m. 130-1°); 15 g. V and 50 g. 98% HCO<sub>2</sub>H, refluxed 45 min., give 10.8 g. 1-(2-diethylaminoethoxy)-4-(1-ethyl-1-butenyl)benzene, b0.7 140-2° (HCl salt, m. 144°); catalytic reduction of 8.2 g. yields 7.3 g. 1-(2-diethylaminoethoxy)-4-(1-ethylbutyl)benzene, b0.5 135° (HCl salt, m. 157-8°). Data are given for the activity of the above compds. against Mycobacterium tuberculosis in the absence and presence of 10% serum.

IT 69-14-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, dihydrochloride 859790-53-7, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(2,6-diiodo-p-phenyleneoxy)]bis-, dihydrochloride (preparation of)  
 RN 69-14-7 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 859790-53-7 CAPLUS  
 CN Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(2,6-diiodo-p-phenyleneoxy)]bis-, dihydrochloride (5CI) (CA INDEX NAME)



● 2 HCl

L17 ANSWER 194 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1952:2596 CAPLUS  
 DN 46:2596  
 OREF 46:455a-i,456a-b  
 TI Synthesis of basic phenol alkyl ethers  
 AU Takahashi, Torizo; Senda, Shigeo  
 CS Univ. Kyoto  
 SO Acta Schol. Med. Univ. Kyoto (1949), 27, 34-42  
 DT Journal


LA Unavailable

AB T.'s earlier syntheses (cf. J. Pharm. Society Japan 63, 555(1943); C.A. 45, 9499i) of basic phenol alkyl ethers (some of which possess ergotlike activity) starting from isoeugenol, dihydroeugenol, vanillic acid, guaiacol (I), vanillin, and o-HOC<sub>6</sub>H<sub>4</sub>CHO (II) are reviewed. Further syntheses of basic ethers from I, II, p- and m-C<sub>6</sub>H<sub>4</sub>(OH)<sub>2</sub>, and safrole (III) are then outlined without exptl. details. Thus, ClCH(CH<sub>2</sub>NEt<sub>2</sub>)<sub>2</sub> (IV), b<sub>15</sub> 116°, prepared from the alc. and SOCl<sub>2</sub>, with 6-allylguaiacol (V) produced the 2,2'-bis(diethylamino)isopropyl ether (the A ether), b<sub>12</sub> 199°, of V. The 2-hydroxy-3-chloropropyl ether (the B ether) (VI), b<sub>10</sub> 187°, of V, prepared from V and (ClCH<sub>2</sub>)<sub>2</sub>CHOH (VII), with Et<sub>2</sub>NH gave the 2-hydroxy-3-(diethylamino)propyl ether (the C ether) (VIII), b<sub>6</sub> 160°, of V. Similarly, the Me ether, b<sub>6</sub> 158-62°, of VI, prepared from V and (ClCH<sub>2</sub>)<sub>2</sub>CHOMe, and Et<sub>2</sub>NH yielded the Me ether, b<sub>15</sub> 213-15°, of VIII. The allyl ether (the D ether), b<sub>178-80°</sub>, of VII, prepared from VII, Ag<sub>2</sub>O, and CH<sub>2</sub>:CHCH<sub>2</sub>Br (IX), with V produced the D ether, b<sub>8</sub> 180-3°, of VI, which with Et<sub>2</sub>NH afforded the D ether, b<sub>9</sub> 197°, of VIII. Et<sub>2</sub>NCH<sub>2</sub>C(OH)MeEt, b<sub>21</sub> 85-7°, from Et<sub>2</sub>NCH<sub>2</sub>Ac and EtMgBr, with SOCl<sub>2</sub> gave the chloride, b<sub>23</sub> 76-7°, which with V yielded the 1-(diethylaminomethyl)-1-methylpropyl ether, b<sub>3</sub> 160°, of V. 3-Allylsalicylaldehyde (X) with (CH<sub>2</sub>Cl)<sub>2</sub> gave the 2-chloroethyl ether, b<sub>5</sub> 125-30°, which with diallylamine yielded the 2-(diallylamino)ethyl ether, b<sub>1</sub> 145°, of X. BrCH<sub>2</sub>CH(OH)Me, prepared by reduction of BrCH<sub>2</sub>Ac with Al(OEt)<sub>3</sub> in C<sub>6</sub>H<sub>6</sub>, with Et<sub>2</sub>NH or reduction of Et<sub>2</sub>NCH<sub>2</sub>Ac with Na-Hg gave Et<sub>2</sub>NCH<sub>2</sub>CH(OH)Me (XI). Et<sub>2</sub>NCH<sub>2</sub>CHClMe, b. 152-5°, from XI and SOCl<sub>2</sub>, and X yielded the 1-methyl-2-(diethylamino)ethyl ether, b<sub>15</sub> 183°, of X. From Et<sub>2</sub>NH and the B ether, b<sub>10</sub> 170°, of X, prepared from X and VII, or from X and Et<sub>2</sub>NCH<sub>2</sub>CH(OH)CH<sub>2</sub>Cl, b<sub>3</sub> 83-5°, prepared from VII and Et<sub>2</sub>NH, was obtained the C ether, b<sub>5</sub> 157-8°, of X. X and IV yielded the A ether, b<sub>7</sub> 197°, of X. p-MeOC<sub>6</sub>H<sub>4</sub>OH with IX gave the D ether, b<sub>13</sub> 148-52°, which rearranged to 4,2-MeO(CH<sub>2</sub>:CHCH<sub>2</sub>)C<sub>6</sub>H<sub>3</sub>OH (XII), b<sub>12</sub> 152-5°. The 2-diethylaminoethyl ether (E ether), b<sub>6</sub> 166°, of XII was prepared from XII and Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl (XIII). The D ether, b<sub>4.5</sub> 128-9°, of XII rearranged to 4,2,6-MeO(CH<sub>2</sub>:CHCH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>2</sub>OH (XIV), b<sub>4</sub> 143°, which with XIII yielded the E ether, b<sub>3</sub> 168-9°, of XIV (b.p. 168-1692 given in the paper). Rearrangement of the D ether of m-MeOC<sub>6</sub>H<sub>4</sub>OH afforded 2,4-HO(MeO)C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>CH:CH<sub>2</sub> (XV), b<sub>3</sub> 114°, which with XIII gave the E ether, b<sub>2</sub> 200-205°, of XV. III with MeI and CH<sub>2</sub>:CHCH<sub>2</sub>MgBr gave, resp., 2-ethoxy-5-allylphenol (XVI) and 2,4,3-buten-1-yloxy-5-allylphenol (XVII), b<sub>5</sub> 130-4° (b.p. 130-1342 given in the paper). XVI and XVII, with XIII, produced the E ethers, b<sub>4</sub> 154-5° and b<sub>4</sub> 175-7°, resp., of XVI and XVII. The D ethers of XVI and XVII, b<sub>4</sub> 129° and b<sub>2</sub> 154°, resp., rearranged under reduced pressure at about 270° to the 6-allyl derivs. (XVIII and XIX), b<sub>3</sub> 133-5° and b<sub>4</sub> 155-60°, resp., of XVI and XVII, which in turn condensed with XIII to produce the E ethers, b<sub>4</sub> 172-5° and b<sub>4</sub> 192-5°, resp., of XVIII and XIX. 25

IT 857393-24-9, Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis[N,N-diethyl-, hydrochloride (preparation of)

RN 857393-24-9 CAPLUS

CN Propylamine, 3,3'-[isopropylidenebis(p-phenyleneoxy)]bis[N,N-diethyl-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

L17 ANSWER 195 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1951:42285 CAPLUS

DN 45:42285

OREF 45:7249e-h

TI Biological activity of a new group of coronary dilators

AU Milla, E.; Grumelli, E.

CS Lab. Maggioni, Milan, Italy

SO Farm. sci. e tec. (Pavia) (1951), 6, 150-69

DT Journal

LA Unavailable


AB The compds. investigated were 4,4'-bis(diethylaminoethoxy)- $\alpha,\alpha'$ -diethylstilbene (I), 4,4'-bis(diethylaminoethoxy)- $\alpha,\alpha'$ -diethylbibenzyl (II), 4-hydroxy-4'-diethylaminoethoxy- $\alpha,\alpha'$ -diethylstilbene (III), and 4-hydroxy-4'-diethylaminoethoxy- $\alpha,\alpha'$ -diethylbibenzyl (IV). In the Allen-Doisy test I showed no estrogenic activity at 5-mg. dose, II was inactive at 1 mg. but was pos. at 5 mg. in 2 out of 6 rats, III and IV were neg. at 0.5, but pos. at 1 and 5 mg. Intravenous injection of 3 mg. caused in anesthetized dogs a drop in blood pressure which was insignificant with II. The effect on the coronary flow in the isolated heart was measured in a newly devised arrangement which is described. Prolonged perfusion with II in Ringer-Locke solution at varying concns. caused coronary dilatation that was markedly superior to that obtained with the previously investigated 4-diethylaminoethoxystilbene (V) at equal concentration. Repetition of the perfusion produced equal responses. II did not change the cardiac rhythm and caused only a slight and fleeting reduction in the systolic amplitude. A constriction of the coronaries following the perfusion was more marked and lasted longer with V than with II. Concns. of adenosine of 1.25  $\gamma$  per cc. produced coronary flow within the same range as obtained with 0.5  $\gamma$  II. The combination of II and V did not cause an addition or enhancement of effects. The other compds. showed also coronary dilator effects but the data are not reported.

IT 2691-45-4, Bibenzyl, 4,4'-bis(2-diethylaminoethoxy)- $\alpha,\alpha'$ -diethyl-


(biol. activity of)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 196 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1951:36114 CAPLUS  
 DN 45:36114  
 OREF 45:6179d-f  
 TI Synthesis of 3-methyl-4-amino-1-naphthol hydrochloride (vitamin K7) and related vitamin-K-active compounds  
 AU Sah, Peter P. T.  
 CS Univ. of California Med. School, San Francisco  
 SO Zeitschrift fuer Vitamin-, Hormon- und Fermentforschung (1950), 3, 324-45  
 CODEN: ZVHFAW; ISSN: 0373-0220  
 DT Journal  
 LA English  
 AB Previously developed methods for the synthesis of vitamin K5 (Sah, et al., C.A. 44, 5858h, 5859a) were adapted. Instead of 2,1-MeC10H6OH, the 3,1-isomer (I) was coupled with diazotized sulfanilic acid to yield the 3-Me homolog of Orange I, which was reduced with SnCl2 and concentrated HCl to vitamin K7. The intermediate I was prepared from 3,1-MeC10H6NH2 by diazotization and decomposition with boiling 50% H2SO4 or from PhCH2CHMeCH2CO2H by cyclization to 3,4-dihydro-3-methyl-1(2H)-naphthalenone and S dehydrogenation at 250°C.  
 IT 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (preparation of)  
 RN 719278-53-2 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (5CI) (CA INDEX NAME)




● 2 I<sup>-</sup>

L17 ANSWER 197 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1951:36113 CAPLUS  
 DN 45:36113  
 OREF 45:6179c-d  
 TI Derivatives of stilbene and diphenylethane (new synthetic curares)  
 AU Cavallini, G.; Massarani, E.  
 CS Lab. Maggioni, Milan  
 SO Farm. sci. e tec. (Pavia) (1950), 5, 501-4  
 DT Journal  
 LA Unavailable  
 AB [p-INMeEt2CH2CH2OC6H4Cet:]2, m. 260-1°, and [p-INMeEt2CH2CH2OC6H4CHet]2 m. 245°, were prepared with 70% yield from the nonmethylated compds. with MeI in CHCl3 solution  
 IT 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (preparation of)  
 RN 719278-53-2 CAPLUS  
 CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide]



hyl-iodide] (5CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

L17 ANSWER 198 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1951:33474 CAPLUS

DN 45:33474

OREF 45:5819f-h

TI Synthetic compounds of curare action

AU Cavallini, G.; Ferrari, W.; Mantegazza, P.

CS Univ. Milan, Italy

SO Farm. sci. e tec. (Pavia) (1951), 6, 63-73

DT Journal


LA Unavailable

AB Mg 542, ( $\alpha, \alpha'$ -diethyl-4,4'-bis(2-diethylaminoethoxy)stilbene-di-MeI) and Mg 547 ( $\alpha, \alpha'$ -diethyl-4,4'-bis(2-diethylaminoethoxy) bibenzyl-di-MeI) produce paralysis in the rabbit, guinea pig, rat, mouse and frog by causing a neuromuscular block. Mg 542 seems to be slightly more potent. The paralyzing i.v. dose is 40 to 50  $\gamma$ /kg. in the rabbit. The frog survives 10 times the dose producing prolonged paralysis. Prostigmine, given before or simultaneously, enhances the paralyzing action. Prior administration of Congo red counteracts Mg 542. The latter does not affect the blood pressure of the conscious dog at high doses. Both compds. injected into the cisterna magna of the rabbit cause a convulsive state resembling that caused by d-tubocurarine. They have, in high concentration, an oxytocic effect on the isolated guinea pig's uterus. Both in low concns. inhibit the cholinesterase in the serum and nerve.

IT 719278-53-2, Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (preparation of)

RN 719278-53-2 CAPLUS

CN Ammonium, [(1,2-diethylethylene)bis(p-phenyleneoxyethylene)]bis[diethylmethyl-iodide] (5CI) (CA INDEX NAME)



● 2 I<sup>-</sup>

L17 ANSWER 199 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1950:44691 CAPLUS

DN 44:44691

OREF 44:8544i,8545a-e

TI Experimental tuberculosis and its chemotherapy

AU Croshaw, Betty; Dickinson, Lois

CS Boots Pure Drug Co., Ltd., Nottingham, UK

SO British Journal of Pharmacology and Chemotherapy (1950), 5, 178-87

CODEN: BJPCAL; ISSN: 0366-0826

DT Journal


LA Unavailable

AB About 1000 compds. of 11 different series were tested in vitro against a human strain of *M. tuberculosis*. The following showed high activity in vitro ( $2 + 10^{-4}$  to  $2 + 10^{-7}$ ) in either the presence or absence of serum: p-hexyloxy- and p-octyloxy-N-phenylbenzamidine, p-butoxy-N-p'-butoxyphenylbenzamidine, 1,3-di(p-N-phenylamidinophenoxy)propane, 1,5-di(p-N-phenylamidinophenoxy)pentane, 1,3-di(p-N-4'-ethoxyphenylamidinophenoxy)propane, 2-nonyldihydroglyoxaline, 1-N-phenylamidinononane, N-phenyl- and N-p-tolylphenylacetamidine, 1-N-p-butoxyphenylamidinocyclohexene; the following ethylamines: diethyl-2-(p-chlorophenoxy)-, diethyl-2-(2',4',6'-trichlorophenoxy)-, diethyl-2-(2',4',6'-triiodophenoxy)-, and diethyl-2-(2',3',5'-trichlorophenoxy)-, 2,4,6-trichloro-N-2'-diethylaminoethyl aniline; acetone and p-1-pyrrolidylbenzaldehyde 3-ethylisothiosemicarbazone, o-nitrobenzaldehyde thiosemicarbazone, benzaldehyde 3-butylisothiosemicarbazone, p-1-pyrrolidyl- and p-dimethylaminobenzaldehyde guanylhydrazones, 2-diethylaminoethyl butyl sulfide, 3,4-bis(p-2-diethylaminoethoxyphenyl)hexane, hexykesorcinol bis(2-diethylaminoethyl) ether, 1,4-bis(2-diethylaminoethoxy)benzene, 1-(2-diethylaminoethoxy)-4-hexylbenzene, p-(1-hydroxy-1-ethylbutyl)phenyl 2-diethylaminoethyl ether, 2-sulfanil-amido-5-methyl-1,3,4-oxadiazole (I), 2-sulfanilamido-5-pentyl- and 2-sulfanilamido-5-methyl-1,3,4-thiadiazoles. None of these compds. was active when tested at the maximum tolerated dose in mice or guinea pigs or both. The LD<sub>50</sub> for mice for the listed compds. ranged from 0.1 to 1.0 mg./g. (orally or subcutaneously) except I which had an LD<sub>50</sub> of 10 mg./g. The following drug combinations were found more effective than either drug alone: licheniforrain + sulphetrone, streptomycin + sulphetrone, and p-aminosalicylic acid + streptomycin. p-Aminosalicylic acid was more effective subcutaneously than orally in guinea pigs. The small scale guinea pig test was found to give more reliable and more convincing results than the mouse test.

IT 2691-45-4, Triethylamine, 2,2'-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-  
(in tuberculosis therapy)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 200 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1950:3703 CAPLUS

DN 44:3703

OREF 44:748c-e

TI New vasoactive substances

AU Cavallini, G.; Massarani, E.

SO Farm. sci. e tec. (Pavia) (1949), 4, 397-9

DT Journal


LA Unavailable

AB cf. C.A. 43, 8059i. Condensation of (p-NaOC<sub>6</sub>H<sub>4</sub>Cet:)<sub>2</sub> and of (p-NaOC<sub>6</sub>H<sub>4</sub>CHet)<sub>2</sub>, resp., with ClCH<sub>2</sub>CH<sub>2</sub>Net<sub>2</sub> gives (p-Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>Cet:)<sub>2</sub> (I) HCl salt, m. 237-8°, soluble in H<sub>2</sub>O, MeOH, EtOH, CHCl<sub>3</sub>, and (p-Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>CHet)<sub>2</sub> (II), HCl salt, m. 226-7°, soluble in the same solvents. With an excess of the first reactants there were obtained: 4-(4-HOC<sub>6</sub>H<sub>4</sub>CH:CH)C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>Net<sub>2</sub> (III) HCl salt, m. 206-7°, soluble in H<sub>2</sub>O, EtOH, MeOH and Me<sub>2</sub>CO, and 4-(4-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>)C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CH<sub>2</sub>Net<sub>2</sub> (IV) HCl salt, m. 208°, soluble in the same solvents. An intravenous dose of 3 mg. per kg. of I or II produces in the dog a drop in blood pressure; 20 to 25 γ cause in the isolated rabbit heart dilatation of the coronary vessels. I and II have no estrogenic activity. III and IV have a still higher dilatory effect on the coronaries and a definite estrogenic action in 1 mg. dose.

IT **107744-23-0**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride (preparation of)

RN 107744-23-0 CAPLUS

CN Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

L17 ANSWER 201 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1949:44705 CAPLUS

DN 43:44705

OREF 43:8060a-b

TI Synergistic antibiotic action of p-aminobenzoic acid and vitamin K in experimental tuberculosis

AU Pisu, I.

SO Farm. sci. e tec. (Pavia) (1949), 4, 273-7

DT Journal


LA Unavailable

AB Guinea pigs infected with tuberculosis bacilli were treated with 0.4 g. p-aminobenzoic acid per kg. and 0.08 g. vitamin K daily. In all animals with glandular as well as pulmonary infection a marked therapeutic action was observed, leading to recovery. The high doses of both vitamins were well tolerated. A synergistic effect is suggested.


IT **2691-45-4**, Triethylamine, 2,2'''-[(1,2-diethylethylene)bis(p-phenyleneoxy)]bis- (pharmacology of)

RN 2691-45-4 CAPLUS

CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



L17 ANSWER 202 OF 202 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1949:44704 CAPLUS  
 DN 43:44704  
 OREF 43:8059i,8060a  
 TI Cancer therapy and substances of vascular activity  
 AU Cavallini, G.; Goisis, M.; Massarani, E.  
 SO Farm. sci. e tec. (Pavia) (1949), 4, 271-2  
 DT Journal  
 LA Unavailable  
 AB cf. C.A. 42, 8340g. 4,4'-Diethylaminoethoxy- $\alpha,\beta$ -diethylstilbene (ROC6H4C(Et):C(Et)C6H4OR) (I) and 4,4'-diethylaminoethoxy- $\alpha,\beta$ -diethyldiphenylethane (ROC6H4CH(Et)CH(Et)C6H4OR (R = -C2H4NEt2)) have no estrogenic activity but affect the blood vessels. I proved clinically to cause similar histological changes as are produced by the corresponding estrogenic substances.  
 IT 2691-45-4, Bibenzyl, 4,4'-bis(2-diethylaminoethoxy)- $\alpha,\alpha'$ -diethyl- (pharmacology of)  
 RN 2691-45-4 CAPLUS  
 CN Ethanamine, 2,2'-[(1,2-diethyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)]bis[N,N-diethyl- (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

Connection closed by remote host  
 END

Unable to generate the STN prompt.  
 Exiting the script...